[
  {
    "id": 10,
    "user_query": "You MUST give a detailed answer to the following question: Name synonym of Acrokeratosis paraneoplastica.",
    "llama-7b_response": "verrucous carcinoma",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 47,
    "user_query": "You MUST give a detailed answer to the following question: Is Weaver syndrome similar to Sotos?",
    "llama-7b_response": "Weaver syndrome and Sotos syndrome are both genetic disorders that affect growth and development, but they are distinct conditions.\n\nWeaver syndrome, also known as synostosis syndrome, is a condition characterized by premature closure of one or more sutures in the skull, resulting in an abnormal head shape and an increased risk of brain damage. This condition is caused by a mutation in the fibroblast growth factor receptor 1 (FGFR1) gene.\n\nSotos syndrome, on the other hand, is a condition caused by a chromosomal abnormality, specifically an extra copy of chromosome 15. This condition is characterized by rapid growth before and after birth, intellectual disability, distinctive facial features, and an increased risk of certain birth defects.\n\nWhile both Weaver syndrome and Sotos syndrome can affect growth and development, they are distinct conditions with different underlying causes and symptoms. Weaver syndrome is caused by a mutation in the FGFR1 gene, while Sotos syndrome is caused by an extra copy of chromosome 15. Additionally, Weaver syndrome is characterized by premature closure of one or more sutures in the skull and an abnormal head shape, while Sotos syndrome is characterized by rapid growth before and after birth, intellectual disability, distinctive facial features, and an increased risk of certain birth defects.",
    "llama-7b_fact_raw": "1. Weaver syndrome is characterized by premature closure of one or more sutures in the skull, resulting in an abnormal head shape and an increased risk of brain damage.\n2. Weaver syndrome is caused by a mutation in the fibroblast growth factor receptor 1 (FGFR1) gene.\n3. Sotos syndrome is caused by a chromosomal abnormality, specifically an extra copy of chromosome 15.\n4. Sotos syndrome is characterized by rapid growth before and after birth, intellectual disability, distinctive facial features, and an increased risk of certain birth defects.\n5. Both Weaver syndrome and Sotos syndrome are genetic disorders that affect growth and development but are distinct conditions with different underlying causes and symptoms.",
    "llama-7b_fact": [
      "Weaver syndrome is characterized by premature closure of one or more sutures in the skull, resulting in an abnormal head shape and an increased risk of brain damage.",
      "Weaver syndrome is caused by a mutation in the fibroblast growth factor receptor 1 (FGFR1) gene.",
      "Sotos syndrome is caused by a chromosomal abnormality, specifically an extra copy of chromosome 15.",
      "Sotos syndrome is characterized by rapid growth before and after birth, intellectual disability, distinctive facial features, and an increased risk of certain birth defects.",
      "Both Weaver syndrome and Sotos syndrome are genetic disorders that affect growth and development but are distinct conditions with different underlying causes and symptoms."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Weaver syndrome is characterized by rapid growth during infancy and early childhood, advanced bone age, and distinctive facial features, not necessarily by premature closure of one or more sutures in the skull.\n2. FALSE [correction]: Weaver syndrome is most commonly caused by a mutation in the EZH2 gene, not the fibroblast growth factor receptor 1 (FGFR1) gene.\n3. FALSE [correction]: Sotos syndrome is not caused by an extra copy of chromosome 15; it is usually caused by a mutation in the NSD1 gene.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 81,
    "user_query": "You MUST give a detailed answer to the following question: List the releases of JASPAR database",
    "llama-7b_response": "The JASPAR database is a comprehensive database of protein-protein interaction data for eukaryotic proteins. It was first released in 2001 and has since been updated several times. Here are the releases of the JASPAR database:\n\n1. JASPAR 2001: The first release of the JASPAR database was in 2001. It contained information on 10,000 protein-protein interactions for 2,000 proteins from human, mouse, and rat.\n2. JASPAR 2004: The second release of the JASPAR database was in 2004. It contained information on 20,000 protein-protein interactions for 4,000 proteins from human, mouse, and rat.\n3. JASPAR 2007: The third release of the JASPAR database was in 2007. It contained information on 30,000 protein-protein interactions for 6,000 proteins from human, mouse, and rat.\n4. JASPAR 2010: The fourth release of the JASPAR database was in 2010. It contained information on 40,000 protein-protein interactions for 8,000 proteins from human, mouse, and rat.\n5. JASPAR 2013: The fifth release of the JASPAR database was in 2013. It contained information on 50,000 protein-protein interactions for 10,000 proteins from human, mouse, and rat.\n6. JASPAR 2016: The sixth release of the JASPAR database was in 2016. It contained information on 60,000 protein-protein interactions for 12,000 proteins from human, mouse, and rat.\n7. JASPAR 2019: The seventh release of the JASPAR database was in 2019. It contained information on 70,000 protein-protein interactions for 14,000 proteins from human, mouse, and rat.\n8. JASPAR 2021: The eighth release of the",
    "llama-7b_fact_raw": "1. The JASPAR database was first released in 2001.\n2. The JASPAR 2004 release contained information on 20,000 protein-protein interactions for 4,000 proteins from human, mouse, and rat.\n3. The JASPAR 2010 release included data on 40,000 protein-protein interactions for 8,000 proteins from human, mouse, and rat.\n4. The JASPAR 2016 release had data on 60,000 protein-protein interactions for 12,000 proteins from human, mouse, and rat.\n5. The JASPAR 2019 release provided information on 70,000 protein-protein interactions for 14,000 proteins from human, mouse, and rat.",
    "llama-7b_fact": [
      "The JASPAR database was first released in 2001.",
      "The JASPAR 2004 release contained information on 20,000 protein-protein interactions for 4,000 proteins from human, mouse, and rat.",
      "The JASPAR 2010 release included data on 40,000 protein-protein interactions for 8,000 proteins from human, mouse, and rat.",
      "The JASPAR 2016 release had data on 60,000 protein-protein interactions for 12,000 proteins from human, mouse, and rat.",
      "The JASPAR 2019 release provided information on 70,000 protein-protein interactions for 14,000 proteins from human, mouse, and rat."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The JASPAR 2004 release did not contain information on protein-protein interactions. JASPAR is a database of transcription factor binding profiles, not protein-protein interactions.\n3. FALSE [correction]: The JASPAR 2010 release did not include data on protein-protein interactions. JASPAR focuses on transcription factor DNA-binding preferences, not protein-protein interactions.\n4. FALSE [correction]: The JASPAR 2016 release did not have data on protein-protein interactions. JASPAR provides data on transcription factor binding sites.\n5. FALSE [correction]: The JASPAR 2019 release did not provide information on protein-protein interactions. JASPAR is a resource for transcription factor binding profiles.",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 99,
    "user_query": "You MUST give a detailed answer to the following question: What is the function of the viral KP4 protein?",
    "llama-7b_response": "The KP4 protein is a viral protein that is encoded by the Kaposi's sarcoma-associated herpesvirus (KSHV), which is a type of herpesvirus that is associated with the development of Kaposi's sarcoma (KS), an aggressive form of cancer that affects the skin and other organs.\n\nThe KP4 protein is a viral oncoprotein that plays a crucial role in the transformation of normal cells into cancer cells. The KP4 protein is a transcriptional activator, which means that it can bind to specific DNA sequences and activate or repress the transcription of target genes.\n\nThe KP4 protein has been shown to activate the transcription of a number of genes that are involved in cell proliferation, survival, and angiogenesis, which are processes that are critical for the development of cancer. For example, the KP4 protein has been shown to activate the transcription of the vascular endothelial growth factor (VEGF) gene, which encodes a protein that promotes angiogenesis and is a key factor in the development of KS.\n\nIn addition to its role in the transcriptional activation of target genes, the KP4 protein also has been shown to interact with a number of cellular proteins, including histone deacetylases (HDACs), which are enzymes that play a role in the regulation of chromatin structure and transcription. The KP4 protein has been shown to inhibit the activity of HDACs, which allows it to promote the transcription of target genes and contribute to the transformation of normal cells into cancer cells.\n\nOverall, the KP4 protein is an important viral oncoprotein that plays a critical role in the development of Kaposi's sarcoma and other forms of cancer associated with KSHV infection.",
    "llama-7b_fact_raw": "1. The KP4 protein is encoded by the Kaposi's sarcoma-associated herpesvirus (KSHV).\n2. KP4 is a viral oncoprotein that contributes to the transformation of normal cells into cancer cells.\n3. The KP4 protein functions as a transcriptional activator, binding to DNA sequences to regulate gene transcription.\n4. KP4 has been shown to activate the transcription of genes involved in cell proliferation, survival, and angiogenesis, such as the VEGF gene.\n5. The KP4 protein can inhibit the activity of histone deacetylases (HDACs), which affects chromatin structure and transcription.",
    "llama-7b_fact": [
      "The KP4 protein is encoded by the Kaposi's sarcoma-associated herpesvirus (KSHV).",
      "KP4 is a viral oncoprotein that contributes to the transformation of normal cells into cancer cells.",
      "The KP4 protein functions as a transcriptional activator, binding to DNA sequences to regulate gene transcription.",
      "KP4 has been shown to activate the transcription of genes involved in cell proliferation, survival, and angiogenesis, such as the VEGF gene.",
      "The KP4 protein can inhibit the activity of histone deacetylases (HDACs), which affects chromatin structure and transcription."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The Kaposi's sarcoma-associated herpesvirus (KSHV) encodes a protein known as Kaposin B, not KP4. KP4 is a protein from Ustilago maydis, a type of fungus.\n2. UNKNOWN: Since KP4 is not encoded by KSHV, the statement about KP4 being a viral oncoprotein that contributes to the transformation of normal cells into cancer cells cannot be confirmed without the correct context.\n3. UNKNOWN: The function of KP4 as a transcriptional activator binding to DNA sequences to regulate gene transcription is not established within the context of KSHV, as KP4 is not a KSHV protein.\n4. UNKNOWN: The claim that KP4 activates the transcription of genes involved in cell proliferation, survival, and angiogenesis, such as the VEGF gene, cannot be verified without the correct context since KP4 is not associated with KSHV.\n5. UNKNOWN: The statement that KP4 can inhibit the activity of histone deacetylases (HDACs) is not verifiable within the context provided, as KP4 is not a protein encoded by KSHV.",
    "llama-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 124,
    "user_query": "You MUST give a detailed answer to the following question: Is DITPA a thyroid hormone analog utilized in experimental and clinical studies",
    "llama-7b_response": "Yes, DITPA (3,5-diiodothyronine) is a thyroid hormone analog that has been studied in both experimental and clinical settings.\n\nDITPA is a synthetic form of the thyroid hormone triiodothyronine (T3), which is produced naturally in the body by the thyroid gland. Like T3, DITPA is a potent regulator of metabolic processes, including energy production, growth, and development.\n\nIn experimental studies, DITPA has been used to investigate the mechanisms of thyroid hormone action and to study the effects of thyroid hormone deficiency and excess. For example, DITPA has been used to investigate the role of T3 in regulating body weight and metabolism, as well as the effects of T3 on various tissues and organs, such as the heart, muscles, and brain.\n\nIn clinical studies, DITPA has been used to treat patients with hypothyroidism, a condition in which the body does not produce enough thyroid hormone. In these studies, DITPA has been used as an alternative to synthetic T4 (levothyroxine) therapy, which is the most commonly used treatment for hypothyroidism. DITPA has been shown to be effective in improving symptoms of hypothyroidism, such as fatigue, weight gain, and depression, and has also been shown to improve metabolic parameters, such as body weight, cholesterol levels, and blood sugar levels.\n\nOverall, DITPA is a promising thyroid hormone analog that has been studied extensively in both experimental and clinical settings. Its use as a treatment for hypothyroidism and other thyroid disorders is still under investigation, and further research is needed to fully understand its potential benefits and risks.",
    "llama-7b_fact_raw": "1. DITPA (3,5-diiodothyronine) is a thyroid hormone analog that has been studied in experimental and clinical settings.\n2. DITPA is a synthetic form of the naturally produced thyroid hormone triiodothyronine (T3).\n3. DITPA has been used in experimental studies to investigate the mechanisms of thyroid hormone action and the effects of thyroid hormone deficiency and excess.\n4. In clinical studies, DITPA has been used to treat patients with hypothyroidism as an alternative to synthetic T4 (levothyroxine) therapy.\n5. DITPA has been shown to improve symptoms of hypothyroidism and metabolic parameters in clinical studies.",
    "llama-7b_fact": [
      "DITPA (3,5-diiodothyronine) is a thyroid hormone analog that has been studied in experimental and clinical settings.",
      "DITPA is a synthetic form of the naturally produced thyroid hormone triiodothyronine (T3).",
      "DITPA has been used in experimental studies to investigate the mechanisms of thyroid hormone action and the effects of thyroid hormone deficiency and excess.",
      "In clinical studies, DITPA has been used to treat patients with hypothyroidism as an alternative to synthetic T4 (levothyroxine) therapy.",
      "DITPA has been shown to improve symptoms of hypothyroidism and metabolic parameters in clinical studies."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: DITPA has been investigated in clinical studies, but it is not a standard treatment for hypothyroidism. Levothyroxine remains the standard therapy for hypothyroidism.\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 144,
    "user_query": "You MUST give a detailed answer to the following question: What is the COUGER tool?",
    "llama-7b_response": "I'm sorry, but I am not familiar with the COUGER tool. Could you provide more context or information about what you are looking for?",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 145,
    "user_query": "You MUST give a detailed answer to the following question: Are there drugs for Tick-borne Encephalitis?",
    "llama-7b_response": "Tick-borne encephalitis (TBE) is a viral infection that can affect the brain and nervous system. There are no specific drugs that can cure TBE, but there are several medications that can help manage the symptoms and reduce the risk of complications.\n\nThe mainstay of treatment for TBE is supportive care, which involves managing symptoms such as fever, headache, and muscle weakness. Acetaminophen or ibuprofen can be used to reduce fever and relieve pain. In some cases, antiviral medications such as ribavirin or oseltamivir may be used to help reduce the severity and duration of symptoms.\n\nIn addition to medications, it is important to protect against tick bites and seek medical attention promptly if a tick bite is suspected. Preventive measures such as using insect repellent, wearing protective clothing, and checking for ticks after spending time outdoors can help reduce the risk of infection.\n\nIt is also important to note that there are currently no licensed vaccines available for TBE. However, several vaccines are in development and may offer protection against TBE in the future.\n\nIn summary, while there are no specific drugs that can cure TBE, supportive care and preventive measures can help manage symptoms and reduce the risk of complications. Antiviral medications may be used to help reduce the severity and duration of symptoms, and several vaccines are in development that may offer protection against TBE in the future.",
    "llama-7b_fact_raw": "1. There are no specific drugs that can cure Tick-borne encephalitis (TBE).\n2. Supportive care is the mainstay of treatment for TBE, managing symptoms such as fever, headache, and muscle weakness.\n3. Acetaminophen or ibuprofen can be used to reduce fever and relieve pain in TBE patients.\n4. Antiviral medications such as ribavirin or oseltamivir may be used to help reduce the severity and duration of TBE symptoms.\n5. There are currently no licensed vaccines available for TBE, but several vaccines are in development.",
    "llama-7b_fact": [
      "There are no specific drugs that can cure Tick-borne encephalitis (TBE).",
      "Supportive care is the mainstay of treatment for TBE, managing symptoms such as fever, headache, and muscle weakness.",
      "Acetaminophen or ibuprofen can be used to reduce fever and relieve pain in TBE patients.",
      "Antiviral medications such as ribavirin or oseltamivir may be used to help reduce the severity and duration of TBE symptoms.",
      "There are currently no licensed vaccines available for TBE, but several vaccines are in development."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: There are no specific antiviral medications proven to be effective for the treatment of Tick-borne encephalitis (TBE). Treatment is supportive.\n5. FALSE [correction]: There are licensed vaccines available for TBE in countries where the disease is common.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 151,
    "user_query": "You MUST give a detailed answer to the following question: Which genome browser database for DNA shape annotations is available?",
    "llama-7b_response": "UCSC Genome Browser",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 174,
    "user_query": "You MUST give a detailed answer to the following question: Which syndromes are associated with mutations in the EZH2 gene?",
    "llama-7b_response": "22q11.2 deletion syndrome",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 193,
    "user_query": "You MUST give a detailed answer to the following question: List human proteins that are subject to a dimer-to-tetramer transition.",
    "llama-7b_response": "There are several human proteins that are known to undergo a dimer-to-tetramer transition, which refers to a change in the number of subunits in a protein complex from a dimer (two subunits) to a tetramer (four subunits). Here are some examples:\n\n1. Hemoglobin: Hemoglobin is a protein in red blood cells that carries oxygen throughout the body. It exists in a dimer form (two subunits) in the bloodstream, but undergoes a tetramer form (four subunits) when it binds to oxygen in the lungs.\n2. Immunoglobulin: Immunoglobulins are proteins that play a role in the immune system. They exist in a dimer form (two subunits) in the bloodstream, but undergo a tetramer form (four subunits) when they bind to antigens.\n3. Cytochrome c: Cytochrome c is a protein that plays a role in cellular respiration. It exists in a dimer form (two subunits) in the mitochondria of cells, but undergoes a tetramer form (four subunits) when it is oxidized.\n4. Ferritin: Ferritin is a protein that stores iron in the body. It exists in a dimer form (two subunits) in the bloodstream, but undergoes a tetramer form (four subunits) when it binds to iron.\n\nThese are just a few examples of human proteins that undergo a dimer-to-tetramer transition. There are likely many more proteins that exhibit this behavior, as the dimer-to-tetramer transition is a common structural feature of many proteins.",
    "llama-7b_fact_raw": "1. Hemoglobin is a protein that carries oxygen in red blood cells and undergoes a transition from a dimer to a tetramer when it binds to oxygen.\n2. Immunoglobulins are proteins involved in the immune system that transition from a dimer to a tetramer upon binding to antigens.\n3. Cytochrome c is a protein involved in cellular respiration that transitions from a dimer to a tetramer when oxidized.\n4. Ferritin is a protein that stores iron and transitions from a dimer to a tetramer upon binding to iron.",
    "llama-7b_fact": [
      "Hemoglobin is a protein that carries oxygen in red blood cells and undergoes a transition from a dimer to a tetramer when it binds to oxygen.",
      "Immunoglobulins are proteins involved in the immune system that transition from a dimer to a tetramer upon binding to antigens.",
      "Cytochrome c is a protein involved in cellular respiration that transitions from a dimer to a tetramer when oxidized.",
      "Ferritin is a protein that stores iron and transitions from a dimer to a tetramer upon binding to iron."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Hemoglobin is a protein that carries oxygen in red blood cells, but it is already a tetramer consisting of two alpha and two beta subunits; it does not transition from a dimer to a tetramer upon binding to oxygen.\n2. FALSE [correction]: Immunoglobulins, or antibodies, are proteins involved in the immune system that can exist in different forms, but they do not transition from a dimer to a tetramer upon binding to antigens. They are typically found as monomers or multimers (such as dimers or pentamers) depending on the class of the antibody.\n3. FALSE [correction]: Cytochrome c is a protein involved in cellular respiration that is found as a monomer, not as a dimer or tetramer, and it does not transition between these states when oxidized.\n4. FALSE [correction]: Ferritin is a protein that stores iron and can form a complex that consists of 24 subunits, not a tetramer. It does not transition from a dimer to a tetramer upon binding to iron.",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 210,
    "user_query": "You MUST give a detailed answer to the following question: Which protein has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein?",
    "llama-7b_response": "Bcl-2",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 218,
    "user_query": "You MUST give a detailed answer to the following question: Has vitamin D has been shown to reduce incidence of falls in older people in clinical trials?",
    "llama-7b_response": "Yes, vitamin D has been shown to reduce the incidence of falls in older people in clinical trials. A meta-analysis of randomized controlled trials (RCTs) found that vitamin D supplementation significantly reduced the risk of falls in older adults by 17% compared to placebo or no treatment. The study also found that higher doses of vitamin D were associated with a greater reduction in the risk of falls. Another RCT found that vitamin D supplementation reduced the risk of falls by 22% in older adults who were at high risk for falls. These findings suggest that vitamin D supplementation may be a useful strategy for preventing falls in older adults.",
    "llama-7b_fact_raw": "1. Vitamin D supplementation has been shown to reduce the incidence of falls in older people in clinical trials.\n2. A meta-analysis of randomized controlled trials found that vitamin D supplementation reduced the risk of falls in older adults by 17% compared to placebo or no treatment.\n3. Higher doses of vitamin D were associated with a greater reduction in the risk of falls according to the study.\n4. An RCT indicated that vitamin D supplementation reduced the risk of falls by 22% in older adults who were at high risk for falls.",
    "llama-7b_fact": [
      "Vitamin D supplementation has been shown to reduce the incidence of falls in older people in clinical trials.",
      "A meta-analysis of randomized controlled trials found that vitamin D supplementation reduced the risk of falls in older adults by 17% compared to placebo or no treatment.",
      "Higher doses of vitamin D were associated with a greater reduction in the risk of falls according to the study.",
      "An RCT indicated that vitamin D supplementation reduced the risk of falls by 22% in older adults who were at high risk for falls."
    ],
    "llama-7b_judge_raw": "1. TRUE: Vitamin D supplementation has been shown in some clinical trials to reduce the incidence of falls in older people.\n2. TRUE: A meta-analysis of randomized controlled trials could have found that vitamin D supplementation reduced the risk of falls in older adults by a certain percentage compared to placebo or no treatment. The specific percentage (17%) would need to be verified against the meta-analysis in question.\n3. UNKNOWN: Without specific details from the study, it is not possible to confirm whether higher doses of vitamin D were associated with a greater reduction in the risk of falls.\n4. UNKNOWN: The specific reduction in risk (22%) would need to be verified against the randomized controlled trial (RCT) mentioned. Without access to the study, the accuracy of this statement cannot be determined.",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 222,
    "user_query": "You MUST give a detailed answer to the following question: Is there any association between Jarid2 and miR-155 in Th17 cells?",
    "llama-7b_response": "Yes, there is an association between Jarid2 and miR-155 in Th17 cells.\n\nmiR-155 is a microRNA that has been implicated in the regulation of Th17 cell differentiation and function. It has been shown to negatively regulate the expression of the transcription factor RORγT, which is a key regulator of Th17 cell differentiation. In addition, miR-155 has also been shown to negatively regulate the expression of Jarid2, a protein that has been implicated in the regulation of cell proliferation and differentiation.\n\nJarid2 has been shown to negatively regulate the differentiation of Th17 cells by inhibiting the expression of the transcription factor RORγT. It has also been shown to negatively regulate the proliferation of Th17 cells by inhibiting the expression of the protein cyclin D1.\n\nTogether, these findings suggest that there is an association between Jarid2 and miR-155 in Th17 cells. miR-155 negatively regulates the expression of Jarid2, which in turn negatively regulates the differentiation and proliferation of Th17 cells.",
    "llama-7b_fact_raw": "1. miR-155 negatively regulates the expression of the transcription factor RORγT, which is crucial for Th17 cell differentiation.\n2. miR-155 has been shown to negatively regulate the expression of Jarid2.\n3. Jarid2 negatively regulates the differentiation of Th17 cells by inhibiting the expression of RORγT.\n4. Jarid2 also negatively regulates the proliferation of Th17 cells by inhibiting the expression of cyclin D1.\n5. There is an association between Jarid2 and miR-155 in the context of Th17 cell differentiation and proliferation.",
    "llama-7b_fact": [
      "miR-155 negatively regulates the expression of the transcription factor RORγT, which is crucial for Th17 cell differentiation.",
      "miR-155 has been shown to negatively regulate the expression of Jarid2.",
      "Jarid2 negatively regulates the differentiation of Th17 cells by inhibiting the expression of RORγT.",
      "Jarid2 also negatively regulates the proliferation of Th17 cells by inhibiting the expression of cyclin D1.",
      "There is an association between Jarid2 and miR-155 in the context of Th17 cell differentiation and proliferation."
    ],
    "llama-7b_judge_raw": "1. TRUE: miR-155 is known to negatively regulate the expression of various genes, including transcription factors like RORγT, which is indeed crucial for Th17 cell differentiation.\n2. TRUE: miR-155 has been reported to negatively regulate the expression of Jarid2 in scientific literature.\n3. TRUE: Jarid2 is known to negatively regulate the differentiation of Th17 cells, and one of the mechanisms by which it does so is by inhibiting the expression of RORγT.\n4. TRUE: Jarid2 has been shown to negatively regulate the proliferation of Th17 cells, and one of the mechanisms is through the inhibition of cyclin D1 expression.\n5. TRUE: Given that miR-155 regulates Jarid2 and both are involved in the differentiation and proliferation of Th17 cells, there is an association between Jarid2 and miR-155 in this context.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 224,
    "user_query": "You MUST give a detailed answer to the following question: How many genes does the human hoxD cluster contain?",
    "llama-7b_response": "The human HOXD cluster contains 13 genes.",
    "llama-7b_fact_raw": "1. The human HOXD cluster contains 13 genes.",
    "llama-7b_fact": [
      "The human HOXD cluster contains 13 genes."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The human HOXD cluster contains 9 genes.",
    "llama-7b_judge": [
      "false"
    ]
  },
  {
    "id": 268,
    "user_query": "You MUST give a detailed answer to the following question: List phosphorylation consensus motifs for Casein Kinase 1 (CK1)?",
    "llama-7b_response": "​",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 305,
    "user_query": "You MUST give a detailed answer to the following question: Which are the different proteins/isoforms encoded but the ASPH (aspartate beta-hydroxylase) gene in humans?",
    "llama-7b_response": "The ASPH (aspartate beta-hydroxylase) gene encodes for the enzyme aspartate beta-hydroxylase, which is involved in the metabolism of amino acids and other compounds in the body. The gene is located on chromosome 11q23.3 and consists of six exons and five introns.\n\nThere are several different proteins and isoforms that are encoded by the ASPH gene in humans. These include:\n\n1. Aspartate beta-hydroxylase: This is the primary protein encoded by the ASPH gene and is responsible for catalyzing the conversion of aspartate to beta-alanine in the urea cycle.\n2. Aspartate beta-hydroxylase long isoform: This isoform of aspartate beta-hydroxylase is longer than the standard isoform and is found primarily in the liver.\n3. Aspartate beta-hydroxylase short isoform: This isoform of aspartate beta-hydroxylase is shorter than the standard isoform and is found primarily in the kidney.\n4. Aspartate beta-hydroxylase 1: This isoform of aspartate beta-hydroxylase is found primarily in the brain and is involved in the metabolism of amino acids and other compounds in the brain.\n5. Aspartate beta-hydroxylase 2: This isoform of aspartate beta-hydroxylase is found primarily in the liver and is involved in the metabolism of amino acids and other compounds in the liver.\n6. Aspartate beta-hydroxylase 3: This isoform of aspartate beta-hydroxylase is found primarily in the kidney and is involved in the metabolism of amino acids and other compounds in the kidney.\n\nOverall, the ASPH gene encodes for several different proteins and isoforms that play important roles in the metabolism of amino acids and other compounds in the body.",
    "llama-7b_fact_raw": "1. The ASPH gene is located on chromosome 11q23.3.\n2. The ASPH gene consists of six exons and five introns.\n3. The primary protein encoded by the ASPH gene is aspartate beta-hydroxylase, which catalyzes the conversion of aspartate to beta-alanine in the urea cycle.\n4. There is a long isoform of aspartate beta-hydroxylase primarily found in the liver.\n5. There is a short isoform of aspartate beta-hydroxylase primarily found in the kidney.",
    "llama-7b_fact": [
      "The ASPH gene is located on chromosome 11q23.3.",
      "The ASPH gene consists of six exons and five introns.",
      "The primary protein encoded by the ASPH gene is aspartate beta-hydroxylase, which catalyzes the conversion of aspartate to beta-alanine in the urea cycle.",
      "There is a long isoform of aspartate beta-hydroxylase primarily found in the liver.",
      "There is a short isoform of aspartate beta-hydroxylase primarily found in the kidney."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The ASPH gene consists of 23 exons, not six.\n3. FALSE [correction]: The primary protein encoded by the ASPH gene is aspartate beta-hydroxylase, but it catalyzes the hydroxylation of aspartyl and asparaginyl residues in proteins, not the conversion of aspartate to beta-alanine in the urea cycle.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 330,
    "user_query": "You MUST give a detailed answer to the following question: When was empagliflozin FDA approved?",
    "llama-7b_response": "July 2014",
    "llama-7b_fact_raw": "1. Empagliflozin was FDA approved in July 2014.",
    "llama-7b_fact": [
      "Empagliflozin was FDA approved in July 2014."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Empagliflozin was FDA approved in August 2014.",
    "llama-7b_judge": [
      "false"
    ]
  },
  {
    "id": 350,
    "user_query": "You MUST give a detailed answer to the following question: What are the results of loss of the protein Lon1 in the plant Arabidopsis?",
    "llama-7b_response": "Loss of the protein Lon1 in the plant Arabidopsis has been shown to result in several phenotypes, including:\n\n1. Increased cell death: Lon1 is involved in the regulation of cell death, and its loss leads to an increase in programmed cell death in Arabidopsis.\n2. Altered stress responses: Lon1 plays a role in the regulation of stress responses in Arabidopsis, and its loss leads to altered responses to various types of stress, including heat, drought, and salt stress.\n3. Changes in gene expression: Loss of Lon1 leads to changes in the expression of a number of genes involved in various biological processes, including cell death, stress responses, and senescence.\n4. Premature senescence: Loss of Lon1 leads to premature senescence in Arabidopsis, which is an accelerated aging process that results in the premature death of plant cells and tissues.\n\nOverall, the loss of Lon1 in Arabidopsis results in a range of phenotypes that are associated with increased cell death, altered stress responses, changes in gene expression, and premature senescence. These phenotypes suggest that Lon1 plays an important role in the regulation of various biological processes in Arabidopsis.",
    "llama-7b_fact_raw": "1. Loss of the protein Lon1 in Arabidopsis leads to increased programmed cell death.\n2. The absence of Lon1 in Arabidopsis results in altered responses to stress such as heat, drought, and salt stress.\n3. Changes in gene expression occur due to the loss of Lon1 in Arabidopsis.\n4. Arabidopsis experiences premature senescence when Lon1 is absent.\n5. Lon1 is involved in the regulation of cell death, stress responses, and senescence in Arabidopsis.",
    "llama-7b_fact": [
      "Loss of the protein Lon1 in Arabidopsis leads to increased programmed cell death.",
      "The absence of Lon1 in Arabidopsis results in altered responses to stress such as heat, drought, and salt stress.",
      "Changes in gene expression occur due to the loss of Lon1 in Arabidopsis.",
      "Arabidopsis experiences premature senescence when Lon1 is absent.",
      "Lon1 is involved in the regulation of cell death, stress responses, and senescence in Arabidopsis."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements provided are consistent with the known functions of Lon proteases in plants, such as Arabidopsis thaliana. Lon proteases are involved in the regulation of various cellular processes, including programmed cell death, stress responses, and senescence. Loss of Lon protease function can lead to the observed phenotypes mentioned in the statements. However, without specific experimental data or a reference to a particular study, the accuracy of these statements cannot be independently verified, but they are consistent with general scientific understanding of Lon protease functions in plants.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 409,
    "user_query": "You MUST give a detailed answer to the following question: Does a linker histone exist in the yeast genome?",
    "llama-7b_response": "Yes, a linker histone exists in the yeast genome.\n\nHistones are proteins that are found in the nucleus of eukaryotic cells and are involved in the organization of DNA into chromatin. Linker histones are a type of histone that plays a role in the formation of higher order chromatin structures, such as nucleosomes and chromatin loops.\n\nIn the yeast genome, there are several different types of linker histones, including H1, H2A, H2B, and H3. These histones are involved in the assembly of nucleosomes and other higher order chromatin structures, and play a role in the regulation of gene expression.\n\nOverall, the presence of linker histones in the yeast genome is an important factor in the regulation of gene expression and the organization of DNA into chromatin.",
    "llama-7b_fact_raw": "1. Linker histones exist in the yeast genome.\n2. Histones are proteins found in the nucleus of eukaryotic cells.\n3. Linker histones contribute to the organization of DNA into chromatin.\n4. Types of linker histones in the yeast genome include H1, H2A, H2B, and H3.\n5. Linker histones in yeast are involved in the assembly of nucleosomes and chromatin structures.",
    "llama-7b_fact": [
      "Linker histones exist in the yeast genome.",
      "Histones are proteins found in the nucleus of eukaryotic cells.",
      "Linker histones contribute to the organization of DNA into chromatin.",
      "Types of linker histones in the yeast genome include H1, H2A, H2B, and H3.",
      "Linker histones in yeast are involved in the assembly of nucleosomes and chromatin structures."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Linker histones such as H1 are generally not found in the yeast Saccharomyces cerevisiae genome; yeast typically have core histones but lack the typical linker histone H1.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: H2A, H2B, and H3 are core histones, not linker histones. The typical linker histone in other eukaryotes is H1, which is generally not found in yeast.\n5. UNKNOWN",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 418,
    "user_query": "You MUST give a detailed answer to the following question: Is there evidence that tomato juice lowers cholesterol levels?",
    "llama-7b_response": "Yes, there is evidence that tomato juice can lower cholesterol levels.\n\nA study published in the Journal of Nutrition in 2009 found that consuming tomato juice daily for four weeks significantly reduced total cholesterol and low-density lipoprotein (LDL) cholesterol levels in adults with elevated cholesterol levels. The study also found that the cholesterol-lowering effects of tomato juice were associated with an increase in the excretion of bile acids in the urine.\n\nAnother study published in the Journal of the American College of Nutrition in 2012 found that consuming tomato juice daily for eight weeks significantly reduced LDL cholesterol levels in adults with elevated cholesterol levels. The study also found that the cholesterol-lowering effects of tomato juice were associated with an increase in the activity of enzymes involved in cholesterol metabolism.\n\nWhile more research is needed to fully understand the mechanisms behind tomato juice's cholesterol-lowering effects, these studies suggest that consuming tomato juice regularly may be a useful strategy for lowering cholesterol levels and reducing the risk of cardiovascular disease.",
    "llama-7b_fact_raw": "1. A study published in the Journal of Nutrition in 2009 indicated that daily consumption of tomato juice for four weeks significantly reduced total cholesterol and LDL cholesterol levels in adults with elevated cholesterol.\n2. The 2009 study in the Journal of Nutrition associated the cholesterol-lowering effects of tomato juice with an increase in the excretion of bile acids in the urine.\n3. A study published in the Journal of the American College of Nutrition in 2012 found that daily consumption of tomato juice for eight weeks significantly reduced LDL cholesterol levels in adults with elevated cholesterol.\n4. The 2012 study in the Journal of the American College of Nutrition linked the cholesterol-lowering effects of tomato juice to an increase in the activity of enzymes involved in cholesterol metabolism.\n5. The studies suggest that regular consumption of tomato juice may be beneficial for lowering cholesterol levels and reducing the risk of cardiovascular disease.",
    "llama-7b_fact": [
      "A study published in the Journal of Nutrition in 2009 indicated that daily consumption of tomato juice for four weeks significantly reduced total cholesterol and LDL cholesterol levels in adults with elevated cholesterol.",
      "The 2009 study in the Journal of Nutrition associated the cholesterol-lowering effects of tomato juice with an increase in the excretion of bile acids in the urine.",
      "A study published in the Journal of the American College of Nutrition in 2012 found that daily consumption of tomato juice for eight weeks significantly reduced LDL cholesterol levels in adults with elevated cholesterol.",
      "The 2012 study in the Journal of the American College of Nutrition linked the cholesterol-lowering effects of tomato juice to an increase in the activity of enzymes involved in cholesterol metabolism.",
      "The studies suggest that regular consumption of tomato juice may be beneficial for lowering cholesterol levels and reducing the risk of cardiovascular disease."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN (without access to the specific study, the truth of this statement cannot be verified)\n2. UNKNOWN (without access to the specific study, the truth of this statement cannot be verified)\n3. UNKNOWN (without access to the specific study, the truth of this statement cannot be verified)\n4. UNKNOWN (without access to the specific study, the truth of this statement cannot be verified)\n5. UNKNOWN (this statement is a general conclusion that may be drawn from the previous statements, but without verifying the results of the studies, it cannot be confirmed as true or false)",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 472,
    "user_query": "You MUST give a detailed answer to the following question: How do Hsp70 and Hsp110 affect mRNA stability?",
    "llama-7b_response": "Hsp70 and Hsp110 are heat shock proteins (HSPs) that play a crucial role in the regulation of mRNA stability. Hsp70 and Hsp110 are involved in the regulation of mRNA stability by interacting with ribonucleic acid (RNA) molecules, such as messenger RNA (mRNA) and ribosomal RNA (rRNA), and modulating their stability and translation.\n\nHsp70 and Hsp110 are involved in the regulation of mRNA stability through several mechanisms:\n\n1. Chaperone activity: Hsp70 and Hsp110 have chaperone activity, which means they can bind to and stabilize RNA molecules, such as mRNA and rRNA, by preventing their degradation by ribonuclease (RNase) enzymes.\n2. mRNA destabilization: Hsp70 and Hsp110 can also destabilize mRNA by interacting with the 5' untranslated region (UTR) of the mRNA, leading to its degradation.\n3. Translation inhibition: Hsp70 and Hsp110 can also inhibit translation of mRNA by interacting with the ribosome and preventing its binding to the mRNA.\n4. mRNA decay: Hsp70 and Hsp110 can also promote the decay of mRNA by interacting with the exon junction complex (EJC), which is involved in the decay of mRNA.\n\nOverall, Hsp70 and Hsp110 play a crucial role in the regulation of mRNA stability by modulating the stability, translation, and decay of RNA molecules, including mRNA.",
    "llama-7b_fact_raw": "1. Hsp70 and Hsp110 are heat shock proteins that are involved in the regulation of mRNA stability.\n2. They have chaperone activity, which allows them to bind to and stabilize RNA molecules, preventing degradation by ribonuclease enzymes.\n3. Hsp70 and Hsp110 can destabilize mRNA by interacting with its 5' untranslated region, leading to degradation.\n4. These proteins can inhibit the translation of mRNA by interacting with the ribosome and preventing its binding to the mRNA.\n5. Hsp70 and Hsp110 can promote the decay of mRNA by interacting with the exon junction complex.",
    "llama-7b_fact": [
      "Hsp70 and Hsp110 are heat shock proteins that are involved in the regulation of mRNA stability.",
      "They have chaperone activity, which allows them to bind to and stabilize RNA molecules, preventing degradation by ribonuclease enzymes.",
      "Hsp70 and Hsp110 can destabilize mRNA by interacting with its 5' untranslated region, leading to degradation.",
      "These proteins can inhibit the translation of mRNA by interacting with the ribosome and preventing its binding to the mRNA.",
      "Hsp70 and Hsp110 can promote the decay of mRNA by interacting with the exon junction complex."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Hsp70 and Hsp110 are heat shock proteins that are primarily involved in protein folding, not the regulation of mRNA stability.\n2. TRUE: They have chaperone activity, which allows them to assist in the proper folding of proteins and prevent aggregation.\n3. FALSE [correction]: Hsp70 and Hsp110 are not typically known to destabilize mRNA by interacting with its 5' untranslated region; their main function is to assist in protein folding.\n4. UNKNOWN: While Hsp70 has been implicated in various roles related to translation, the statement is too specific without context, and it is not clear if Hsp70 or Hsp110 directly interact with the ribosome to inhibit translation in the manner described.\n5. FALSE [correction]: Hsp70 and Hsp110 are not typically associated with promoting the decay of mRNA by interacting with the exon junction complex; they are more commonly known for their role in protein folding and stabilization.",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 481,
    "user_query": "You MUST give a detailed answer to the following question: Which deiodinases are present in skeletal  muscle?",
    "llama-7b_response": "Deiodinases are enzymes that regulate the activity of the thyroid hormones, triiodothyronine (T3) and thyroxine (T4). In skeletal muscle, three types of deiodinases have been identified: type 1 (D1), type 2a (D2a), and type 2b (D2b).\n\nType 1 deiodinase (D1) is also known as the type 2 iodothyronine deiodinase (D2) and is responsible for converting T4 to T3 in skeletal muscle. D1 is found in both skeletal and cardiac muscle, as well as in other tissues such as the pituitary gland and the adrenal gland. D1 plays a crucial role in regulating the activity of the thyroid hormones in these tissues.\n\nType 2a deiodinase (D2a) is also known as the type 3 iodothyronine deiodinase (D3) and is responsible for converting T4 to T3 in skeletal muscle. D2a is primarily found in skeletal muscle and plays a key role in regulating the activity of the thyroid hormones in this tissue.\n\nType 2b deiodinase (D2b) is also known as the type 4 iodothyronine deiodinase (D4) and is responsible for converting T4 to T3 in skeletal muscle. D2b is primarily found in skeletal muscle and plays a key role in regulating the activity of the thyroid hormones in this tissue.\n\nIn summary, the three types of deiodinases present in skeletal muscle are type 1 (D1), type 2a (D2a), and type 2b (D2b). These enzymes play a crucial role in regulating the activity of the thyroid hormones in skeletal muscle and are important for maintaining normal muscle function.",
    "llama-7b_fact_raw": "1. Three types of deiodinases identified in skeletal muscle are type 1 (D1), type 2a (D2a), and type 2b (D2b).\n2. Type 1 deiodinase (D1) is responsible for converting thyroxine (T4) to triiodothyronine (T3) in skeletal muscle.\n3. Type 1 deiodinase (D1) is found in both skeletal and cardiac muscle, as well as in the pituitary gland and the adrenal gland.\n4. Type 2a deiodinase (D2a) is primarily found in skeletal muscle and is responsible for converting T4 to T3.\n5. Type 2b deiodinase (D2b) is primarily found in skeletal muscle and is responsible for converting T4 to T3.",
    "llama-7b_fact": [
      "Three types of deiodinases identified in skeletal muscle are type 1 (D1), type 2a (D2a), and type 2b (D2b).",
      "Type 1 deiodinase (D1) is responsible for converting thyroxine (T4) to triiodothyronine (T3) in skeletal muscle.",
      "Type 1 deiodinase (D1) is found in both skeletal and cardiac muscle, as well as in the pituitary gland and the adrenal gland.",
      "Type 2a deiodinase (D2a) is primarily found in skeletal muscle and is responsible for converting T4 to T3.",
      "Type 2b deiodinase (D2b) is primarily found in skeletal muscle and is responsible for converting T4 to T3."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Three types of deiodinases identified in humans are type 1 (D1), type 2 (D2), and type 3 (D3). There is no specific subtype such as 2a or 2b for skeletal muscle.\n2. TRUE: Type 1 deiodinase (D1) is indeed responsible for converting thyroxine (T4) to triiodothyronine (T3), although it is not limited to skeletal muscle.\n3. TRUE: Type 1 deiodinase (D1) is found in a variety of tissues, including skeletal and cardiac muscle, as well as in the liver, kidney, pituitary gland, and thyroid gland.\n4. FALSE [correction]: Type 2 deiodinase (D2) is found in skeletal muscle among other tissues, and it is responsible for converting T4 to T3, but there is no subtype called D2a that is specifically associated with skeletal muscle.\n5. FALSE [correction]: There is no type 2b deiodinase (D2b) identified in skeletal muscle or elsewhere. Type 2 deiodinase (D2) is the enzyme that converts T4 to T3 in various tissues, including the central nervous system and skeletal muscle.",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 534,
    "user_query": "You MUST give a detailed answer to the following question: List inflammatory caspase proteins?",
    "llama-7b_response": "Caspases are a family of enzymes that play a central role in the process of programmed cell death, also known as apoptosis. Inflammatory caspases are a subset of caspases that are specifically activated in response to inflammatory signals. There are several inflammatory caspases that have been identified, including:\n\n1. Caspase-1: also known as interleukin-1 beta-converting enzyme (ICE), is activated by pro-inflammatory cytokines such as interleukin-1 beta (IL-1β) and tumor necrosis factor-alpha (TNF-α). Caspase-1 plays a key role in the inflammatory response and is involved in the processing and activation of pro-inflammatory cytokines such as IL-1β and IL-18.\n2. Caspase-4: is activated by pro-inflammatory cytokines such as TNF-α and IL-1β. Caspase-4 plays a role in the inflammatory response and is involved in the processing and activation of pro-inflammatory cytokines such as IL-1β and IL-18.\n3. Caspase-5: is activated by pro-inflammatory cytokines such as TNF-α and IL-1β. Caspase-5 plays a role in the inflammatory response and is involved in the processing and activation of pro-inflammatory cytokines such as IL-1β and IL-18.\n4. Caspase-6: is activated by pro-inflammatory cytokines such as TNF-α and IL-1β. Caspase-6 plays a role in the inflammatory response and is involved in the processing and activation of pro-inflammatory cytokines such as IL-1β and IL-18.\n5. Caspase-7: is activated by pro-inflammatory cytokines such as TNF-α and IL-1β. Caspase-7 plays a role in the inflammatory response and is involved in the processing and activation of pro-inflammatory cytokines such as IL-1β and IL-1",
    "llama-7b_fact_raw": "1. Caspase-1 is also known as interleukin-1 beta-converting enzyme (ICE).\n2. Caspase-1 is involved in the processing and activation of pro-inflammatory cytokines such as IL-1β and IL-18.\n3. Caspase-4 is involved in the inflammatory response and the processing and activation of cytokines like IL-1β and IL-18.\n4. Caspase-5 is activated by pro-inflammatory cytokines and plays a role in the inflammatory response.\n5. Caspase-6 is involved in the processing and activation of pro-inflammatory cytokines such as IL-1β and IL-18.",
    "llama-7b_fact": [
      "Caspase-1 is also known as interleukin-1 beta-converting enzyme (ICE).",
      "Caspase-1 is involved in the processing and activation of pro-inflammatory cytokines such as IL-1β and IL-18.",
      "Caspase-4 is involved in the inflammatory response and the processing and activation of cytokines like IL-1β and IL-18.",
      "Caspase-5 is activated by pro-inflammatory cytokines and plays a role in the inflammatory response.",
      "Caspase-6 is involved in the processing and activation of pro-inflammatory cytokines such as IL-1β and IL-18."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE - Caspase-4, similar to caspase-1, is involved in the inflammatory response and can promote the processing of pro-inflammatory cytokines, although it is more specifically associated with the non-canonical inflammasome pathway.\n4. FALSE [correction]: Caspase-5, like caspase-1 and caspase-4, is involved in the inflammatory response, but it is not activated by pro-inflammatory cytokines. Instead, it forms part of the inflammasome complex that activates caspase-1.\n5. FALSE [correction]: Caspase-6 is primarily involved in the apoptotic pathway and is not known for processing and activating pro-inflammatory cytokines such as IL-1β and IL-18.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 579,
    "user_query": "You MUST give a detailed answer to the following question: Is there any link between the aurora B kinase and the polycomb protein ring1B?",
    "llama-7b_response": "Yes, there is a link between the aurora B kinase and the polycomb protein ring1B.\n\nAurora B kinase is a serine/threonine protein kinase that plays a crucial role in the regulation of mitosis, the process of cell division. It is involved in the formation of the mitotic spindle, the structure that separates the chromosomes during cell division. Ring1B is a member of the polycomb family of proteins, which are involved in the regulation of gene expression.\n\nResearch has shown that the activity of aurora B kinase is regulated by the polycomb protein ring1B. Specifically, ring1B has been shown to interact with and inhibit the activity of aurora B kinase. This interaction occurs through the binding of ring1B to the C-terminal region of aurora B kinase, which results in the inhibition of its kinase activity.\n\nFurthermore, research has shown that the expression of ring1B can be regulated by aurora B kinase. In particular, the activity of aurora B kinase has been shown to increase the expression of ring1B, leading to the formation of a positive feedback loop that further regulates the activity of aurora B kinase.\n\nOverall, these findings suggest that the interaction between aurora B kinase and ring1B plays an important role in the regulation of mitosis and the control of gene expression.",
    "llama-7b_fact_raw": "1. Aurora B kinase is a serine/threonine protein kinase involved in the regulation of mitosis.\n2. Ring1B is a member of the polycomb family of proteins, which regulate gene expression.\n3. Ring1B interacts with and inhibits the activity of aurora B kinase by binding to its C-terminal region.\n4. The activity of aurora B kinase can increase the expression of ring1B.\n5. The interaction between aurora B kinase and ring1B forms a positive feedback loop that regulates the activity of aurora B kinase.",
    "llama-7b_fact": [
      "Aurora B kinase is a serine/threonine protein kinase involved in the regulation of mitosis.",
      "Ring1B is a member of the polycomb family of proteins, which regulate gene expression.",
      "Ring1B interacts with and inhibits the activity of aurora B kinase by binding to its C-terminal region.",
      "The activity of aurora B kinase can increase the expression of ring1B.",
      "The interaction between aurora B kinase and ring1B forms a positive feedback loop that regulates the activity of aurora B kinase."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe first two statements are accurate descriptions of Aurora B kinase and Ring1B. However, without specific scientific literature or studies to confirm the interactions and regulatory mechanisms mentioned in statements 3, 4, and 5, it is not possible to determine the truthfulness of these statements. These interactions can be quite complex and context-dependent, requiring experimental evidence to validate.",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 597,
    "user_query": "You MUST give a detailed answer to the following question: What are the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates?",
    "llama-7b_response": "The most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates are known as \"splicing enhancers\" and \"splicing silencers,\" respectively.\n\nSplicing enhancers are non-canonical sequence motifs that enhance the efficiency of splicing at the donor splice site. They are typically located upstream of the donor splice site and can be classified into two types: exonic and intronic. Exonic splicing enhancers (ESEs) are located in the 5' untranslated region (5' UTR) of a gene and enhance splicing by recruiting the splicing machinery to the donor splice site. Intronic splicing enhancers (ISEs) are located within an intron and also enhance splicing by recruiting the splicing machinery to the donor splice site.\n\nSplicing silencers, on the other hand, are non-canonical sequence motifs that suppress splicing at the acceptor splice site. They are typically located downstream of the acceptor splice site and can also be classified into two types: exonic and intronic. Exonic splicing silencers (ESSs) are located in the 3' untranslated region (3' UTR) of a gene and suppress splicing by interfering with the recognition of the acceptor splice site by the splicing machinery. Intronic splicing silencers (ISSs) are located within an intron and also suppress splicing by interfering with the recognition of the acceptor splice site by the splicing machinery.\n\nThese non-canonical sequence motifs play a crucial role in the regulation of alternative splicing, which is a key mechanism for generating functional diversity in eukaryotic genomes.",
    "llama-7b_fact_raw": "1. Non-canonical sequence motifs that enhance splicing at the donor splice site in vertebrates are known as \"splicing enhancers.\"\n2. Exonic splicing enhancers (ESEs) are located in the 5' untranslated region (5' UTR) of a gene.\n3. Intronic splicing enhancers (ISEs) are located within an intron.\n4. Non-canonical sequence motifs that suppress splicing at the acceptor splice site in vertebrates are known as \"splicing silencers.\"\n5. Exonic splicing silencers (ESSs) are located in the 3' untranslated region (3' UTR) of a gene.",
    "llama-7b_fact": [
      "Non-canonical sequence motifs that enhance splicing at the donor splice site in vertebrates are known as \"splicing enhancers.\"",
      "Exonic splicing enhancers (ESEs) are located in the 5' untranslated region (5' UTR) of a gene.",
      "Intronic splicing enhancers (ISEs) are located within an intron.",
      "Non-canonical sequence motifs that suppress splicing at the acceptor splice site in vertebrates are known as \"splicing silencers.\"",
      "Exonic splicing silencers (ESSs) are located in the 3' untranslated region (3' UTR) of a gene."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Exonic splicing enhancers (ESEs) are typically located within the exonic regions of a gene, not specifically in the 5' untranslated region (5' UTR).\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Exonic splicing silencers (ESSs) can be located within the exonic regions of a gene, not limited to the 3' untranslated region (3' UTR). They can also be found in introns.",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 629,
    "user_query": "You MUST give a detailed answer to the following question: Which event results in the acetylation of S6K1?",
    "llama-7b_response": "insulin",
    "llama-7b_fact_raw": "1. Insulin results in the acetylation of S6K1.",
    "llama-7b_fact": [
      "Insulin results in the acetylation of S6K1."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n\nThe statement \"Insulin results in the acetylation of S6K1\" is specific to cellular biochemistry, and without the proper context or reference, it is difficult to determine its accuracy. Insulin does have various effects on cellular processes and signaling pathways, including those involving S6 kinase 1 (S6K1), which is a protein involved in protein synthesis and cell growth. Insulin can lead to the activation of S6K1, typically through phosphorylation rather than acetylation. However, without specific scientific evidence or a detailed passage to confirm the statement about acetylation, the truth of this statement remains unknown.",
    "llama-7b_judge": [
      "unknown"
    ]
  },
  {
    "id": 632,
    "user_query": "You MUST give a detailed answer to the following question: What is the cause of episodic ataxia type 6?",
    "llama-7b_response": "The cause of episodic ataxia type 6 is a mutation in the CACNA1A gene.",
    "llama-7b_fact_raw": "1. Episodic ataxia type 6 is caused by a mutation in the CACNA1A gene.",
    "llama-7b_fact": [
      "Episodic ataxia type 6 is caused by a mutation in the CACNA1A gene."
    ],
    "llama-7b_judge_raw": "1. TRUE",
    "llama-7b_judge": [
      "true"
    ]
  },
  {
    "id": 646,
    "user_query": "You MUST give a detailed answer to the following question: Are chromomethylases present in animal genomes?",
    "llama-7b_response": "Yes, chromomethylases are present in animal genomes. Chromomethylases are enzymes that add methyl groups to DNA, and they play a role in regulating gene expression. They are found in many organisms, including animals. In animals, chromomethylases are typically involved in the regulation of gene expression during development and in response to environmental cues. For example, they can help to silence genes that are not needed at a particular time, or to activate genes that are needed for a specific process.",
    "llama-7b_fact_raw": "1. Chromomethylases are enzymes that add methyl groups to DNA.\n2. Chromomethylases play a role in regulating gene expression.\n3. Chromomethylases are found in many organisms, including animals.\n4. In animals, chromomethylases are involved in the regulation of gene expression during development.\n5. Chromomethylases can help to silence or activate genes in response to environmental cues.",
    "llama-7b_fact": [
      "Chromomethylases are enzymes that add methyl groups to DNA.",
      "Chromomethylases play a role in regulating gene expression.",
      "Chromomethylases are found in many organisms, including animals.",
      "In animals, chromomethylases are involved in the regulation of gene expression during development.",
      "Chromomethylases can help to silence or activate genes in response to environmental cues."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Chromomethylases are typically found in plants and some microorganisms, but not in animals. In animals, DNA methylation is generally performed by DNA methyltransferases (DNMTs).\n4. FALSE [correction]: Since chromomethylases are not found in animals, they are not involved in the regulation of gene expression during animal development. In animals, this role is performed by DNA methyltransferases (DNMTs) and other regulatory proteins.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 650,
    "user_query": "You MUST give a detailed answer to the following question: List packages for transcription factor binding sites' (TFBS) analysis available in R/Bioconductor",
    "llama-7b_response": "There are several packages available in R/Bioconductor for the analysis of transcription factor binding sites (TFBS). Here are some of the most commonly used packages:\n\n1. ChIPpeakAnno: This package is used for the annotation of ChIP-seq data, including the identification of binding sites for transcription factors.\n2. DNase-seq: This package is used for the analysis of DNase-seq data, which is used to identify regions of the genome that have been degraded by the enzyme DNase I.\n3. GRO-seq: This package is used for the analysis of GRO-seq data, which is used to identify regions of the genome that are accessible to RNA polymerase.\n4. HOMER: This package is used for the prediction of binding sites for transcription factors based on sequence motifs.\n5. motifclust: This package is used for the clustering of transcription factor binding sites based on their sequence motifs.\n6. PeakSeq: This package is used for the analysis of ChIP-seq data, including the identification of binding sites for transcription factors.\n7. RNAPII-seq: This package is used for the analysis of RNA polymerase II (RNAPII) occupancy data, which is used to identify regions of the genome that are actively being transcribed.\n\nThese are just a few of the many packages available in R/Bioconductor for the analysis of TFBS. The choice of package will depend on the specific type of data being analyzed and the goals of the analysis.",
    "llama-7b_fact_raw": "1. ChIPpeakAnno is a package in R/Bioconductor used for annotating ChIP-seq data and identifying transcription factor binding sites.\n2. DNase-seq is a package in R/Bioconductor for analyzing DNase-seq data to identify regions degraded by DNase I.\n3. GRO-seq is a package in R/Bioconductor used for analyzing GRO-seq data to identify regions accessible to RNA polymerase.\n4. HOMER is a package in R/Bioconductor used for predicting transcription factor binding sites based on sequence motifs.\n5. motifclust is a package in R/Bioconductor for clustering transcription factor binding sites based on their sequence motifs.",
    "llama-7b_fact": [
      "ChIPpeakAnno is a package in R/Bioconductor used for annotating ChIP-seq data and identifying transcription factor binding sites.",
      "DNase-seq is a package in R/Bioconductor for analyzing DNase-seq data to identify regions degraded by DNase I.",
      "GRO-seq is a package in R/Bioconductor used for analyzing GRO-seq data to identify regions accessible to RNA polymerase.",
      "HOMER is a package in R/Bioconductor used for predicting transcription factor binding sites based on sequence motifs.",
      "motifclust is a package in R/Bioconductor for clustering transcription factor binding sites based on their sequence motifs."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: DNase-seq is not a package but a technique for identifying regions of DNA that are accessible to the enzyme DNase I, which can be indicative of transcription factor binding sites or regions of open chromatin. The analysis of DNase-seq data can be performed using various software tools, but DNase-seq itself is not a package.\n3. FALSE [correction]: GRO-seq is not a package but a technique known as Global Run-On Sequencing, which is used to measure nascent RNA transcription and identify regions of active transcription. The analysis of GRO-seq data can be performed using various software tools, but GRO-seq itself is not a package.\n4. FALSE [correction]: HOMER is a suite of tools for motif discovery and next-generation sequencing analysis, but it is not specifically a package in R/Bioconductor. It is a standalone software that can be used in conjunction with R/Bioconductor but is not part of the Bioconductor project.\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 721,
    "user_query": "You MUST give a detailed answer to the following question: List clinical trials for prevention of sarcopenia",
    "llama-7b_response": "Certainly, here are some clinical trials for the prevention of sarcopenia:\n\n1. Sarcopenia Prevention with Resistance Training (SPRT): This is a randomized controlled trial that aimed to determine the effectiveness of resistance training in preventing sarcopenia in older adults. The study found that resistance training was effective in preventing sarcopenia and improving muscle function in older adults.\n2. Sarcopenia: Prevention and Treatment (SPAT): This is a randomized controlled trial that aimed to determine the effectiveness of resistance training and protein supplementation in preventing and treating sarcopenia in older adults. The study found that a combination of resistance training and protein supplementation was effective in preventing and treating sarcopenia and improving muscle function in older adults.\n3. Sarcopenia: Prevention and Treatment (SPAT-2): This is a randomized controlled trial that aimed to determine the effectiveness of resistance training and protein supplementation in preventing and treating sarcopenia in older adults. The study found that a combination of resistance training and protein supplementation was effective in preventing and treating sarcopenia and improving muscle function in older adults.\n4. Sarcopenia: Prevention and Treatment (SPAT-3): This is a randomized controlled trial that aimed to determine the effectiveness of resistance training and protein supplementation in preventing and treating sarcopenia in older adults. The study found that a combination of resistance training and protein supplementation was effective in preventing and treating sarcopenia and improving muscle function in older adults.\n5. Sarcopenia: Prevention and Treatment (SPAT-4): This is a randomized controlled trial that aimed to determine the effectiveness of resistance training and protein supplementation in preventing and treating sarcopenia in older adults. The study found that a combination of resistance training and protein supplementation was effective in preventing and treating sarcopenia and improving muscle function in older adults.\n6. Sarcopenia: Prevention and Treatment (SPAT-5): This is a randomized controlled trial that aimed to determine the effectiveness of resistance training",
    "llama-7b_fact_raw": "1. The Sarcopenia Prevention with Resistance Training (SPRT) is a randomized controlled trial focused on the prevention of sarcopenia in older adults through resistance training.\n2. The SPAT trial is a randomized controlled trial that tested the effectiveness of resistance training and protein supplementation in preventing and treating sarcopenia in older adults.\n3. The SPAT-2 trial is a continuation of the SPAT trial, also a randomized controlled trial, with similar objectives and methods.\n4. The SPAT-3 trial is another randomized controlled trial in the series, aiming to determine the effectiveness of resistance training and protein supplementation on sarcopenia in older adults.\n5. The SPAT-4 trial is part of the same series of randomized controlled trials, focusing on the prevention and treatment of sarcopenia with resistance training and protein supplementation.",
    "llama-7b_fact": [
      "The Sarcopenia Prevention with Resistance Training (SPRT) is a randomized controlled trial focused on the prevention of sarcopenia in older adults through resistance training.",
      "The SPAT trial is a randomized controlled trial that tested the effectiveness of resistance training and protein supplementation in preventing and treating sarcopenia in older adults.",
      "The SPAT-2 trial is a continuation of the SPAT trial, also a randomized controlled trial, with similar objectives and methods.",
      "The SPAT-3 trial is another randomized controlled trial in the series, aiming to determine the effectiveness of resistance training and protein supplementation on sarcopenia in older adults.",
      "The SPAT-4 trial is part of the same series of randomized controlled trials, focusing on the prevention and treatment of sarcopenia with resistance training and protein supplementation."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information about the SPRT, SPAT, SPAT-2, SPAT-3, and SPAT-4 trials, it is not possible to determine the accuracy of these statements. These could be hypothetical trials or specific to a certain study that is not widely recognized or available in the public domain as of my knowledge cutoff date.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 722,
    "user_query": "You MUST give a detailed answer to the following question: Which is the database of molecular recognition features in membrane proteins?",
    "llama-7b_response": "There are several databases that contain information on molecular recognition features in membrane proteins, including:\n\n1. The Protein Data Bank (PDB): The PDB is a database of three-dimensional structural data for proteins, nucleic acids, and complex assemblies. It contains information on the structure of membrane proteins, including their molecular recognition features.\n2. The Database of Membrane Proteins (DMP): The DMP is a comprehensive database of structural and functional information on membrane proteins. It contains information on the molecular recognition features of membrane proteins, including their interactions with other proteins and small molecules.\n3. The Membrane Protein Structural Database (MPSD): The MPSD is a database of three-dimensional structures of membrane proteins. It contains information on the molecular recognition features of membrane proteins, including their interactions with other proteins and small molecules.\n4. The Membrane Protein Structural Biology Center (MPSBC): The MPSBC is a database of three-dimensional structures of membrane proteins. It contains information on the molecular recognition features of membrane proteins, including their interactions with other proteins and small molecules.\n\nOverall, these databases provide valuable information on the molecular recognition features of membrane proteins, and can be used to study the structure and function of these important biomolecules.",
    "llama-7b_fact_raw": "1. The Protein Data Bank (PDB) is a database that contains three-dimensional structural data for proteins, nucleic acids, and complex assemblies.\n2. The Database of Membrane Proteins (DMP) provides structural and functional information on membrane proteins.\n3. The Membrane Protein Structural Database (MPSD) is a database that includes three-dimensional structures of membrane proteins.\n4. The Membrane Protein Structural Biology Center (MPSBC) is a database that offers three-dimensional structures of membrane proteins.",
    "llama-7b_fact": [
      "The Protein Data Bank (PDB) is a database that contains three-dimensional structural data for proteins, nucleic acids, and complex assemblies.",
      "The Database of Membrane Proteins (DMP) provides structural and functional information on membrane proteins.",
      "The Membrane Protein Structural Database (MPSD) is a database that includes three-dimensional structures of membrane proteins.",
      "The Membrane Protein Structural Biology Center (MPSBC) is a database that offers three-dimensional structures of membrane proteins."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The Membrane Protein Structural Biology Consortium (MPSBC) is not a database; it is a research consortium that aims to determine the structures of membrane proteins.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 745,
    "user_query": "You MUST give a detailed answer to the following question: Is rivaroxaban metabolized in kidneys?",
    "llama-7b_response": "Yes, rivaroxaban is metabolized in the kidneys.\n\nRivaroxaban is a direct factor Xa inhibitor that is primarily metabolized by the liver via cytochrome P450 enzymes, particularly CYP3A4 and CYP2C9. However, the kidneys also play a role in the elimination of rivaroxaban from the body.\n\nRivaroxaban is primarily excreted in the urine as the glucuronide conjugate of its metabolite, O-desmethyl rivaroxaban. The kidneys are responsible for the formation of glucuronide conjugates, which are water-soluble compounds that can be excreted in the urine.\n\nTherefore, kidney function is an important factor to consider when administering rivaroxaban, as impaired kidney function may result in increased plasma concentrations of the drug and an increased risk of adverse effects. Dosage adjustments may be necessary in patients with renal impairment.",
    "llama-7b_fact_raw": "1. Rivaroxaban is metabolized by the liver via cytochrome P450 enzymes, particularly CYP3A4 and CYP2C9.\n2. The kidneys play a role in the elimination of rivaroxaban from the body.\n3. Rivaroxaban is primarily excreted in the urine as the glucuronide conjugate of its metabolite, O-desmethyl rivaroxaban.\n4. The kidneys are responsible for the formation of glucuronide conjugates.\n5. Impaired kidney function can result in increased plasma concentrations of rivaroxaban and an increased risk of adverse effects.",
    "llama-7b_fact": [
      "Rivaroxaban is metabolized by the liver via cytochrome P450 enzymes, particularly CYP3A4 and CYP2C9.",
      "The kidneys play a role in the elimination of rivaroxaban from the body.",
      "Rivaroxaban is primarily excreted in the urine as the glucuronide conjugate of its metabolite, O-desmethyl rivaroxaban.",
      "The kidneys are responsible for the formation of glucuronide conjugates.",
      "Impaired kidney function can result in increased plasma concentrations of rivaroxaban and an increased risk of adverse effects."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Rivaroxaban is primarily excreted in the urine as unchanged drug, not as the glucuronide conjugate of its metabolite.\n4. FALSE [correction]: The formation of glucuronide conjugates is primarily a function of the liver, not the kidneys.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 763,
    "user_query": "You MUST give a detailed answer to the following question: Which genes are regulated by TRalpha2  in the heart?",
    "llama-7b_response": "Transient receptor potential (TRP) channels are a family of cation channels that are activated by a diverse range of extracellular stimuli, including temperature, mechanical stress, and chemical signals. TRP channels play important roles in various physiological processes, including sensory perception, cellular signaling, and the regulation of ion homeostasis.\n\nTransient receptor potential ankyrin 1 (TRPA1) and transient receptor potential vanilloid 1 (TRPV1) are two members of the TRP channel family that have been extensively studied in the context of cardiovascular physiology and pathophysiology. TRPA1 and TRPV1 are expressed in various tissues, including the heart, where they play important roles in the regulation of cardiovascular function.\n\nTransient receptor potential ankyrin 2 (TRPA2) is another member of the TRP channel family that has been implicated in the regulation of cardiovascular function. TRPA2 is expressed in various tissues, including the heart, where it plays a role in the regulation of cardiac contractility and electrical activity.\n\nTransient receptor potential ankyrin 3 (TRPA3) is another member of the TRP channel family that has been implicated in the regulation of cardiovascular function. TRPA3 is expressed in various tissues, including the heart, where it plays a role in the regulation of cardiac contractility and electrical activity.\n\nTransient receptor potential ankyrin 4 (TRPA4) is another member of the TRP channel family that has been implicated in the regulation of cardiovascular function. TRPA4 is expressed in various tissues, including the heart, where it plays a role in the regulation of cardiac contractility and electrical activity.\n\nTransient receptor potential ankyrin 5 (TRPA5) is another member of the TRP channel family that has been implicated in the regulation of cardiovascular function. TRPA5 is expressed in various tissues, including the heart, where it plays a role in the regulation of cardiac contractility and electrical activity.\n\nTransient receptor potential ankyrin 6 (TRPA6) is another member of the TRP channel family",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 786,
    "user_query": "You MUST give a detailed answer to the following question: List available biomedical question answering systems.",
    "llama-7b_response": "There are several biomedical question answering (QA) systems available, including:\n\n1. Clinical Question Answering System (CQAS): A system developed by the National Center for Biotechnology Information (NCBI) that provides answers to clinical questions posed in natural language.\n2. BioASQ: A series of challenges organized by the European Bioinformatics Institute (EMBL-EBI) that aim to evaluate the performance of QA systems on biomedical literature.\n3. Biocreative: A series of challenges organized by the National Center for Biomedical Ontology (NCBO) that aim to evaluate the performance of QA systems on biomedical literature.\n4. Biomedical Question Answering System (BQAS): A system developed by the National Center for Biotechnology Information (NCBI) that provides answers to biomedical questions posed in natural language.\n5. Evidence-Based Medicine Question Answering System (EBMQAS): A system developed by the National Center for Biotechnology Information (NCBI) that provides answers to evidence-based medicine questions posed in natural language.\n6. Question Answering on Biomedical Texts (QABT): A system developed by the National Center for Biotechnology Information (NCBI) that provides answers to biomedical questions posed in natural language.\n7. Question Answering on Biomedical Texts (QABT): A system developed by the National Center for Biotechnology Information (NCBI) that provides answers to biomedical questions posed in natural language.\n8. Question Answering on Biomedical Texts (QABT): A system developed by the National Center for Biotechnology Information (NCBI) that provides answers to biomedical questions posed in natural language.\n9. Question Answering on Biomedical Texts (QABT): A system developed by the National Center for Biotechnology Information (NCBI) that provides answers to biomedical questions posed in natural language.\n10. Question Answering on Biomedical Texts (QABT): A system developed by the National Center for Biotechnology Information (NCBI) that provides answers to biomedical questions posed in natural language.\n11. Question Answering on Biomedical Texts (QABT): A system developed by",
    "llama-7b_fact_raw": "1. The Clinical Question Answering System (CQAS) was developed by the National Center for Biotechnology Information (NCBI).\n2. BioASQ is a series of challenges organized by the European Bioinformatics Institute (EMBL-EBI) to evaluate biomedical question answering systems.\n3. Biocreative is a series of challenges organized by the National Center for Biomedical Ontology (NCBO) to evaluate biomedical question answering systems.\n4. The Biomedical Question Answering System (BQAS) was developed by the National Center for Biotechnology Information (NCBI).\n5. The Evidence-Based Medicine Question Answering System (EBMQAS) was developed by the National Center for Biotechnology Information (NCBI).",
    "llama-7b_fact": [
      "The Clinical Question Answering System (CQAS) was developed by the National Center for Biotechnology Information (NCBI).",
      "BioASQ is a series of challenges organized by the European Bioinformatics Institute (EMBL-EBI) to evaluate biomedical question answering systems.",
      "Biocreative is a series of challenges organized by the National Center for Biomedical Ontology (NCBO) to evaluate biomedical question answering systems.",
      "The Biomedical Question Answering System (BQAS) was developed by the National Center for Biotechnology Information (NCBI).",
      "The Evidence-Based Medicine Question Answering System (EBMQAS) was developed by the National Center for Biotechnology Information (NCBI)."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. FALSE [correction]: BioCreative is a series of challenges organized to evaluate text mining and information extraction systems applied to the biomedical domain, but it is not specifically organized by the National Center for Biomedical Ontology (NCBO). BioCreative stands for Critical Assessment of Information Extraction systems in Biology.\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements regarding the development of specific systems by the National Center for Biotechnology Information (NCBI) such as CQAS, BQAS, and EBMQAS are not well-known facts and would require specific knowledge or a reliable source to confirm their accuracy.",
    "llama-7b_judge": [
      "unknown",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 794,
    "user_query": "You MUST give a detailed answer to the following question: Which trancription factor activates the betalain pathway?",
    "llama-7b_response": "The transcription factor that activates the betalain pathway has not yet been identified. The betalain pathway is a secondary metabolic pathway that is involved in the biosynthesis of betalain pigments, which are responsible for the red, purple, and yellow colors of certain plant species. The pathway is initiated by the expression of genes that encode enzymes involved in the biosynthesis of betalain pigments, but the transcription factor that activates this gene expression has not yet been identified.",
    "llama-7b_fact_raw": "1. The transcription factor that activates the betalain pathway has not yet been identified.\n2. The betalain pathway is involved in the biosynthesis of betalain pigments.\n3. Betalain pigments are responsible for the red, purple, and yellow colors of certain plant species.\n4. The betalain pathway is initiated by the expression of genes that encode enzymes for the biosynthesis of betalain pigments.",
    "llama-7b_fact": [
      "The transcription factor that activates the betalain pathway has not yet been identified.",
      "The betalain pathway is involved in the biosynthesis of betalain pigments.",
      "Betalain pigments are responsible for the red, purple, and yellow colors of certain plant species.",
      "The betalain pathway is initiated by the expression of genes that encode enzymes for the biosynthesis of betalain pigments."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-7b_judge": [
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 883,
    "user_query": "You MUST give a detailed answer to the following question: Global quantitative phosphoproteomic analyses are emerging. List the preferred technologies for the enrichment for phosphorylated peptides?",
    "llama-7b_response": "There are several technologies that are commonly used for the enrichment of phosphorylated peptides in global quantitative phosphoproteomic analyses. Some of the most commonly used technologies include:\n\n1. IMAC (Immobilized Metal Affinity Chromatography): IMAC is a widely used technique for the enrichment of phosphorylated peptides. It utilizes immobilized metal ions, such as nickel or gold, to selectively bind phosphorylated peptides.\n2. TiO2 (Titanium Dioxide) beads: TiO2 beads are another commonly used technology for the enrichment of phosphorylated peptides. They are coated with a layer of titanium dioxide, which selectively binds to phosphorylated peptides.\n3. Phosphopeptide enrichment by immunoaffinity chromatography: This technique involves the use of antibodies that specifically recognize phosphorylated peptides. The antibodies are immobilized on a column, and the phosphorylated peptides bind to the antibodies, while non-phosphorylated peptides pass through.\n4. Phosphopeptide enrichment by reversed-phase chromatography: This technique involves the use of reversed-phase high-performance liquid chromatography (HPLC) to enrich for phosphorylated peptides. The phosphorylated peptides are more hydrophobic than non-phosphorylated peptides, and thus tend to elute later from the column.\n5. Phosphopeptide enrichment by strong cation exchange chromatography: This technique involves the use of strong cation exchange chromatography to enrich for phosphorylated peptides. The phosphorylated peptides are positively charged, and thus tend to bind to the negatively charged resin.\n\nIt is worth noting that the choice of technology for the enrichment of phosphorylated peptides will depend on the specific goals of the study, as well as the characteristics of the sample being analyzed.",
    "llama-7b_fact_raw": "1. IMAC (Immobilized Metal Affinity Chromatography) is used for the enrichment of phosphorylated peptides and utilizes immobilized metal ions.\n2. Titanium Dioxide (TiO2) beads are used for the enrichment of phosphorylated peptides and are coated with a layer of titanium dioxide.\n3. Phosphopeptide enrichment by immunoaffinity chromatography uses antibodies that specifically recognize phosphorylated peptides.\n4. Phosphopeptide enrichment by reversed-phase chromatography uses reversed-phase high-performance liquid chromatography (HPLC) to enrich for phosphorylated peptides.\n5. Phosphopeptide enrichment by strong cation exchange chromatography uses strong cation exchange chromatography to enrich for phosphorylated peptides.",
    "llama-7b_fact": [
      "IMAC (Immobilized Metal Affinity Chromatography) is used for the enrichment of phosphorylated peptides and utilizes immobilized metal ions.",
      "Titanium Dioxide (TiO2) beads are used for the enrichment of phosphorylated peptides and are coated with a layer of titanium dioxide.",
      "Phosphopeptide enrichment by immunoaffinity chromatography uses antibodies that specifically recognize phosphorylated peptides.",
      "Phosphopeptide enrichment by reversed-phase chromatography uses reversed-phase high-performance liquid chromatography (HPLC) to enrich for phosphorylated peptides.",
      "Phosphopeptide enrichment by strong cation exchange chromatography uses strong cation exchange chromatography to enrich for phosphorylated peptides."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: IMAC (Immobilized Metal Affinity Chromatography) is used for the enrichment of phosphorylated peptides but typically utilizes immobilized metal ions such as iron or zinc, not titanium.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Phosphopeptide enrichment by reversed-phase chromatography does not specifically enrich for phosphorylated peptides; it separates peptides based on hydrophobicity, and phosphorylated peptides may be less retained due to their increased polarity.\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 901,
    "user_query": "You MUST give a detailed answer to the following question: Which disorder is rated by Palmini classification?",
    "llama-7b_response": "dystonia",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 905,
    "user_query": "You MUST give a detailed answer to the following question: Are viruses involved in the etiology of human subacute thyroiditis?",
    "llama-7b_response": "Subacute thyroiditis, also known as De Quervain's thyroiditis, is an inflammatory condition that affects the thyroid gland. It is characterized by pain in the front of the neck, enlargement of the thyroid gland, and elevated levels of thyroid hormones in the blood. The exact cause of subacute thyroiditis is not well understood, but it is believed to be an autoimmune disorder.\n\nViruses have been implicated in the etiology of subacute thyroiditis, but the role of viruses is not well established. Some studies have suggested that viral infections, such as the mumps virus, may play a role in the development of subacute thyroiditis. However, other studies have found no association between viral infections and subacute thyroiditis.\n\nIt is also possible that other factors, such as genetic susceptibility and environmental triggers, may contribute to the development of subacute thyroiditis. Further research is needed to better understand the role of viruses in the etiology of subacute thyroiditis.\n\nIn summary, while viruses have been implicated in the etiology of subacute thyroiditis, the role of viruses is not well established. Further research is needed to better understand the factors that contribute to the development of subacute thyroiditis.",
    "llama-7b_fact_raw": "1. Subacute thyroiditis is also known as De Quervain's thyroiditis.\n2. Subacute thyroiditis is characterized by pain in the front of the neck, enlargement of the thyroid gland, and elevated levels of thyroid hormones in the blood.\n3. The exact cause of subacute thyroiditis is not well understood and is believed to be an autoimmune disorder.\n4. Some studies have suggested a possible role of viral infections, such as the mumps virus, in the development of subacute thyroiditis.\n5. Other studies have found no association between viral infections and subacute thyroiditis.",
    "llama-7b_fact": [
      "Subacute thyroiditis is also known as De Quervain's thyroiditis.",
      "Subacute thyroiditis is characterized by pain in the front of the neck, enlargement of the thyroid gland, and elevated levels of thyroid hormones in the blood.",
      "The exact cause of subacute thyroiditis is not well understood and is believed to be an autoimmune disorder.",
      "Some studies have suggested a possible role of viral infections, such as the mumps virus, in the development of subacute thyroiditis.",
      "Other studies have found no association between viral infections and subacute thyroiditis."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The exact cause of subacute thyroiditis is not well understood, but it is believed to be related to a viral infection rather than being an autoimmune disorder.\n4. TRUE\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 963,
    "user_query": "You MUST give a detailed answer to the following question: Is STAT3 involved in EIF2AK2-dependent suppression of autophagy?",
    "llama-7b_response": "STAT3 (Signal Transducer and Activator of Transcription 3) is a transcription factor that plays a crucial role in the regulation of various cellular processes, including cell proliferation, differentiation, and survival. STAT3 has been implicated in the regulation of autophagy, a cellular process involved in the degradation and recycling of cellular components.\n\nEIF2AK2 (Eukaryotic Initiation Factor 2 Alpha Kinase 2), also known as PKR (Double-Stranded RNA-Activated Protein Kinase), is a protein kinase that plays a crucial role in the regulation of cellular stress responses, including the innate immune response to viral infections. EIF2AK2 has been implicated in the regulation of autophagy, as it has been shown to negatively regulate autophagy by inhibiting the activity of the ULK1 (Unc-51-like kinase 1) complex, which is a key regulator of autophagy.\n\nThere is evidence to suggest that STAT3 may be involved in the regulation of EIF2AK2-dependent suppression of autophagy. For example, studies have shown that STAT3 can interact with and activate EIF2AK2, leading to the inhibition of autophagy. Additionally, STAT3 has been shown to regulate the expression of genes involved in the regulation of autophagy, such as BECN1 (Beclin 1), which is a key regulator of autophagy.\n\nOverall, while there is evidence to suggest that STAT3 may be involved in the regulation of EIF2AK2-dependent suppression of autophagy, the precise mechanisms by which STAT3 regulates autophagy remain to be fully elucidated. Further research is needed to fully understand the complex interplay between STAT3 and EIF2AK2 in the regulation of autophagy.",
    "llama-7b_fact_raw": "1. STAT3 is a transcription factor that is involved in cell proliferation, differentiation, and survival.\n2. STAT3 has been implicated in the regulation of autophagy.\n3. EIF2AK2, also known as PKR, is a protein kinase that negatively regulates autophagy by inhibiting the ULK1 complex.\n4. Studies have shown that STAT3 can interact with and activate EIF2AK2, which leads to the inhibition of autophagy.\n5. STAT3 regulates the expression of genes involved in autophagy regulation, such as BECN1.",
    "llama-7b_fact": [
      "STAT3 is a transcription factor that is involved in cell proliferation, differentiation, and survival.",
      "STAT3 has been implicated in the regulation of autophagy.",
      "EIF2AK2, also known as PKR, is a protein kinase that negatively regulates autophagy by inhibiting the ULK1 complex.",
      "Studies have shown that STAT3 can interact with and activate EIF2AK2, which leads to the inhibition of autophagy.",
      "STAT3 regulates the expression of genes involved in autophagy regulation, such as BECN1."
    ],
    "llama-7b_judge_raw": "1. TRUE: STAT3 is indeed a transcription factor that plays a role in cell proliferation, differentiation, and survival.\n2. TRUE: STAT3 has been implicated in the regulation of autophagy, a cellular degradation process.\n3. TRUE: EIF2AK2, also known as PKR, is a protein kinase that can negatively regulate autophagy, including through interactions with the ULK1 complex.\n4. UNKNOWN: The interaction between STAT3 and EIF2AK2 and the specific regulatory effects on autophagy are complex and context-dependent, and without specific references, it's difficult to confirm the accuracy of this statement.\n5. UNKNOWN: While STAT3 does regulate the expression of various genes, the specific regulation of BECN1, a gene involved in autophagy, by STAT3 would require a specific reference to confirm its accuracy.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 973,
    "user_query": "You MUST give a detailed answer to the following question: Describe what is the usage of the Theatre software tool for genomic analysis.",
    "llama-7b_response": "The Theatre software tool is a genomic analysis tool that is used to visualize and analyze large-scale genomic data. It is designed to help researchers and clinicians better understand the structure and organization of the human genome, as well as to identify genetic variations that may be associated with disease.\n\nOne of the key features of Theatre is its ability to handle very large datasets, such as those generated by next-generation sequencing (NGS) technologies. These datasets can contain billions of base pairs of DNA sequence data, and Theatre is able to process and analyze this data quickly and efficiently.\n\nAnother important feature of Theatre is its ability to visualize genomic data in a variety of ways. For example, it can generate maps of the human genome that show the location of different genes and other genomic features, as well as visualize the distribution of genetic variations across the genome. These visualizations can help researchers and clinicians better understand the structure and organization of the human genome and identify potential genetic variants that may be associated with disease.\n\nIn addition to its visualization capabilities, Theatre also includes a number of analysis tools that can be used to identify and analyze specific genomic features. For example, it can be used to identify regions of the genome that are enriched for certain types of genetic variations, such as single nucleotide polymorphisms (SNPs) or copy number variations (CNVs). It can also be used to identify regions of the genome that are likely to contain functional elements, such as genes or regulatory elements.\n\nOverall, the Theatre software tool is a valuable tool for genomic analysis, and is used by researchers and clinicians around the world to better understand the structure and organization of the human genome and to identify potential genetic variants that may be associated with disease.",
    "llama-7b_fact_raw": "1. The Theatre software tool is used for visualizing and analyzing large-scale genomic data.\n2. Theatre is designed to process and analyze data generated by next-generation sequencing (NGS) technologies.\n3. The software can generate maps of the human genome showing the location of genes and other genomic features.\n4. Theatre can visualize the distribution of genetic variations across the human genome.\n5. The tool includes analysis features to identify regions enriched for genetic variations like SNPs or CNVs.",
    "llama-7b_fact": [
      "The Theatre software tool is used for visualizing and analyzing large-scale genomic data.",
      "Theatre is designed to process and analyze data generated by next-generation sequencing (NGS) technologies.",
      "The software can generate maps of the human genome showing the location of genes and other genomic features.",
      "Theatre can visualize the distribution of genetic variations across the human genome.",
      "The tool includes analysis features to identify regions enriched for genetic variations like SNPs or CNVs."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN (The statement may refer to a specific software tool named \"Theatre,\" but without additional context or knowledge about this specific tool, it's not possible to confirm its purpose.)\n2. UNKNOWN (As with the first statement, without additional context about the specific software tool named \"Theatre,\" it's not possible to confirm its capabilities regarding next-generation sequencing data.)\n3. UNKNOWN (Again, without more information about the specific features of the \"Theatre\" software tool, the ability to generate maps of the human genome showing the location of genes and other genomic features cannot be confirmed.)\n4. UNKNOWN (The ability of the \"Theatre\" software tool to visualize the distribution of genetic variations across the human genome cannot be confirmed without further context.)\n5. UNKNOWN (Without additional information, it cannot be confirmed whether the \"Theatre\" software tool includes analysis features to identify regions enriched for genetic variations like SNPs or CNVs.)",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 997,
    "user_query": "You MUST give a detailed answer to the following question: Which  is the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences",
    "llama-7b_response": "The Smith-Waterman algorithm is a dynamic programming algorithm used for the alignment of two sequences. The execution time (complexity) of the Smith-Waterman algorithm depends on several factors, including the length of the sequences being aligned, the similarity between the sequences, and the gap penalty and extension penalty used in the algorithm.\n\nIn general, the execution time of the Smith-Waterman algorithm increases exponentially with the length of the sequences being aligned. For example, if the two sequences being aligned are of length n, the Smith-Waterman algorithm has a time complexity of O(n^2). This means that as the length of the sequences increases, the execution time of the algorithm also increases.\n\nThe gap penalty and extension penalty used in the Smith-Waterman algorithm can also affect the execution time of the algorithm. A larger gap penalty will result in more gaps being inserted in the alignment, which can increase the execution time of the algorithm. Similarly, a larger extension penalty will result in more extensions being added to the alignment, which can also increase the execution time of the algorithm.\n\nIn summary, the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences depends on the length of the sequences, the similarity between the sequences, and the gap penalty and extension penalty used in the algorithm. As the length of the sequences increases, the execution time of the algorithm also increases, and the choice of gap penalty and extension penalty can also affect the execution time of the algorithm.",
    "llama-7b_fact_raw": "1. The Smith-Waterman algorithm is a dynamic programming algorithm used for the alignment of two sequences.\n2. The time complexity of the Smith-Waterman algorithm is O(n^2) when aligning two sequences of length n.\n3. The execution time of the Smith-Waterman algorithm increases exponentially with the length of the sequences being aligned.\n4. The gap penalty and extension penalty used in the Smith-Waterman algorithm can affect the execution time of the algorithm.\n5. A larger gap penalty or extension penalty in the Smith-Waterman algorithm can increase the execution time of the algorithm.",
    "llama-7b_fact": [
      "The Smith-Waterman algorithm is a dynamic programming algorithm used for the alignment of two sequences.",
      "The time complexity of the Smith-Waterman algorithm is O(n^2) when aligning two sequences of length n.",
      "The execution time of the Smith-Waterman algorithm increases exponentially with the length of the sequences being aligned.",
      "The gap penalty and extension penalty used in the Smith-Waterman algorithm can affect the execution time of the algorithm.",
      "A larger gap penalty or extension penalty in the Smith-Waterman algorithm can increase the execution time of the algorithm."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The execution time of the Smith-Waterman algorithm increases quadratically, not exponentially, with the length of the sequences being aligned, as it has a time complexity of O(n^2).\n4. FALSE [correction]: The gap penalty and extension penalty used in the Smith-Waterman algorithm do not affect the execution time of the algorithm; they affect the scoring of the alignments.\n5. FALSE [correction]: A larger gap penalty or extension penalty in the Smith-Waterman algorithm does not increase the execution time of the algorithm; it affects the scoring and therefore the resulting alignment, but not the time complexity.",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 1004,
    "user_query": "You MUST give a detailed answer to the following question: Which SLC family is FLVCR1 a member of?",
    "llama-7b_response": "folate receptor",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 1047,
    "user_query": "You MUST give a detailed answer to the following question: List GATA-1 interacting partners as discovered with the help of the biotinylation tagging approach.",
    "llama-7b_response": "GATA-1 (GATA binding protein 1) is a transcription factor that plays a crucial role in the regulation of gene expression in various cell types, including hematopoietic stem cells and cardiac progenitor cells. GATA-1 interacts with a wide range of proteins, including other transcription factors, coactivators, and corepressors, to regulate the transcription of target genes.\n\nOne approach used to identify GATA-1 interacting partners is the biotinylation tagging approach, which involves the biotinylation of GATA-1 and subsequent affinity purification of biotinylated proteins that interact with GATA-1. This approach has been used to identify a number of proteins that interact with GATA-1.\n\nHere are some of the GATA-1 interacting partners that have been identified using the biotinylation tagging approach:\n\n1. TBP (TATA box binding protein): TBP is a general transcription factor that binds to the TATA box element in the promoter region of many genes. TBP interacts with GATA-1 to form a complex that binds to the promoter region of target genes.\n2. NCoA-2 (Nuclear coactivator 2): NCoA-2 is a coactivator that enhances the transcriptional activity of GATA-1 and other transcription factors.\n3. HDAC1 (Histone deacetylase 1): HDAC1 is a corepressor that interacts with GATA-1 to repress the transcription of target genes.\n4. HDAC2 (Histone deacetylase 2): HDAC2 is a corepressor that interacts with GATA-1 to repress the transcription of target genes.\n5. HDAC3 (Histone deacetylase 3): HDAC3 is a corepressor that interacts with GATA-1 to repress the transcription of target genes.\n6. HDAC4 (Histone deacetylase 4): HDAC4 is a corepressor that interacts with GATA-1 to repress the transcription of target genes.\n7. HDAC5 (Histone deacetylase",
    "llama-7b_fact_raw": "1. TBP (TATA box binding protein) has been identified as a GATA-1 interacting partner using the biotinylation tagging approach.\n2. NCoA-2 (Nuclear coactivator 2) enhances the transcriptional activity of GATA-1 and has been identified as an interacting partner through the biotinylation tagging approach.\n3. HDAC1 (Histone deacetylase 1) interacts with GATA-1 to repress the transcription of target genes and has been identified using the biotinylation tagging approach.\n4. HDAC2 (Histone deacetylase 2) has been identified as a GATA-1 interacting partner that represses the transcription of target genes using the biotinylation tagging approach.\n5. HDAC3 (Histone deacetylase 3) is a corepressor that interacts with GATA-1, identified through the biotinylation tagging approach.",
    "llama-7b_fact": [
      "TBP (TATA box binding protein) has been identified as a GATA-1 interacting partner using the biotinylation tagging approach.",
      "NCoA-2 (Nuclear coactivator 2) enhances the transcriptional activity of GATA-1 and has been identified as an interacting partner through the biotinylation tagging approach.",
      "HDAC1 (Histone deacetylase 1) interacts with GATA-1 to repress the transcription of target genes and has been identified using the biotinylation tagging approach.",
      "HDAC2 (Histone deacetylase 2) has been identified as a GATA-1 interacting partner that represses the transcription of target genes using the biotinylation tagging approach.",
      "HDAC3 (Histone deacetylase 3) is a corepressor that interacts with GATA-1, identified through the biotinylation tagging approach."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided are very specific to molecular biology and the interactions between proteins. Without access to the specific scientific literature or experimental results that confirm these interactions and the methods used to identify them, it is not possible to accurately determine the truthfulness of these statements. The biotinylation tagging approach is a legitimate scientific method used to study protein interactions, but whether it was used to identify the interactions between GATA-1 and the mentioned proteins (TBP, NCoA-2, HDAC1, HDAC2, HDAC3) cannot be confirmed without the appropriate context or references.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1072,
    "user_query": "You MUST give a detailed answer to the following question: What is the outcome of TAF10 interacting with the GATA1 transcription factor?",
    "llama-7b_response": "TAF10 is a transcriptional co-activator that interacts with GATA1, a transcription factor that plays a crucial role in the regulation of genes involved in cardiac development and function. The interaction between TAF10 and GATA1 leads to the recruitment of other transcriptional co-activators, such as p300 and histone acetyltransferases, to the GATA1 binding site on the DNA. This results in the activation of gene transcription and the expression of genes involved in cardiac development and function.\n\nIn particular, the interaction between TAF10 and GATA1 has been shown to play a crucial role in the regulation of genes involved in cardiac hypertrophy, a condition characterized by an increase in the size of the heart muscle cells. The activation of genes involved in cardiac hypertrophy by TAF10 and GATA1 leads to an increase in the production of proteins involved in the growth and survival of cardiac muscle cells, which can contribute to the development of cardiac hypertrophy.\n\nIn summary, the interaction between TAF10 and GATA1 leads to the activation of gene transcription and the expression of genes involved in cardiac development and function, including those involved in cardiac hypertrophy. The activation of these genes can contribute to the development and progression of cardiac hypertrophy, a condition characterized by an increase in the size of the heart muscle cells.",
    "llama-7b_fact_raw": "1. TAF10 is a transcriptional co-activator that interacts with the GATA1 transcription factor.\n2. GATA1 plays a crucial role in the regulation of genes involved in cardiac development and function.\n3. The interaction between TAF10 and GATA1 leads to the recruitment of other transcriptional co-activators, such as p300 and histone acetyltransferases.\n4. This interaction results in the activation of gene transcription and the expression of genes involved in cardiac development and function.\n5. The activation of genes involved in cardiac hypertrophy by TAF10 and GATA1 can contribute to the development of cardiac hypertrophy, which is characterized by an increase in the size of heart muscle cells.",
    "llama-7b_fact": [
      "TAF10 is a transcriptional co-activator that interacts with the GATA1 transcription factor.",
      "GATA1 plays a crucial role in the regulation of genes involved in cardiac development and function.",
      "The interaction between TAF10 and GATA1 leads to the recruitment of other transcriptional co-activators, such as p300 and histone acetyltransferases.",
      "This interaction results in the activation of gene transcription and the expression of genes involved in cardiac development and function.",
      "The activation of genes involved in cardiac hypertrophy by TAF10 and GATA1 can contribute to the development of cardiac hypertrophy, which is characterized by an increase in the size of heart muscle cells."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: GATA1 plays a crucial role in the regulation of genes involved in erythroid and megakaryocytic differentiation, not specifically cardiac development and function.\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1082,
    "user_query": "You MUST give a detailed answer to the following question: Are there any Decision support systems for chronic pain management ?",
    "llama-7b_response": "Yes, there are several decision support systems for chronic pain management. These systems are designed to help healthcare providers and patients make informed decisions about the management of chronic pain. Some examples of decision support systems for chronic pain management include:\n\n1. Pain Management Decision Support System (PM-DSS): This is a web-based decision support system that provides clinicians with evidence-based recommendations for the management of chronic pain. The system is designed to help clinicians select the most appropriate treatment options for their patients based on their individual needs and preferences.\n2. Clinical Decision Support for Chronic Pain (CDS-CP): This is a decision support system that provides clinicians with evidence-based recommendations for the management of chronic pain. The system is designed to help clinicians select the most appropriate treatment options for their patients based on their individual needs and preferences.\n3. Chronic Pain Management Decision Support System (CPMDSS): This is a web-based decision support system that provides clinicians with evidence-based recommendations for the management of chronic pain. The system is designed to help clinicians select the most appropriate treatment options for their patients based on their individual needs and preferences.\n4. Pain Management Decision Support System (PM-DSS): This is a web-based decision support system that provides clinicians with evidence-based recommendations for the management of chronic pain. The system is designed to help clinicians select the most appropriate treatment options for their patients based on their individual needs and preferences.\n5. Clinical Decision Support for Chronic Pain (CDS-CP): This is a decision support system that provides clinicians with evidence-based recommendations for the management of chronic pain. The system is designed to help clinicians select the most appropriate treatment options for their patients based on their individual needs and preferences.\n6. Chronic Pain Management Decision Support System (CPMDSS): This is a web-based decision support system that provides clinicians with evidence-based recommendations for the management of chronic pain. The system is designed to help clinicians select the most appropriate treatment options for their patients based on their individual needs and preferences.\n7. Pain Management Decision Support System (PM-DSS): This is a web-based decision support system that provides clinicians with evidence-based recommendations for the management of chronic",
    "llama-7b_fact_raw": "1. There are decision support systems available for chronic pain management.\n2. The Pain Management Decision Support System (PM-DSS) is a web-based system that provides evidence-based recommendations for chronic pain management.\n3. The Clinical Decision Support for Chronic Pain (CDS-CP) offers evidence-based recommendations to clinicians for managing chronic pain.\n4. The Chronic Pain Management Decision Support System (CPMDSS) is a web-based tool designed to assist clinicians in choosing treatment options for chronic pain based on individual patient needs and preferences.\n5. These decision support systems are intended to help healthcare providers and patients make informed decisions regarding chronic pain management.",
    "llama-7b_fact": [
      "There are decision support systems available for chronic pain management.",
      "The Pain Management Decision Support System (PM-DSS) is a web-based system that provides evidence-based recommendations for chronic pain management.",
      "The Clinical Decision Support for Chronic Pain (CDS-CP) offers evidence-based recommendations to clinicians for managing chronic pain.",
      "The Chronic Pain Management Decision Support System (CPMDSS) is a web-based tool designed to assist clinicians in choosing treatment options for chronic pain based on individual patient needs and preferences.",
      "These decision support systems are intended to help healthcare providers and patients make informed decisions regarding chronic pain management."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1149,
    "user_query": "You MUST give a detailed answer to the following question: Which is the subcellular localization of the protein angiogenin?",
    "llama-7b_response": "Angiogenin is a type of protein that is involved in the process of angiogenesis, which is the formation of new blood vessels from pre-existing ones. The subcellular localization of angiogenin can vary depending on the cell type and the stage of the angiogenic process.\n\nIn general, angiogenin is found in the cytosol of cells, which is the fluid inside the cell that surrounds the nucleus and other organelles. However, during the early stages of angiogenesis, angiogenin can be found in the nucleus of cells. This is because angiogenin plays a role in the transcription of genes that are involved in the process of angiogenesis.\n\nOnce new blood vessels have formed, angiogenin can be found in the extracellular matrix, which is the material that surrounds cells and holds them together. This is because angiogenin plays a role in the formation of a matrix that supports the newly formed blood vessels.\n\nOverall, the subcellular localization of angiogenin can vary depending on the cell type and the stage of the angiogenic process. However, it is generally found in the cytosol of cells during the early stages of angiogenesis and in the extracellular matrix once new blood vessels have formed.",
    "llama-7b_fact_raw": "1. Angiogenin is involved in the process of angiogenesis, which is the formation of new blood vessels from pre-existing ones.\n2. Angiogenin is generally found in the cytosol of cells.\n3. During the early stages of angiogenesis, angiogenin can be located in the nucleus of cells.\n4. Angiogenin plays a role in the transcription of genes involved in angiogenesis.\n5. Angiogenin can be found in the extracellular matrix once new blood vessels have formed.",
    "llama-7b_fact": [
      "Angiogenin is involved in the process of angiogenesis, which is the formation of new blood vessels from pre-existing ones.",
      "Angiogenin is generally found in the cytosol of cells.",
      "During the early stages of angiogenesis, angiogenin can be located in the nucleus of cells.",
      "Angiogenin plays a role in the transcription of genes involved in angiogenesis.",
      "Angiogenin can be found in the extracellular matrix once new blood vessels have formed."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Angiogenin is not typically found in the extracellular matrix; it is a secreted protein that acts on cells to promote angiogenesis, but its presence in the extracellular matrix after new blood vessels have formed is not a characteristic feature of its function.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1161,
    "user_query": "You MUST give a detailed answer to the following question: How does ranolazine affect kinase signaling activation in the heart?",
    "llama-7b_response": "RANOLIDE",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 1225,
    "user_query": "You MUST give a detailed answer to the following question: Is the regulation of Vsr endonuclease independent of the growth phase of bacteria?",
    "llama-7b_response": "Yes, the regulation of the VSR endonuclease is independent of the growth phase of bacteria. The VSR endonuclease is a restriction-modification system that is present in many bacterial species and is involved in the defense against foreign DNA. The regulation of the VSR endonuclease is complex and involves multiple factors, including the growth phase of the bacteria, the presence of DNA damage, and the availability of certain nutrients.\n\nIn general, the activity of the VSR endonuclease is highest during the exponential growth phase of bacteria and decreases as the bacteria enter stationary phase. However, the regulation of the VSR endonuclease is not solely dependent on the growth phase of the bacteria. Other factors, such as the presence of DNA damage and the availability of certain nutrients, can also affect the activity of the endonuclease.\n\nFor example, the activity of the VSR endonuclease can be increased by DNA damage, such as that caused by UV radiation or certain antibiotics. In addition, the availability of certain nutrients, such as amino acids and nucleotides, can also affect the activity of the endonuclease.\n\nOverall, the regulation of the VSR endonuclease is complex and involves multiple factors, including the growth phase of the bacteria, the presence of DNA damage, and the availability of certain nutrients. However, the regulation of the endonuclease is not solely dependent on the growth phase of the bacteria.",
    "llama-7b_fact_raw": "1. The VSR endonuclease is a restriction-modification system present in many bacterial species.\n2. The activity of the VSR endonuclease is generally highest during the exponential growth phase of bacteria.\n3. The regulation of the VSR endonuclease is not solely dependent on the growth phase of bacteria.\n4. DNA damage, such as that caused by UV radiation or certain antibiotics, can increase the activity of the VSR endonuclease.\n5. The availability of certain nutrients, like amino acids and nucleotides, can affect the activity of the VSR endonuclease.",
    "llama-7b_fact": [
      "The VSR endonuclease is a restriction-modification system present in many bacterial species.",
      "The activity of the VSR endonuclease is generally highest during the exponential growth phase of bacteria.",
      "The regulation of the VSR endonuclease is not solely dependent on the growth phase of bacteria.",
      "DNA damage, such as that caused by UV radiation or certain antibiotics, can increase the activity of the VSR endonuclease.",
      "The availability of certain nutrients, like amino acids and nucleotides, can affect the activity of the VSR endonuclease."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The VSR endonuclease is not a restriction-modification system; it is a very short patch repair (VSP) system that repairs mismatches in DNA.\n2. UNKNOWN\n3. TRUE: The regulation of the VSR endonuclease is likely to be complex and not solely dependent on the growth phase of bacteria, as it is involved in DNA repair mechanisms which can be influenced by various factors.\n4. TRUE: DNA damage can indeed induce DNA repair mechanisms, and thus can increase the activity of enzymes involved in those processes, including the VSR endonuclease.\n5. UNKNOWN",
    "llama-7b_judge": [
      "false",
      "unknown",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1233,
    "user_query": "You MUST give a detailed answer to the following question: What are the computational tools for the prediction of beta-barrel transmembrane proteins?",
    "llama-7b_response": "There are several computational tools available for the prediction of beta-barrel transmembrane proteins, including:\n\n1. PSIPRED: PSIPRED (Protein Secondary Structure Predictor) is a web server that predicts the secondary structure of a protein based on its amino acid sequence. PSIPRED can predict beta-barrel transmembrane proteins with a high degree of accuracy.\n2. TMHMM: TMHMM (Transmembrane Helices of Microbial Toxins Homology-based Method) is a web server that predicts the presence of transmembrane helices in a protein sequence. TMHMM can be used to identify beta-barrel transmembrane proteins with a high degree of accuracy.\n3. SOSUI: SOSUI (Secondary Structure of Proteins from Unknown Initial Sequence) is a web server that predicts the secondary structure of a protein based on its amino acid sequence. SOSUI can predict beta-barrel transmembrane proteins with a high degree of accuracy.\n4. PONDR-FIT: PONDR-FIT (Predicting the Orientation of the First Transmembrane Helix in Targets) is a web server that predicts the orientation of the first transmembrane helix in a protein sequence. PONDR-FIT can be used to identify beta-barrel transmembrane proteins with a high degree of accuracy.\n5. Phobius: Phobius is a web server that predicts the presence of transmembrane helices in a protein sequence. Phobius can be used to identify beta-barrel transmembrane proteins with a high degree of accuracy.\n\nOverall, these computational tools can be used in combination to predict the presence of beta-barrel transmembrane proteins with a high degree of accuracy.",
    "llama-7b_fact_raw": "1. PSIPRED is a computational tool that predicts the secondary structure of proteins based on amino acid sequences.\n2. TMHMM is a computational tool designed to predict transmembrane helices in protein sequences.\n3. SOSUI is a web server that predicts the secondary structure of proteins from their amino acid sequences.\n4. PONDR-FIT is a computational tool that predicts the orientation of the first transmembrane helix in protein sequences.\n5. Phobius is a web server that predicts the presence of transmembrane helices in protein sequences.",
    "llama-7b_fact": [
      "PSIPRED is a computational tool that predicts the secondary structure of proteins based on amino acid sequences.",
      "TMHMM is a computational tool designed to predict transmembrane helices in protein sequences.",
      "SOSUI is a web server that predicts the secondary structure of proteins from their amino acid sequences.",
      "PONDR-FIT is a computational tool that predicts the orientation of the first transmembrane helix in protein sequences.",
      "Phobius is a web server that predicts the presence of transmembrane helices in protein sequences."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: SOSUI is a web server that predicts the membrane helices in proteins, not specifically the secondary structure of proteins.\n4. FALSE [correction]: PONDR-FIT is a computational tool that predicts protein disorder, not the orientation of the first transmembrane helix in protein sequences.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 1251,
    "user_query": "You MUST give a detailed answer to the following question: Galassi classification is used for which disorder?",
    "llama-7b_response": "dystonia",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 1304,
    "user_query": "You MUST give a detailed answer to the following question: List common features of Shapiro syndrome",
    "llama-7b_response": "​",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 1320,
    "user_query": "You MUST give a detailed answer to the following question: Which disease is linked to mutations within BRAG1?",
    "llama-7b_response": "cancer",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 1362,
    "user_query": "You MUST give a detailed answer to the following question: Which protein is the main inhibitor of protein phosphatase 1 (PP1)?",
    "llama-7b_response": "okadaic acid",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 1374,
    "user_query": "You MUST give a detailed answer to the following question: Which mechanisms underlie adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis?",
    "llama-7b_response": "Adaptive mutagenesis, also known as stationary-phase mutagenesis, is a mechanism by which bacteria, such as Bacillus subtilis, can increase their mutation rates in response to stressful conditions, such as starvation or exposure to antibiotics. There are several mechanisms that underlie adaptive mutagenesis in B. subtilis:\n\n1. DNA damage: DNA damage, such as that caused by reactive oxygen species (ROS) or DNA-damaging antibiotics, can activate the SOS response in B. subtilis. The SOS response leads to an increase in the mutation rate, which can help the bacteria survive and repair the DNA damage.\n2. Transcriptional regulation: The transcriptional regulator Spo0A plays a key role in the regulation of adaptive mutagenesis in B. subtilis. When Spo0A is activated by DNA damage or other stressful conditions, it activates the expression of genes involved in DNA repair and mutagenesis, such as uvrA and recA.\n3. DNA repair: B. subtilis has several mechanisms for repairing DNA damage, including homologous recombination and non-homologous end joining. When DNA damage occurs, the bacteria can use these mechanisms to repair the damage and prevent mutations from occurring. However, if the damage is too severe, the bacteria may choose to mutate instead of repairing the DNA.\n4. Mutator mutations: B. subtilis can also acquire mutator mutations, which increase the mutation rate. These mutations can occur spontaneously or be induced by DNA-damaging agents. Mutator mutations can increase the bacteria's ability to adapt to stressful conditions by allowing more mutations to occur, which can lead to the selection of beneficial mutations.\n\nOverall, adaptive mutagenesis in B. subtilis is a complex process that involves multiple mechanisms, including DNA damage, transcriptional regulation, DNA repair, and mutator mutations. These mechanisms allow the bacteria to increase their mutation rates in response to stressful conditions, which can help them survive and adapt to their environment.",
    "llama-7b_fact_raw": "1. Bacillus subtilis can increase its mutation rates in response to stressful conditions such as starvation or exposure to antibiotics.\n2. The SOS response in B. subtilis can be activated by DNA damage, leading to an increased mutation rate.\n3. The transcriptional regulator Spo0A in B. subtilis activates the expression of genes involved in DNA repair and mutagenesis when activated by DNA damage or other stressful conditions.\n4. Bacillus subtilis has DNA repair mechanisms such as homologous recombination and non-homologous end joining.\n5. Mutator mutations in B. subtilis can increase the mutation rate and occur spontaneously or be induced by DNA-damaging agents.",
    "llama-7b_fact": [
      "Bacillus subtilis can increase its mutation rates in response to stressful conditions such as starvation or exposure to antibiotics.",
      "The SOS response in B. subtilis can be activated by DNA damage, leading to an increased mutation rate.",
      "The transcriptional regulator Spo0A in B. subtilis activates the expression of genes involved in DNA repair and mutagenesis when activated by DNA damage or other stressful conditions.",
      "Bacillus subtilis has DNA repair mechanisms such as homologous recombination and non-homologous end joining.",
      "Mutator mutations in B. subtilis can increase the mutation rate and occur spontaneously or be induced by DNA-damaging agents."
    ],
    "llama-7b_judge_raw": "1. TRUE: Bacillus subtilis, like many bacteria, can increase its mutation rates under stressful conditions such as starvation or exposure to antibiotics, a phenomenon known as stress-induced mutagenesis.\n\n2. FALSE [correction]: The SOS response is a well-known bacterial response to DNA damage that leads to an increased mutation rate. However, the SOS response is most commonly associated with Escherichia coli and some other bacteria, not Bacillus subtilis. B. subtilis has a different system called the SOS-like response or the DNA damage checkpoint response.\n\n3. FALSE [correction]: The transcriptional regulator Spo0A in B. subtilis is primarily known for its role in initiating sporulation and regulating genes involved in this process. It is not directly activated by DNA damage or stressful conditions to activate DNA repair and mutagenesis genes. Spo0A is more involved in the transition to a dormant spore state in response to nutrient limitation.\n\n4. TRUE: Bacillus subtilis has DNA repair mechanisms, including homologous recombination. However, non-homologous end joining (NHEJ) is not typically found in B. subtilis; it is more commonly associated with eukaryotic cells.\n\n5. TRUE: Mutator mutations can increase the mutation rate in B. subtilis and can occur spontaneously or be induced by DNA-damaging agents. These mutations often affect the genes involved in DNA replication fidelity or repair mechanisms.",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1399,
    "user_query": "You MUST give a detailed answer to the following question: What causes erucism?",
    "llama-7b_response": "Erucic acid is a type of fatty acid that can be found in certain types of vegetable oils, such as rapeseed (also known as canola) oil. Erucic acid can cause erucism, which is a rare condition characterized by the accumulation of erucic acid in the body's tissues.\n\nErucic acid can accumulate in the body's tissues due to the consumption of foods that contain high levels of erucic acid, such as rapeseed oil. Erucic acid can also be produced in the body as a result of certain genetic mutations that affect the way the body processes fatty acids.\n\nThe accumulation of erucic acid in the body's tissues can cause a range of symptoms, including joint pain, inflammation, and damage to the heart and other organs. In severe cases, erucism can lead to the development of heart disease, liver disease, and other serious health problems.\n\nIt is important for individuals to be aware of the potential risks associated with consuming high levels of erucic acid and to avoid foods that contain high levels of this fatty acid. In addition, individuals who have a family history of erucism or other health problems related to the accumulation of erucic acid in the body should speak with their healthcare provider about the potential risks and benefits of consuming rapeseed oil or other foods that contain high levels of erucic acid.",
    "llama-7b_fact_raw": "1. Erucic acid is a type of fatty acid found in certain vegetable oils, such as rapeseed (canola) oil.\n2. Erucism is a condition characterized by the accumulation of erucic acid in the body's tissues.\n3. High levels of erucic acid consumption, such as from rapeseed oil, can lead to erucism.\n4. Certain genetic mutations can cause the body to produce erucic acid, leading to its accumulation.\n5. Symptoms of erucism can include joint pain, inflammation, and damage to the heart and other organs.",
    "llama-7b_fact": [
      "Erucic acid is a type of fatty acid found in certain vegetable oils, such as rapeseed (canola) oil.",
      "Erucism is a condition characterized by the accumulation of erucic acid in the body's tissues.",
      "High levels of erucic acid consumption, such as from rapeseed oil, can lead to erucism.",
      "Certain genetic mutations can cause the body to produce erucic acid, leading to its accumulation.",
      "Symptoms of erucism can include joint pain, inflammation, and damage to the heart and other organs."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Erucism is not a recognized medical condition characterized by the accumulation of erucic acid in the body's tissues. The term \"erucism\" is not commonly used in medical literature to describe a condition related to erucic acid.\n3. FALSE [correction]: While high levels of erucic acid were once thought to be harmful, current research suggests that the consumption of erucic acid from sources like rapeseed oil is not a health concern for most people. However, there have been concerns in the past about potential heart-related conditions in animals consuming high levels of erucic acid, which led to the development of low-erucic acid rapeseed (LEAR) varieties.\n4. UNKNOWN\n5. FALSE [correction]: Since \"erucism\" is not a recognized medical condition, the symptoms listed are not specifically associated with the accumulation of erucic acid. However, there have been concerns in the past about potential heart-related conditions in animals consuming high levels of erucic acid, but these effects have not been conclusively demonstrated in humans.",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1413,
    "user_query": "You MUST give a detailed answer to the following question: What are the indications for hydrochlorothiazide?",
    "llama-7b_response": "Hydrochlorothiazide is a diuretic medication that is commonly used to treat hypertension (high blood pressure) and edema (swelling) caused by various conditions, such as heart failure, liver disease, and kidney disease. It works by increasing the production of urine, which helps to reduce blood pressure and remove excess fluid from the body.\n\nHydrochlorothiazide is also used to treat other conditions, such as nephrotic syndrome (a condition that causes excessive protein in the urine) and diabetes insipidus (a condition that causes excessive thirst and urination).\n\nIn addition to its medicinal uses, hydrochlorothiazide is also sometimes used as a \"water pill\" or diuretic to increase the amount of urine produced by the body. This can be helpful in treating conditions such as edema caused by conditions such as heart failure, liver disease, and kidney disease.\n\nIt is important for individuals taking hydrochlorothiazide to have their blood pressure and electrolyte levels monitored regularly, as this medication can cause changes in these levels. Additionally, individuals taking hydrochlorothiazide should avoid dehydration by drinking plenty of fluids and avoiding excessive exercise and exposure to heat.\n\nIn summary, hydrochlorothiazide is a diuretic medication that is commonly used to treat hypertension, edema, nephrotic syndrome, and diabetes insipidus. It works by increasing the production of urine, which helps to reduce blood pressure and remove excess fluid from the body. It is important for individuals taking hydrochlorothiazide to have their blood pressure and electrolyte levels monitored regularly and to avoid dehydration.",
    "llama-7b_fact_raw": "1. Hydrochlorothiazide is used to treat hypertension (high blood pressure).\n2. Hydrochlorothiazide is used to treat edema (swelling) caused by conditions such as heart failure, liver disease, and kidney disease.\n3. Hydrochlorothiazide is used to treat nephrotic syndrome, a condition that causes excessive protein in the urine.\n4. Hydrochlorothiazide is used to treat diabetes insipidus, a condition that causes excessive thirst and urination.\n5. Individuals taking hydrochlorothiazide should have their blood pressure and electrolyte levels monitored regularly.",
    "llama-7b_fact": [
      "Hydrochlorothiazide is used to treat hypertension (high blood pressure).",
      "Hydrochlorothiazide is used to treat edema (swelling) caused by conditions such as heart failure, liver disease, and kidney disease.",
      "Hydrochlorothiazide is used to treat nephrotic syndrome, a condition that causes excessive protein in the urine.",
      "Hydrochlorothiazide is used to treat diabetes insipidus, a condition that causes excessive thirst and urination.",
      "Individuals taking hydrochlorothiazide should have their blood pressure and electrolyte levels monitored regularly."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Hydrochlorothiazide is not typically used to treat nephrotic syndrome. It may help with edema related to nephrotic syndrome, but the primary treatment for nephrotic syndrome involves addressing the underlying cause and may include other types of medications.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1447,
    "user_query": "You MUST give a detailed answer to the following question: Has silicon been used in treatment of  incontinence ?",
    "llama-7b_response": "Yes, silicone has been used in the treatment of incontinence. Silicone is a synthetic material that has been used in various medical applications, including the treatment of urinary incontinence.\n\nSilicone has been used in the treatment of stress urinary incontinence (SUI), which is a type of urinary incontinence that occurs due to pressure on the bladder during activities that put pressure on the abdomen, such as coughing, sneezing, or exercise. Silicone is used to create a supportive sling that is placed around the urethra and bladder neck, which helps to hold the bladder in place and prevent urine leakage.\n\nSilicone is also used in the treatment of urge incontinence, which is a type of urinary incontinence that occurs due to an overactive bladder. Silicone is used to create a pessary, which is a device that is placed in the vagina to help support the bladder and prevent urine leakage.\n\nSilicone is a safe and effective material for use in the treatment of incontinence. However, it is important for patients to discuss the risks and benefits of silicone treatment with their healthcare provider before deciding on a treatment option.",
    "llama-7b_fact_raw": "1. Silicone has been used in the treatment of urinary incontinence.\n2. Silicone is used to create a supportive sling for treating stress urinary incontinence (SUI).\n3. Stress urinary incontinence occurs due to pressure on the bladder during activities like coughing, sneezing, or exercise.\n4. Silicone is used to create a pessary for the treatment of urge incontinence.\n5. Urge incontinence is associated with an overactive bladder.",
    "llama-7b_fact": [
      "Silicone has been used in the treatment of urinary incontinence.",
      "Silicone is used to create a supportive sling for treating stress urinary incontinence (SUI).",
      "Stress urinary incontinence occurs due to pressure on the bladder during activities like coughing, sneezing, or exercise.",
      "Silicone is used to create a pessary for the treatment of urge incontinence.",
      "Urge incontinence is associated with an overactive bladder."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: A pessary is typically made of rubber, plastic, or silicone, but it is not exclusively made of silicone, and its primary purpose is to support pelvic organs and not specifically for the treatment of urge incontinence.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1454,
    "user_query": "You MUST give a detailed answer to the following question: What is the association between moon cycle and rupture risk of intracranial aneurysms?",
    "llama-7b_response": "The association between the moon cycle and rupture risk of intracranial aneurysms is a topic of ongoing research and debate. Some studies have suggested that there may be a link between the phases of the moon and the rupture risk of intracranial aneurysms, while others have found no such association.\n\nIntracranial aneurysms are abnormal bulges in the wall of an artery that supplies blood to the brain. These aneurysms can rupture and cause a subarachnoid hemorrhage, which can be a life-threatening condition. Rupture of an intracranial aneurysm is a complex process that is influenced by a variety of factors, including the size and shape of the aneurysm, the blood flow through the aneurysm, and the overall health of the blood vessels in the brain.\n\nSome studies have suggested that the phases of the moon may play a role in the rupture risk of intracranial aneurysms. For example, some studies have found that the risk of rupture of an intracranial aneurysm may be higher during the full moon phase than during other phases of the moon. Other studies, however, have found no such association.\n\nIt is worth noting that the association between the moon cycle and rupture risk of intracranial aneurysms is still a topic of ongoing research and debate. While some studies have suggested a link, others have found no such association. More research is needed to fully understand the relationship between the moon cycle and the rupture risk of intracranial aneurysms.\n\nIn summary, the association between the moon cycle and rupture risk of intracranial aneurysms is a topic of ongoing research and debate. Some studies have suggested that there may be a link between the phases of the moon and the rupture risk of intracranial aneurysms, while others have found no such association. More research is needed to fully understand the relationship between the moon cycle and the rupture risk of intracranial aneurysms.",
    "llama-7b_fact_raw": "1. Intracranial aneurysms are abnormal bulges in the wall of an artery that supplies blood to the brain.\n2. Rupture of an intracranial aneurysm can cause a subarachnoid hemorrhage, which can be life-threatening.\n3. Some studies have suggested that the risk of rupture of an intracranial aneurysm may be higher during the full moon phase.\n4. Other studies have found no association between the moon cycle and the rupture risk of intracranial aneurysms.\n5. The association between the moon cycle and rupture risk of intracranial aneurysms is still a topic of ongoing research and debate.",
    "llama-7b_fact": [
      "Intracranial aneurysms are abnormal bulges in the wall of an artery that supplies blood to the brain.",
      "Rupture of an intracranial aneurysm can cause a subarachnoid hemorrhage, which can be life-threatening.",
      "Some studies have suggested that the risk of rupture of an intracranial aneurysm may be higher during the full moon phase.",
      "Other studies have found no association between the moon cycle and the rupture risk of intracranial aneurysms.",
      "The association between the moon cycle and rupture risk of intracranial aneurysms is still a topic of ongoing research and debate."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1477,
    "user_query": "You MUST give a detailed answer to the following question: Does HuR protein regulate the splicing process?",
    "llama-7b_response": "Yes, HuR (Hu antigen R) protein has been shown to regulate the splicing process.\n\nHuR is a small RNA-binding protein that plays a crucial role in the regulation of gene expression at the post-transcriptional level. It has been implicated in various biological processes, including the regulation of splicing.\n\nStudies have shown that HuR can bind to both pre-mRNA and mature mRNA, and its binding to pre-mRNA can affect the splicing process. For example, HuR has been shown to interact with splicing factors and regulate their activity, leading to changes in the splicing pattern of target genes.\n\nFurthermore, HuR has been implicated in the regulation of alternative splicing, which is a process by which multiple splicing variants can be produced from a single gene. Alternative splicing can result in the production of different proteins with distinct functions, and HuR has been shown to play a role in the regulation of alternative splicing events.\n\nOverall, these studies suggest that HuR protein can regulate the splicing process by interacting with splicing factors and altering their activity, leading to changes in the splicing pattern of target genes and the production of alternative splicing variants.",
    "llama-7b_fact_raw": "1. HuR (Hu antigen R) protein regulates the splicing process.\n2. HuR is involved in the regulation of gene expression at the post-transcriptional level.\n3. HuR can bind to both pre-mRNA and mature mRNA.\n4. HuR's interaction with splicing factors can lead to changes in the splicing pattern of target genes.\n5. HuR plays a role in the regulation of alternative splicing, which allows for multiple splicing variants from a single gene.",
    "llama-7b_fact": [
      "HuR (Hu antigen R) protein regulates the splicing process.",
      "HuR is involved in the regulation of gene expression at the post-transcriptional level.",
      "HuR can bind to both pre-mRNA and mature mRNA.",
      "HuR's interaction with splicing factors can lead to changes in the splicing pattern of target genes.",
      "HuR plays a role in the regulation of alternative splicing, which allows for multiple splicing variants from a single gene."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: HuR (Hu antigen R) protein does not regulate the splicing process; it is primarily involved in mRNA stability and translation regulation.\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1492,
    "user_query": "You MUST give a detailed answer to the following question: Describe the known functions for the prothymosin alpha c-terminal peptide?",
    "llama-7b_response": "Prothymosin alpha (PTMA) is a small protein that plays a crucial role in the development and function of the immune system. The c-terminal peptide of PTMA, which is located at the carboxy-terminus of the protein, has been shown to have several known functions.\n\nOne of the known functions of the c-terminal peptide of PTMA is its ability to interact with and inhibit the activity of the transcription factor NF-κB. NF-κB is a key regulator of immune and inflammatory responses, and its dysregulation has been implicated in a variety of diseases, including cancer and autoimmune disorders. By inhibiting the activity of NF-κB, the c-terminal peptide of PTMA may help to regulate immune and inflammatory responses and prevent the development of these diseases.\n\nIn addition to its role in regulating NF-κB activity, the c-terminal peptide of PTMA has also been shown to have antioxidant properties. Oxidative stress, which is caused by an imbalance between the production of reactive oxygen species and the body's ability to detoxify them, has been implicated in the development of a variety of diseases, including cancer and cardiovascular disease. By scavenging reactive oxygen species, the c-terminal peptide of PTMA may help to protect against oxidative stress and prevent the development of these diseases.\n\nFurthermore, the c-terminal peptide of PTMA has also been shown to have anti-inflammatory properties. Inflammation is a natural response to injury or infection, but chronic inflammation can lead to the development of a variety of diseases, including cancer and autoimmune disorders. By inhibiting the activity of inflammatory mediators, such as cytokines and chemokines, the c-terminal peptide of PTMA may help to regulate inflammation and prevent the development of these diseases.\n\nOverall, the c-terminal peptide of PTMA has been shown to have several known functions, including its ability to interact with and inhibit the activity of",
    "llama-7b_fact_raw": "1. The c-terminal peptide of Prothymosin alpha (PTMA) can interact with and inhibit the activity of the transcription factor NF-κB.\n2. NF-κB is a key regulator of immune and inflammatory responses.\n3. The c-terminal peptide of PTMA has antioxidant properties that may protect against oxidative stress.\n4. Oxidative stress has been implicated in the development of diseases such as cancer and cardiovascular disease.\n5. The c-terminal peptide of PTMA has anti-inflammatory properties that may help regulate inflammation and prevent certain diseases.",
    "llama-7b_fact": [
      "The c-terminal peptide of Prothymosin alpha (PTMA) can interact with and inhibit the activity of the transcription factor NF-κB.",
      "NF-κB is a key regulator of immune and inflammatory responses.",
      "The c-terminal peptide of PTMA has antioxidant properties that may protect against oxidative stress.",
      "Oxidative stress has been implicated in the development of diseases such as cancer and cardiovascular disease.",
      "The c-terminal peptide of PTMA has anti-inflammatory properties that may help regulate inflammation and prevent certain diseases."
    ],
    "llama-7b_judge_raw": "1. TRUE: The c-terminal peptide of Prothymosin alpha (PTMA) has been reported to interact with and inhibit the activity of the transcription factor NF-κB.\n2. TRUE: NF-κB is indeed a key regulator of immune and inflammatory responses.\n3. UNKNOWN: Without specific evidence or references provided in the context, it is difficult to determine the accuracy of the statement regarding the antioxidant properties of the c-terminal peptide of PTMA.\n4. TRUE: Oxidative stress is widely recognized as a contributing factor in the development of various diseases, including cancer and cardiovascular disease.\n5. UNKNOWN: Similar to statement 3, without specific evidence or references, it is difficult to determine the accuracy of the statement regarding the anti-inflammatory properties of the c-terminal peptide of PTMA.",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1516,
    "user_query": "You MUST give a detailed answer to the following question: Which peptide plays a pivotal role in human cystatin C fibrillization?",
    "llama-7b_response": "cystatin C",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 1574,
    "user_query": "You MUST give a detailed answer to the following question: Does the concentration of protein HIF-1α increase after the administration of the cytoprotective prodrug\"amifostine\" (ethyol) ?",
    "llama-7b_response": "The concentration of protein hypoxia-inducible factor 1α (HIF-1α) is not directly affected by the administration of the cytoprotective prodrug amifostine (ethyol). HIF-1α is a protein that plays a key role in the response to low oxygen levels (hypoxia) in cells. It is involved in the upregulation of genes that help cells adapt to low oxygen conditions, such as the production of erythropoietin (EPO), which stimulates the production of red blood cells.\n\nAmifostine (ethyol) is a cytoprotective agent that is used to protect cells against the toxic effects of chemotherapy and radiation therapy. It is a prodrug, which means that it is not active until it is metabolized in the body. Amifostine (ethyol) is metabolized by the liver into two active metabolites, diethylystilbestrol (DES) and diethylstilbestrol (DES), which are responsible for its cytoprotective effects.\n\nWhile amifostine (ethyol) has been shown to protect cells against the toxic effects of chemotherapy and radiation therapy, it does not directly affect the concentration of HIF-1α. The mechanism by which amifostine (ethyol) exerts its cytoprotective effects is not fully understood, but it is thought to involve the protection of cells against oxidative stress and the inhibition of apoptosis (programmed cell death).\n\nIn summary, while amifostine (ethyol) is a cytoprotective agent that has been shown to protect cells against the toxic effects of chemotherapy and radiation therapy, it does not directly affect the concentration of HIF-1α.",
    "llama-7b_fact_raw": "1. The concentration of protein hypoxia-inducible factor 1α (HIF-1α) is not directly affected by the administration of the cytoprotective prodrug amifostine (ethyol).\n2. HIF-1α is involved in the upregulation of genes that help cells adapt to low oxygen conditions.\n3. Amifostine (ethyol) is used to protect cells against the toxic effects of chemotherapy and radiation therapy.\n4. Amifostine (ethyol) is a prodrug that is metabolized into two active metabolites, diethylystilbestrol (DES) and diethylstilbestrol (DES).\n5. The cytoprotective effects of amifostine (ethyol) are thought to involve the protection of cells against oxidative stress and the inhibition of apoptosis.",
    "llama-7b_fact": [
      "The concentration of protein hypoxia-inducible factor 1α (HIF-1α) is not directly affected by the administration of the cytoprotective prodrug amifostine (ethyol).",
      "HIF-1α is involved in the upregulation of genes that help cells adapt to low oxygen conditions.",
      "Amifostine (ethyol) is used to protect cells against the toxic effects of chemotherapy and radiation therapy.",
      "Amifostine (ethyol) is a prodrug that is metabolized into two active metabolites, diethylystilbestrol (DES) and diethylstilbestrol (DES).",
      "The cytoprotective effects of amifostine (ethyol) are thought to involve the protection of cells against oxidative stress and the inhibition of apoptosis."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN: The effect of amifostine on HIF-1α concentration can vary depending on the experimental conditions and the specific context in which it is used. Without specific data or research findings, it is not possible to definitively say whether the concentration of HIF-1α is directly affected by the administration of amifostine.\n2. TRUE: HIF-1α is indeed involved in the cellular response to hypoxia, which includes the upregulation of genes that help cells adapt to low oxygen conditions.\n3. TRUE: Amifostine is used to protect normal cells from the damage caused by chemotherapy and radiation therapy.\n4. FALSE [correction]: Amifostine is metabolized into an active free thiol metabolite, WR-1065, not diethylystilbestrol (DES) and diethylstilbestrol (DES), which are unrelated compounds.\n5. TRUE: The cytoprotective effects of amifostine are associated with its ability to scavenge free radicals, thereby protecting cells against oxidative stress, and it may also inhibit apoptosis.",
    "llama-7b_judge": [
      "unknown",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1588,
    "user_query": "You MUST give a detailed answer to the following question: Which histone marks are deposited by Set7?",
    "llama-7b_response": "Set7 is a histone methyltransferase that adds a methyl group to histone H3 at lysine 79 (H3K79me1) and histone H3 at lysine 56 (H3K56me1) [1]. These histone marks are associated with transcriptionally active regions of the genome, such as promoters and enhancers, and play a role in the regulation of gene expression [2].\n\nSet7 is a member of the SUV39H family of histone methyltransferases, which also includes SUV39H1, SUV39H2, and SUV39H3. These enzymes differ in their substrate specificity and tissue expression patterns [3]. SUV39H1 and SUV39H2 primarily methylate histone H3 at lysine 9 (H3K9me1) and histone H3 at lysine 27 (H3K27me1), respectively, while SUV39H3 methylates histone H3 at lysine 79 (H3K79me1) and histone H3 at lysine 56 (H3K56me1) [4].\n\nSet7 has been shown to play a role in the regulation of gene expression during development and in response to environmental cues [5]. For example, Set7 has been shown to be involved in the regulation of the circadian clock in Arabidopsis thaliana, where it methylates histone H3 at lysine 79 (H3K79me1) and histone H3 at lysine 56 (H3K56me1) at the promoters of clock-controlled genes [6].\n\nIn summary, Set7 adds the histone marks H3K79me1 and H3K56me1 to histone H3, which are associated with transcriptionally active regions of the genome and play a role in the regulation of gene expression. Set7 is a member of the SUV39H family of histone methyltransferases and is involved in the regulation of gene expression during development and in response to environmental cues.",
    "llama-7b_fact_raw": "1. Set7 is a histone methyltransferase that adds a methyl group to histone H3 at lysine 79 (H3K79me1).\n2. Set7 also adds a methyl group to histone H3 at lysine 56 (H3K56me1).\n3. The histone marks H3K79me1 and H3K56me1 are associated with transcriptionally active regions of the genome.\n4. SUV39H1 and SUV39H2 primarily methylate histone H3 at lysine 9 and lysine 27, respectively.\n5. Set7 has been shown to be involved in the regulation of the circadian clock in Arabidopsis thaliana by methylating histone H3 at lysine 79 and lysine 56 at the promoters of clock-controlled genes.",
    "llama-7b_fact": [
      "Set7 is a histone methyltransferase that adds a methyl group to histone H3 at lysine 79 (H3K79me1).",
      "Set7 also adds a methyl group to histone H3 at lysine 56 (H3K56me1).",
      "The histone marks H3K79me1 and H3K56me1 are associated with transcriptionally active regions of the genome.",
      "SUV39H1 and SUV39H2 primarily methylate histone H3 at lysine 9 and lysine 27, respectively.",
      "Set7 has been shown to be involved in the regulation of the circadian clock in Arabidopsis thaliana by methylating histone H3 at lysine 79 and lysine 56 at the promoters of clock-controlled genes."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Set7 (also known as SETD7) is a histone methyltransferase that adds a methyl group to histone H3 at lysine 4 (H3K4me1), not lysine 79.\n2. FALSE [correction]: Set7 does not add a methyl group to histone H3 at lysine 56 (H3K56me1); this modification is typically associated with other enzymes.\n3. TRUE: The histone marks H3K79me1 and H3K56me1 are indeed associated with transcriptionally active regions of the genome, although Set7 is not responsible for these particular modifications.\n4. FALSE [correction]: SUV39H1 and SUV39H2 primarily methylate histone H3 at lysine 9 (H3K9me3), not lysine 27. Lysine 27 methylation (H3K27me3) is typically associated with the Polycomb group protein EZH2.\n5. UNKNOWN: Without specific literature to confirm or deny the involvement of Set7 in the regulation of the circadian clock in Arabidopsis thaliana through methylation at lysine 79 and lysine 56, the truth of this statement cannot be determined.",
    "llama-7b_judge": [
      "false",
      "false",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1620,
    "user_query": "You MUST give a detailed answer to the following question: How many disulfide bridges has the protein hepcidin got?",
    "llama-7b_response": "Hepcidin is a protein that plays a crucial role in regulating iron metabolism in the body. It is produced primarily by hepatocytes in the liver and acts as a negative regulator of iron absorption from the gut. Hepcidin binds to and inhibits the activity of divalent metal transporter 1 (DMT1), a protein that facilitates the uptake of iron from the gut into enterocytes.\n\nThe structure of hepcidin is characterized by a conserved cysteine-rich N-terminal domain and a less conserved C-terminal domain. The N-terminal domain contains four cysteine residues that form three disulfide bridges, while the C-terminal domain contains two cysteine residues that also form disulfide bonds. These disulfide bonds help to stabilize the structure of the protein and prevent its degradation by proteases.\n\nTherefore, hepcidin has a total of six cysteine residues, three of which form three disulfide bridges in the N-terminal domain and two of which form two disulfide bonds in the C-terminal domain.",
    "llama-7b_fact_raw": "1. Hepcidin is a protein that regulates iron metabolism in the body.\n2. Hepcidin is produced primarily by hepatocytes in the liver.\n3. Hepcidin binds to and inhibits the activity of divalent metal transporter 1 (DMT1).\n4. The N-terminal domain of hepcidin contains four cysteine residues that form three disulfide bridges.\n5. The C-terminal domain of hepcidin contains two cysteine residues that form one disulfide bond.",
    "llama-7b_fact": [
      "Hepcidin is a protein that regulates iron metabolism in the body.",
      "Hepcidin is produced primarily by hepatocytes in the liver.",
      "Hepcidin binds to and inhibits the activity of divalent metal transporter 1 (DMT1).",
      "The N-terminal domain of hepcidin contains four cysteine residues that form three disulfide bridges.",
      "The C-terminal domain of hepcidin contains two cysteine residues that form one disulfide bond."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Hepcidin binds to and inhibits the activity of ferroportin, not divalent metal transporter 1 (DMT1).\n4. FALSE [correction]: The N-terminal domain of hepcidin contains eight cysteine residues that form four disulfide bridges.\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1643,
    "user_query": "You MUST give a detailed answer to the following question: What is the localization of the protein encoded by the gene DNAJC11?",
    "llama-7b_response": "The protein encoded by the gene DNAJC11 is localized to the endoplasmic reticulum (ER) in mammalian cells. The ER is a membrane-bound organelle that is involved in a variety of cellular processes, including protein folding, modification, and transport. The localization of DNAJC11 to the ER suggests that it may play a role in the proper folding and processing of proteins within this organelle.",
    "llama-7b_fact_raw": "1. The protein encoded by the gene DNAJC11 is localized to the endoplasmic reticulum in mammalian cells.\n2. The endoplasmic reticulum is involved in protein folding, modification, and transport.\n3. The localization of DNAJC11 to the endoplasmic reticulum suggests it may be involved in protein folding and processing within the organelle.",
    "llama-7b_fact": [
      "The protein encoded by the gene DNAJC11 is localized to the endoplasmic reticulum in mammalian cells.",
      "The endoplasmic reticulum is involved in protein folding, modification, and transport.",
      "The localization of DNAJC11 to the endoplasmic reticulum suggests it may be involved in protein folding and processing within the organelle."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1655,
    "user_query": "You MUST give a detailed answer to the following question: Are ultraconserved elements depleted among copy number variants (CNVs)?",
    "llama-7b_response": "Ultraconserved elements (UCEs) are non-coding regions of the genome that are highly conserved across different species, including humans and other primates. These regions are thought to be important for the regulation of gene expression and may play a role in the development and function of the brain.\n\nCopy number variants (CNVs) are variations in the number of copies of a particular region of the genome. CNVs can arise through a variety of mechanisms, including duplication or deletion of large stretches of DNA.\n\nIt is possible that UCEs may be depleted among CNVs, meaning that CNVs are more likely to occur in regions of the genome that are not UCEs. This is because UCEs are highly conserved and may be more difficult to duplicate or delete, making them less likely to be involved in the formation of CNVs.\n\nHowever, it is also possible that UCEs may be overrepresented among CNVs, meaning that CNVs are more likely to occur in regions of the genome that contain UCEs. This is because UCEs may be important for the regulation of gene expression and may play a role in the development and function of the brain, making them more likely to be involved in the formation of CNVs.\n\nOverall, the relationship between UCEs and CNVs is complex and likely depends on a variety of factors, including the specific mechanism by which the CNV arises and the role of UCEs in the regulation of gene expression. Further research is needed to fully understand this relationship.",
    "llama-7b_fact_raw": "1. Ultraconserved elements (UCEs) are non-coding regions of the genome that are highly conserved across different species.\n2. UCEs are thought to be important for the regulation of gene expression and may play a role in brain development and function.\n3. Copy number variants (CNVs) are variations in the number of copies of a particular region of the genome.\n4. CNVs can arise through mechanisms such as duplication or deletion of large stretches of DNA.\n5. The relationship between UCEs and CNVs is complex and not fully understood, requiring further research.",
    "llama-7b_fact": [
      "Ultraconserved elements (UCEs) are non-coding regions of the genome that are highly conserved across different species.",
      "UCEs are thought to be important for the regulation of gene expression and may play a role in brain development and function.",
      "Copy number variants (CNVs) are variations in the number of copies of a particular region of the genome.",
      "CNVs can arise through mechanisms such as duplication or deletion of large stretches of DNA.",
      "The relationship between UCEs and CNVs is complex and not fully understood, requiring further research."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1665,
    "user_query": "You MUST give a detailed answer to the following question: Which is the substrate of the haspin kinase during mitosis?",
    "llama-7b_response": "tubulin",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 1696,
    "user_query": "You MUST give a detailed answer to the following question: What is the mechanism of viroid replication?",
    "llama-7b_response": "A viroid is a small, non-coding RNA molecule that can infect plants and cause disease. The mechanism of viroid replication is unique and different from that of other viruses.\n\nViroids do not have the ability to replicate using the host's cellular machinery, such as ribosomes or DNA polymerase. Instead, they rely on the host's RNA-dependent RNA polymerase (RdRp) to synthesize new copies of the viroid. The RdRp is recruited to the viroid genome and uses the viroid RNA as a template to synthesize complementary RNA strands. This process is known as transcription.\n\nOnce the new RNA strands are synthesized, they are released from the host cell and can infect other cells. The newly synthesized RNA strands can also serve as templates for the RdRp to synthesize more copies of the viroid RNA. This process of transcription and replication can continue indefinitely, making viroids self-replicating.\n\nIn summary, the mechanism of viroid replication involves the recruitment of the host's RNA-dependent RNA polymerase (RdRp) to the viroid genome, which uses the viroid RNA as a template to synthesize complementary RNA strands. These newly synthesized RNA strands can serve as templates for the RdRp to synthesize more copies of the viroid RNA, leading to self-replication.",
    "llama-7b_fact_raw": "1. Viroids are small, non-coding RNA molecules that can infect plants and cause disease.\n2. Viroids replicate using the host's RNA-dependent RNA polymerase (RdRp), not ribosomes or DNA polymerase.\n3. The host's RdRp uses the viroid RNA as a template to synthesize complementary RNA strands.\n4. Newly synthesized RNA strands from viroids can infect other cells.\n5. The replication process of viroids is self-replicating, as the newly synthesized RNA strands can serve as templates for further synthesis.",
    "llama-7b_fact": [
      "Viroids are small, non-coding RNA molecules that can infect plants and cause disease.",
      "Viroids replicate using the host's RNA-dependent RNA polymerase (RdRp), not ribosomes or DNA polymerase.",
      "The host's RdRp uses the viroid RNA as a template to synthesize complementary RNA strands.",
      "Newly synthesized RNA strands from viroids can infect other cells.",
      "The replication process of viroids is self-replicating, as the newly synthesized RNA strands can serve as templates for further synthesis."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1723,
    "user_query": "You MUST give a detailed answer to the following question: Does fibronectin constitute a serum biomarker for Duchenne muscular dystrophy?",
    "llama-7b_response": "Fibronectin is a protein that plays a role in cell-to-cell and cell-to-matrix adhesion and is found in the extracellular matrix. It has been suggested that fibronectin may be a potential serum biomarker for Duchenne muscular dystrophy (DMD).\n\nDMD is a genetic disorder that affects the muscles and is characterized by progressive muscle degeneration and weakness. The disease is caused by a mutation in the dystrophin gene, which results in the absence of the protein dystrophin. Dystrophin is important for maintaining the structural integrity of muscle fibers and is involved in muscle contraction.\n\nFibronectin has been found to be elevated in the serum of patients with DMD. In one study, researchers measured the levels of fibronectin in the serum of patients with DMD and healthy controls and found that the levels of fibronectin were significantly higher in the patients with DMD. The researchers also found that the levels of fibronectin were positively correlated with the severity of the disease.\n\nAnother study found that fibronectin was elevated in the serum of patients with DMD and that the levels of fibronectin were positively correlated with the levels of creatine kinase, a marker of muscle damage.\n\nThese findings suggest that fibronectin may be a potential serum biomarker for DMD. However, further studies are needed to confirm this finding and to determine the specific role of fibronectin in the pathophysiology of DMD.",
    "llama-7b_fact_raw": "1. Fibronectin is a protein involved in cell-to-cell and cell-to-matrix adhesion and is found in the extracellular matrix.\n2. Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness due to a mutation in the dystrophin gene.\n3. The absence of the protein dystrophin is a result of the mutation in the dystrophin gene in DMD patients.\n4. In a study, fibronectin levels were found to be elevated in the serum of patients with DMD compared to healthy controls.\n5. The levels of fibronectin in the serum of patients with DMD were positively correlated with the severity of the disease and with the levels of creatine kinase.",
    "llama-7b_fact": [
      "Fibronectin is a protein involved in cell-to-cell and cell-to-matrix adhesion and is found in the extracellular matrix.",
      "Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness due to a mutation in the dystrophin gene.",
      "The absence of the protein dystrophin is a result of the mutation in the dystrophin gene in DMD patients.",
      "In a study, fibronectin levels were found to be elevated in the serum of patients with DMD compared to healthy controls.",
      "The levels of fibronectin in the serum of patients with DMD were positively correlated with the severity of the disease and with the levels of creatine kinase."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nThe first three statements are accurate descriptions of fibronectin, Duchenne muscular dystrophy, and the role of dystrophin in DMD. However, without specific details about the study mentioned in statements 4 and 5, it is not possible to verify the accuracy of these claims. Therefore, the response to these statements is \"UNKNOWN\".",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1763,
    "user_query": "You MUST give a detailed answer to the following question: Data from which major epigenome projects are contained in the DeepBlue epigenomic data server?",
    "llama-7b_response": "The DeepBlue epigenomic data server contains data from several major epigenome projects, including:\n\n1. The Encyclopedia of DNA Elements (ENCODE) project, which aims to identify and characterize all functional elements in the human genome.\n2. The Roadmap Epigenomics Project, which aims to create a comprehensive catalog of human epigenetic marks and identify their roles in health and disease.\n3. The FANTOM5 project, which aims to identify and characterize functional elements in the mouse genome, including enhancers, promoters, and other regulatory elements.\n4. The Epigenomic Roadmap Project, which aims to create a comprehensive catalog of human epigenetic marks and identify their roles in health and disease.\n5. The 1000 Genomes Project, which aims to create a comprehensive catalog of human genetic variation and provide a resource for studying human genetics and disease.\n\nThese projects have generated a large amount of data on epigenetic marks, such as DNA methylation and histone modifications, across a variety of tissues and cell types. The DeepBlue epigenomic data server provides access to this data, as well as tools for analyzing and interpreting the data.",
    "llama-7b_fact_raw": "1. The DeepBlue epigenomic data server contains data from the Encyclopedia of DNA Elements (ENCODE) project.\n2. Data from the Roadmap Epigenomics Project is included in the DeepBlue epigenomic data server.\n3. The FANTOM5 project data, which focuses on the mouse genome, is available on the DeepBlue epigenomic data server.\n4. The Epigenomic Roadmap Project's data is part of the DeepBlue epigenomic data server's collection.\n5. The 1000 Genomes Project data is contained within the DeepBlue epigenomic data server.",
    "llama-7b_fact": [
      "The DeepBlue epigenomic data server contains data from the Encyclopedia of DNA Elements (ENCODE) project.",
      "Data from the Roadmap Epigenomics Project is included in the DeepBlue epigenomic data server.",
      "The FANTOM5 project data, which focuses on the mouse genome, is available on the DeepBlue epigenomic data server.",
      "The Epigenomic Roadmap Project's data is part of the DeepBlue epigenomic data server's collection.",
      "The 1000 Genomes Project data is contained within the DeepBlue epigenomic data server."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The FANTOM5 project primarily focuses on the human genome, not the mouse genome.\n4. TRUE\n5. FALSE [correction]: The 1000 Genomes Project data is not typically considered epigenomic data and is not part of the DeepBlue epigenomic data server's collection, which focuses on epigenomic datasets.",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 1792,
    "user_query": "You MUST give a detailed answer to the following question: Which tool employs self organizing maps for analyzing synonymous codon usage?",
    "llama-7b_response": "PHYLIP",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 1793,
    "user_query": "You MUST give a detailed answer to the following question: What is MINDY-1?",
    "llama-7b_response": "I'm sorry, but I don't have enough information to answer your question about MINDY-1. Could you please provide more context or clarify your question?",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 1810,
    "user_query": "You MUST give a detailed answer to the following question: Which software package is available for the analysis of conserved genomic loci?",
    "llama-7b_response": "BLAST",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 1860,
    "user_query": "You MUST give a detailed answer to the following question: Please list 3 diseases associated with the PIEZO2 gene.",
    "llama-7b_response": "PIEZO2 is a gene that encodes for a protein called Piezo2, which is a member of the Piezo family of ion channels. These channels are responsible for sensing mechanical stimuli, such as pressure, and transducing them into electrical signals that can be transmitted to the nervous system. Mutations in the PIEZO2 gene have been associated with a number of diseases, including:\n\n1. Hereditary hemorrhagic telangiectasia (HHT): HHT is a genetic disorder that affects the blood vessels, causing them to become abnormally fragile and prone to bleeding. HHT is caused by mutations in multiple genes, including PIEZO2.\n2. Ehlers-Danlos syndrome (EDS): EDS is a group of genetic disorders that affect the connective tissues in the body, including the skin, joints, and blood vessels. Mutations in the PIEZO2 gene have been associated with a subtype of EDS called EDS type IV, which is characterized by abnormal blood vessel function.\n3. Autosomal dominant nocturnal hemoglobinuria (AD-NHB): AD-NHB is a rare genetic disorder that affects the body's ability to produce red blood cells. Mutations in the PIEZO2 gene have been associated with AD-NHB, which is characterized by low levels of hemoglobin in the blood and an increased risk of bleeding.",
    "llama-7b_fact_raw": "1. Mutations in the PIEZO2 gene have been associated with Hereditary hemorrhagic telangiectasia (HHT).\n2. Mutations in the PIEZO2 gene have been associated with a subtype of Ehlers-Danlos syndrome (EDS) called EDS type IV.\n3. Mutations in the PIEZO2 gene have been associated with Autosomal dominant nocturnal hemoglobinuria (AD-NHB).",
    "llama-7b_fact": [
      "Mutations in the PIEZO2 gene have been associated with Hereditary hemorrhagic telangiectasia (HHT).",
      "Mutations in the PIEZO2 gene have been associated with a subtype of Ehlers-Danlos syndrome (EDS) called EDS type IV.",
      "Mutations in the PIEZO2 gene have been associated with Autosomal dominant nocturnal hemoglobinuria (AD-NHB)."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Mutations in the ENG, ACVRL1, and SMAD4 genes have been associated with Hereditary hemorrhagic telangiectasia (HHT), not the PIEZO2 gene.\n2. FALSE [correction]: Mutations in the COL3A1 gene have been associated with a subtype of Ehlers-Danlos syndrome (EDS) called EDS type IV, also known as vascular EDS, not the PIEZO2 gene.\n3. FALSE [correction]: Autosomal dominant nocturnal hemoglobinuria (AD-NHB) is not a recognized medical condition. Paroxysmal nocturnal hemoglobinuria (PNH) is a related term, but it is not associated with mutations in the PIEZO2 gene. PNH is caused by acquired mutations in the PIGA gene.",
    "llama-7b_judge": [
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 1867,
    "user_query": "You MUST give a detailed answer to the following question: What is promoted by ERAP1-ERAP2 dimerization?",
    "llama-7b_response": "ERAP1 and ERAP2 are two members of the ER-associated degradation (ERAD) pathway, which is responsible for the elimination of misfolded or damaged proteins from the endoplasmic reticulum (ER) in eukaryotic cells. The ERAD pathway involves the formation of a complex between ER-resident proteins, such as ERAP1 and ERAP2, and the misfolded protein, which is then transported to the ER lumen and degraded by the proteasome.\n\nERAP1 and ERAP2 dimerization plays a crucial role in the promotion of ERAD. The dimerization of ERAP1 and ERAP2 is required for the formation of a stable complex with the misfolded protein, which is necessary for its transport to the ER lumen and subsequent degradation by the proteasome. The dimerization of ERAP1 and ERAP2 also enhances their ability to recognize and bind to misfolded proteins, allowing for a more efficient clearance of damaged or misfolded proteins from the ER.\n\nIn summary, ERAP1-ERAP2 dimerization is an important step in the ERAD pathway, which promotes the elimination of misfolded or damaged proteins from the ER and contributes to the maintenance of protein homeostasis in eukaryotic cells.",
    "llama-7b_fact_raw": "1. ERAP1 and ERAP2 are involved in the ER-associated degradation (ERAD) pathway in eukaryotic cells.\n2. The ERAD pathway is responsible for the elimination of misfolded or damaged proteins from the endoplasmic reticulum.\n3. Dimerization of ERAP1 and ERAP2 is required for the formation of a stable complex with misfolded proteins.\n4. The dimerization of ERAP1 and ERAP2 enhances their ability to recognize and bind to misfolded proteins.\n5. ERAP1-ERAP2 dimerization contributes to the maintenance of protein homeostasis in eukaryotic cells.",
    "llama-7b_fact": [
      "ERAP1 and ERAP2 are involved in the ER-associated degradation (ERAD) pathway in eukaryotic cells.",
      "The ERAD pathway is responsible for the elimination of misfolded or damaged proteins from the endoplasmic reticulum.",
      "Dimerization of ERAP1 and ERAP2 is required for the formation of a stable complex with misfolded proteins.",
      "The dimerization of ERAP1 and ERAP2 enhances their ability to recognize and bind to misfolded proteins.",
      "ERAP1-ERAP2 dimerization contributes to the maintenance of protein homeostasis in eukaryotic cells."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: ERAP1 and ERAP2 are involved in the processing of peptide antigens for presentation by MHC class I molecules, not in the ER-associated degradation (ERAD) pathway.\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe ERAP1 and ERAP2 enzymes are known for their role in trimming peptides for presentation by MHC class I molecules, which is distinct from the ERAD pathway that deals with the degradation of misfolded proteins. The specific interactions and requirements for dimerization of ERAP1 and ERAP2 in relation to misfolded proteins are not well-established in the provided context, hence the \"UNKNOWN\" responses for statements 3, 4, and 5.",
    "llama-7b_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1890,
    "user_query": "You MUST give a detailed answer to the following question: What is the function of R-spondin 1 and noggin in non-damaged gallbladders?",
    "llama-7b_response": "R-spondin 1 and noggin are both inhibitors of bone morphogenetic protein (BMP) signaling. BMPs are a family of signaling molecules that play a crucial role in the development and maintenance of various tissues, including the gallbladder.\n\nIn non-damaged gallbladders, R-spondin 1 and noggin help to maintain the normal function of the gallbladder by inhibiting the activity of BMPs. Specifically, R-spondin 1 and noggin bind to and inhibit the activity of BMP receptors on the surface of gallbladder cells, preventing the cells from responding to BMP signals.\n\nWithout the inhibitory effect of R-spondin 1 and noggin, the activity of BMPs would be increased in the gallbladder, leading to the formation of excessive connective tissue and the development of gallstones. Therefore, the normal function of R-spondin 1 and noggin in non-damaged gallbladders is to maintain the delicate balance of BMP signaling and prevent the formation of gallstones.",
    "llama-7b_fact_raw": "1. R-spondin 1 and noggin are inhibitors of bone morphogenetic protein (BMP) signaling.\n2. BMPs play a crucial role in the development and maintenance of various tissues, including the gallbladder.\n3. R-spondin 1 and noggin maintain the normal function of the gallbladder by inhibiting the activity of BMPs.\n4. R-spondin 1 and noggin bind to and inhibit the activity of BMP receptors on gallbladder cells.\n5. The normal function of R-spondin 1 and noggin in non-damaged gallbladders is to prevent the formation of excessive connective tissue and gallstones.",
    "llama-7b_fact": [
      "R-spondin 1 and noggin are inhibitors of bone morphogenetic protein (BMP) signaling.",
      "BMPs play a crucial role in the development and maintenance of various tissues, including the gallbladder.",
      "R-spondin 1 and noggin maintain the normal function of the gallbladder by inhibiting the activity of BMPs.",
      "R-spondin 1 and noggin bind to and inhibit the activity of BMP receptors on gallbladder cells.",
      "The normal function of R-spondin 1 and noggin in non-damaged gallbladders is to prevent the formation of excessive connective tissue and gallstones."
    ],
    "llama-7b_judge_raw": "1. TRUE: R-spondin 1 and noggin are indeed known to be inhibitors of bone morphogenetic protein (BMP) signaling. R-spondin 1 enhances Wnt signaling, which can have an interplay with BMP signaling, while noggin is a well-known direct antagonist of BMPs.\n2. TRUE: BMPs are important signaling molecules that play a critical role in the development, differentiation, and maintenance of various tissues and organs, including the gallbladder.\n3. UNKNOWN: While R-spondin 1 and noggin inhibit BMP signaling, which is important for tissue development and maintenance, the specific role of these inhibitors in maintaining the normal function of the gallbladder is not clearly stated and would require specific biological evidence.\n4. FALSE [correction]: R-spondin 1 does not directly bind to and inhibit BMP receptors. Instead, it modulates the Wnt signaling pathway. Noggin, on the other hand, binds to BMPs, preventing them from interacting with their receptors, but it does not bind directly to the receptors themselves.\n5. UNKNOWN: The statement about the normal function of R-spondin 1 and noggin in non-damaged gallbladders to prevent the formation of excessive connective tissue and gallstones is specific and would require evidence from scientific studies. Without such evidence, the truth of this statement cannot be determined.",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1937,
    "user_query": "You MUST give a detailed answer to the following question: Does NADPH oxidase 5 require any subunit for function?",
    "llama-7b_response": "Yes, NADPH oxidase 5 (NOX5) requires all four subunits (gp91phox, p22phox, p40phox, and p44phox) for its enzymatic activity.\n\nNOX5 is a member of the NADPH oxidase family of enzymes, which generate reactive oxygen species (ROS) as a byproduct of the oxidation of NADPH. The enzymatic activity of NADPH oxidase is regulated by the association of its subunits, and NOX5 is no exception.\n\nThe four subunits of NOX5 (gp91phox, p22phox, p40phox, and p44phox) are required for the enzymatic activity of NOX5. The gp91phox subunit is the catalytic subunit of NOX5 and is responsible for the oxidation of NADPH. The p22phox, p40phox, and p44phox subunits are non-catalytic subunits that interact with the gp91phox subunit to form the active enzyme complex.\n\nThe absence of any one of these subunits results in a loss of enzymatic activity, indicating that NOX5 requires all four subunits for its function.\n\nIn summary, NOX5 requires all four subunits (gp91phox, p22phox, p40phox, and p44phox) for its enzymatic activity, and the absence of any one of these subunits results in a loss of enzymatic activity.",
    "llama-7b_fact_raw": "1. NADPH oxidase 5 (NOX5) requires all four subunits (gp91phox, p22phox, p40phox, and p44phox) for its enzymatic activity.\n2. The gp91phox subunit is the catalytic subunit of NOX5.\n3. The p22phox, p40phox, and p44phox subunits are non-catalytic subunits that interact with the gp91phox subunit to form the active enzyme complex.\n4. The absence of any one of the subunits (gp91phox, p22phox, p40phox, and p44phox) results in a loss of enzymatic activity for NOX5.",
    "llama-7b_fact": [
      "NADPH oxidase 5 (NOX5) requires all four subunits (gp91phox, p22phox, p40phox, and p44phox) for its enzymatic activity.",
      "The gp91phox subunit is the catalytic subunit of NOX5.",
      "The p22phox, p40phox, and p44phox subunits are non-catalytic subunits that interact with the gp91phox subunit to form the active enzyme complex.",
      "The absence of any one of the subunits (gp91phox, p22phox, p40phox, and p44phox) results in a loss of enzymatic activity for NOX5."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: NADPH oxidase 5 (NOX5) does not require the subunits gp91phox, p22phox, p40phox, and p44phox for its enzymatic activity. NOX5 is a calcium-dependent enzyme that functions independently of these subunits, which are associated with other NOX family members, such as NOX2.\n2. FALSE [correction]: The gp91phox subunit is not the catalytic subunit of NOX5; it is the catalytic subunit of NOX2. NOX5 has its own catalytic subunit that is not gp91phox.\n3. FALSE [correction]: The p22phox, p40phox, and p44phox subunits are not non-catalytic subunits that interact with NOX5. These subunits are part of the NOX2 complex, not NOX5.\n4. FALSE [correction]: The absence of the subunits gp91phox, p22phox, p40phox, and p44phox does not affect the enzymatic activity of NOX5, as NOX5 does not require these subunits to be active.",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 1944,
    "user_query": "You MUST give a detailed answer to the following question: What is the connection between furin and hepcidin?",
    "llama-7b_response": "Furin and hepcidin are both proteins that play important roles in regulating iron metabolism in the body.\n\nFurin is an enzyme that is involved in the processing and activation of various proteins, including hepcidin. Specifically, furin cleaves the N-terminal peptide of hepcidin, releasing the mature, biologically active form of the protein.\n\nHepcidin is a small, peptide hormone that is produced primarily by hepatocytes in the liver. It is the primary regulator of iron absorption and homeostasis in the body. Hepcidin acts by binding to and inhibiting the absorption of iron by enterocytes in the small intestine.\n\nThe connection between furin and hepcidin is that furin plays a critical role in the processing and activation of hepcidin. Specifically, furin cleaves the N-terminal peptide of hepcidin, releasing the mature, biologically active form of the protein. This allows hepcidin to bind to and inhibit the absorption of iron by enterocytes in the small intestine, thereby regulating iron metabolism in the body.\n\nTherefore, the connection between furin and hepcidin is that they both play important roles in regulating iron metabolism in the body, with furin playing a critical role in the processing and activation of hepcidin.",
    "llama-7b_fact_raw": "1. Furin is an enzyme that is involved in the processing and activation of various proteins, including hepcidin.\n2. Furin cleaves the N-terminal peptide of hepcidin to release the mature, biologically active form of the protein.\n3. Hepcidin is a peptide hormone produced primarily by hepatocytes in the liver.\n4. Hepcidin is the primary regulator of iron absorption and homeostasis in the body.\n5. Hepcidin regulates iron metabolism by binding to and inhibiting the absorption of iron by enterocytes in the small intestine.",
    "llama-7b_fact": [
      "Furin is an enzyme that is involved in the processing and activation of various proteins, including hepcidin.",
      "Furin cleaves the N-terminal peptide of hepcidin to release the mature, biologically active form of the protein.",
      "Hepcidin is a peptide hormone produced primarily by hepatocytes in the liver.",
      "Hepcidin is the primary regulator of iron absorption and homeostasis in the body.",
      "Hepcidin regulates iron metabolism by binding to and inhibiting the absorption of iron by enterocytes in the small intestine."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Furin does not cleave the N-terminal peptide of hepcidin. Instead, furin is involved in the activation of various precursor proteins by cleaving their specific sites, but not hepcidin. Hepcidin is synthesized as a prepropeptide, and its maturation involves the removal of an N-terminal signal peptide and a C-terminal propeptide to produce the active form, but this process is not mediated by furin.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Hepcidin regulates iron metabolism by binding to and causing the internalization and degradation of ferroportin, a protein that exports iron from cells, including enterocytes in the small intestine and macrophages. This action reduces the amount of iron absorbed from the diet and released from recycled red blood cells, not by directly inhibiting the absorption of iron by enterocytes.",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1956,
    "user_query": "You MUST give a detailed answer to the following question: Which is the largest metabolic gene cluster in yeast?",
    "llama-7b_response": "glycolysi",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 1967,
    "user_query": "You MUST give a detailed answer to the following question: What is the role of LIMT lncRNA?",
    "llama-7b_response": "The role of LIMT lncRNA (long non-coding RNA) has not yet been fully elucidated, but it is known to be involved in the regulation of gene expression. LIMT lncRNA has been found to be expressed in a variety of tissues and cell types, including the brain, heart, and pancreas.\n\nSeveral studies have suggested that LIMT lncRNA may play a role in the regulation of cell proliferation, differentiation, and apoptosis. For example, one study found that overexpression of LIMT lncRNA in cancer cells led to increased cell proliferation and decreased apoptosis, while another study found that knockdown of LIMT lncRNA in cancer cells led to decreased cell proliferation and increased apoptosis.\n\nAdditionally, LIMT lncRNA has been found to be involved in the regulation of the Wnt/β-catenin signaling pathway, which is a key regulator of cell proliferation and differentiation in many tissues. One study found that LIMT lncRNA interacts with the Wnt/β-catenin signaling pathway and regulates its activity, while another study found that knockdown of LIMT lncRNA in cancer cells leads to decreased Wnt/β-catenin signaling and decreased cell proliferation.\n\nOverall, these studies suggest that LIMT lncRNA may play a role in the regulation of cell proliferation, differentiation, and apoptosis, and may be involved in the regulation of the Wnt/β-catenin signaling pathway. However, further research is needed to fully understand the role of LIMT lncRNA in these processes.",
    "llama-7b_fact_raw": "1. LIMT lncRNA is involved in the regulation of gene expression.\n2. LIMT lncRNA is expressed in various tissues and cell types, including the brain, heart, and pancreas.\n3. Overexpression of LIMT lncRNA in cancer cells has been associated with increased cell proliferation and decreased apoptosis.\n4. Knockdown of LIMT lncRNA in cancer cells has been associated with decreased cell proliferation and increased apoptosis.\n5. LIMT lncRNA has been found to interact with the Wnt/β-catenin signaling pathway, which is important for cell proliferation and differentiation.",
    "llama-7b_fact": [
      "LIMT lncRNA is involved in the regulation of gene expression.",
      "LIMT lncRNA is expressed in various tissues and cell types, including the brain, heart, and pancreas.",
      "Overexpression of LIMT lncRNA in cancer cells has been associated with increased cell proliferation and decreased apoptosis.",
      "Knockdown of LIMT lncRNA in cancer cells has been associated with decreased cell proliferation and increased apoptosis.",
      "LIMT lncRNA has been found to interact with the Wnt/β-catenin signaling pathway, which is important for cell proliferation and differentiation."
    ],
    "llama-7b_judge_raw": "1. TRUE - LIMT lncRNA (long intergenic non-protein coding RNA, muscle and heart) is indeed involved in the regulation of gene expression.\n2. TRUE - LncRNAs, including LIMT, are often expressed in various tissues and cell types, and it is plausible that LIMT lncRNA is expressed in the brain, heart, and pancreas among others.\n3. UNKNOWN - Without specific research data or studies to reference, it is not possible to confirm the association of overexpression of LIMT lncRNA with increased cell proliferation and decreased apoptosis in cancer cells.\n4. UNKNOWN - Similarly, without specific research data or studies, it is not possible to confirm the association of knockdown of LIMT lncRNA with decreased cell proliferation and increased apoptosis in cancer cells.\n5. UNKNOWN - The interaction of LIMT lncRNA with the Wnt/β-catenin signaling pathway is specific and would require research evidence to confirm. Without such evidence, the statement's accuracy cannot be determined.",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1984,
    "user_query": "You MUST give a detailed answer to the following question: Which R / bioconductor package is used for performing SNP enrichment analysis?",
    "llama-7b_response": "GenABEL",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 2015,
    "user_query": "You MUST give a detailed answer to the following question: Which are the key players on radial glial specification to ependymal cells?",
    "llama-7b_response": "Radial glial cells are a type of glial cell that play a crucial role in the development of the central nervous system (CNS). During embryonic development, radial glial cells give rise to ependymal cells, which form the ependyma, a layer of cells that lines the ventricular system of the brain and spinal cord.\n\nThere are several key players involved in the specification of radial glial cells to ependymal cells. These include:\n\n1. Sonic hedgehog (Shh) signaling: Shh is a key signaling molecule that plays a crucial role in the specification of radial glial cells to ependymal cells. Shh signaling promotes the differentiation of radial glial cells into ependymal cells by activating the expression of genes involved in ependymal cell differentiation, such as Sox2 and Olig2.\n2. Wnt signaling: Wnt signaling also plays a role in the specification of radial glial cells to ependymal cells. Wnt signaling inhibits the differentiation of radial glial cells into ependymal cells by suppressing the expression of genes involved in ependymal cell differentiation, such as Sox2 and Olig2.\n3. Notch signaling: Notch signaling also plays a role in the specification of radial glial cells to ependymal cells. Notch signaling promotes the differentiation of radial glial cells into ependymal cells by activating the expression of genes involved in ependymal cell differentiation, such as Sox2 and Olig2.\n4. TGF-β signaling: TGF-β signaling also plays a role in the specification of radial glial cells to ependymal cells. TGF-β signaling inhibits the differentiation of radial glial cells into ependymal cells by suppressing the expression of genes involved in ependymal cell differentiation, such as Sox2 and Olig2.\n\nOverall, the specification of radial glial cells to ependymal cells involves a complex interplay between multiple signaling pathways, including Shh, Wnt, Notch, and TGF-β signaling. These signaling pathways work together to promote the differentiation of radial gli",
    "llama-7b_fact_raw": "1. Radial glial cells give rise to ependymal cells during embryonic development.\n2. Sonic hedgehog (Shh) signaling is involved in the differentiation of radial glial cells into ependymal cells.\n3. Wnt signaling can inhibit the differentiation of radial glial cells into ependymal cells.\n4. Notch signaling promotes the differentiation of radial glial cells into ependymal cells.\n5. TGF-β signaling inhibits the differentiation of radial glial cells into ependymal cells.",
    "llama-7b_fact": [
      "Radial glial cells give rise to ependymal cells during embryonic development.",
      "Sonic hedgehog (Shh) signaling is involved in the differentiation of radial glial cells into ependymal cells.",
      "Wnt signaling can inhibit the differentiation of radial glial cells into ependymal cells.",
      "Notch signaling promotes the differentiation of radial glial cells into ependymal cells.",
      "TGF-β signaling inhibits the differentiation of radial glial cells into ependymal cells."
    ],
    "llama-7b_judge_raw": "1. TRUE: Radial glial cells are known to give rise to various types of cells in the central nervous system, including ependymal cells, during embryonic development.\n2. TRUE: Sonic hedgehog (Shh) signaling is one of the pathways involved in the differentiation of various cell types in the central nervous system, including the differentiation of radial glial cells.\n3. UNKNOWN: The role of Wnt signaling in the differentiation of radial glial cells into ependymal cells is complex and context-dependent, and without specific information, it is difficult to determine the truth of this statement.\n4. TRUE: Notch signaling is known to play a role in maintaining the progenitor state of radial glial cells, and it can promote the differentiation of these cells into various cell types, including ependymal cells, depending on the context.\n5. UNKNOWN: TGF-β signaling has multiple roles in the central nervous system and can have different effects on cell differentiation depending on the context. Without specific information, it is difficult to determine the truth of this statement regarding the inhibition of radial glial cell differentiation into ependymal cells.",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2065,
    "user_query": "You MUST give a detailed answer to the following question: How are triple negative gliomas characterized?",
    "llama-7b_response": "Triple negative gliomas (TNGs) are a subtype of glioma, which is a type of brain tumor. TNGs are characterized by the absence of three biomarkers: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). These biomarkers are typically found in other types of cancer, but not in TNGs.\n\nIn addition to the absence of these biomarkers, TNGs are also characterized by their aggressive behavior and poor prognosis. They tend to grow rapidly and are often resistant to standard treatments such as radiation and chemotherapy.\n\nAnother characteristic of TNGs is that they tend to occur more frequently in younger adults, with a median age of diagnosis of 30-40 years. They also tend to occur more frequently in women than in men.\n\nTNGs are typically diagnosed through a combination of imaging tests, such as magnetic resonance imaging (MRI) and computed tomography (CT) scans, and biopsy. Once diagnosed, treatment options for TNGs typically include surgery to remove as much of the tumor as possible, followed by radiation therapy and chemotherapy.",
    "llama-7b_fact_raw": "1. Triple negative gliomas are characterized by the absence of three biomarkers: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2).\n2. Triple negative gliomas are known for their aggressive behavior and poor prognosis.\n3. These tumors tend to grow rapidly and are often resistant to standard treatments such as radiation and chemotherapy.\n4. Triple negative gliomas occur more frequently in younger adults, with a median age of diagnosis of 30-40 years.\n5. Triple negative gliomas are more common in women than in men.",
    "llama-7b_fact": [
      "Triple negative gliomas are characterized by the absence of three biomarkers: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2).",
      "Triple negative gliomas are known for their aggressive behavior and poor prognosis.",
      "These tumors tend to grow rapidly and are often resistant to standard treatments such as radiation and chemotherapy.",
      "Triple negative gliomas occur more frequently in younger adults, with a median age of diagnosis of 30-40 years.",
      "Triple negative gliomas are more common in women than in men."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Triple negative gliomas are characterized by the absence of three biomarkers: IDH1, 1p/19q co-deletion, and ATRX. The absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) is typically used to describe triple-negative breast cancer, not gliomas.\n2. TRUE\n3. TRUE\n4. UNKNOWN: The statement about the median age of diagnosis for triple negative gliomas is not standard knowledge and can vary based on different studies and populations. Without specific data or a reference, the age range cannot be confirmed as true or false.\n5. UNKNOWN: The prevalence of triple negative gliomas in women versus men is not a well-established fact and can depend on the specific type of glioma and demographic factors. Without specific data or a reference, this statement cannot be confirmed as true or false.",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2069,
    "user_query": "You MUST give a detailed answer to the following question: What is TOPAZ1?",
    "llama-7b_response": "TOPAZ1 is a cryptographic algorithm that is used to encrypt and decrypt data. It is a stream cipher, which means that it operates on a continuous stream of data, rather than on individual blocks of data. TOPAZ1 uses a 128-bit key to encrypt and decrypt data, and it is designed to be fast and efficient. It is often used in conjunction with other cryptographic algorithms to provide additional security.",
    "llama-7b_fact_raw": "1. TOPAZ1 is a cryptographic algorithm used for data encryption and decryption.\n2. TOPAZ1 operates as a stream cipher.\n3. TOPAZ1 encrypts and decrypts data using a 128-bit key.\n4. TOPAZ1 is designed to be fast and efficient.\n5. TOPAZ1 is sometimes used in conjunction with other cryptographic algorithms to enhance security.",
    "llama-7b_fact": [
      "TOPAZ1 is a cryptographic algorithm used for data encryption and decryption.",
      "TOPAZ1 operates as a stream cipher.",
      "TOPAZ1 encrypts and decrypts data using a 128-bit key.",
      "TOPAZ1 is designed to be fast and efficient.",
      "TOPAZ1 is sometimes used in conjunction with other cryptographic algorithms to enhance security."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information about a cryptographic algorithm named TOPAZ1, it is not possible to determine the truth of these statements. TOPAZ1 is not a widely recognized or standard cryptographic algorithm as of my knowledge cutoff date in 2023. It could be a proprietary or less-known algorithm, or it might not exist at all. Therefore, without additional context or information, the truthfulness of these statements cannot be ascertained.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2075,
    "user_query": "You MUST give a detailed answer to the following question: Which gene controls the expression of GATA-1 isoforms?",
    "llama-7b_response": "Gata1",
    "llama-7b_fact_raw": "1. The Gata1 gene controls the expression of GATA-1 isoforms.",
    "llama-7b_fact": [
      "The Gata1 gene controls the expression of GATA-1 isoforms."
    ],
    "llama-7b_judge_raw": "1. TRUE",
    "llama-7b_judge": [
      "true"
    ]
  },
  {
    "id": 2076,
    "user_query": "You MUST give a detailed answer to the following question: What is MIRA-seq?",
    "llama-7b_response": "MIRA-seq (Mutation Identification by High-throughput Sequencing) is a next-generation sequencing (NGS) based method for identifying somatic mutations in cancer cells. It is a targeted sequencing approach that focuses on specific regions of the genome known to harbor mutations in cancer, such as hotspots in oncogenes and tumor suppressor genes.\n\nThe MIRA-seq method involves the following steps:\n\n1. Sample preparation: The starting material for MIRA-seq is a tumor biopsy or cell line. The sample is fragmented into small pieces, and the DNA is isolated.\n2. Library preparation: The isolated DNA is fragmented into smaller pieces, and adapters are added to the ends of the fragments to allow them to be sequenced. The fragments are then enriched for specific regions of the genome, such as hotspots in oncogenes and tumor suppressor genes.\n3. Sequencing: The enriched fragments are then sequenced using NGS technology. The resulting data is analyzed to identify mutations in the targeted regions of the genome.\n4. Data analysis: The sequencing data is analyzed to identify mutations in the targeted regions of the genome. This involves mapping the sequencing reads to the reference genome, identifying mutations by comparing the reads to a reference genome, and validating the mutations by Sanger sequencing or other methods.\n\nMIRA-seq has several advantages over other methods for identifying somatic mutations, such as whole-genome sequencing (WGS) and targeted sequencing. It is faster and less expensive than WGS, and it can focus on specific regions of the genome that are known to harbor mutations in cancer. Additionally, MIRA-seq can identify mutations that are not captured by targeted sequencing, such as low-frequency mutations and mutations in non-coding regions of the genome.\n\nOverall, MIRA-seq is a powerful tool for identifying somatic mutations in cancer cells, and it has the potential to improve our understanding of cancer biology and inform the development of targeted therapies.",
    "llama-7b_fact_raw": "1. MIRA-seq stands for Mutation Identification by High-throughput Sequencing.\n2. MIRA-seq is a targeted sequencing approach that focuses on specific regions of the genome known to harbor mutations in cancer.\n3. The starting material for MIRA-seq can be a tumor biopsy or cell line.\n4. MIRA-seq involves sequencing the enriched DNA fragments using next-generation sequencing (NGS) technology.\n5. MIRA-seq is designed to be faster and less expensive than whole-genome sequencing (WGS).",
    "llama-7b_fact": [
      "MIRA-seq stands for Mutation Identification by High-throughput Sequencing.",
      "MIRA-seq is a targeted sequencing approach that focuses on specific regions of the genome known to harbor mutations in cancer.",
      "The starting material for MIRA-seq can be a tumor biopsy or cell line.",
      "MIRA-seq involves sequencing the enriched DNA fragments using next-generation sequencing (NGS) technology.",
      "MIRA-seq is designed to be faster and less expensive than whole-genome sequencing (WGS)."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: MIRA-seq stands for Methylation-based Inference of Regulatory Activity sequencing.\n2. FALSE [correction]: MIRA-seq is not specifically targeted to regions known to harbor mutations in cancer; it is a method used to infer regulatory activity based on DNA methylation patterns.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2108,
    "user_query": "You MUST give a detailed answer to the following question: What is the indication of ARCALYST?",
    "llama-7b_response": "rheumatoid arthriti",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 2170,
    "user_query": "You MUST give a detailed answer to the following question: List the human acrocentric chromosomes that are involved in Robertsonian translocation.",
    "llama-7b_response": "Robertsonian translocation is a type of chromosomal rearrangement that results in the fusion of two acrocentric chromosomes. The human acrocentric chromosomes involved in Robertsonian translocation are chromosomes 13, 14, 15, and 21.",
    "llama-7b_fact_raw": "1. Robertsonian translocation is a chromosomal rearrangement involving the fusion of two acrocentric chromosomes.\n2. The human acrocentric chromosomes that can be involved in Robertsonian translocation include chromosomes 13, 14, 15, and 21.",
    "llama-7b_fact": [
      "Robertsonian translocation is a chromosomal rearrangement involving the fusion of two acrocentric chromosomes.",
      "The human acrocentric chromosomes that can be involved in Robertsonian translocation include chromosomes 13, 14, 15, and 21."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The human acrocentric chromosomes that can be involved in Robertsonian translocation include chromosomes 13, 14, 15, 21, and 22.",
    "llama-7b_judge": [
      "true",
      "false"
    ]
  },
  {
    "id": 2237,
    "user_query": "You MUST give a detailed answer to the following question: Which R package could be used for the identification of pediatric brain tumors?",
    "llama-7b_response": "There is no single R package that can be used for the identification of pediatric brain tumors. However, there are several R packages that can be used for analyzing and visualizing medical imaging data, which could potentially be used for the identification of pediatric brain tumors. Some examples of R packages that are commonly used for medical imaging analysis include:\n\n1. Image: This package provides functions for image processing and analysis. It can be used for tasks such as image registration, segmentation, and feature extraction.\n2. FreeSurfer: This package provides tools for processing and analyzing brain imaging data, including MRI and DTI data. It can be used for tasks such as skull stripping, cortical surface reconstruction, and tractography.\n3. nipy: This package provides functions for image processing and analysis, with a focus on neuroimaging data. It can be used for tasks such as image registration, segmentation, and feature extraction.\n4. spm: This package provides tools for processing and analyzing MRI data, with a focus on functional MRI (fMRI) data. It can be used for tasks such as image registration, spatial normalization, and statistical analysis of fMRI data.\n\nIt is worth noting that these packages are not specifically designed for the identification of pediatric brain tumors, but rather for the analysis of medical imaging data in general. However, they can be used in combination with other tools and methods to support the identification of pediatric brain tumors.",
    "llama-7b_fact_raw": "1. The R package \"Image\" provides functions for image processing and analysis.\n2. The R package \"FreeSurfer\" provides tools for processing and analyzing brain imaging data, including MRI and DTI data.\n3. The R package \"nipy\" provides functions for neuroimaging data processing and analysis.\n4. The R package \"spm\" provides tools for processing and analyzing MRI data, specifically functional MRI (fMRI) data.",
    "llama-7b_fact": [
      "The R package \"Image\" provides functions for image processing and analysis.",
      "The R package \"FreeSurfer\" provides tools for processing and analyzing brain imaging data, including MRI and DTI data.",
      "The R package \"nipy\" provides functions for neuroimaging data processing and analysis.",
      "The R package \"spm\" provides tools for processing and analyzing MRI data, specifically functional MRI (fMRI) data."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The R package for image processing and analysis is called \"imager,\" not \"Image.\"\n2. FALSE [correction]: \"FreeSurfer\" is not an R package; it is a standalone software suite for processing and analyzing brain imaging data.\n3. FALSE [correction]: \"nipy\" is a Python-based platform, not an R package, for neuroimaging data processing and analysis.\n4. FALSE [correction]: \"spm\" stands for Statistical Parametric Mapping, which is a software package, but it is not an R package. It is primarily used with MATLAB for processing and analyzing MRI data, specifically fMRI data.",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2246,
    "user_query": "You MUST give a detailed answer to the following question: Is NEMO a zinc finger protein?",
    "llama-7b_response": "Yes, NEMO (Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha) is a zinc finger protein.\n\nZinc finger proteins are a family of transcription factors that contain one or more zinc-binding domains in their structure. These domains allow zinc finger proteins to recognize specific DNA sequences and regulate gene expression.\n\nNEMO is a key component of the IKK (IkappaB kinase) complex, which plays a central role in the NF-kappaB signaling pathway. NF-kappaB is a transcription factor that regulates the expression of genes involved in cell growth, differentiation, and immune response.\n\nThe IKK complex phosphorylates and activates the NF-kappaB inhibitor protein IkappaB, leading to its degradation and the release of active NF-kappaB. NEMO is a zinc finger protein that interacts with the IKK complex and plays a critical role in this process.\n\nTherefore, NEMO is a zinc finger protein that plays a crucial role in the NF-kappaB signaling pathway by interacting with the IKK complex and regulating the expression of genes involved in cell growth, differentiation, and immune response.",
    "llama-7b_fact_raw": "1. NEMO stands for Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha.\n2. NEMO is a zinc finger protein.\n3. Zinc finger proteins are transcription factors that have zinc-binding domains.\n4. The IKK complex, which includes NEMO, is involved in the NF-kappaB signaling pathway.\n5. NF-kappaB is a transcription factor that regulates genes related to cell growth, differentiation, and immune response.",
    "llama-7b_fact": [
      "NEMO stands for Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha.",
      "NEMO is a zinc finger protein.",
      "Zinc finger proteins are transcription factors that have zinc-binding domains.",
      "The IKK complex, which includes NEMO, is involved in the NF-kappaB signaling pathway.",
      "NF-kappaB is a transcription factor that regulates genes related to cell growth, differentiation, and immune response."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: NEMO is not a zinc finger protein; it is an essential regulatory component of the IκB kinase (IKK) complex.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2247,
    "user_query": "You MUST give a detailed answer to the following question: Does TFIIS affect nucleosome positioning?",
    "llama-7b_response": "Transcription factor IIS (TFIIS) is a general transcription factor that plays a crucial role in the initiation of RNA polymerase II-mediated transcription. TFIIS is composed of three subunits: TFIIS-alpha, TFIIS-beta, and TFIIS-gamma. TFIIS-alpha and TFIIS-beta interact with the RNA polymerase II holoenzyme, while TFIIS-gamma interacts with the TFIIS-alpha and TFIIS-beta subunits.\n\nThe role of TFIIS in nucleosome positioning has been the subject of much research. Nucleosomes are the basic units of chromatin, and they consist of DNA wrapped around a core of histone proteins. Nucleosome positioning is an important aspect of gene regulation, as it determines the accessibility of DNA to transcription factors and other regulatory proteins.\n\nTFIIS has been shown to affect nucleosome positioning in several ways. Firstly, TFIIS can displace nucleosomes from the promoter region of a gene, allowing the RNA polymerase II holoenzyme to access the DNA and initiate transcription. This is achieved through the interaction between TFIIS-alpha and TFIIS-beta subunits and the RNA polymerase II holoenzyme.\n\nSecondly, TFIIS can also promote the formation of open chromatin regions, which are regions of chromatin that are more accessible to transcription factors and other regulatory proteins. This is achieved through the interaction between TFIIS-alpha and TFIIS-beta subunits and the histone acetyltransferase p300. p300 is a transcriptional co-activator that can acetylate histones, leading to the displacement of nucleosomes and the formation of open chromatin regions.\n\nIn summary, TFIIS plays an important role in the initiation of RNA polymerase II-mediated transcription by displacing nucleosomes from the promoter region of a gene and promoting the formation of open chromatin regions. These effects on nucleosome positioning can have a significant impact on gene regulation and the",
    "llama-7b_fact_raw": "1. Transcription factor IIS (TFIIS) is composed of three subunits: TFIIS-alpha, TFIIS-beta, and TFIIS-gamma.\n2. TFIIS-alpha and TFIIS-beta interact with the RNA polymerase II holoenzyme.\n3. TFIIS-gamma interacts with the TFIIS-alpha and TFIIS-beta subunits.\n4. TFIIS can displace nucleosomes from the promoter region of a gene to facilitate the initiation of transcription by RNA polymerase II.\n5. TFIIS can promote the formation of open chromatin regions through interaction with the histone acetyltransferase p300.",
    "llama-7b_fact": [
      "Transcription factor IIS (TFIIS) is composed of three subunits: TFIIS-alpha, TFIIS-beta, and TFIIS-gamma.",
      "TFIIS-alpha and TFIIS-beta interact with the RNA polymerase II holoenzyme.",
      "TFIIS-gamma interacts with the TFIIS-alpha and TFIIS-beta subunits.",
      "TFIIS can displace nucleosomes from the promoter region of a gene to facilitate the initiation of transcription by RNA polymerase II.",
      "TFIIS can promote the formation of open chromatin regions through interaction with the histone acetyltransferase p300."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. FALSE [correction]: TFIIS does not displace nucleosomes from the promoter region to facilitate the initiation of transcription by RNA polymerase II. Instead, TFIIS is involved in the process of transcription elongation by RNA polymerase II, where it can stimulate the cleavage of nascent RNA, allowing the polymerase to recover from a stalled state.\n5. UNKNOWN",
    "llama-7b_judge": [
      "unknown",
      "true",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2262,
    "user_query": "You MUST give a detailed answer to the following question: Do origins of replication close to yeast centromeres fire early or late?",
    "llama-7b_response": "The origin of replication (ori) that is closest to the centromere of yeast (Saccharomyces cerevisiae) fires early during the S phase of the cell cycle. This is in contrast to the origins of replication that are located further away from the centromere, which fire late during the S phase.\n\nThe timing of replication at different origins of replication is determined by the position of the origins relative to the centromere. The centromere is a specialized region of the chromosome that plays a crucial role in the proper separation of sister chromatids during cell division. The origins of replication are the points at which DNA replication begins, and the timing of replication at each origin is determined by the position of the origin relative to the centromere.\n\nThe origins of replication that are closest to the centromere fire early during the S phase of the cell cycle, while the origins of replication that are located further away from the centromere fire late during the S phase. This is because the early-firing origins are located on the side of the chromosome that is closest to the spindle fibers during mitosis or meiosis, and are therefore more accessible to the replication machinery. In contrast, the late-firing origins are located on the side of the chromosome that is further away from the spindle fibers, and are therefore less accessible to the replication machinery.\n\nThe timing of replication at different origins of replication is important for ensuring that the correct amount of DNA is replicated during each cell division. If an origin of replication fires too early or too late, it can lead to errors in DNA replication and genetic instability. Therefore, the precise regulation of the timing of replication at different origins of replication is crucial for the proper functioning of the cell.",
    "llama-7b_fact_raw": "1. The origin of replication closest to the centromere of yeast (Saccharomyces cerevisiae) fires early during the S phase of the cell cycle.\n2. Origins of replication located further away from the centromere in yeast fire late during the S phase.\n3. The centromere is a specialized region of the chromosome important for the separation of sister chromatids during cell division.\n4. The timing of replication at each origin in yeast is determined by the position of the origin relative to the centromere.\n5. Early-firing origins are located closer to the spindle fibers during mitosis or meiosis, making them more accessible to the replication machinery.",
    "llama-7b_fact": [
      "The origin of replication closest to the centromere of yeast (Saccharomyces cerevisiae) fires early during the S phase of the cell cycle.",
      "Origins of replication located further away from the centromere in yeast fire late during the S phase.",
      "The centromere is a specialized region of the chromosome important for the separation of sister chromatids during cell division.",
      "The timing of replication at each origin in yeast is determined by the position of the origin relative to the centromere.",
      "Early-firing origins are located closer to the spindle fibers during mitosis or meiosis, making them more accessible to the replication machinery."
    ],
    "llama-7b_judge_raw": "1. TRUE: In yeast (Saccharomyces cerevisiae), the origins of replication closest to the centromere do tend to fire early during the S phase of the cell cycle.\n2. TRUE: Origins of replication located further away from the centromere in yeast generally fire later during the S phase.\n3. TRUE: The centromere is indeed a specialized region of the chromosome that is crucial for the proper separation of sister chromatids during cell division.\n4. TRUE: The timing of replication at each origin in yeast is influenced by the position of the origin relative to the centromere, among other factors.\n5. FALSE [correction]: Early-firing origins are not necessarily located closer to the spindle fibers during mitosis or meiosis. The statement about their accessibility to the replication machinery due to proximity to spindle fibers is not accurate. The accessibility to replication machinery is more related to the chromatin structure and regulatory proteins associated with the origins of replication.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2268,
    "user_query": "You MUST give a detailed answer to the following question: Which are the properties of mammalian GA-sequences?",
    "llama-7b_response": "Mammalian GA-sequences are a type of non-coding RNA that are found in the genomes of many mammalian species, including humans. They are characterized by a specific sequence motif, known as the GA-motif, which consists of two guanosine (G) nucleotides followed by an adenosine (A) nucleotide.\n\nIn addition to the GA-motif, mammalian GA-sequences also have several other properties:\n\n1. Location: Mammalian GA-sequences are typically found in introns, or non-coding regions, of genes.\n2. Length: The length of mammalian GA-sequences can vary, but they are typically less than 100 nucleotides in length.\n3. Transcription: Mammalian GA-sequences are not transcribed, or translated, into proteins. Instead, they are thought to play a role in RNA-mediated regulation of gene expression.\n4. Stability: Mammalian GA-sequences are relatively stable and can persist in the genome for long periods of time.\n5. Conservation: Mammalian GA-sequences are highly conserved across different species, suggesting that they play an important role in the function of the genome.\n6. Function: The exact function of mammalian GA-sequences is not fully understood, but they are thought to play a role in RNA-mediated regulation of gene expression, including the splicing of pre-mRNA and the formation of ribonucleoprotein complexes.\n\nOverall, mammalian GA-sequences are an important class of non-coding RNA that play a critical role in the regulation of gene expression in mammalian cells.",
    "llama-7b_fact_raw": "1. Mammalian GA-sequences are a type of non-coding RNA found in many mammalian species, including humans.\n2. The GA-motif in mammalian GA-sequences consists of two guanosine (G) nucleotides followed by an adenosine (A) nucleotide.\n3. Mammalian GA-sequences are typically found in introns of genes.\n4. The length of mammalian GA-sequences is typically less than 100 nucleotides.\n5. Mammalian GA-sequences are highly conserved across different mammalian species.",
    "llama-7b_fact": [
      "Mammalian GA-sequences are a type of non-coding RNA found in many mammalian species, including humans.",
      "The GA-motif in mammalian GA-sequences consists of two guanosine (G) nucleotides followed by an adenosine (A) nucleotide.",
      "Mammalian GA-sequences are typically found in introns of genes.",
      "The length of mammalian GA-sequences is typically less than 100 nucleotides.",
      "Mammalian GA-sequences are highly conserved across different mammalian species."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN: The term \"GA-sequences\" is not a standard term in genetics, and without additional context, it's unclear whether this refers to a specific type of non-coding RNA. Non-coding RNAs do exist in many mammalian species, including humans, but \"GA-sequences\" is not specific enough to determine the truth of the statement.\n\n2. UNKNOWN: Without a clear definition of \"GA-sequences,\" it's not possible to confirm the composition of the GA-motif. In general, motifs in genetic sequences can consist of various nucleotide patterns, but without specific information about GA-sequences, the composition of the GA-motif cannot be verified.\n\n3. UNKNOWN: While it is true that non-coding RNA sequences can be found in introns, the statement specifically refers to \"mammalian GA-sequences,\" which have not been clearly defined. Therefore, it's not possible to confirm whether they are typically found in introns.\n\n4. UNKNOWN: The length of non-coding RNA sequences can vary widely, and without specific information about \"mammalian GA-sequences,\" it's not possible to confirm the typical length of these sequences.\n\n5. UNKNOWN: Conservation across species is a feature of some non-coding RNA sequences, but without clear information about what \"mammalian GA-sequences\" are, it's not possible to confirm their level of conservation across different mammalian species.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2291,
    "user_query": "You MUST give a detailed answer to the following question: How many Groucho-related genes (GRG) are contained in the mouse genome?",
    "llama-7b_response": "The number of Groucho-related genes (GRG) contained in the mouse genome is currently unknown.\n\nGroucho-related genes (GRG) are a family of transcriptional repressors that play a critical role in regulating gene expression during development. They are named after the Drosophila gene Groucho, which was the first member of the family to be identified. The Groucho family of genes is conserved across species, including mammals, and has been implicated in a variety of biological processes, including cellular differentiation, embryonic development, and tumor suppression.\n\nHowever, the exact number of Groucho-related genes in the mouse genome has not yet been determined. This is because the Groucho family of genes is highly conserved across species, and the number of genes in the family can vary depending on the species being studied. In addition, the Groucho family of genes can also undergo gene duplication and divergence, which can further complicate efforts to determine the exact number of genes in the family.\n\nIn summary, the number of Groucho-related genes (GRG) contained in the mouse genome is currently unknown, and further research is needed to determine the exact number of genes in the family.",
    "llama-7b_fact_raw": "1. The number of Groucho-related genes (GRG) in the mouse genome is currently unknown.\n2. Groucho-related genes are a family of transcriptional repressors.\n3. The Groucho family of genes is named after the Drosophila gene Groucho, which was the first member identified.\n4. The Groucho family of genes is conserved across species, including mammals.\n5. Groucho-related genes have been implicated in cellular differentiation, embryonic development, and tumor suppression.",
    "llama-7b_fact": [
      "The number of Groucho-related genes (GRG) in the mouse genome is currently unknown.",
      "Groucho-related genes are a family of transcriptional repressors.",
      "The Groucho family of genes is named after the Drosophila gene Groucho, which was the first member identified.",
      "The Groucho family of genes is conserved across species, including mammals.",
      "Groucho-related genes have been implicated in cellular differentiation, embryonic development, and tumor suppression."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2304,
    "user_query": "You MUST give a detailed answer to the following question: Which RNA polymerase II subunit carries RNA cleavage activity?",
    "llama-7b_response": "holoenzyme",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 2321,
    "user_query": "You MUST give a detailed answer to the following question: What is the genetic basis of Ohdo syndrome?",
    "llama-7b_response": "Ohdo syndrome is a rare genetic disorder caused by mutations in the TMEM132 gene. The TMEM132 gene provides instructions for making a protein called transient receptor potential cation channel, subfamily M, member 13 (TRPM13). This protein is involved in the function of sensory neurons, which are nerve cells that transmit information about sensations such as pain, temperature, and touch.\n\nMutations in the TMEM132 gene can result in the production of a non-functional or abnormal TRPM13 protein. This can disrupt the normal function of sensory neurons, leading to the symptoms of Ohdo syndrome.\n\nThe specific symptoms of Ohdo syndrome can vary from person to person, but they typically include severe pain, muscle stiffness, and joint contractures. Some people with Ohdo syndrome may also have intellectual disability, seizures, and other neurological abnormalities.\n\nOhdo syndrome is inherited in an autosomal recessive pattern, which means that a person with the disorder has two copies of the mutated TMEM132 gene, one of which is inherited from each parent.",
    "llama-7b_fact_raw": "1. Ohdo syndrome is a rare genetic disorder caused by mutations in the TMEM132 gene.\n2. The TMEM132 gene is responsible for making a protein called transient receptor potential cation channel, subfamily M, member 13 (TRPM13).\n3. Mutations in the TMEM132 gene can lead to the production of a non-functional or abnormal TRPM13 protein.\n4. Symptoms of Ohdo syndrome typically include severe pain, muscle stiffness, and joint contractures.\n5. Ohdo syndrome is inherited in an autosomal recessive pattern, requiring two copies of the mutated gene for the disorder to manifest.",
    "llama-7b_fact": [
      "Ohdo syndrome is a rare genetic disorder caused by mutations in the TMEM132 gene.",
      "The TMEM132 gene is responsible for making a protein called transient receptor potential cation channel, subfamily M, member 13 (TRPM13).",
      "Mutations in the TMEM132 gene can lead to the production of a non-functional or abnormal TRPM13 protein.",
      "Symptoms of Ohdo syndrome typically include severe pain, muscle stiffness, and joint contractures.",
      "Ohdo syndrome is inherited in an autosomal recessive pattern, requiring two copies of the mutated gene for the disorder to manifest."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Ohdo syndrome is a rare genetic disorder, but it is not caused by mutations in the TMEM132 gene. It is associated with mutations in several genes, including MED12, KAT6B, and SALL1.\n2. FALSE [correction]: The TMEM132 gene does not exist. The TRPM3 gene is responsible for making a protein called transient receptor potential cation channel, subfamily M, member 3 (TRPM3), not TRPM13.\n3. FALSE [correction]: Since the TMEM132 gene does not exist, this statement is incorrect. Mutations in the genes associated with Ohdo syndrome can lead to the production of non-functional or abnormal proteins related to those genes.\n4. FALSE [correction]: Symptoms of Ohdo syndrome typically include intellectual disability, distinctive facial features, and dental anomalies. Severe pain, muscle stiffness, and joint contractures are not typical symptoms of Ohdo syndrome.\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2331,
    "user_query": "You MUST give a detailed answer to the following question: Which R/Bioconductor package has been developed for the analysis of psychiatric disease genes?",
    "llama-7b_response": "GeneNetwork",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 2360,
    "user_query": "You MUST give a detailed answer to the following question: Describe swirl sign in intracerebral hemorrhage.",
    "llama-7b_response": "Intracerebral hemorrhage (ICH) is a type of stroke that occurs when there is bleeding within the brain. One of the characteristic features of ICH is the presence of a swirl sign on imaging studies.\n\nThe swirl sign in ICH is caused by the movement of blood within the brain, which creates a swirling pattern on imaging studies such as computed tomography (CT) or magnetic resonance imaging (MRI). The swirl sign can be seen on both non-contrast and contrast-enhanced imaging studies.\n\nThe swirl sign is not specific to ICH and can also be seen in other conditions that cause bleeding within the brain, such as subarachnoid hemorrhage and cerebral venous sinus thrombosis. However, the presence of a swirl sign on imaging studies is highly suggestive of ICH.\n\nThe swirl sign is an important diagnostic feature of ICH because it helps to differentiate ICH from other types of stroke, such as ischemic stroke, which is caused by a blockage of blood flow to the brain. The swirl sign can also help to identify the location and extent of the bleeding within the brain, which is important for determining the best course of treatment.\n\nIn summary, the swirl sign is a characteristic feature of intracerebral hemorrhage and is caused by the movement of blood within the brain. The presence of a swirl sign on imaging studies is highly suggestive of ICH and helps to differentiate it from other types of stroke.",
    "llama-7b_fact_raw": "1. Intracerebral hemorrhage (ICH) is a type of stroke characterized by bleeding within the brain.\n2. The swirl sign in ICH is caused by the movement of blood within the brain, creating a swirling pattern on imaging studies.\n3. The swirl sign can be seen on computed tomography (CT) or magnetic resonance imaging (MRI).\n4. The swirl sign is not specific to ICH and can also be seen in conditions like subarachnoid hemorrhage and cerebral venous sinus thrombosis.\n5. The presence of a swirl sign helps to differentiate ICH from other types of stroke, such as ischemic stroke.",
    "llama-7b_fact": [
      "Intracerebral hemorrhage (ICH) is a type of stroke characterized by bleeding within the brain.",
      "The swirl sign in ICH is caused by the movement of blood within the brain, creating a swirling pattern on imaging studies.",
      "The swirl sign can be seen on computed tomography (CT) or magnetic resonance imaging (MRI).",
      "The swirl sign is not specific to ICH and can also be seen in conditions like subarachnoid hemorrhage and cerebral venous sinus thrombosis.",
      "The presence of a swirl sign helps to differentiate ICH from other types of stroke, such as ischemic stroke."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The swirl sign is specific to ICH and is not typically seen in conditions like subarachnoid hemorrhage or cerebral venous sinus thrombosis, which have their own characteristic imaging features.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2392,
    "user_query": "You MUST give a detailed answer to the following question: What induces Arabidopsis ROF1 expression?",
    "llama-7b_response": "Arabidopsis ROF1 is a transcription factor that plays a crucial role in regulating the expression of genes involved in the biosynthesis of flavonoids, a class of plant secondary metabolites. ROF1 expression is induced in response to various stimuli, including biotic and abiotic stresses, such as drought, salt, and temperature stress, as well as treatment with plant hormones, such as abscisic acid (ABA) and salicylic acid (SA).\n\n1. Biotic stress: ROF1 expression is induced in response to various biotic stresses, such as bacterial and fungal infections. For example, Arabidopsis plants infected with the bacterium Pseudomonas syringae pv. tomato (Pst) or the fungus Botrytis cinerea exhibit increased ROF1 expression. This suggests that ROF1 plays a role in the plant's defense response against pathogens.\n2. Abiotic stress: ROF1 expression is also induced in response to various abiotic stresses, such as drought, salt, and temperature stress. For example, Arabidopsis plants subjected to drought stress exhibit increased ROF1 expression, which suggests that ROF1 plays a role in the plant's response to water deficit. Similarly, Arabidopsis plants exposed to high salinity or high temperature exhibit increased ROF1 expression, which suggests that ROF1 plays a role in the plant's response to abiotic stress.\n3. Plant hormones: ROF1 expression is also induced in response to treatment with plant hormones, such as ABA and SA. For example, Arabidopsis plants treated with ABA exhibit increased ROF1 expression, which suggests that ROF1 plays a role in the plant's response to ABA-mediated stress. Similarly, Arabidopsis plants treated with SA exhibit increased ROF1 expression, which suggests that ROF1 plays a role in the plant's response to SA-mediated stress.\n\nIn summary, Arabidopsis ROF1 expression is induced in response to various stimuli, including biotic and abiotic stresses, as well as treatment with plant hormones. This suggests that ROF1 plays a crucial role in regulating the expression of genes involved in the bio",
    "llama-7b_fact_raw": "1. Arabidopsis ROF1 expression is induced in response to biotic stresses such as bacterial and fungal infections.\n2. Arabidopsis plants infected with Pseudomonas syringae pv. tomato or Botrytis cinerea exhibit increased ROF1 expression.\n3. Arabidopsis ROF1 expression is induced in response to abiotic stresses such as drought, salt, and temperature stress.\n4. Arabidopsis plants treated with abscisic acid (ABA) exhibit increased ROF1 expression.\n5. Arabidopsis plants treated with salicylic acid (SA) exhibit increased ROF1 expression.",
    "llama-7b_fact": [
      "Arabidopsis ROF1 expression is induced in response to biotic stresses such as bacterial and fungal infections.",
      "Arabidopsis plants infected with Pseudomonas syringae pv. tomato or Botrytis cinerea exhibit increased ROF1 expression.",
      "Arabidopsis ROF1 expression is induced in response to abiotic stresses such as drought, salt, and temperature stress.",
      "Arabidopsis plants treated with abscisic acid (ABA) exhibit increased ROF1 expression.",
      "Arabidopsis plants treated with salicylic acid (SA) exhibit increased ROF1 expression."
    ],
    "llama-7b_judge_raw": "1. TRUE: Arabidopsis ROF1 (AtFKBP62) expression is known to be induced in response to various biotic stresses, including bacterial and fungal infections.\n2. TRUE: Arabidopsis plants infected with Pseudomonas syringae pv. tomato (a bacterium) or Botrytis cinerea (a fungus) have been reported to show increased ROF1 expression as part of their defense response.\n3. TRUE: Arabidopsis ROF1 expression is also known to be induced by abiotic stresses such as drought, salt, and temperature stress, which are common environmental challenges that plants face.\n4. TRUE: Abscisic acid (ABA) is a plant hormone that is involved in the response to abiotic stress, and it has been shown to induce the expression of ROF1 in Arabidopsis plants.\n5. TRUE: Salicylic acid (SA) is another plant hormone that plays a role in the plant defense response, particularly against biotic stress, and it can induce the expression of ROF1 in Arabidopsis plants.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2398,
    "user_query": "You MUST give a detailed answer to the following question: What protein is the most common cause of hereditary  renal amyloidosis?",
    "llama-7b_response": "transthyretin",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 2407,
    "user_query": "You MUST give a detailed answer to the following question: Has the proteome of mice hippocampus been analysed?",
    "llama-7b_response": "Yes, the proteome of mice hippocampus has been analyzed in several studies. The hippocampus is a critical region of the brain involved in learning, memory, and emotional regulation, and its proteome, or the set of proteins expressed in the hippocampus, is an important area of research.\n\nOne study used two-dimensional gel electrophoresis and mass spectrometry to analyze the proteome of the hippocampus in mice. The study identified over 1,000 proteins, including several known to be involved in synaptic plasticity, a process that underlies learning and memory.\n\nAnother study used a similar approach to analyze the proteome of the hippocampus in mice with Alzheimer's disease, a neurodegenerative disorder characterized by memory loss and other cognitive deficits. The study identified several proteins that were differentially expressed in the hippocampus of Alzheimer's disease mice compared to healthy mice, including several involved in synaptic plasticity and neurotransmission.\n\nOverall, these studies have provided valuable insights into the proteome of the hippocampus in mice and have implications for our understanding of hippocampal function and dysfunction in various neurological disorders.",
    "llama-7b_fact_raw": "1. The proteome of mice hippocampus has been analyzed in several studies.\n2. The hippocampus is involved in learning, memory, and emotional regulation.\n3. One study identified over 1,000 proteins in the hippocampus of mice using two-dimensional gel electrophoresis and mass spectrometry.\n4. Synaptic plasticity proteins were among those identified in the proteomic analysis of the mice hippocampus.\n5. A study on mice with Alzheimer's disease found several proteins differentially expressed in the hippocampus compared to healthy mice.",
    "llama-7b_fact": [
      "The proteome of mice hippocampus has been analyzed in several studies.",
      "The hippocampus is involved in learning, memory, and emotional regulation.",
      "One study identified over 1,000 proteins in the hippocampus of mice using two-dimensional gel electrophoresis and mass spectrometry.",
      "Synaptic plasticity proteins were among those identified in the proteomic analysis of the mice hippocampus.",
      "A study on mice with Alzheimer's disease found several proteins differentially expressed in the hippocampus compared to healthy mice."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2409,
    "user_query": "You MUST give a detailed answer to the following question: Are mouse chromosomes acrocentric?",
    "llama-7b_response": "Yes, mouse chromosomes are acrocentric.\n\nAcrocentric chromosomes are a type of chromosome that has a short arm (p arm) that is shorter than the long arm (q arm). This is in contrast to metacentric chromosomes, which have an equal length of both arms. Acrocentric chromosomes are found in many mammals, including humans and mice.\n\nIn mice, the acrocentric chromosomes are numbered as follows: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, and X and Y. The p arm of each acrocentric chromosome is shorter than the q arm.\n\nThe acrocentric chromosomes are important in meiosis, the process by which sex cells (gametes) are produced. During meiosis, homologous chromosomes pair up and exchange genetic information. In the case of acrocentric chromosomes, the p arm of one homologous chromosome pairs with the q arm of the other homologous chromosome. This helps to ensure that the genetic information on each chromosome is properly shuffled and segregated during meiosis.\n\nOverall, the acrocentric chromosomes play an important role in the genetic makeup of mice and other mammals.",
    "llama-7b_fact_raw": "1. Mouse chromosomes are acrocentric.\n2. Acrocentric chromosomes have a short arm (p arm) that is shorter than the long arm (q arm).\n3. Humans also have acrocentric chromosomes.\n4. The acrocentric chromosomes in mice are numbered from 1 to 19, including the sex chromosomes X and Y.\n5. During meiosis, the p arm of one acrocentric chromosome pairs with the q arm of the other homologous chromosome.",
    "llama-7b_fact": [
      "Mouse chromosomes are acrocentric.",
      "Acrocentric chromosomes have a short arm (p arm) that is shorter than the long arm (q arm).",
      "Humans also have acrocentric chromosomes.",
      "The acrocentric chromosomes in mice are numbered from 1 to 19, including the sex chromosomes X and Y.",
      "During meiosis, the p arm of one acrocentric chromosome pairs with the q arm of the other homologous chromosome."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The acrocentric chromosomes in mice are numbered from 1 to 19, excluding the sex chromosomes X and Y.\n5. FALSE [correction]: During meiosis, the p arm of an acrocentric chromosome does not pair with the q arm of the other homologous chromosome. Instead, homologous chromosomes (including their p and q arms) pair with each other along their entire lengths.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 2417,
    "user_query": "You MUST give a detailed answer to the following question: Which siRNA based drug is in clinical trials for the treatment of pancreatic cancer?",
    "llama-7b_response": "gemcitabine",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 2419,
    "user_query": "You MUST give a detailed answer to the following question: What is the HPG pore?",
    "llama-7b_response": "The HPG (Hypothalamic-Pituitary-Gonadal) pore is a hypothetical structure that is thought to exist in the brains of some animals, including humans. It is named for the three endocrine glands that it is believed to connect to: the hypothalamus, pituitary gland, and gonads (testes or ovaries).\n\nThe HPG pore is thought to play a role in the regulation of hormones and other substances that are produced by the endocrine glands. Specifically, it is believed to allow communication between the endocrine glands and the nervous system, which could help to regulate hormone levels and other physiological processes.\n\nThere is currently no scientific evidence to support the existence of the HPG pore, and it is not recognized as a legitimate anatomical structure by the medical community. The concept of the HPG pore is still the subject of ongoing research and debate among scientists and medical professionals.",
    "llama-7b_fact_raw": "1. The HPG pore is a hypothetical structure thought to exist in the brains of some animals, including humans.\n2. It is named after the three endocrine glands it is believed to connect: the hypothalamus, pituitary gland, and gonads.\n3. The HPG pore is theorized to play a role in the regulation of hormones produced by the endocrine glands.\n4. The HPG pore is believed to allow communication between the endocrine glands and the nervous system.\n5. There is no scientific evidence to support the existence of the HPG pore as a legitimate anatomical structure.",
    "llama-7b_fact": [
      "The HPG pore is a hypothetical structure thought to exist in the brains of some animals, including humans.",
      "It is named after the three endocrine glands it is believed to connect: the hypothalamus, pituitary gland, and gonads.",
      "The HPG pore is theorized to play a role in the regulation of hormones produced by the endocrine glands.",
      "The HPG pore is believed to allow communication between the endocrine glands and the nervous system.",
      "There is no scientific evidence to support the existence of the HPG pore as a legitimate anatomical structure."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The term \"HPG pore\" is not recognized in scientific literature as a structure in the brain. The correct term is the HPG axis, which stands for the hypothalamic-pituitary-gonadal axis.\n2. TRUE: The HPG axis is named after the hypothalamus, pituitary gland, and gonads.\n3. TRUE: The HPG axis is indeed involved in the regulation of hormones produced by these endocrine glands.\n4. TRUE: The HPG axis facilitates communication between the endocrine system and the nervous system.\n5. TRUE: Since the HPG pore is not a recognized anatomical structure, there is no scientific evidence for its existence. However, the HPG axis is a well-established concept in endocrinology.",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2472,
    "user_query": "You MUST give a detailed answer to the following question: What is the 959 Nematode Genomes initiative?",
    "llama-7b_response": "The 959 Nematode Genomes initiative is a large-scale project aimed at sequencing and analyzing the genomes of a diverse set of nematode species. Nematodes are a phylum of roundworms that includes a wide range of species, including parasitic worms, plant-feeding nematodes, and free-living soil-dwelling nematodes. The goal of the 959 Nematode Genomes initiative is to sequence and analyze the genomes of at least 959 different nematode species in order to gain a better understanding of the diversity and evolution of this group of organisms.\n\nThe 959 Nematode Genomes initiative is being carried out by a consortium of researchers from around the world, and is being funded by a number of different organizations, including the National Institutes of Health (NIH) and the National Science Foundation (NSF). The sequencing and analysis of the nematode genomes is being carried out using a variety of different techniques and technologies, including next-generation sequencing and computational analysis.\n\nOne of the main goals of the 959 Nematode Genomes initiative is to provide a resource for the study of nematode biology and evolution. By sequencing and analyzing the genomes of a diverse set of nematode species, researchers hope to gain a better understanding of the genetic basis of nematode traits and behaviors, as well as the evolutionary relationships between different nematode species. This information will be useful for a variety of different fields, including agriculture, medicine, and biotechnology.\n\nOverall, the 959 Nematode Genomes initiative is a large-scale project that aims to provide a valuable resource for the study of nematode biology and evolution. By sequencing and analyzing the genomes of a diverse set of nematode species, researchers hope to gain a better understanding of the genetic basis of nematode traits and behaviors, as well as the evolutionary relationships between different nematode species. This information will be useful for a variety of different fields, including agriculture, medicine, and biotechnology.",
    "llama-7b_fact_raw": "1. The 959 Nematode Genomes initiative aims to sequence and analyze the genomes of at least 959 different nematode species.\n2. Nematodes are a phylum of roundworms that includes parasitic worms, plant-feeding nematodes, and free-living soil-dwelling nematodes.\n3. The initiative is being carried out by a consortium of researchers from around the world.\n4. Funding for the initiative comes from various organizations, including the National Institutes of Health (NIH) and the National Science Foundation (NSF).\n5. The project employs techniques such as next-generation sequencing and computational analysis for the sequencing and analysis of the nematode genomes.",
    "llama-7b_fact": [
      "The 959 Nematode Genomes initiative aims to sequence and analyze the genomes of at least 959 different nematode species.",
      "Nematodes are a phylum of roundworms that includes parasitic worms, plant-feeding nematodes, and free-living soil-dwelling nematodes.",
      "The initiative is being carried out by a consortium of researchers from around the world.",
      "Funding for the initiative comes from various organizations, including the National Institutes of Health (NIH) and the National Science Foundation (NSF).",
      "The project employs techniques such as next-generation sequencing and computational analysis for the sequencing and analysis of the nematode genomes."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN (While it is plausible that organizations like the NIH and NSF could fund such an initiative, without specific information about the funding sources for the 959 Nematode Genomes initiative, the statement cannot be verified as true or false.)\n5. TRUE (Next-generation sequencing and computational analysis are common techniques used in genome sequencing projects, so this statement is likely true, but without specific details about the project's methods, it is assumed to be true based on common practices.)",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2557,
    "user_query": "You MUST give a detailed answer to the following question: Which R package has been developed for analyzing Non-invasive prenatal testing (NIPT) data?",
    "llama-7b_response": "There is currently no R package specifically developed for analyzing Non-invasive prenatal testing (NIPT) data. However, there are several R packages that can be used for analyzing genetic and genomic data, which can be applied to NIPT data. Some of these packages include:\n\n1. GenABEL: This package provides tools for genome-wide association studies (GWAS) and other types of genetic association studies.\n2. PLINK: This package is used for managing and analyzing large sets of genetic and genomic data.\n3. GCTA: This package is used for genome-wide complex trait analysis, which can be applied to NIPT data.\n4. BGLR: This package is used for Bayesian genetic linkage analysis, which can be applied to NIPT data.\n5. GEMMA: This package is used for genome-wide association mapping, which can be applied to NIPT data.\n\nIt's worth noting that these packages are not specifically designed for NIPT data, but they can be used for analyzing genetic and genomic data in general, which can be applied to NIPT data.",
    "llama-7b_fact_raw": "1. There is no R package specifically developed for analyzing Non-invasive prenatal testing (NIPT) data.\n2. The GenABEL R package provides tools for genome-wide association studies (GWAS) and other types of genetic association studies.\n3. The PLINK R package is used for managing and analyzing large sets of genetic and genomic data.\n4. The GCTA R package is used for genome-wide complex trait analysis.\n5. The GEMMA R package is used for genome-wide association mapping.",
    "llama-7b_fact": [
      "There is no R package specifically developed for analyzing Non-invasive prenatal testing (NIPT) data.",
      "The GenABEL R package provides tools for genome-wide association studies (GWAS) and other types of genetic association studies.",
      "The PLINK R package is used for managing and analyzing large sets of genetic and genomic data.",
      "The GCTA R package is used for genome-wide complex trait analysis.",
      "The GEMMA R package is used for genome-wide association mapping."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: There are R packages specifically developed for analyzing Non-invasive prenatal testing (NIPT) data, such as the \"NIPTeR\" package.\n2. TRUE\n3. FALSE [correction]: PLINK is not an R package, but a standalone software tool used for managing and analyzing large sets of genetic and genomic data.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2560,
    "user_query": "You MUST give a detailed answer to the following question: Describe Achenbach’s syndrome.",
    "llama-7b_response": "Achenbach's syndrome, also known as Achenbach's disease, is a rare genetic disorder that affects the eyes and other parts of the body. It is caused by mutations in the COL11A1 gene, which provides instructions for making a protein called type XI collagen. Type XI collagen is an important component of the extracellular matrix, which is the complex network of proteins, carbohydrates, and other substances that surrounds and supports cells in the body.\n\nThe main features of Achenbach's syndrome are abnormalities in the eyes, including cataracts, retinal detachment, and glaucoma. These eye problems can lead to vision loss and blindness if not treated properly. In addition to eye problems, people with Achenbach's syndrome may also have skeletal abnormalities, such as short stature, bowing of the legs, and abnormal curvature of the spine (scoliosis). Some people with Achenbach's syndrome may also have other health problems, such as hearing loss, heart defects, and kidney abnormalities.\n\nAchenbach's syndrome is inherited in an autosomal recessive pattern, which means that a person needs to have two copies of the mutated COL11A1 gene, one from each parent, to develop the condition. It is estimated that Achenbach's syndrome affects about 1 in 50,000 people worldwide. There is currently no cure for Achenbach's syndrome, but treatments can help manage some of the symptoms and prevent further damage to the eyes and other parts of the body.",
    "llama-7b_fact_raw": "1. Achenbach's syndrome is caused by mutations in the COL11A1 gene.\n2. The COL11A1 gene provides instructions for making type XI collagen.\n3. Achenbach's syndrome can lead to eye problems such as cataracts, retinal detachment, and glaucoma.\n4. The syndrome is inherited in an autosomal recessive pattern.\n5. Achenbach's syndrome affects about 1 in 50,000 people worldwide.",
    "llama-7b_fact": [
      "Achenbach's syndrome is caused by mutations in the COL11A1 gene.",
      "The COL11A1 gene provides instructions for making type XI collagen.",
      "Achenbach's syndrome can lead to eye problems such as cataracts, retinal detachment, and glaucoma.",
      "The syndrome is inherited in an autosomal recessive pattern.",
      "Achenbach's syndrome affects about 1 in 50,000 people worldwide."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Achenbach's syndrome is not caused by mutations in the COL11A1 gene. It is a condition characterized by spontaneous bruising, primarily in the hands, and its cause is not well understood.\n2. TRUE\n3. FALSE [correction]: Achenbach's syndrome is not typically associated with eye problems such as cataracts, retinal detachment, and glaucoma. It primarily involves spontaneous bruising of the hands or fingers.\n4. FALSE [correction]: Achenbach's syndrome is not known to be inherited in an autosomal recessive pattern; the cause of the syndrome is not clearly understood, and it is not typically considered a genetic disorder.\n5. UNKNOWN",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2581,
    "user_query": "You MUST give a detailed answer to the following question: Which algorithm is used for detection of long repeat expansions?",
    "llama-7b_response": "liding window",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 2582,
    "user_query": "You MUST give a detailed answer to the following question: Which brain tumors does neuroligin-3 promote?",
    "llama-7b_response": "glioblastoma",
    "llama-7b_fact_raw": "1. Neuroligin-3 promotes glioblastoma.",
    "llama-7b_fact": [
      "Neuroligin-3 promotes glioblastoma."
    ],
    "llama-7b_judge_raw": "1. TRUE\n\nNeuroligin-3 has been shown in studies to promote the growth of glioblastoma, which is an aggressive type of brain cancer.",
    "llama-7b_judge": [
      "true"
    ]
  },
  {
    "id": 2586,
    "user_query": "You MUST give a detailed answer to the following question: What is the approximate size of gas vesicles?",
    "llama-7b_response": "Gas vacuoles, also known as gas vesicles or balloon cells, are small, gas-filled organelles found in some bacteria and archaea. The size of gas vacuoles varies among different organisms, but they are typically on the order of 1-100 nanometers in diameter. The exact size of gas vacuoles can depend on a variety of factors, including the species of bacteria or archaea and the environmental conditions in which they are found. For example, some species of bacteria may have larger gas vacuoles than others under the same growth conditions. Additionally, the size of gas vacuoles can be affected by factors such as temperature, pH, and the availability of nutrients.",
    "llama-7b_fact_raw": "1. Gas vesicles, also known as gas vacuoles or balloon cells, are found in some bacteria and archaea.\n2. The diameter of gas vesicles typically ranges from 1 to 100 nanometers.\n3. The size of gas vesicles can vary depending on the species of bacteria or archaea.\n4. Environmental conditions can influence the size of gas vesicles.\n5. Factors such as temperature, pH, and nutrient availability can affect the size of gas vesicles.",
    "llama-7b_fact": [
      "Gas vesicles, also known as gas vacuoles or balloon cells, are found in some bacteria and archaea.",
      "The diameter of gas vesicles typically ranges from 1 to 100 nanometers.",
      "The size of gas vesicles can vary depending on the species of bacteria or archaea.",
      "Environmental conditions can influence the size of gas vesicles.",
      "Factors such as temperature, pH, and nutrient availability can affect the size of gas vesicles."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The diameter of gas vesicles typically ranges from about 45 to 200 nanometers, not 1 to 100 nanometers.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2589,
    "user_query": "You MUST give a detailed answer to the following question: List BET proteins.",
    "llama-7b_response": "BET (Bromodomain and Extra-terminal domain) proteins are a family of epigenetic regulators that play a crucial role in the regulation of gene expression. BET proteins are characterized by the presence of two distinct domains: the bromodomain, which recognizes acetylated lysine residues on histone tails, and the extra-terminal (ET) domain, which is involved in protein-protein interactions and transcriptional regulation.\n\nHere is a list of BET proteins:\n\n1. BRD2 (Bromodomain and Extra-terminal domain 2)\n2. BRD3 (Bromodomain and Extra-terminal domain 3)\n3. BRD4 (Bromodomain and Extra-terminal domain 4)\n4. BRD5 (Bromodomain and Extra-terminal domain 5)\n5. BRD6 (Bromodomain and Extra-terminal domain 6)\n6. BRD7 (Bromodomain and Extra-terminal domain 7)\n7. BRD8 (Bromodomain and Extra-terminal domain 8)\n8. BRD9 (Bromodomain and Extra-terminal domain 9)\n9. BAP1 (Bromodomain and Extra-terminal domain 1-associated protein 1)\n10. BAP2 (Bromodomain and Extra-terminal domain 2)\n11. BAP3 (Bromodomain and Extra-terminal domain 3)\n12. BAP4 (Bromodomain and Extra-terminal domain 4)\n13. BAP5 (Bromodomain and Extra-terminal domain 5)\n14. BAP6 (Bromodomain and Extra-terminal domain 6)\n15. BAP7 (Bromodomain and Extra-terminal domain 7)\n16. BAP8 (Bromodomain and Extra-terminal domain 8)\n17. BAP9 (Bromodomain and Extra-terminal domain 9)\n1",
    "llama-7b_fact_raw": "1. BET proteins are a family of epigenetic regulators.\n2. BET proteins have a bromodomain that recognizes acetylated lysine residues on histone tails.\n3. BET proteins have an extra-terminal (ET) domain involved in protein-protein interactions and transcriptional regulation.\n4. BRD2, BRD3, and BRD4 are members of the BET protein family.\n5. BAP1 is referred to as Bromodomain and Extra-terminal domain 1-associated protein 1.",
    "llama-7b_fact": [
      "BET proteins are a family of epigenetic regulators.",
      "BET proteins have a bromodomain that recognizes acetylated lysine residues on histone tails.",
      "BET proteins have an extra-terminal (ET) domain involved in protein-protein interactions and transcriptional regulation.",
      "BRD2, BRD3, and BRD4 are members of the BET protein family.",
      "BAP1 is referred to as Bromodomain and Extra-terminal domain 1-associated protein 1."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: BAP1 stands for BRCA1 associated protein-1, which is a different protein and not a member of the BET protein family.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2610,
    "user_query": "You MUST give a detailed answer to the following question: Which algorithm has been developed for prediction of protein subcellular localization using deep learning?",
    "llama-7b_response": "There are several algorithms that have been developed for the prediction of protein subcellular localization using deep learning, including:\n\n1. Convolutional Neural Networks (CNNs): CNNs have been used to predict the subcellular localization of proteins based on their amino acid sequences. In this approach, the amino acid sequences of the proteins are represented as images, and the CNN is trained to classify the images into different subcellular localization categories.\n2. Recurrent Neural Networks (RNNs): RNNs have been used to predict the subcellular localization of proteins based on their amino acid sequences. In this approach, the amino acid sequences of the proteins are represented as sequences, and the RNN is trained to predict the next amino acid in the sequence based on the previous amino acids.\n3. Long Short-Term Memory (LSTM) Networks: LSTMs have been used to predict the subcellular localization of proteins based on their amino acid sequences. In this approach, the amino acid sequences of the proteins are represented as sequences, and the LSTM is trained to predict the next amino acid in the sequence based on the previous amino acids.\n4. Generative Adversarial Networks (GANs): GANs have been used to predict the subcellular localization of proteins based on their amino acid sequences. In this approach, the amino acid sequences of the proteins are represented as sequences, and the GAN is trained to generate new sequences that predict the next amino acid in the sequence based on the previous amino acids.\n5. Transformers: Transformers have been used to predict the subcellular localization of proteins based on their amino acid sequences. In this approach, the amino acid sequences of the proteins are represented as sequences, and the Transformer is trained to predict the next amino acid in the sequence based on the previous amino acids.",
    "llama-7b_fact_raw": "1. Convolutional Neural Networks (CNNs) have been used to predict the subcellular localization of proteins from their amino acid sequences.\n2. Recurrent Neural Networks (RNNs) have been utilized for predicting protein subcellular localization by representing amino acid sequences as sequences.\n3. Long Short-Term Memory (LSTM) Networks have been applied to predict protein subcellular localization using amino acid sequence data.\n4. Generative Adversarial Networks (GANs) have been employed to generate new sequences that can predict protein subcellular localization from amino acid sequences.\n5. Transformers have been used in the prediction of protein subcellular localization by analyzing amino acid sequences.",
    "llama-7b_fact": [
      "Convolutional Neural Networks (CNNs) have been used to predict the subcellular localization of proteins from their amino acid sequences.",
      "Recurrent Neural Networks (RNNs) have been utilized for predicting protein subcellular localization by representing amino acid sequences as sequences.",
      "Long Short-Term Memory (LSTM) Networks have been applied to predict protein subcellular localization using amino acid sequence data.",
      "Generative Adversarial Networks (GANs) have been employed to generate new sequences that can predict protein subcellular localization from amino acid sequences.",
      "Transformers have been used in the prediction of protein subcellular localization by analyzing amino acid sequences."
    ],
    "llama-7b_judge_raw": "1. TRUE: Convolutional Neural Networks (CNNs) have indeed been used to predict the subcellular localization of proteins from their amino acid sequences. CNNs are effective in extracting features from sequence data and have been applied in bioinformatics for various prediction tasks, including protein subcellular localization.\n\n2. TRUE: Recurrent Neural Networks (RNNs) are well-suited for sequential data and have been utilized for predicting protein subcellular localization by representing amino acid sequences as sequences. RNNs can capture the sequential information in amino acid chains, which is important for understanding protein function and localization.\n\n3. TRUE: Long Short-Term Memory (LSTM) Networks, a special kind of RNN, have been applied to predict protein subcellular localization using amino acid sequence data. LSTMs are designed to avoid the long-term dependency problem, making them effective for sequence prediction tasks in bioinformatics.\n\n4. FALSE [correction]: Generative Adversarial Networks (GANs) have been employed in various fields to generate new data that is similar to the original data. However, their primary use is not to predict protein subcellular localization from amino acid sequences. Instead, they are more commonly used to generate new data for augmentation or to create synthetic data that can be used for other purposes.\n\n5. TRUE: Transformers, which are models that rely on self-attention mechanisms, have been used in the prediction of protein subcellular localization by analyzing amino acid sequences. Transformers have shown great success in various sequence modeling tasks and are increasingly being applied in the field of bioinformatics.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2634,
    "user_query": "You MUST give a detailed answer to the following question: What is MULTOVL?",
    "llama-7b_response": "I'm sorry, but I don't have enough information to answer your question about MULTOVL. Could you please provide more context or clarify your question?",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 2660,
    "user_query": "You MUST give a detailed answer to the following question: Can GDF15 be a biomarker for metformin treatment?",
    "llama-7b_response": "GDF15 (growth differentiation factor 15) is a protein that is involved in the regulation of inflammation and metabolism. Metformin is a commonly used medication for the treatment of type 2 diabetes, and it has been shown to reduce the levels of GDF15 in the blood. However, the relationship between GDF15 and metformin treatment is complex and not fully understood.\n\nStudies have shown that GDF15 levels are elevated in individuals with type 2 diabetes, and that metformin treatment can reduce these levels. This suggests that GDF15 may be a biomarker for the effectiveness of metformin treatment. However, other studies have found that GDF15 levels are also elevated in individuals without diabetes, and that metformin treatment does not reduce these levels. This suggests that GDF15 may not be a reliable biomarker for metformin treatment.\n\nFurther research is needed to fully understand the relationship between GDF15 and metformin treatment. It is possible that GDF15 may be a useful biomarker for the effectiveness of metformin treatment in certain populations or under certain conditions. However, more research is needed to determine the role of GDF15 as a biomarker for metformin treatment.",
    "llama-7b_fact_raw": "1. GDF15 (growth differentiation factor 15) is involved in the regulation of inflammation and metabolism.\n2. Metformin is a medication used for the treatment of type 2 diabetes.\n3. Metformin has been shown to reduce the levels of GDF15 in the blood.\n4. GDF15 levels are elevated in individuals with type 2 diabetes.\n5. The relationship between GDF15 levels and metformin treatment is not fully understood and requires further research.",
    "llama-7b_fact": [
      "GDF15 (growth differentiation factor 15) is involved in the regulation of inflammation and metabolism.",
      "Metformin is a medication used for the treatment of type 2 diabetes.",
      "Metformin has been shown to reduce the levels of GDF15 in the blood.",
      "GDF15 levels are elevated in individuals with type 2 diabetes.",
      "The relationship between GDF15 levels and metformin treatment is not fully understood and requires further research."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Metformin has been shown to increase the levels of GDF15 in the blood.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2664,
    "user_query": "You MUST give a detailed answer to the following question: Is recursive splicing more common in short introns?",
    "llama-7b_response": "Recursive splicing, also known as intron retention, is the process by which an intron is retained in the mature mRNA transcript, rather than being spliced out during the splicing process. Recursive splicing has been observed in a variety of organisms, including plants, animals, and fungi.\n\nThere is some evidence to suggest that recursive splicing may be more common in short introns. Short introns are introns that are relatively small in size, typically ranging from a few hundred to a few thousand base pairs in length. Short introns are more likely to be retained in the mature mRNA transcript because they are less likely to be spliced out due to the time and energy required for the splicing process. Additionally, short introns may be more likely to interfere with the splicing process, which can lead to their retention in the mature mRNA transcript.\n\nHowever, it is worth noting that the relationship between recursive splicing and intron length is complex and not fully understood. Recursive splicing has been observed in introns of varying lengths, and the factors that contribute to recursive splicing are likely to be complex and multifaceted.\n\nIn summary, while there is some evidence to suggest that recursive splicing may be more common in short introns, the relationship between recursive splicing and intron length is complex and not fully understood. Further research is needed to fully understand the factors that contribute to recursive splicing and its prevalence in different types of introns.",
    "llama-7b_fact_raw": "1. Recursive splicing, also known as intron retention, involves retaining an intron in the mature mRNA transcript.\n2. Short introns typically range from a few hundred to a few thousand base pairs in length.\n3. Short introns are more likely to be retained in the mature mRNA transcript because they are less likely to be spliced out.\n4. Recursive splicing has been observed in a variety of organisms, including plants, animals, and fungi.\n5. The relationship between recursive splicing and intron length is not fully understood and requires further research.",
    "llama-7b_fact": [
      "Recursive splicing, also known as intron retention, involves retaining an intron in the mature mRNA transcript.",
      "Short introns typically range from a few hundred to a few thousand base pairs in length.",
      "Short introns are more likely to be retained in the mature mRNA transcript because they are less likely to be spliced out.",
      "Recursive splicing has been observed in a variety of organisms, including plants, animals, and fungi.",
      "The relationship between recursive splicing and intron length is not fully understood and requires further research."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Recursive splicing is a process where a long intron is removed in multiple steps, not the retention of an intron in the mature mRNA transcript. Intron retention is a different type of alternative splicing event where an intron is indeed retained in the mature mRNA.\n2. TRUE\n3. FALSE [correction]: Short introns are more likely to be efficiently spliced out due to their size, which makes them less likely to be retained in the mature mRNA transcript compared to longer introns.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2679,
    "user_query": "You MUST give a detailed answer to the following question: What is the TALE-iD method used for?",
    "llama-7b_response": "The TALE-iD method is used for the identification of transcription factor binding sites (TFBSs) in DNA sequences. TFBSs are short sequences of DNA that are recognized by specific transcription factors (TFs) and play a crucial role in the regulation of gene expression. The TALE-iD method uses a technique called \"transcription factor ChIP-Seq\" to identify TFBSs.\n\nTranscription factor ChIP-Seq involves the following steps:\n\n1. Chromatin immunoprecipitation (ChIP): The TF of interest is immunoprecipitated from the chromatin using an antibody specific to the TF. This isolates the TF-DNA complexes from the rest of the chromatin.\n2. DNA sequencing: The isolated TF-DNA complexes are then sequenced to obtain the DNA sequence around the TF binding site.\n3. Identification of TFBSs: The sequencing data is then analyzed to identify the TFBSs. The TALE-iD method uses a machine learning approach to identify TFBSs by comparing the sequencing data to a large database of known TFBSs.\n\nThe TALE-iD method has several advantages over other methods for the identification of TFBSs, including its ability to identify TFBSs with high specificity and sensitivity, and its ability to identify TFBSs in complex genomic regions. The TALE-iD method has been used to identify TFBSs in a variety of organisms, including humans, mice, and plants, and has been applied to a wide range of research areas, including gene regulation, epigenetics, and drug discovery.",
    "llama-7b_fact_raw": "1. The TALE-iD method is used for the identification of transcription factor binding sites in DNA sequences.\n2. Transcription factor binding sites are short sequences of DNA that are recognized by specific transcription factors.\n3. The TALE-iD method uses transcription factor ChIP-Seq to identify transcription factor binding sites.\n4. Chromatin immunoprecipitation (ChIP) is a step in the TALE-iD method where the transcription factor of interest is immunoprecipitated using a specific antibody.\n5. The TALE-iD method has been used to identify transcription factor binding sites in various organisms, including humans, mice, and plants.",
    "llama-7b_fact": [
      "The TALE-iD method is used for the identification of transcription factor binding sites in DNA sequences.",
      "Transcription factor binding sites are short sequences of DNA that are recognized by specific transcription factors.",
      "The TALE-iD method uses transcription factor ChIP-Seq to identify transcription factor binding sites.",
      "Chromatin immunoprecipitation (ChIP) is a step in the TALE-iD method where the transcription factor of interest is immunoprecipitated using a specific antibody.",
      "The TALE-iD method has been used to identify transcription factor binding sites in various organisms, including humans, mice, and plants."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The TALE-iD method does not use ChIP-Seq; it is a method that uses transcription activator-like effectors (TALEs) to identify transcription factor binding sites.\n4. FALSE [correction]: Chromatin immunoprecipitation (ChIP) is a step in ChIP-Seq, not in the TALE-iD method. TALE-iD uses a different approach involving TALEs.\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2747,
    "user_query": "You MUST give a detailed answer to the following question: Which Lisp framework has been developed for image processing?",
    "llama-7b_response": "There are several Lisp frameworks that have been developed for image processing, including:\n\n1. Common Lisp Image Processing Library (CLIP): CLIP is a Common Lisp library for image processing and analysis. It provides a wide range of image processing functions, including image filtering, morphological operations, and feature extraction.\n2. Lisp Machine Image Processing Library (LMIP): LMIP is a Lisp machine library for image processing and analysis. It provides a wide range of image processing functions, including image filtering, morphological operations, and feature extraction.\n3. Lisp Image Processing Library (LIP): LIP is a Lisp library for image processing and analysis. It provides a wide range of image processing functions, including image filtering, morphological operations, and feature extraction.\n4. Lisp Image Processing System (LIPS): LIPS is a Lisp system for image processing and analysis. It provides a wide range of image processing functions, including image filtering, morphological operations, and feature extraction.\n5. Lisp Image Processing Toolkit (LIPT): LIPT is a Lisp toolkit for image processing and analysis. It provides a wide range of image processing functions, including image filtering, morphological operations, and feature extraction.",
    "llama-7b_fact_raw": "1. The Common Lisp Image Processing Library (CLIP) is a library for image processing and analysis in Common Lisp.\n2. The Lisp Machine Image Processing Library (LMIP) is a library for image processing and analysis on Lisp machines.\n3. The Lisp Image Processing Library (LIP) is a library for image processing and analysis in Lisp.\n4. The Lisp Image Processing System (LIPS) is a system for image processing and analysis in Lisp.\n5. The Lisp Image Processing Toolkit (LIPT) is a toolkit for image processing and analysis in Lisp.",
    "llama-7b_fact": [
      "The Common Lisp Image Processing Library (CLIP) is a library for image processing and analysis in Common Lisp.",
      "The Lisp Machine Image Processing Library (LMIP) is a library for image processing and analysis on Lisp machines.",
      "The Lisp Image Processing Library (LIP) is a library for image processing and analysis in Lisp.",
      "The Lisp Image Processing System (LIPS) is a system for image processing and analysis in Lisp.",
      "The Lisp Image Processing Toolkit (LIPT) is a toolkit for image processing and analysis in Lisp."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN: Without specific information about a library named \"Common Lisp Image Processing Library (CLIP),\" it is not possible to verify the accuracy of this statement.\n2. UNKNOWN: The existence of a \"Lisp Machine Image Processing Library (LMIP)\" is not well-known, and without additional context, it is not possible to verify the accuracy of this statement.\n3. UNKNOWN: The statement about the \"Lisp Image Processing Library (LIP)\" cannot be verified without additional information.\n4. UNKNOWN: The existence of a \"Lisp Image Processing System (LIPS)\" cannot be confirmed without more context.\n5. UNKNOWN: The statement regarding the \"Lisp Image Processing Toolkit (LIPT)\" cannot be verified without further information.\n\nNote: The statements provided are very specific and pertain to potentially niche or less well-documented libraries or systems within the Lisp programming community. Without additional context or sources, it is not possible to accurately determine the truth of these statements.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2759,
    "user_query": "You MUST give a detailed answer to the following question: How many genes in S. cerevisiae are the result of an ancient whole genome duplication?",
    "llama-7b_response": "30",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 2763,
    "user_query": "You MUST give a detailed answer to the following question: Which complex is bound by estrogen-related receptor β (Esrrb)?",
    "llama-7b_response": "estradiol",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 2842,
    "user_query": "You MUST give a detailed answer to the following question: What is the role of ZCCHC17?",
    "llama-7b_response": "ZCCHC17 (zinc finger CCCH-type containing 17) is a gene that encodes a protein with a zinc finger domain and a coiled-coil domain. The function of ZCCHC17 is not well understood, but it has been suggested to play a role in the regulation of gene expression.\n\nZinc finger proteins are known to bind to specific DNA sequences, and the zinc finger domain of ZCCHC17 is thought to be involved in binding to DNA. The coiled-coil domain of ZCCHC17 is thought to be involved in protein-protein interactions, and it has been suggested that ZCCHC17 may interact with other proteins to regulate gene expression.\n\nSeveral studies have suggested that ZCCHC17 may play a role in the regulation of immune response and inflammation. For example, one study found that ZCCHC17 was upregulated in the blood of patients with systemic lupus erythematosus, a chronic autoimmune disorder characterized by inflammation. Another study found that ZCCHC17 was upregulated in the brains of mice with experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis, a chronic inflammatory disorder of the central nervous system.\n\nOverall, while the function of ZCCHC17 is not well understood, it is clear that it plays a role in the regulation of gene expression and may be involved in the regulation of immune response and inflammation. Further research is needed to fully understand the role of ZCCHC17 in human health and disease.",
    "llama-7b_fact_raw": "1. ZCCHC17 is a gene that encodes a protein with a zinc finger domain and a coiled-coil domain.\n2. The zinc finger domain of ZCCHC17 is thought to be involved in binding to DNA.\n3. The coiled-coil domain of ZCCHC17 is thought to be involved in protein-protein interactions.\n4. ZCCHC17 has been suggested to play a role in the regulation of immune response and inflammation.\n5. ZCCHC17 was found to be upregulated in the blood of patients with systemic lupus erythematosus and in the brains of mice with experimental autoimmune encephalomyelitis.",
    "llama-7b_fact": [
      "ZCCHC17 is a gene that encodes a protein with a zinc finger domain and a coiled-coil domain.",
      "The zinc finger domain of ZCCHC17 is thought to be involved in binding to DNA.",
      "The coiled-coil domain of ZCCHC17 is thought to be involved in protein-protein interactions.",
      "ZCCHC17 has been suggested to play a role in the regulation of immune response and inflammation.",
      "ZCCHC17 was found to be upregulated in the blood of patients with systemic lupus erythematosus and in the brains of mice with experimental autoimmune encephalomyelitis."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nThe first four statements are consistent with general knowledge about the functions of zinc finger domains and coiled-coil domains in proteins, and it is plausible that ZCCHC17 could be involved in immune response and inflammation given these domains' roles. However, without specific literature or research data to confirm the fifth statement about ZCCHC17 being upregulated in patients with systemic lupus erythematosus and in the brains of mice with experimental autoimmune encephalomyelitis, it is not possible to determine its accuracy. Therefore, the response to the fifth statement is UNKNOWN.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2861,
    "user_query": "You MUST give a detailed answer to the following question: Which proteins form the nuclear pore basket in human cells?",
    "llama-7b_response": "The nuclear pore complex (NPC) is a large protein complex that regulates the flow of molecules between the nucleus and the cytoplasm in eukaryotic cells. The NPC consists of two main components: the nucleoplasmic side and the cytoplasmic side. The nucleoplasmic side of the NPC is made up of a basket-like structure called the nuclear pore basket, which is formed by a group of proteins called the nucleoporins.\n\nThe nucleoporins are a family of highly conserved proteins that are essential for the proper functioning of the NPC. There are 19 different nucleoporins that have been identified in humans, and they can be divided into three main classes: nucleoporin 100 (Nup100), nucleoporin 153 (Nup153), and nucleoporin 180 (Nup180).\n\nThe nucleoporin 100 (Nup100) proteins are the most abundant nucleoporins in the NPC and are responsible for forming the basket-like structure of the nucleoplasmic side of the NPC. The Nup100 proteins are made up of two subunits, Nup100a and Nup100b, which interact with each other to form a ring-like structure. The Nup100 proteins also interact with other nucleoporins, such as Nup153 and Nup180, to form the nucleoplasmic side of the NPC.\n\nThe nucleoporin 153 (Nup153) proteins are also important components of the NPC and are responsible for regulating the transport of molecules through the NPC. Nup153 proteins interact with both Nup100 and Nup180 proteins to form the nucleoplasmic side of the NPC.\n\nThe nucleoporin 180 (Nup180) proteins are also important components of the NPC and are responsible for regulating the transport of molecules through the NPC. Nup180 proteins interact with both Nup100 and Nup153 proteins to form the nucleoplasmic side of the NPC.",
    "llama-7b_fact_raw": "1. The nuclear pore complex (NPC) regulates the flow of molecules between the nucleus and the cytoplasm in eukaryotic cells.\n2. The nuclear pore basket is a structure on the nucleoplasmic side of the NPC formed by a group of proteins called nucleoporins.\n3. There are 19 different nucleoporins identified in humans.\n4. Nucleoporin 100 (Nup100) proteins are the most abundant in the NPC and are responsible for forming the basket-like structure of the nucleoplasmic side.\n5. Nucleoporin 153 (Nup153) and Nucleoporin 180 (Nup180) proteins are components of the NPC that regulate the transport of molecules through the NPC.",
    "llama-7b_fact": [
      "The nuclear pore complex (NPC) regulates the flow of molecules between the nucleus and the cytoplasm in eukaryotic cells.",
      "The nuclear pore basket is a structure on the nucleoplasmic side of the NPC formed by a group of proteins called nucleoporins.",
      "There are 19 different nucleoporins identified in humans.",
      "Nucleoporin 100 (Nup100) proteins are the most abundant in the NPC and are responsible for forming the basket-like structure of the nucleoplasmic side.",
      "Nucleoporin 153 (Nup153) and Nucleoporin 180 (Nup180) proteins are components of the NPC that regulate the transport of molecules through the NPC."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: There are around 30 different nucleoporins identified in humans, not 19.\n4. FALSE [correction]: Nucleoporin 100 (Nup100) is not the most abundant in the NPC, and it is not responsible for forming the basket-like structure of the nucleoplasmic side. The basket-like structure is formed by a different set of nucleoporins, such as Nup153.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2919,
    "user_query": "You MUST give a detailed answer to the following question: What type of topoisomerase inhibitor is gepotidacin?",
    "llama-7b_response": "Topoisomerase inhibitor",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 2943,
    "user_query": "You MUST give a detailed answer to the following question: Describe Canvas SPW",
    "llama-7b_response": "I'm sorry, but I am not familiar with Canvas SPW. Can you provide more context or information about what you are looking for?",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 2960,
    "user_query": "You MUST give a detailed answer to the following question: List STING agonists.",
    "llama-7b_response": "STING (Stimulator of Interferon Genes) is a cytosolic DNA sensor that plays a crucial role in the innate immune response against viral infections. Upon binding to double-stranded DNA, STING activates a signaling cascade that leads to the activation of interferon (IFN) genes, resulting in the production of type I interferons (IFN-alpha and IFN-beta) and other antiviral cytokines.\n\nAgonists of STING, also known as STING activators or STING agonists, are compounds or agents that stimulate the activity of STING and induce an immune response against viral infections. Here are some examples of STING agonists:\n\n1. Cyclic di-GMP (c-di-GMP): c-di-GMP is a bacterial second messenger that regulates various cellular processes, including DNA repair, biofilm formation, and virulence. Recent studies have shown that c-di-GMP can activate STING and induce an antiviral response in mammalian cells.\n2. CpG oligodeoxynucleotides: CpG oligodeoxynucleotides are short, unmethylated DNA sequences that contain a high proportion of cytosine-phosphate-guanine (CpG) dinucleotides. CpG oligodeoxynucleotides have been shown to activate STING and induce an antiviral response in various cell types.\n3. Poly(I:C): Poly(I:C) is a synthetic analog of double-stranded RNA that can activate STING and induce an antiviral response in mammalian cells. Poly(I:C) has been used in various preclinical and clinical studies as a potential therapeutic agent for the treatment of viral infections.\n4. Resveratrol: Resveratrol is a polyphenolic compound found in various plants, including grapes, berries, and peanuts. Recent studies have shown that resveratrol can activate STING and induce an antiviral response in mammalian cells.\n5.",
    "llama-7b_fact_raw": "1. STING (Stimulator of Interferon Genes) is a cytosolic DNA sensor that activates interferon genes upon binding to double-stranded DNA.\n2. Cyclic di-GMP (c-di-GMP) is a bacterial second messenger that can activate STING in mammalian cells.\n3. CpG oligodeoxynucleotides are short DNA sequences that can activate STING and induce an antiviral response.\n4. Poly(I:C) is a synthetic analog of double-stranded RNA that can activate STING in mammalian cells.\n5. Resveratrol is a polyphenolic compound that has been shown to activate STING and induce an antiviral response in mammalian cells.",
    "llama-7b_fact": [
      "STING (Stimulator of Interferon Genes) is a cytosolic DNA sensor that activates interferon genes upon binding to double-stranded DNA.",
      "Cyclic di-GMP (c-di-GMP) is a bacterial second messenger that can activate STING in mammalian cells.",
      "CpG oligodeoxynucleotides are short DNA sequences that can activate STING and induce an antiviral response.",
      "Poly(I:C) is a synthetic analog of double-stranded RNA that can activate STING in mammalian cells.",
      "Resveratrol is a polyphenolic compound that has been shown to activate STING and induce an antiviral response in mammalian cells."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Cyclic di-GMP (c-di-GMP) is a bacterial second messenger, but it does not activate STING in mammalian cells. STING is activated by cyclic dinucleotides produced by the mammalian cell itself or by bacterial cyclic dinucleotides, but c-di-GMP is not typically involved in activating STING in mammalian cells.\n3. TRUE\n4. FALSE [correction]: Poly(I:C) is a synthetic analog of double-stranded RNA that activates Toll-like receptor 3 (TLR3) and other receptors involved in the antiviral response, not STING, which is a sensor for double-stranded DNA.\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2964,
    "user_query": "You MUST give a detailed answer to the following question: Describe SLIC-CAGE",
    "llama-7b_response": "SLIC-CAGE is an acronym that stands for \"Single Layer Integrated Circuit - Computer-Aided Geometric Engineering.\" It is a computer-aided design (CAD) software tool that is used for the design and analysis of integrated circuits (ICs) and other microelectronic devices.\n\nThe SLIC-CAGE software is used to create detailed 2D and 3D models of ICs and other microelectronic devices. These models can be used to simulate and analyze the performance of the devices, including their electrical characteristics, thermal behavior, and reliability.\n\nThe SLIC-CAGE software is designed to be user-friendly and intuitive, making it easy for designers and engineers to create accurate and detailed models of ICs and other microelectronic devices. The software includes a range of features and tools that can be used to customize and optimize the design of the devices, including the ability to import and export data in a variety of formats.\n\nOverall, SLIC-CAGE is a valuable tool for the design and analysis of integrated circuits and other microelectronic devices, and it is widely used in the semiconductor industry.",
    "llama-7b_fact_raw": "1. SLIC-CAGE stands for \"Single Layer Integrated Circuit - Computer-Aided Geometric Engineering.\"\n2. SLIC-CAGE is a computer-aided design (CAD) software tool.\n3. The software is used for the design and analysis of integrated circuits (ICs) and other microelectronic devices.\n4. SLIC-CAGE allows for the creation of detailed 2D and 3D models of ICs and microelectronic devices.\n5. The software includes features that enable the import and export of data in various formats.",
    "llama-7b_fact": [
      "SLIC-CAGE stands for \"Single Layer Integrated Circuit - Computer-Aided Geometric Engineering.\"",
      "SLIC-CAGE is a computer-aided design (CAD) software tool.",
      "The software is used for the design and analysis of integrated circuits (ICs) and other microelectronic devices.",
      "SLIC-CAGE allows for the creation of detailed 2D and 3D models of ICs and microelectronic devices.",
      "The software includes features that enable the import and export of data in various formats."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: SLIC-CAGE does not stand for \"Single Layer Integrated Circuit - Computer-Aided Geometric Engineering.\" There is no widely recognized CAD tool by this name, and the acronym does not correspond to a known software in the field of integrated circuits or CAD.\n2. FALSE [correction]: Since SLIC-CAGE is not a recognized CAD tool, this statement is also false.\n3. FALSE [correction]: As SLIC-CAGE is not an established software for designing integrated circuits, this statement is incorrect.\n4. FALSE [correction]: Since SLIC-CAGE is not a recognized tool, it does not allow for the creation of detailed 2D and 3D models of ICs and microelectronic devices.\n5. FALSE [correction]: As SLIC-CAGE is not an established software, it does not include features for importing and exporting data in various formats.",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2978,
    "user_query": "You MUST give a detailed answer to the following question: What are the roles of LEM-3?",
    "llama-7b_response": "LEM-3, also known as leucine-rich repeat-containing G protein-coupled receptor 3, is a protein that belongs to the family of G protein-coupled receptors (GPCRs). GPCRs are a large family of receptors that are activated by a variety of extracellular signals, including hormones, neurotransmitters, and other signaling molecules.\n\nThe exact function of LEM-3 is not fully understood, but it is thought to play a role in the regulation of various physiological processes, including cell growth, differentiation, and apoptosis (programmed cell death). Studies have shown that LEM-3 may be involved in the regulation of the Wnt signaling pathway, which plays a crucial role in the control of cell proliferation, differentiation, and tissue development.\n\nIn addition to its role in the Wnt signaling pathway, LEM-3 has also been implicated in the regulation of other signaling pathways, including the TGF-β signaling pathway, which is involved in the regulation of cell growth, differentiation, and apoptosis.\n\nOverall, LEM-3 appears to play a critical role in the regulation of various physiological processes, and its dysregulation has been implicated in the development of various diseases, including cancer. Further research is needed to fully understand the functions of LEM-3 and its role in human health and disease.",
    "llama-7b_fact_raw": "1. LEM-3 is a protein that belongs to the family of G protein-coupled receptors (GPCRs).\n2. G protein-coupled receptors are activated by a variety of extracellular signals, including hormones, neurotransmitters, and other signaling molecules.\n3. LEM-3 is thought to play a role in the regulation of cell growth, differentiation, and apoptosis.\n4. LEM-3 may be involved in the regulation of the Wnt signaling pathway, which is important for cell proliferation, differentiation, and tissue development.\n5. LEM-3 has been implicated in the regulation of the TGF-β signaling pathway.",
    "llama-7b_fact": [
      "LEM-3 is a protein that belongs to the family of G protein-coupled receptors (GPCRs).",
      "G protein-coupled receptors are activated by a variety of extracellular signals, including hormones, neurotransmitters, and other signaling molecules.",
      "LEM-3 is thought to play a role in the regulation of cell growth, differentiation, and apoptosis.",
      "LEM-3 may be involved in the regulation of the Wnt signaling pathway, which is important for cell proliferation, differentiation, and tissue development.",
      "LEM-3 has been implicated in the regulation of the TGF-β signaling pathway."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: LEM-3 is not a protein that belongs to the family of G protein-coupled receptors (GPCRs). LEM domain-containing protein 3 (LEM-3) is actually involved in DNA damage response and repair.\n2. TRUE\n3. UNKNOWN: Without specific scientific literature or context, it is difficult to confirm the exact role of LEM-3 in cell growth, differentiation, and apoptosis.\n4. UNKNOWN: The involvement of LEM-3 in the Wnt signaling pathway is not well-established without specific context or references.\n5. UNKNOWN: Similarly, the role of LEM-3 in the regulation of the TGF-β signaling pathway cannot be confirmed without additional information.",
    "llama-7b_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2992,
    "user_query": "You MUST give a detailed answer to the following question: List the releases of tmVar",
    "llama-7b_response": "I'm sorry, but I don't have information on the releases of tmVar. Can you provide more context or clarify your question?",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3018,
    "user_query": "You MUST give a detailed answer to the following question: Which is the database of somatic mutations in normal cells?",
    "llama-7b_response": "1000 Genomes Project",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3037,
    "user_query": "You MUST give a detailed answer to the following question: Are there graph kernel libraries available implemented in JAVA?",
    "llama-7b_response": "Yes, there are several graph kernel libraries available implemented in Java. Some of the popular ones include:\n\n1. JGraphT: JGraphT is a Java library for working with graphs and networks. It provides a high-level API for creating and manipulating graphs, as well as for querying and analyzing their properties. JGraphT supports various types of graphs, including undirected and directed graphs, weighted and unweighted graphs, and multigraphs.\n2. NetworkX: NetworkX is a Python library for working with graphs and networks. It provides a high-level API for creating and manipulating graphs, as well as for querying and analyzing their properties. NetworkX supports various types of graphs, including undirected and directed graphs, weighted and unweighted graphs, and multigraphs. NetworkX has a Java port called NetworkX-Java, which provides a Java API for working with graphs and networks.\n3. Graph5J: Graph5J is a Java library for working with graphs and networks. It provides a high-level API for creating and manipulating graphs, as well as for querying and analyzing their properties. Graph5J supports various types of graphs, including undirected and directed graphs, weighted and unweighted graphs, and multigraphs.\n4. JUNG: JUNG is a Java library for working with graphs and networks. It provides a high-level API for creating and manipulating graphs, as well as for querying and analyzing their properties. JUNG supports various types of graphs, including undirected and directed graphs, weighted and unweighted graphs, and multigraphs.\n\nThese are just a few examples of the many graph kernel libraries available in Java. Each library has its own strengths and weaknesses, and the choice of which one to use will depend on the specific requirements of the application.",
    "llama-7b_fact_raw": "1. JGraphT is a Java library designed for working with graphs and networks.\n2. NetworkX is primarily a Python library, but it has a Java port called NetworkX-Java.\n3. Graph5J is a Java library for working with graphs and networks.\n4. JUNG is a Java library that provides an API for creating, manipulating, and analyzing graphs and networks.\n5. Each of the mentioned libraries supports various types of graphs, including undirected and directed graphs, weighted and unweighted graphs, and multigraphs.",
    "llama-7b_fact": [
      "JGraphT is a Java library designed for working with graphs and networks.",
      "NetworkX is primarily a Python library, but it has a Java port called NetworkX-Java.",
      "Graph5J is a Java library for working with graphs and networks.",
      "JUNG is a Java library that provides an API for creating, manipulating, and analyzing graphs and networks.",
      "Each of the mentioned libraries supports various types of graphs, including undirected and directed graphs, weighted and unweighted graphs, and multigraphs."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: NetworkX is a Python library for working with graphs and networks, and there is no official Java port called NetworkX-Java.\n3. FALSE [correction]: There is no well-known Java library for working with graphs and networks named Graph5J. It might be a typo or a fictional library.\n4. TRUE\n5. TRUE (assuming the statement refers to JGraphT, NetworkX, and JUNG, which all support various types of graphs as mentioned)",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3045,
    "user_query": "You MUST give a detailed answer to the following question: List the four advances integrated into the SHERLOCKv2 platform.",
    "llama-7b_response": "Sure, here are the four advances integrated into the SHERLOCKv2 platform:\n\n1. Machine learning algorithms: The SHERLOCKv2 platform uses machine learning algorithms to analyze large amounts of data and identify patterns and anomalies. These algorithms are integrated into the platform to provide real-time threat detection and response capabilities.\n2. Behavioral analytics: The SHERLOCKv2 platform uses behavioral analytics to detect and respond to advanced threats. Behavioral analytics involves analyzing the behavior of users, devices, and applications to identify anomalies and potential threats.\n3. User and entity behavior analytics (UEBA): The SHERLOCKv2 platform uses user and entity behavior analytics (UEBA) to detect and respond to advanced threats. UEBA involves analyzing the behavior of users and entities within an organization to identify potential threats and anomalies.\n4. Artificial intelligence (AI): The SHERLOCKv2 platform uses artificial intelligence (AI) to analyze large amounts of data and identify patterns and anomalies. AI is integrated into the platform to provide real-time threat detection and response capabilities.\n\nOverall, the SHERLOCKv2 platform integrates these four advances to provide a comprehensive solution for detecting and responding to advanced threats. By leveraging machine learning algorithms, behavioral analytics, UEBA, and AI, the platform is able to provide real-time threat detection and response capabilities to help organizations protect their networks and data from advanced threats.",
    "llama-7b_fact_raw": "1. The SHERLOCKv2 platform uses machine learning algorithms to provide real-time threat detection and response capabilities.\n2. Behavioral analytics are utilized by the SHERLOCKv2 platform to detect and respond to advanced threats.\n3. User and entity behavior analytics (UEBA) are employed by the SHERLOCKv2 platform to identify potential threats and anomalies.\n4. Artificial intelligence (AI) is integrated into the SHERLOCKv2 platform for analyzing data and identifying patterns and anomalies.",
    "llama-7b_fact": [
      "The SHERLOCKv2 platform uses machine learning algorithms to provide real-time threat detection and response capabilities.",
      "Behavioral analytics are utilized by the SHERLOCKv2 platform to detect and respond to advanced threats.",
      "User and entity behavior analytics (UEBA) are employed by the SHERLOCKv2 platform to identify potential threats and anomalies.",
      "Artificial intelligence (AI) is integrated into the SHERLOCKv2 platform for analyzing data and identifying patterns and anomalies."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n\nNote: The statements provided suggest that the SHERLOCKv2 platform incorporates various technologies such as machine learning, behavioral analytics, UEBA, and AI for threat detection and response. Without specific details to contradict these claims, they are assumed to be true based on the context given. If the context provided is hypothetical or from a fictional source, the responses would be based on the information within that context.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3078,
    "user_query": "You MUST give a detailed answer to the following question: Describe the bartender algorithm",
    "llama-7b_response": "The bartender algorithm, also known as the bartender problem, is a classic problem in computer science that involves scheduling tasks in a way that minimizes the total time required to complete them.\n\nThe problem is inspired by the task of a bartender who has to serve drinks to a group of patrons in a bar. Each patron has a preference for a specific type of drink, and the bartender has to serve the drinks in a way that satisfies all the patrons' preferences.\n\nThe bartender problem can be modeled as a scheduling problem, where the tasks are the different types of drinks, and the preferences of the patrons are the constraints. The goal is to find a schedule that minimizes the total time required to serve all the drinks.\n\nThe bartender algorithm is a simple greedy algorithm that solves the bartender problem. The algorithm works as follows:\n\n1. Start with an empty schedule, which means that no drinks have been served yet.\n2. For each patron, find the earliest time at which their preferred drink can be served.\n3. Add the patron's preferred drink to the schedule at the earliest time found in step 2.\n4. Repeat steps 2 and 3 for all patrons.\n5. The resulting schedule is the optimal solution to the bartender problem.\n\nThe bartender algorithm has a time complexity of O(n\\*m), where n is the number of patrons and m is the number of drinks. This is because the algorithm visits each patron and each drink once, and the time complexity of each visit is O(n) and O(m), respectively.\n\nThe bartender algorithm is a simple and efficient solution to the bartender problem, but it may not always produce the optimal solution. In some cases, a more sophisticated algorithm may be needed to find the optimal solution.",
    "llama-7b_fact_raw": "1. The bartender algorithm is a problem in computer science that involves scheduling tasks to minimize the total time required to complete them.\n2. The bartender problem is inspired by a bartender serving drinks to patrons with specific preferences.\n3. The bartender problem can be modeled as a scheduling problem with tasks as different types of drinks and patrons' preferences as constraints.\n4. The bartender algorithm is a greedy algorithm that aims to find a schedule minimizing the total time to serve all drinks.\n5. The time complexity of the bartender algorithm is O(n*m), where n is the number of patrons and m is the number of drinks.",
    "llama-7b_fact": [
      "The bartender algorithm is a problem in computer science that involves scheduling tasks to minimize the total time required to complete them.",
      "The bartender problem is inspired by a bartender serving drinks to patrons with specific preferences.",
      "The bartender problem can be modeled as a scheduling problem with tasks as different types of drinks and patrons' preferences as constraints.",
      "The bartender algorithm is a greedy algorithm that aims to find a schedule minimizing the total time to serve all drinks.",
      "The time complexity of the bartender algorithm is O(n*m), where n is the number of patrons and m is the number of drinks."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The bartender algorithm is not a standard problem in computer science; the term might be a colloquial or metaphorical reference. A well-known problem involving scheduling tasks is the \"barbershop problem\" or \"sleeping barber problem,\" but it is not typically referred to as the bartender problem.\n2. UNKNOWN: Without specific context or a recognized definition in computer science literature, it's unclear whether the bartender problem as described is a recognized problem or an analogy created for a specific scenario.\n3. UNKNOWN: As with statement 2, without a recognized definition, it's unclear if this is an accurate model for the so-called bartender problem.\n4. UNKNOWN: Since the bartender algorithm is not a standard term in computer science, it's unclear whether it is a greedy algorithm or what its aims are.\n5. UNKNOWN: Without a recognized definition of the bartender algorithm, the time complexity cannot be determined. The time complexity would depend on the specific algorithm and problem definition.",
    "llama-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3100,
    "user_query": "You MUST give a detailed answer to the following question: Which web-based pedigree editors are available?",
    "llama-7b_response": "There are several web-based pedigree editors available, including:\n\n1. MyHeritage: MyHeritage is a popular web-based genealogy platform that allows users to create and manage their family trees, search for ancestors, and collaborate with other family members.\n2. Ancestry: Ancestry is another popular web-based genealogy platform that offers a range of tools for creating and managing family trees, searching for ancestors, and sharing information with other family members.\n3. My Family: My Family is a web-based genealogy platform that allows users to create and manage their family trees, search for ancestors, and collaborate with other family members.\n4. Geni: Geni is a web-based genealogy platform that allows users to create and manage their family trees, search for ancestors, and collaborate with other family members.\n5. WeRelate: WeRelate is a web-based genealogy platform that allows users to create and manage their family trees, search for ancestors, and collaborate with other family members.\n6. WikiTree: WikiTree is a web-based genealogy platform that allows users to create and manage their family trees, search for ancestors, and collaborate with other family members.\n7. My Life: My Life is a web-based genealogy platform that allows users to create and manage their family trees, search for ancestors, and collaborate with other family members.",
    "llama-7b_fact_raw": "1. MyHeritage is a web-based genealogy platform that includes a pedigree editor.\n2. Ancestry is a web-based genealogy platform that offers tools for creating and managing family trees.\n3. Geni is a web-based genealogy platform that allows users to create and manage their family trees.\n4. WeRelate is a web-based genealogy platform that provides features for creating and managing family trees.\n5. WikiTree is a web-based genealogy platform that enables users to create and manage their family trees and collaborate with others.",
    "llama-7b_fact": [
      "MyHeritage is a web-based genealogy platform that includes a pedigree editor.",
      "Ancestry is a web-based genealogy platform that offers tools for creating and managing family trees.",
      "Geni is a web-based genealogy platform that allows users to create and manage their family trees.",
      "WeRelate is a web-based genealogy platform that provides features for creating and managing family trees.",
      "WikiTree is a web-based genealogy platform that enables users to create and manage their family trees and collaborate with others."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3107,
    "user_query": "You MUST give a detailed answer to the following question: Which curated databases exist for spider-venom toxins?",
    "llama-7b_response": "There are several curated databases that exist for spider venom toxins. Here are some of the most notable ones:\n\n1. Spider Toxin Database (STD): The Spider Toxin Database is a comprehensive database of spider venom toxins that was developed by researchers at the University of Melbourne in Australia. The database contains information on the chemical structure, biological activity, and pharmacological effects of spider venom toxins. It also includes information on the species of spider that produces the toxin and the prey species that the spider targets. The database is available online and can be accessed through the University of Melbourne website.\n2. World Spider Catalog (WSC): The World Spider Catalog (WSC) is a comprehensive database of spider species that was developed by researchers at the American Museum of Natural History in New York City. The database includes information on the biology, distribution, and taxonomy of spider species, as well as information on the venom of some species. The database is available online and can be accessed through the American Museum of Natural History website.\n3. Arachnology Database: The Arachnology Database is a comprehensive database of spider species that was developed by researchers at the University of California, Riverside. The database includes information on the biology, distribution, and taxonomy of spider species, as well as information on the venom of some species. The database is available online and can be accessed through the University of California, Riverside website.\n4. VenomDB: VenomDB is a database of venom peptides and proteins that was developed by researchers at the University of Melbourne in Australia. The database contains information on the chemical structure, biological activity, and pharmacological effects of venom peptides and proteins from a wide range of organisms, including spiders. The database is available online and can be accessed through the University of Melbourne website.\n\nThese are just a few examples of the many curated databases that exist for spider venom toxins. Each of these databases provides valuable information for researchers studying the biology and pharmacology of spider venom toxins.",
    "llama-7b_fact_raw": "1. The Spider Toxin Database (STD) was developed by researchers at the University of Melbourne in Australia and contains information on spider venom toxins.\n2. The World Spider Catalog (WSC) was developed by researchers at the American Museum of Natural History in New York City and includes information on spider species and their venom.\n3. The Arachnology Database was developed by researchers at the University of California, Riverside and includes information on spider species and their venom.\n4. VenomDB was developed by researchers at the University of Melbourne in Australia and contains information on venom peptides and proteins from various organisms, including spiders.",
    "llama-7b_fact": [
      "The Spider Toxin Database (STD) was developed by researchers at the University of Melbourne in Australia and contains information on spider venom toxins.",
      "The World Spider Catalog (WSC) was developed by researchers at the American Museum of Natural History in New York City and includes information on spider species and their venom.",
      "The Arachnology Database was developed by researchers at the University of California, Riverside and includes information on spider species and their venom.",
      "VenomDB was developed by researchers at the University of Melbourne in Australia and contains information on venom peptides and proteins from various organisms, including spiders."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The World Spider Catalog (WSC) was developed by researchers at the American Museum of Natural History in New York City and includes information on spider species, but it does not specifically include information on their venom.\n3. UNKNOWN\n4. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3111,
    "user_query": "You MUST give a detailed answer to the following question: Does Axitinib prolong survival of Pancreatic Cancer patients?",
    "llama-7b_response": "Axitinib is a tyrosine kinase inhibitor that is used to treat advanced renal cell carcinoma and advanced melanoma. It works by inhibiting the activity of vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptors, which can help to reduce the growth and spread of cancer cells.\n\nThere have been several clinical trials that have investigated the use of axitinib in the treatment of pancreatic cancer. One study, known as the PANCH trial, found that the use of axitinib in combination with gemcitabine and nab-paclitaxel did not improve overall survival compared to gemcitabine and nab-paclitaxel alone in patients with metastatic pancreatic ductal adenocarcinoma.\n\nAnother study, known as the AXIS trial, found that the use of axitinib in combination with gemcitabine and nab-paclitaxel did not improve overall survival compared to gemcitabine and nab-paclitaxel alone in patients with metastatic pancreatic ductal adenocarcinoma. However, the study also found that axitinib did improve progression-free survival compared to gemcitabine and nab-paclitaxel alone.\n\nOverall, the evidence regarding the use of axitinib in the treatment of pancreatic cancer is mixed. While some studies have found that it may improve progression-free survival, other studies have not found any benefit in terms of overall survival. More research is needed to fully understand the role of axitinib in the treatment of pancreatic cancer.",
    "llama-7b_fact_raw": "1. Axitinib is used to treat advanced renal cell carcinoma and advanced melanoma.\n2. Axitinib inhibits the activity of vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptors.\n3. The PANCH trial investigated the use of axitinib in combination with gemcitabine and nab-paclitaxel for metastatic pancreatic ductal adenocarcinoma.\n4. The PANCH trial found no improvement in overall survival with the addition of axitinib to gemcitabine and nab-paclitaxel for metastatic pancreatic ductal adenocarcinoma.\n5. The AXIS trial found that axitinib improved progression-free survival but not overall survival when combined with gemcitabine and nab-paclitaxel for metastatic pancreatic ductal adenocarcinoma.",
    "llama-7b_fact": [
      "Axitinib is used to treat advanced renal cell carcinoma and advanced melanoma.",
      "Axitinib inhibits the activity of vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptors.",
      "The PANCH trial investigated the use of axitinib in combination with gemcitabine and nab-paclitaxel for metastatic pancreatic ductal adenocarcinoma.",
      "The PANCH trial found no improvement in overall survival with the addition of axitinib to gemcitabine and nab-paclitaxel for metastatic pancreatic ductal adenocarcinoma.",
      "The AXIS trial found that axitinib improved progression-free survival but not overall survival when combined with gemcitabine and nab-paclitaxel for metastatic pancreatic ductal adenocarcinoma."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Axitinib is used to treat advanced renal cell carcinoma, but there is no evidence that it is approved for the treatment of advanced melanoma.\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: The AXIS trial compared axitinib with sorafenib in the treatment of advanced renal cell carcinoma and found that axitinib improved progression-free survival. It did not involve gemcitabine and nab-paclitaxel for metastatic pancreatic ductal adenocarcinoma.",
    "llama-7b_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3113,
    "user_query": "You MUST give a detailed answer to the following question: Through which protein interaction does MLP regulate F-actin dynamics?",
    "llama-7b_response": "Myosin-light-chain phosphatase (MLP) is an enzyme that dephosphorylates and inactivates myosin-light-chain kinase (MLCK), which is involved in the regulation of actin-myosin interactions in smooth muscle cells. MLP has been shown to play a role in the regulation of F-actin dynamics in various cell types, including smooth muscle cells.\n\nOne mechanism by which MLP regulates F-actin dynamics is through its interaction with the Arp2/3 complex, which is a key regulator of actin polymerization. The Arp2/3 complex is activated by WASP (Wiskott-Aldrich Syndrome Protein) and WASP-like proteins, which are proteins that bind to and activate the Arp2/3 complex. MLP has been shown to bind to and inhibit the activity of the Arp2/3 complex, which in turn inhibits the polymerization of F-actin.\n\nAnother mechanism by which MLP regulates F-actin dynamics is through its interaction with the formin family of proteins, which are involved in the assembly and elongation of F-actin. MLP has been shown to bind to and inhibit the activity of the formin family of proteins, which in turn inhibits the assembly and elongation of F-actin.\n\nIn summary, MLP regulates F-actin dynamics through its interaction with the Arp2/3 complex and the formin family of proteins, which are key regulators of actin-myosin interactions in smooth muscle cells.",
    "llama-7b_fact_raw": "1. Myosin-light-chain phosphatase (MLP) dephosphorylates and inactivates myosin-light-chain kinase (MLCK).\n2. MLP plays a role in the regulation of F-actin dynamics in various cell types, including smooth muscle cells.\n3. MLP interacts with the Arp2/3 complex, which is a key regulator of actin polymerization.\n4. MLP has been shown to bind to and inhibit the activity of the Arp2/3 complex.\n5. MLP regulates F-actin dynamics through its interaction with the formin family of proteins.",
    "llama-7b_fact": [
      "Myosin-light-chain phosphatase (MLP) dephosphorylates and inactivates myosin-light-chain kinase (MLCK).",
      "MLP plays a role in the regulation of F-actin dynamics in various cell types, including smooth muscle cells.",
      "MLP interacts with the Arp2/3 complex, which is a key regulator of actin polymerization.",
      "MLP has been shown to bind to and inhibit the activity of the Arp2/3 complex.",
      "MLP regulates F-actin dynamics through its interaction with the formin family of proteins."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Myosin-light-chain phosphatase (MLP) dephosphorylates and inactivates myosin light chain, not myosin-light-chain kinase (MLCK). MLCK is the enzyme that phosphorylates myosin light chain, which is then dephosphorylated by MLP.\n2. TRUE\n3. UNKNOWN: Without specific context or references, it is unclear whether MLP directly interacts with the Arp2/3 complex. The Arp2/3 complex is indeed a key regulator of actin polymerization, but the interaction with MLP is not commonly established knowledge.\n4. UNKNOWN: As with the previous statement, without specific context or references, it is unclear whether MLP has been shown to bind to and inhibit the activity of the Arp2/3 complex.\n5. UNKNOWN: The interaction of MLP with the formin family of proteins and its regulation of F-actin dynamics through this interaction is not a widely recognized or established fact in the field of cell biology. More context or a specific reference is needed to verify this statement.",
    "llama-7b_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3125,
    "user_query": "You MUST give a detailed answer to the following question: How many pseudokinases are there in the human kinome?",
    "llama-7b_response": "There are approximately 500 pseudokinases in the human kinome.",
    "llama-7b_fact_raw": "1. There are approximately 500 pseudokinases in the human kinome.",
    "llama-7b_fact": [
      "There are approximately 500 pseudokinases in the human kinome."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: There are approximately 90 pseudokinases in the human kinome.",
    "llama-7b_judge": [
      "false"
    ]
  },
  {
    "id": 3139,
    "user_query": "You MUST give a detailed answer to the following question: List 3 apoE mimetics.",
    "llama-7b_response": "ApoE (apolipoprotein E) is a protein that plays an important role in the transport and metabolism of lipids in the bloodstream. It is a major protein component of high-density lipoproteins (HDL), which are responsible for transporting cholesterol from the liver to the liver for excretion.\n\nApoE mimetics are compounds that mimic the function of apoE in the transport and metabolism of lipids. Here are three examples of apoE mimetics:\n\n1. Pravastatin: Pravastatin is a cholesterol-lowering medication that works by inhibiting the enzyme HMG-CoA reductase, which is involved in the production of cholesterol in the liver. Pravastatin has been shown to increase the levels of HDL cholesterol and reduce the levels of low-density lipoprotein (LDL) cholesterol, both of which are beneficial for cardiovascular health.\n2. Resveratrol: Resveratrol is a compound found in the skin of red grapes and other fruits and vegetables. It has been shown to have anti-inflammatory and antioxidant properties, and has been suggested to have potential benefits for cardiovascular health. Resveratrol has been shown to increase the levels of HDL cholesterol and reduce the levels of LDL cholesterol, both of which are beneficial for cardiovascular health.\n3. Curcumin: Curcumin is a compound found in the spice turmeric. It has been shown to have anti-inflammatory and antioxidant properties, and has been suggested to have potential benefits for cardiovascular health. Curcumin has been shown to increase the levels of HDL cholesterol and reduce the levels of LDL cholesterol, both of which are beneficial for cardiovascular health.\n\nOverall, apoE mimetics are compounds that mimic the function of apoE in the transport and metabolism of lipids. Pravastatin, resveratrol, and curcumin are examples of apoE mimetics that have been shown to have potential benefit",
    "llama-7b_fact_raw": "1. ApoE (apolipoprotein E) is a protein that plays a role in the transport and metabolism of lipids in the bloodstream.\n2. ApoE is a major protein component of high-density lipoproteins (HDL).\n3. Pravastatin is a cholesterol-lowering medication that inhibits the enzyme HMG-CoA reductase.\n4. Resveratrol is a compound found in the skin of red grapes and has been shown to have anti-inflammatory and antioxidant properties.\n5. Curcumin is a compound found in turmeric and has been shown to have anti-inflammatory and antioxidant properties.",
    "llama-7b_fact": [
      "ApoE (apolipoprotein E) is a protein that plays a role in the transport and metabolism of lipids in the bloodstream.",
      "ApoE is a major protein component of high-density lipoproteins (HDL).",
      "Pravastatin is a cholesterol-lowering medication that inhibits the enzyme HMG-CoA reductase.",
      "Resveratrol is a compound found in the skin of red grapes and has been shown to have anti-inflammatory and antioxidant properties.",
      "Curcumin is a compound found in turmeric and has been shown to have anti-inflammatory and antioxidant properties."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: ApoE is a major protein component of very low-density lipoproteins (VLDL) and chylomicrons, not high-density lipoproteins (HDL).\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3140,
    "user_query": "You MUST give a detailed answer to the following question: What are there sex differences in SAMHD1 activity?",
    "llama-7b_response": "Sex differences in SAMHD1 activity have not been extensively studied, but there is some evidence to suggest that there may be differences between men and women.\n\nSAMHD1 is an important regulator of the HIV-1 life cycle, and its activity is critical for controlling viral replication. Studies have shown that SAMHD1 inhibits HIV-1 replication by depleting the intracellular pool of deoxynucleoside triphosphates (dNTPs), which are required for HIV-1 reverse transcription.\n\nWhile the overall function of SAMHD1 is similar in men and women, there may be some differences in the regulation of SAMHD1 activity between the two sexes. For example, studies have shown that estrogen can regulate SAMHD1 activity in certain cell types, such as breast cancer cells. In these cells, estrogen has been shown to increase SAMHD1 activity, which in turn inhibits HIV-1 replication.\n\nHowever, the role of estrogen in regulating SAMHD1 activity in other cell types, such as immune cells, has not been well studied. It is also possible that there may be other factors that influence SAMHD1 activity in men and women differently.\n\nOverall, while there is some evidence to suggest that there may be sex differences in SAMHD1 activity, more research is needed to fully understand the role of SAMHD1 in the regulation of HIV-1 replication in men and women.",
    "llama-7b_fact_raw": "1. SAMHD1 is an important regulator of the HIV-1 life cycle.\n2. SAMHD1 activity is critical for controlling viral replication by depleting the intracellular pool of deoxynucleoside triphosphates (dNTPs).\n3. SAMHD1 inhibits HIV-1 replication by depleting dNTPs required for HIV-1 reverse transcription.\n4. Estrogen has been shown to regulate SAMHD1 activity in certain cell types, such as breast cancer cells.\n5. In breast cancer cells, increased SAMHD1 activity due to estrogen inhibits HIV-1 replication.",
    "llama-7b_fact": [
      "SAMHD1 is an important regulator of the HIV-1 life cycle.",
      "SAMHD1 activity is critical for controlling viral replication by depleting the intracellular pool of deoxynucleoside triphosphates (dNTPs).",
      "SAMHD1 inhibits HIV-1 replication by depleting dNTPs required for HIV-1 reverse transcription.",
      "Estrogen has been shown to regulate SAMHD1 activity in certain cell types, such as breast cancer cells.",
      "In breast cancer cells, increased SAMHD1 activity due to estrogen inhibits HIV-1 replication."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nThe first three statements are true as SAMHD1 is indeed known to be an important regulator of the HIV-1 life cycle, and its activity is critical for controlling viral replication by depleting the intracellular pool of deoxynucleoside triphosphates, which are necessary for HIV-1 reverse transcription.\n\nThe fourth and fifth statements are more specific and would require specific scientific evidence to confirm. Without the context of the specific studies or data that discuss the regulation of SAMHD1 activity by estrogen in breast cancer cells and the subsequent effect on HIV-1 replication, it is not possible to determine the truthfulness of these statements. Therefore, they are marked as UNKNOWN.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3205,
    "user_query": "You MUST give a detailed answer to the following question: Does RUNX2 inhibit astrocyte differentiation?",
    "llama-7b_response": "Yes, RUNX2 has been shown to inhibit astrocyte differentiation.\n\nRUNX2 is a transcription factor that plays a crucial role in the differentiation of oligodendrocyte progenitor cells (OPCs) into mature oligodendrocytes, which are responsible for myelin formation in the central nervous system (CNS). However, the role of RUNX2 in the differentiation of astrocytes, which are the most abundant glial cells in the CNS, is less clear.\n\nSeveral studies have shown that RUNX2 can inhibit astrocyte differentiation. For example, a study published in the journal Molecular and Cellular Biology in 2003 found that overexpression of RUNX2 in OPCs inhibited their differentiation into mature oligodendrocytes and promoted their differentiation into astrocytes in vitro. Another study published in the journal Glia in 2011 found that RUNX2 was downregulated during the differentiation of OPCs into mature oligodendrocytes, and that overexpression of RUNX2 in OPCs inhibited their differentiation into mature oligodendrocytes and promoted their differentiation into astrocytes in vitro.\n\nThese findings suggest that RUNX2 may play a role in the regulation of astrocyte differentiation by inhibiting the differentiation of OPCs into mature oligodendrocytes and promoting their differentiation into astrocytes. However, further studies are needed to fully understand the mechanisms by which RUNX2 regulates astrocyte differentiation.",
    "llama-7b_fact_raw": "1. RUNX2 is a transcription factor that plays a role in the differentiation of oligodendrocyte progenitor cells into mature oligodendrocytes.\n2. Mature oligodendrocytes are responsible for myelin formation in the central nervous system.\n3. A study published in the journal Molecular and Cellular Biology in 2003 found that overexpression of RUNX2 inhibited the differentiation of OPCs into mature oligodendrocytes.\n4. The same study from 2003 also found that overexpression of RUNX2 promoted the differentiation of OPCs into astrocytes in vitro.\n5. A study published in the journal Glia in 2011 reported that RUNX2 was downregulated during the differentiation of OPCs into mature oligodendrocytes.",
    "llama-7b_fact": [
      "RUNX2 is a transcription factor that plays a role in the differentiation of oligodendrocyte progenitor cells into mature oligodendrocytes.",
      "Mature oligodendrocytes are responsible for myelin formation in the central nervous system.",
      "A study published in the journal Molecular and Cellular Biology in 2003 found that overexpression of RUNX2 inhibited the differentiation of OPCs into mature oligodendrocytes.",
      "The same study from 2003 also found that overexpression of RUNX2 promoted the differentiation of OPCs into astrocytes in vitro.",
      "A study published in the journal Glia in 2011 reported that RUNX2 was downregulated during the differentiation of OPCs into mature oligodendrocytes."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: RUNX2 is a transcription factor known for its role in bone development and osteoblast differentiation, not in the differentiation of oligodendrocyte progenitor cells (OPCs) into mature oligodendrocytes.\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe corrections and responses are based on the known role of RUNX2 in bone development. The specific findings of studies published in journals would require access to those studies to verify the statements related to them.",
    "llama-7b_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3209,
    "user_query": "You MUST give a detailed answer to the following question: Where, in the body, would the Cobb-Stainsby excision arthroplasty be performed?",
    "llama-7b_response": "wrist",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3243,
    "user_query": "You MUST give a detailed answer to the following question: Does GRHL2 over-expression lead to EMT?",
    "llama-7b_response": "Yes, GRHL2 over-expression has been shown to lead to epithelial-to-mesenchymal transition (EMT) in certain cell types.\n\nEpithelial-to-mesenchymal transition (EMT) is a process by which epithelial cells lose their cell-cell adhesion and acquire a mesenchymal phenotype, characterized by the loss of cell-cell adhesion, the upregulation of mesenchymal genes, and the downregulation of epithelial genes. This process is crucial for embryonic development, tissue repair, and cancer progression.\n\nGRHL2 is a transcription factor that plays a crucial role in regulating the expression of genes involved in EMT. Over-expression of GRHL2 has been shown to induce EMT in various cell types, including epithelial cells, by activating the transcription of genes involved in the mesenchymal phenotype, such as N-cadherin and vimentin.\n\nIn summary, GRHL2 over-expression can lead to EMT in certain cell types by activating the transcription of genes involved in the mesenchymal phenotype. This process is crucial for embryonic development, tissue repair, and cancer progression.",
    "llama-7b_fact_raw": "1. GRHL2 over-expression has been shown to lead to epithelial-to-mesenchymal transition (EMT) in certain cell types.\n2. EMT is characterized by the loss of cell-cell adhesion and the acquisition of a mesenchymal phenotype.\n3. GRHL2 is a transcription factor that regulates the expression of genes involved in EMT.\n4. Over-expression of GRHL2 induces EMT by activating the transcription of mesenchymal genes such as N-cadherin and vimentin.\n5. EMT is important for processes like embryonic development, tissue repair, and cancer progression.",
    "llama-7b_fact": [
      "GRHL2 over-expression has been shown to lead to epithelial-to-mesenchymal transition (EMT) in certain cell types.",
      "EMT is characterized by the loss of cell-cell adhesion and the acquisition of a mesenchymal phenotype.",
      "GRHL2 is a transcription factor that regulates the expression of genes involved in EMT.",
      "Over-expression of GRHL2 induces EMT by activating the transcription of mesenchymal genes such as N-cadherin and vimentin.",
      "EMT is important for processes like embryonic development, tissue repair, and cancer progression."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3254,
    "user_query": "You MUST give a detailed answer to the following question: Which T-UCRs have been implicated in lung cancer?",
    "llama-7b_response": "There are several T-cell receptors (TCRs) that have been implicated in lung cancer. T-cell receptors are a type of immune cell receptor that is expressed on the surface of T cells, a type of immune cell that plays a key role in the immune system's response to infections and cancer.\n\nOne T-cell receptor that has been implicated in lung cancer is the T-cell receptor alpha (TCRα). TCRα is a type of T-cell receptor that is expressed on the surface of T cells and plays a key role in the immune system's response to infections and cancer.\n\nAnother T-cell receptor that has been implicated in lung cancer is the T-cell receptor gamma (TCRγ). TCRγ is a type of T-cell receptor that is expressed on the surface of T cells and plays a key role in the immune system's response to infections and cancer.\n\nThere are also other T-cell receptors that have been implicated in lung cancer, such as the T-cell receptor delta (TCRδ). TCRδ is a type of T-cell receptor that is expressed on the surface of T cells and plays a key role in the immune system's response to infections and cancer.\n\nOverall, T-cell receptors play a key role in the immune system's response to infections and cancer, and several T-cell receptors have been implicated in the development and progression of lung cancer.",
    "llama-7b_fact_raw": "1. T-cell receptor alpha (TCRα) has been implicated in lung cancer.\n2. T-cell receptor gamma (TCRγ) has been implicated in lung cancer.\n3. T-cell receptor delta (TCRδ) has been implicated in lung cancer.\n4. T-cell receptors are expressed on the surface of T cells.\n5. T-cell receptors play a key role in the immune system's response to infections and cancer.",
    "llama-7b_fact": [
      "T-cell receptor alpha (TCRα) has been implicated in lung cancer.",
      "T-cell receptor gamma (TCRγ) has been implicated in lung cancer.",
      "T-cell receptor delta (TCRδ) has been implicated in lung cancer.",
      "T-cell receptors are expressed on the surface of T cells.",
      "T-cell receptors play a key role in the immune system's response to infections and cancer."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. TRUE\n\nThe statements regarding the specific T-cell receptors (TCRα, TCRγ, TCRδ) being implicated in lung cancer require specific scientific evidence or research findings to confirm their accuracy. Without the context of the passage or additional information, it is not possible to determine the truthfulness of these statements. However, it is known that T-cell receptors are indeed expressed on the surface of T cells and play a crucial role in the immune response to infections and cancer, which makes statements 4 and 5 true.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3268,
    "user_query": "You MUST give a detailed answer to the following question: What is known about the orphan receptor GPR151?",
    "llama-7b_response": "GPR151 (G-protein-coupled receptor 151) is an orphan receptor that belongs to the G-protein-coupled receptor (GPCR) family. GPCRs are a large family of transmembrane proteins that are activated by a variety of extracellular signals, including hormones, neurotransmitters, and drugs. GPR151 is primarily expressed in the brain, particularly in the hippocampus, and has been implicated in several neurological processes, including learning and memory, anxiety, and depression.\n\nTo date, very little is known about the function of GPR151. However, several studies have suggested that it may play a role in the regulation of anxiety and depression. For example, research has shown that GPR151 is highly expressed in the hippocampus, a region of the brain known to be involved in the regulation of anxiety and mood. Additionally, studies using animal models have shown that manipulating the expression of GPR151 can affect anxiety-like behavior and depression-like behavior.\n\nDespite these findings, more research is needed to fully understand the function of GPR151 and its potential as a therapeutic target for the treatment of neurological disorders.",
    "llama-7b_fact_raw": "1. GPR151 is an orphan receptor that is part of the G-protein-coupled receptor (GPCR) family.\n2. G-protein-coupled receptors are activated by various extracellular signals, including hormones, neurotransmitters, and drugs.\n3. GPR151 is primarily expressed in the brain, especially in the hippocampus.\n4. GPR151 has been implicated in neurological processes such as learning and memory, anxiety, and depression.\n5. Research using animal models suggests that manipulating the expression of GPR151 can affect anxiety-like and depression-like behaviors.",
    "llama-7b_fact": [
      "GPR151 is an orphan receptor that is part of the G-protein-coupled receptor (GPCR) family.",
      "G-protein-coupled receptors are activated by various extracellular signals, including hormones, neurotransmitters, and drugs.",
      "GPR151 is primarily expressed in the brain, especially in the hippocampus.",
      "GPR151 has been implicated in neurological processes such as learning and memory, anxiety, and depression.",
      "Research using animal models suggests that manipulating the expression of GPR151 can affect anxiety-like and depression-like behaviors."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nThe first three statements are factual and can be verified based on scientific knowledge about GPR151 and GPCRs. The fourth and fifth statements are more specific and would require access to current scientific research to verify their accuracy. Without specific studies or evidence to reference, the truth of these statements remains unknown.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3285,
    "user_query": "You MUST give a detailed answer to the following question: List the attenuated live viruses contained in the Fluzone intradermal quadrivalent vaccine.",
    "llama-7b_response": "The Fluzone intradermal quadrivalent vaccine is a live attenuated influenza vaccine (LAIV) that contains four different strains of influenza virus: influenza A (H1N1), influenza A (H3N2), influenza B (Yamagata lineage), and influenza B (Victoria lineage). The vaccine is administered by intradermal injection, which involves injecting the vaccine into the top layer of the skin.\n\nThe specific strains of influenza virus contained in the Fluzone intradermal quadrivalent vaccine are:\n\n* Influenza A (H1N1) strain: A/California/7/2009 (H1N1)\n* Influenza A (H3N2) strain: A/Switzerland/9715233/2013 (H3N2)\n* Influenza B (Yamagata lineage) strain: B/Phuket/3073/2013 (Yamagata lineage)\n* Influenza B (Victoria lineage) strain: B/Brisbane/60/2008 (Victoria lineage)\n\nThe Fluzone intradermal quadrivalent vaccine is approved for use in adults and children aged 18 years and older. It is intended for use as an annual influenza vaccine to prevent influenza disease caused by the strains contained in the vaccine.",
    "llama-7b_fact_raw": "1. The Fluzone intradermal quadrivalent vaccine contains four different strains of influenza virus.\n2. The strains included are influenza A (H1N1), influenza A (H3N2), influenza B (Yamagata lineage), and influenza B (Victoria lineage).\n3. The influenza A (H1N1) strain in the vaccine is A/California/7/2009 (H1N1).\n4. The influenza A (H3N2) strain in the vaccine is A/Switzerland/9715233/2013 (H3N2).\n5. The Fluzone intradermal quadrivalent vaccine is approved for use in adults and children aged 18 years and older.",
    "llama-7b_fact": [
      "The Fluzone intradermal quadrivalent vaccine contains four different strains of influenza virus.",
      "The strains included are influenza A (H1N1), influenza A (H3N2), influenza B (Yamagata lineage), and influenza B (Victoria lineage).",
      "The influenza A (H1N1) strain in the vaccine is A/California/7/2009 (H1N1).",
      "The influenza A (H3N2) strain in the vaccine is A/Switzerland/9715233/2013 (H3N2).",
      "The Fluzone intradermal quadrivalent vaccine is approved for use in adults and children aged 18 years and older."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: The Fluzone intradermal quadrivalent vaccine is approved for use in adults aged 18 through 64 years.",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3345,
    "user_query": "You MUST give a detailed answer to the following question: Which part of the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus?",
    "llama-7b_response": "promoter",
    "llama-7b_fact_raw": "1. The promoter part of the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus.",
    "llama-7b_fact": [
      "The promoter part of the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus."
    ],
    "llama-7b_judge_raw": "UNKNOWN\n\nThe statement provided is very specific and would require access to current scientific research or genetic studies to confirm or refute. Without such information, it is not possible to determine the truthfulness of the statement regarding the genetic association between the promoter part of the TNFR2 gene and Systemic Lupus Erythematosus.",
    "llama-7b_judge": [
      "unknown"
    ]
  },
  {
    "id": 3353,
    "user_query": "You MUST give a detailed answer to the following question: Is there a vaccine for peanut allergy?",
    "llama-7b_response": "Yes, there is a vaccine for peanut allergy. The vaccine is called Palivizumab and it is used to prevent severe allergic reactions to peanuts in people who are at high risk of having an allergic reaction. The vaccine is given as an injection and is usually given to children who have a history of severe allergic reactions to peanuts or who have a family history of peanut allergy. The vaccine works by increasing the body's immunity to peanuts, making it less likely that the person will have a severe allergic reaction if they come into contact with peanuts. The vaccine is not a cure for peanut allergy, but it can help to reduce the risk of severe allergic reactions in people who are at high risk of having an allergic reaction.",
    "llama-7b_fact_raw": "1. There is a vaccine for peanut allergy.\n2. The vaccine for peanut allergy is called Palivizumab.\n3. Palivizumab is used to prevent severe allergic reactions to peanuts in high-risk individuals.\n4. The vaccine is administered as an injection.\n5. Palivizumab is usually given to children with a history of severe allergic reactions to peanuts or who have a family history of peanut allergy.",
    "llama-7b_fact": [
      "There is a vaccine for peanut allergy.",
      "The vaccine for peanut allergy is called Palivizumab.",
      "Palivizumab is used to prevent severe allergic reactions to peanuts in high-risk individuals.",
      "The vaccine is administered as an injection.",
      "Palivizumab is usually given to children with a history of severe allergic reactions to peanuts or who have a family history of peanut allergy."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: As of my knowledge cutoff in 2023, there is no approved vaccine for peanut allergy. Treatments for peanut allergies are generally focused on managing symptoms and avoiding exposure.\n2. FALSE [correction]: Palivizumab is not a vaccine for peanut allergy. It is a monoclonal antibody used to prevent severe respiratory syncytial virus (RSV) infections in high-risk infants and young children.\n3. FALSE [correction]: Palivizumab is not used to prevent allergic reactions to peanuts. It is used to prevent RSV infection.\n4. TRUE: Palivizumab is administered as an injection, specifically an intramuscular injection.\n5. FALSE [correction]: Palivizumab is given to prevent RSV infection in high-risk infants and young children, not for the prevention of allergic reactions to peanuts.",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 3365,
    "user_query": "You MUST give a detailed answer to the following question: What is particular about the mouse Fxy gene's chromosomal position?",
    "llama-7b_response": "The Fxy gene is located on the X chromosome.",
    "llama-7b_fact_raw": "1. The Fxy gene is located on the X chromosome.",
    "llama-7b_fact": [
      "The Fxy gene is located on the X chromosome."
    ],
    "llama-7b_judge_raw": "UNKNOWN\n\n[Explanation]: Without specific scientific context or a reference to a known gene, it's impossible to verify the location of a gene named \"Fxy\" on the X chromosome. The statement is too vague to determine its accuracy.",
    "llama-7b_judge": [
      "unknown"
    ]
  },
  {
    "id": 3397,
    "user_query": "You MUST give a detailed answer to the following question: What is the basis of the methidiumpropyl-EDTA sequencing (MPE-seq) method?",
    "llama-7b_response": "The basis of the methidiumpropyl-EDTA sequencing (MPE-seq) method is the incorporation of the nucleotide analog methidiumpropyl-EDTA (MP-EDTA) into DNA during replication. MPE-seq is a high-throughput sequencing method that can be used to sequence large numbers of DNA molecules simultaneously.\n\nThe MPE-seq method is based on the ability of the nucleotide analog MP-EDTA to incorporate into DNA during replication. MP-EDTA is a modified form of the nucleotide analog EDTA, which is a chelating agent that binds to metal ions. MP-EDTA is similar to EDTA, but it has a methyl group attached to one of the nitrogen atoms. This methyl group allows MP-EDTA to incorporate into DNA more easily than EDTA.\n\nIn the MPE-seq method, a DNA template is incubated with a solution containing MP-EDTA and DNA polymerase. During replication, the DNA polymerase incorporates MP-EDTA into the growing DNA strand, resulting in the formation of modified DNA molecules. These modified DNA molecules can then be sequenced using standard DNA sequencing techniques, such as Illumina sequencing.\n\nThe MPE-seq method has several advantages over other sequencing methods, including high throughput, low cost, and the ability to sequence large numbers of DNA molecules simultaneously. It has been used to sequence large numbers of DNA molecules from a variety of sources, including bacteria, archaea, and eukaryotic cells.\n\nOverall, the basis of the MPE-seq method is the incorporation of the nucleotide analog MP-EDTA into DNA during replication, which allows for the sequencing of large numbers of DNA molecules using standard DNA sequencing techniques.",
    "llama-7b_fact_raw": "1. Methidiumpropyl-EDTA sequencing (MPE-seq) is a high-throughput sequencing method.\n2. The nucleotide analog methidiumpropyl-EDTA (MP-EDTA) is incorporated into DNA during replication in the MPE-seq method.\n3. MP-EDTA is a modified form of the nucleotide analog EDTA, with a methyl group attached to one of the nitrogen atoms.\n4. In MPE-seq, DNA polymerase incorporates MP-EDTA into the growing DNA strand during replication.\n5. The MPE-seq method can be used to sequence DNA from various sources, including bacteria, archaea, and eukaryotic cells.",
    "llama-7b_fact": [
      "Methidiumpropyl-EDTA sequencing (MPE-seq) is a high-throughput sequencing method.",
      "The nucleotide analog methidiumpropyl-EDTA (MP-EDTA) is incorporated into DNA during replication in the MPE-seq method.",
      "MP-EDTA is a modified form of the nucleotide analog EDTA, with a methyl group attached to one of the nitrogen atoms.",
      "In MPE-seq, DNA polymerase incorporates MP-EDTA into the growing DNA strand during replication.",
      "The MPE-seq method can be used to sequence DNA from various sources, including bacteria, archaea, and eukaryotic cells."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN: Without additional context, it's unclear whether Methidiumpropyl-EDTA sequencing (MPE-seq) is a high-throughput sequencing method as it is not a widely recognized or standard sequencing technique.\n2. FALSE [correction]: Methidiumpropyl-EDTA (MP-EDTA) is not a nucleotide analog and is not incorporated into DNA during replication. MP-EDTA is a chemical compound that can bind to DNA and is used in footprinting techniques to study DNA-protein interactions, not in a sequencing method.\n3. FALSE [correction]: MP-EDTA is not a modified form of the nucleotide analog EDTA. EDTA (ethylenediaminetetraacetic acid) is a chelating agent that binds metal ions, and it is not a nucleotide or a base analog. Methidiumpropyl-EDTA is a different compound that contains a methidium group and an EDTA-like chelating group, but it is not simply EDTA with a methyl group attached to a nitrogen atom.\n4. FALSE [correction]: Since MP-EDTA is not a nucleotide analog, DNA polymerase does not incorporate it into the growing DNA strand during replication. This statement is based on a misunderstanding of the compound's role and properties.\n5. UNKNOWN: Given that MPE-seq is not established as a sequencing method, it is unclear whether it can be used to sequence DNA from various sources. The ability to sequence DNA from bacteria, archaea, and eukaryotic cells would depend on the specifics of the sequencing method, which are not provided here.",
    "llama-7b_judge": [
      "unknown",
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3400,
    "user_query": "You MUST give a detailed answer to the following question: Which programming language has been used for implementing GWAR?",
    "llama-7b_response": "C++",
    "llama-7b_fact_raw": "1. The programming language used for implementing GWAR is C++.",
    "llama-7b_fact": [
      "The programming language used for implementing GWAR is C++."
    ],
    "llama-7b_judge_raw": "UNKNOWN\n\n[Explanation]: Without additional context about what GWAR refers to, it is impossible to determine the veracity of the statement. GWAR could refer to a specific software, project, or acronym that is not universally recognized, and without further information, the programming language used for its implementation cannot be confirmed.",
    "llama-7b_judge": [
      "unknown"
    ]
  },
  {
    "id": 3406,
    "user_query": "You MUST give a detailed answer to the following question: Does xaliproden improve prognosis of amyotrophic lateral sclerosis?",
    "llama-7b_response": "Xaliproden is a drug that has been studied for its potential to slow the progression of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. However, there is currently insufficient evidence to determine whether xaliproden improves the prognosis of ALS.\n\nXaliproden is a selective adenosine A2A receptor antagonist, which means that it blocks the action of adenosine A2A receptors in the body. Adenosine is a molecule that plays a role in several physiological processes, including the regulation of inflammation and the function of immune cells. Some studies have suggested that adenosine may play a role in the progression of ALS by promoting inflammation and the death of motor neurons, which are the nerve cells that control muscle movement.\n\nXaliproden has been studied in several clinical trials as a potential treatment for ALS. Some studies have suggested that xaliproden may slow the progression of ALS by reducing inflammation and preserving the function of motor neurons. However, other studies have found no benefit from xaliproden treatment.\n\nIn summary, while xaliproden has shown some promise as a potential treatment for ALS, there is currently insufficient evidence to determine whether it improves the prognosis of the disease. Further research is needed to fully understand the potential benefits and risks of xaliproden in the treatment of ALS.",
    "llama-7b_fact_raw": "1. Xaliproden has been studied for its potential to slow the progression of amyotrophic lateral sclerosis (ALS).\n2. Xaliproden is a selective adenosine A2A receptor antagonist.\n3. Adenosine is involved in the regulation of inflammation and the function of immune cells.\n4. Clinical trials have been conducted to evaluate xaliproden as a treatment for ALS.\n5. There is currently insufficient evidence to determine whether xaliproden improves the prognosis of ALS.",
    "llama-7b_fact": [
      "Xaliproden has been studied for its potential to slow the progression of amyotrophic lateral sclerosis (ALS).",
      "Xaliproden is a selective adenosine A2A receptor antagonist.",
      "Adenosine is involved in the regulation of inflammation and the function of immune cells.",
      "Clinical trials have been conducted to evaluate xaliproden as a treatment for ALS.",
      "There is currently insufficient evidence to determine whether xaliproden improves the prognosis of ALS."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Xaliproden is not a selective adenosine A2A receptor antagonist; it is a serotonergic compound that acts as a 5-HT1A receptor agonist.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3410,
    "user_query": "You MUST give a detailed answer to the following question: In which chromosome are transgenes inserted in the case of the LiPS-A3S line?",
    "llama-7b_response": "In the LiPS-A3S line, transgenes are inserted in the X chromosome.",
    "llama-7b_fact_raw": "1. In the LiPS-A3S line, transgenes are inserted in the X chromosome.",
    "llama-7b_fact": [
      "In the LiPS-A3S line, transgenes are inserted in the X chromosome."
    ],
    "llama-7b_judge_raw": "UNKNOWN\n\nWithout additional context or information about the \"LiPS-A3S line\" and what it pertains to (e.g., a specific scientific study, a genetic engineering project, etc.), it is not possible to determine the accuracy of the statement.",
    "llama-7b_judge": [
      "unknown"
    ]
  },
  {
    "id": 3430,
    "user_query": "You MUST give a detailed answer to the following question: Which tool exist for predicting drug synergy with deep learning?",
    "llama-7b_response": "There are several tools available for predicting drug synergy using deep learning, including:\n\n1. DeepDive: DeepDive is a deep learning model developed by researchers at the University of California, San Francisco (UCSF) that can predict the synergy between two drugs. The model uses a combination of convolutional neural networks (CNNs) and long short-term memory (LSTM) networks to analyze drug activity data and predict the likelihood of synergy.\n2. DrugB6: DrugB6 is a machine learning model developed by researchers at the University of California, San Diego (UCSD) that can predict the synergy between two drugs. The model uses a combination of decision trees and support vector machines (SVMs) to analyze drug activity data and predict the likelihood of synergy.\n3. SynergyNet: SynergyNet is a deep learning model developed by researchers at the University of California, San Francisco (UCSF) that can predict the synergy between two drugs. The model uses a combination of convolutional neural networks (CNNs) and long short-term memory (LSTM) networks to analyze drug activity data and predict the likelihood of synergy.\n\nThese are just a few examples of the many tools available for predicting drug synergy using deep learning. Each tool has its own strengths and weaknesses, and the choice of tool will depend on the specific needs and goals of the researcher.",
    "llama-7b_fact_raw": "1. DeepDive is a deep learning model developed by researchers at the University of California, San Francisco (UCSF) for predicting drug synergy.\n2. DeepDive uses a combination of convolutional neural networks (CNNs) and long short-term memory (LSTM) networks.\n3. DrugB6 is a machine learning model developed by researchers at the University of California, San Diego (UCSD) for predicting drug synergy.\n4. DrugB6 uses a combination of decision trees and support vector machines (SVMs).\n5. SynergyNet is a deep learning model developed by researchers at the University of California, San Francisco (UCSF) for predicting drug synergy.",
    "llama-7b_fact": [
      "DeepDive is a deep learning model developed by researchers at the University of California, San Francisco (UCSF) for predicting drug synergy.",
      "DeepDive uses a combination of convolutional neural networks (CNNs) and long short-term memory (LSTM) networks.",
      "DrugB6 is a machine learning model developed by researchers at the University of California, San Diego (UCSD) for predicting drug synergy.",
      "DrugB6 uses a combination of decision trees and support vector machines (SVMs).",
      "SynergyNet is a deep learning model developed by researchers at the University of California, San Francisco (UCSF) for predicting drug synergy."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN: Without specific information about a deep learning model named \"DeepDive\" developed at UCSF for predicting drug synergy, the truth of this statement cannot be determined.\n2. UNKNOWN: Since the existence of \"DeepDive\" is not confirmed, the architecture it uses (CNNs and LSTM networks) cannot be confirmed either.\n3. UNKNOWN: Without specific information about a machine learning model named \"DrugB6\" developed at UCSD for predicting drug synergy, the truth of this statement cannot be determined.\n4. UNKNOWN: Since the existence of \"DrugB6\" is not confirmed, the methods it uses (decision trees and SVMs) cannot be confirmed either.\n5. UNKNOWN: Without specific information about a deep learning model named \"SynergyNet\" developed at UCSF for predicting drug synergy, the truth of this statement cannot be determined.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3433,
    "user_query": "You MUST give a detailed answer to the following question: Which cloud-based platform has been developed for comparing GWAS?",
    "llama-7b_response": "There are several cloud-based platforms that have been developed for comparing genome-wide association studies (GWAS), including:\n\n1. The National Center for Biotechnology Information's (NCBI) dbGaP (https://www.ncbi.nlm.nih.gov/gap): dbGaP is a public database of genetic association data for human traits and diseases. It provides a platform for storing, analyzing, and sharing GWAS data.\n2. The National Human Genome Research Institute's (NHGRI) Genome Variation Server (GVS) (https://www.ncbi.nlm.nih.gov/gvs): GVS is a web-based platform for storing, analyzing, and sharing genetic variation data, including GWAS data.\n3. The European Bioinformatics Institute's (EBI) ArrayExpress (<https://www.ebi.ac.uk/arrayexpress/>): ArrayExpress is a public database of functional genomics experiments, including GWAS data.\n4. The European Molecular Biology Laboratory's (EMBL-EBI) ArrayExpress (<https://www.ebi.ac.uk/arrayexpress/>): ArrayExpress is a public database of functional genomics experiments, including GWAS data.\n5. The European Molecular Biology Laboratory's (EMBL-EBI) ArrayExpress (<https://www.ebi.ac.uk/arrayexpress/>): ArrayExpress is a public database of functional genomics experiments, including GWAS data.\n6. The European Molecular Biology Laboratory's (EMBL-EBI) ArrayExpress (<https://www.ebi.ac.uk/arrayexpress/>): ArrayExpress is a public database of functional genomics experiments, including GWAS data.\n7. The European Molecular Biology Laboratory's (EMBL-EBI) ArrayExpress (<https://www.ebi.ac.uk/arrayexpress/>): ArrayExpress is a public database of functional genomics experiments, including GWAS data.\n8. The European Molecular Biology Laboratory's (EMBL-EBI) ArrayExpress (<https://www.ebi.ac.uk/arrayexpress/>): ArrayExpress is a",
    "llama-7b_fact_raw": "1. The National Center for Biotechnology Information's dbGaP is a public database for genetic association data related to human traits and diseases.\n2. The National Human Genome Research Institute's Genome Variation Server is a web-based platform for storing, analyzing, and sharing genetic variation data.\n3. The European Bioinformatics Institute's ArrayExpress is a public database of functional genomics experiments, including GWAS data.\n4. dbGaP provides a platform for storing, analyzing, and sharing GWAS data.\n5. GVS and ArrayExpress are platforms developed for comparing genome-wide association studies (GWAS).",
    "llama-7b_fact": [
      "The National Center for Biotechnology Information's dbGaP is a public database for genetic association data related to human traits and diseases.",
      "The National Human Genome Research Institute's Genome Variation Server is a web-based platform for storing, analyzing, and sharing genetic variation data.",
      "The European Bioinformatics Institute's ArrayExpress is a public database of functional genomics experiments, including GWAS data.",
      "dbGaP provides a platform for storing, analyzing, and sharing GWAS data.",
      "GVS and ArrayExpress are platforms developed for comparing genome-wide association studies (GWAS)."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The Genome Variation Server (GVS) was a web-based platform for storing, analyzing, and sharing genetic variation data, but it was maintained by the SeattleSNPs Program for Genomic Applications at the University of Washington, not the National Human Genome Research Institute.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: GVS (Genome Variation Server) was designed for analyzing and visualizing genetic variation data, not specifically for comparing GWAS. ArrayExpress is a database for functional genomics experiments, which may include GWAS data, but it is not specifically developed for comparing GWAS.",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3434,
    "user_query": "You MUST give a detailed answer to the following question: Can CMB305 be used against sarcomas?",
    "llama-7b_response": "Yes, CMB305 can be used against sarcomas.\n\nSarcomas are a type of cancer that affects the soft tissues of the body, including muscles, tendons, ligaments, and fat. They can also affect the bones and joints. Sarcomas are relatively rare cancers, accounting for only about 1% of all cancers.\n\nCMB305 is a type of immunotherapy drug that works by stimulating the body's immune system to attack cancer cells. It is made from a patient's own white blood cells, which are collected and modified in the laboratory to produce chimeric antigen receptors (CARs) on their surface. These CARs allow the modified white blood cells to recognize and attack cancer cells that express a specific protein called CD19.\n\nCMB305 has been shown to be effective in treating B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL), which are both types of cancer that express the CD19 protein. However, it is not clear whether CMB305 is effective against sarcomas, as there have been no clinical trials specifically testing its use against this type of cancer.\n\nIt is possible that CMB305 could be effective against sarcomas, as the CD19 protein is expressed on the surface of some sarcoma cells. However, more research would be needed to determine the safety and effectiveness of using CMB305 to treat sarcomas.\n\nIn summary, while CMB305 has been shown to be effective against certain types of cancer, such as B-cell acute lymphoblastic leukemia and diffuse large B-cell lymphoma, it is not clear whether it is effective against sarcomas. Further research is needed to determine the safety and effectiveness of using CMB305 to treat sarcomas.",
    "llama-7b_fact_raw": "1. Sarcomas are a type of cancer that affects the soft tissues of the body, including muscles, tendons, ligaments, and fat.\n2. Sarcomas can also affect the bones and joints.\n3. Sarcomas account for about 1% of all cancers.\n4. CMB305 is an immunotherapy drug that stimulates the immune system to attack cancer cells.\n5. CMB305 has been shown to be effective in treating B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL).",
    "llama-7b_fact": [
      "Sarcomas are a type of cancer that affects the soft tissues of the body, including muscles, tendons, ligaments, and fat.",
      "Sarcomas can also affect the bones and joints.",
      "Sarcomas account for about 1% of all cancers.",
      "CMB305 is an immunotherapy drug that stimulates the immune system to attack cancer cells.",
      "CMB305 has been shown to be effective in treating B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL)."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Sarcomas primarily affect the soft tissues of the body. When they affect the bones, they are typically referred to as bone sarcomas or osteosarcomas, which are a distinct category from soft tissue sarcomas.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: CMB305 is an investigational cancer vaccine targeting NY-ESO-1, a protein expressed in several types of cancer. It is designed to stimulate the immune system to fight cancer cells, but there is no specific evidence provided here that it has been shown to be effective in treating B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL). Without specific evidence, the effectiveness of CMB305 in treating these particular cancers cannot be confirmed.",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3461,
    "user_query": "You MUST give a detailed answer to the following question: What are manifestations of the Saint's Triad?",
    "llama-7b_response": "The manifestations of the Saint's Triad, also known as the Three Saints, are the physical, emotional, and mental aspects of a person's being. These aspects are interconnected and influence each other, and when in balance, they contribute to a person's overall well-being and happiness.\n\nThe physical aspect of the Saint's Triad refers to the body and its functions. This includes things like physical health, energy levels, and the ability to perform physical tasks. A balanced physical aspect is important for overall health and well-being.\n\nThe emotional aspect of the Saint's Triad refers to a person's emotions and feelings. This includes things like happiness, sadness, anger, and fear. A balanced emotional aspect is important for maintaining positive relationships and good mental health.\n\nThe mental aspect of the Saint's Triad refers to a person's thoughts, beliefs, and understanding of the world. This includes things like intelligence, creativity, and problem-solving skills. A balanced mental aspect is important for making informed decisions and achieving personal and professional goals.\n\nWhen all three aspects of the Saint's Triad are in balance, a person is said to be in a state of equilibrium. However, when one or more aspects are out of balance, a person may experience imbalance or disharmony, which can lead to physical, emotional, or mental distress.\n\nIn conclusion, the manifestations of the Saint's Triad are the physical, emotional, and mental aspects of a person's being, which are interconnected and influence each other. When in balance, they contribute to a person's overall well-being and happiness, but when out of balance, they can lead to imbalance or disharmony.",
    "llama-7b_fact_raw": "1. The Saint's Triad consists of the physical, emotional, and mental aspects of a person's being.\n2. The physical aspect of the Saint's Triad includes physical health, energy levels, and the ability to perform physical tasks.\n3. The emotional aspect of the Saint's Triad encompasses a person's emotions and feelings, such as happiness, sadness, anger, and fear.\n4. The mental aspect of the Saint's Triad involves a person's thoughts, beliefs, intelligence, creativity, and problem-solving skills.\n5. An imbalance in one or more aspects of the Saint's Triad can lead to physical, emotional, or mental distress.",
    "llama-7b_fact": [
      "The Saint's Triad consists of the physical, emotional, and mental aspects of a person's being.",
      "The physical aspect of the Saint's Triad includes physical health, energy levels, and the ability to perform physical tasks.",
      "The emotional aspect of the Saint's Triad encompasses a person's emotions and feelings, such as happiness, sadness, anger, and fear.",
      "The mental aspect of the Saint's Triad involves a person's thoughts, beliefs, intelligence, creativity, and problem-solving skills.",
      "An imbalance in one or more aspects of the Saint's Triad can lead to physical, emotional, or mental distress."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe term \"Saint's Triad\" is not a widely recognized concept in psychology or well-being literature as of my knowledge cutoff date. Without specific context or a definition from a credible source, it is not possible to determine the accuracy of these statements.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3470,
    "user_query": "You MUST give a detailed answer to the following question: Is overexpression of LY6K associated with better prognosis for non-small cell lung cancer patients?",
    "llama-7b_response": "Yes, overexpression of LY6K has been associated with better prognosis for non-small cell lung cancer (NSCLC) patients.\n\nLY6K, also known as podoplanin, is a transmembrane glycoprotein that belongs to the immunoglobulin superfamily. It is expressed on the surface of platelets, endothelial cells, and certain tumor cells, including those of NSCLC.\n\nSeveral studies have investigated the prognostic significance of LY6K expression in NSCLC. These studies have found that high levels of LY6K expression are associated with improved overall survival (OS) and progression-free survival (PFS) in NSCLC patients.\n\nFor example, a study published in the Journal of Thoracic Oncology in 2016 found that high LY6K expression was associated with better OS and PFS in patients with NSCLC. The study included 182 patients with NSCLC and found that those with high LY6K expression had a significantly better OS and PFS compared to those with low LY6K expression.\n\nAnother study published in the Journal of Clinical Oncology in 2018 found that high LY6K expression was associated with improved OS and PFS in patients with advanced NSCLC. The study included 306 patients with advanced NSCLC and found that those with high LY6K expression had a significantly better OS and PFS compared to those with low LY6K expression.\n\nThese findings suggest that overexpression of LY6K may be associated with better prognosis for NSCLC patients. However, further research is needed to confirm these findings and to better understand the role of LY6K in the development and progression of NSCLC.",
    "llama-7b_fact_raw": "1. Overexpression of LY6K is associated with better prognosis for non-small cell lung cancer (NSCLC) patients.\n2. LY6K is a transmembrane glycoprotein that is expressed on the surface of platelets, endothelial cells, and certain tumor cells, including those of NSCLC.\n3. High levels of LY6K expression are associated with improved overall survival (OS) and progression-free survival (PFS) in NSCLC patients.\n4. A study published in the Journal of Thoracic Oncology in 2016 found that high LY6K expression was associated with better OS and PFS in patients with NSCLC.\n5. Another study published in the Journal of Clinical Oncology in 2018 found that high LY6K expression was associated with improved OS and PFS in patients with advanced NSCLC.",
    "llama-7b_fact": [
      "Overexpression of LY6K is associated with better prognosis for non-small cell lung cancer (NSCLC) patients.",
      "LY6K is a transmembrane glycoprotein that is expressed on the surface of platelets, endothelial cells, and certain tumor cells, including those of NSCLC.",
      "High levels of LY6K expression are associated with improved overall survival (OS) and progression-free survival (PFS) in NSCLC patients.",
      "A study published in the Journal of Thoracic Oncology in 2016 found that high LY6K expression was associated with better OS and PFS in patients with NSCLC.",
      "Another study published in the Journal of Clinical Oncology in 2018 found that high LY6K expression was associated with improved OS and PFS in patients with advanced NSCLC."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Overexpression of LY6K is generally associated with a poor prognosis for non-small cell lung cancer (NSCLC) patients.\n2. TRUE\n3. FALSE [correction]: High levels of LY6K expression are generally associated with poor overall survival (OS) and progression-free survival (PFS) in NSCLC patients.\n4. FALSE [correction]: Without the specific article from the Journal of Thoracic Oncology, it is difficult to confirm the findings. However, based on the general understanding that high LY6K expression is associated with poor prognosis, this statement is likely false.\n5. FALSE [correction]: Without the specific article from the Journal of Clinical Oncology, it is difficult to confirm the findings. However, based on the general understanding that high LY6K expression is associated with poor prognosis, this statement is likely false.",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3473,
    "user_query": "You MUST give a detailed answer to the following question: List Cdk targets that are dephosphorylated during cytokinesis",
    "llama-7b_response": "Cdk targets that are dephosphorylated during cytokinesis include the following:\n\n1. Cyclin B1: Cyclin B1 is dephosphorylated by Cdk1 during cytokinesis, leading to its degradation by the ubiquitin-proteasome pathway.\n2. Cyclin A: Cyclin A is dephosphorylated by Cdk2 during cytokinesis, leading to its degradation by the ubiquitin-proteasome pathway.\n3. Cyclin B2: Cyclin B2 is dephosphorylated by Cdk1 during cytokinesis, leading to its degradation by the ubiquitin-proteasome pathway.\n4. Cyclin A2: Cyclin A2 is dephosphorylated by Cdk2 during cytokinesis, leading to its degradation by the ubiquitin-proteasome pathway.\n5. Cyclin B3: Cyclin B3 is dephosphorylated by Cdk1 during cytokinesis, leading to its degradation by the ubiquitin-proteasome pathway.\n6. Cyclin A3: Cyclin A3 is dephosphorylated by Cdk2 during cytokinesis, leading to its degradation by the ubiquitin-proteasome pathway.\n7. Cyclin B4: Cyclin B4 is dephosphorylated by Cdk1 during cytokinesis, leading to its degradation by the ubiquitin-proteasome pathway.\n8. Cyclin A4: Cyclin A4 is dephosphorylated by Cdk2 during cytokinesis, leading to its degradation by the ubiquitin-proteasome pathway.\n9. Cyclin B5: Cyclin B5 is dephosphorylated by Cdk1 during cytokinesis, leading to its degradation by the ubiquitin-proteasome pathway.\n10. Cyclin A5: Cyclin A5 is dephosphorylated by Cdk2 during cytokinesis, leading to its degradation by the ubi",
    "llama-7b_fact_raw": "1. Cyclin B1 is dephosphorylated by Cdk1 during cytokinesis.\n2. Cyclin A is dephosphorylated by Cdk2 during cytokinesis.\n3. Cyclin B2 is dephosphorylated by Cdk1 during cytokinesis.\n4. Cyclin A2 is dephosphorylated by Cdk2 during cytokinesis.\n5. Cyclin B3 is dephosphorylated by Cdk1 during cytokinesis.",
    "llama-7b_fact": [
      "Cyclin B1 is dephosphorylated by Cdk1 during cytokinesis.",
      "Cyclin A is dephosphorylated by Cdk2 during cytokinesis.",
      "Cyclin B2 is dephosphorylated by Cdk1 during cytokinesis.",
      "Cyclin A2 is dephosphorylated by Cdk2 during cytokinesis.",
      "Cyclin B3 is dephosphorylated by Cdk1 during cytokinesis."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Cyclin B1 is phosphorylated by Cdk1 during mitosis, not dephosphorylated during cytokinesis.\n2. UNKNOWN: The specific role of Cyclin A dephosphorylation by Cdk2 during cytokinesis is not well-established and may vary depending on the organism and cell type.\n3. UNKNOWN: The specific role of Cyclin B2 dephosphorylation by Cdk1 during cytokinesis is not well-established and may vary depending on the organism and cell type.\n4. UNKNOWN: The specific role of Cyclin A2 dephosphorylation by Cdk2 during cytokinesis is not well-established and may vary depending on the organism and cell type.\n5. UNKNOWN: The specific role of Cyclin B3 dephosphorylation by Cdk1 during cytokinesis is not well-established and may vary depending on the organism and cell type.",
    "llama-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3508,
    "user_query": "You MUST give a detailed answer to the following question: What is Xanamem?",
    "llama-7b_response": "Xanamem is a drug that is used to treat the symptoms of mild to moderate Alzheimer's disease. It belongs to a class of drugs called cholinergic agonists, which work by increasing the levels of a chemical called acetylcholine in the brain. Acetylcholine is a neurotransmitter that is important for memory and cognitive function.\n\nXanamem is available in the form of a tablet that is taken orally. It is usually taken once daily, with or without food. The dosage of Xanamem that is recommended for the treatment of Alzheimer's disease varies depending on the individual and the severity of their symptoms. It is important for patients to follow their doctor's instructions carefully when taking Xanamem, as the dosage may need to be adjusted based on the individual's response to the medication.\n\nIt is important for patients to note that Xanamem is not a cure for Alzheimer's disease, and it may not completely reverse the symptoms of the condition. However, it can help to improve memory and cognitive function, and may help to slow the progression of the disease.\n\nIt is also important for patients to be aware of the potential side effects of Xanamem, which may include nausea, vomiting, diarrhea, and constipation. In rare cases, Xanamem may also cause muscle spasms, restlessness, and insomnia. It is important for patients to let their doctor know if they experience any side effects while taking Xanamem.",
    "llama-7b_fact_raw": "1. Xanamem is used to treat the symptoms of mild to moderate Alzheimer's disease.\n2. Xanamem belongs to a class of drugs called cholinergic agonists.\n3. Cholinergic agonists like Xanamem work by increasing levels of acetylcholine in the brain.\n4. Xanamem is administered in tablet form and is usually taken once daily.\n5. Xanamem is not a cure for Alzheimer's disease but may improve memory and cognitive function.",
    "llama-7b_fact": [
      "Xanamem is used to treat the symptoms of mild to moderate Alzheimer's disease.",
      "Xanamem belongs to a class of drugs called cholinergic agonists.",
      "Cholinergic agonists like Xanamem work by increasing levels of acetylcholine in the brain.",
      "Xanamem is administered in tablet form and is usually taken once daily.",
      "Xanamem is not a cure for Alzheimer's disease but may improve memory and cognitive function."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: Xanamem is not a cholinergic agonist; it is designed to block the production of excess cortisol by inhibiting the activity of the enzyme 11β-HSD1.\n3. FALSE [correction]: Cholinergic agonists work by increasing levels of acetylcholine in the brain, but Xanamem works by a different mechanism, targeting cortisol production.\n4. UNKNOWN\n5. TRUE",
    "llama-7b_judge": [
      "unknown",
      "false",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3520,
    "user_query": "You MUST give a detailed answer to the following question: What is the role of the Hof1-Cyk3 interaction in yeast?",
    "llama-7b_response": "The Hof1-Cyk3 interaction plays a crucial role in the regulation of cytokinesis in yeast. Hof1 is a protein that is involved in the regulation of the actin cytoskeleton, while Cyk3 is a protein that is involved in the regulation of the microtubule cytoskeleton. The Hof1-Cyk3 interaction allows for the coordination of the actin and microtubule cytoskeletons during cytokinesis, which is the process of dividing the cell into two daughter cells.\n\nDuring cytokinesis, the actin and microtubule cytoskeletons work together to divide the cell into two daughter cells. The Hof1-Cyk3 interaction allows for the coordination of these two cytoskeletons, as Cyk3 interacts with the actin cytoskeleton through its interaction with the Arp2/3 complex, while Hof1 interacts with the microtubule cytoskeleton through its interaction with the Kip3 protein.\n\nThe Hof1-Cyk3 interaction is also involved in the regulation of the actin cytoskeleton during the cell cycle. During interphase, the actin cytoskeleton is involved in the formation of the mitotic spindle, while during metaphase, the actin cytoskeleton is involved in the separation of the chromosomes. The Hof1-Cyk3 interaction allows for the coordination of the actin cytoskeleton during these different stages of the cell cycle.\n\nOverall, the Hof1-Cyk3 interaction plays a crucial role in the regulation of the actin and microtubule cytoskeletons during cytokinesis and the cell cycle in yeast. The coordination of these two cytoskeletons allows for the proper division of the cell into two daughter cells, and the regulation of the actin cytoskeleton during different stages of the cell cycle.",
    "llama-7b_fact_raw": "1. The Hof1-Cyk3 interaction is involved in the regulation of cytokinesis in yeast.\n2. Hof1 is a protein that regulates the actin cytoskeleton in yeast.\n3. Cyk3 is a protein that regulates the microtubule cytoskeleton in yeast.\n4. The Hof1-Cyk3 interaction coordinates the actin and microtubule cytoskeletons during the process of cell division in yeast.\n5. The Hof1-Cyk3 interaction is involved in the regulation of the actin cytoskeleton during different stages of the yeast cell cycle.",
    "llama-7b_fact": [
      "The Hof1-Cyk3 interaction is involved in the regulation of cytokinesis in yeast.",
      "Hof1 is a protein that regulates the actin cytoskeleton in yeast.",
      "Cyk3 is a protein that regulates the microtubule cytoskeleton in yeast.",
      "The Hof1-Cyk3 interaction coordinates the actin and microtubule cytoskeletons during the process of cell division in yeast.",
      "The Hof1-Cyk3 interaction is involved in the regulation of the actin cytoskeleton during different stages of the yeast cell cycle."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Cyk3 is a protein that is involved in the regulation of cytokinesis in yeast, but it is not specifically known for regulating the microtubule cytoskeleton.\n4. FALSE [correction]: The Hof1-Cyk3 interaction is known to be involved in the regulation of cytokinesis, which is the process of cell division, particularly coordinating events at the cell cortex, but there is no specific evidence that it coordinates the actin and microtubule cytoskeletons together during this process.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 3598,
    "user_query": "You MUST give a detailed answer to the following question: Which T-UCRs have been implicated in gastric cancer?",
    "llama-7b_response": "There are several T-UCRs that have been implicated in gastric cancer, including:\n\n1. TNF-alpha: TNF-alpha is a pro-inflammatory cytokine that has been implicated in the development of gastric cancer. High levels of TNF-alpha have been found in the stomach tissue of patients with gastric cancer, and TNF-alpha has been shown to promote the growth and survival of gastric cancer cells in vitro.\n2. IL-1beta: IL-1beta is a pro-inflammatory cytokine that has been implicated in the development of gastric cancer. High levels of IL-1beta have been found in the stomach tissue of patients with gastric cancer, and IL-1beta has been shown to promote the growth and survival of gastric cancer cells in vitro.\n3. IFN-gamma: IFN-gamma is a pro-inflammatory cytokine that has been implicated in the development of gastric cancer. High levels of IFN-gamma have been found in the stomach tissue of patients with gastric cancer, and IFN-gamma has been shown to promote the growth and survival of gastric cancer cells in vitro.\n4. IL-6: IL-6 is a pro-inflammatory cytokine that has been implicated in the development of gastric cancer. High levels of IL-6 have been found in the stomach tissue of patients with gastric cancer, and IL-6 has been shown to promote the growth and survival of gastric cancer cells in vitro.\n5. IL-8: IL-8 is a pro-inflammatory cytokine that has been implicated in the development of gastric cancer. High levels of IL-8 have been found in the stomach tissue of patients with gastric cancer, and IL-8 has been shown to promote the growth and survival of gastric cancer cells in vitro.\n6. TGF-beta: TGF-beta is a cytokine that has been implicated in the development of gastric cancer. High levels of TGF-beta have been found in the stomach tissue of patients with gastric cancer, and TG",
    "llama-7b_fact_raw": "1. TNF-alpha is a cytokine that has been implicated in the development of gastric cancer.\n2. High levels of TNF-alpha have been found in the stomach tissue of patients with gastric cancer.\n3. IL-1beta is a cytokine that has been implicated in the development of gastric cancer.\n4. High levels of IL-6 have been found in the stomach tissue of patients with gastric cancer.\n5. TGF-beta is a cytokine that has been implicated in the development of gastric cancer.",
    "llama-7b_fact": [
      "TNF-alpha is a cytokine that has been implicated in the development of gastric cancer.",
      "High levels of TNF-alpha have been found in the stomach tissue of patients with gastric cancer.",
      "IL-1beta is a cytokine that has been implicated in the development of gastric cancer.",
      "High levels of IL-6 have been found in the stomach tissue of patients with gastric cancer.",
      "TGF-beta is a cytokine that has been implicated in the development of gastric cancer."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nTNF-alpha, IL-1beta, IL-6, and TGF-beta are all cytokines that have been implicated in the development of various cancers, including gastric cancer. They can contribute to the tumor microenvironment and influence cancer progression. High levels of these cytokines have been found in the stomach tissue of patients with gastric cancer, suggesting a role in the disease's pathogenesis.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3607,
    "user_query": "You MUST give a detailed answer to the following question: What is the Lupus Severity Index (LSI)?",
    "llama-7b_response": "The Lupus Severity Index (LSI) is a tool used to assess the severity of systemic lupus erythematosus (SLE), a chronic autoimmune disorder that can affect various organs and systems in the body. The LSI was developed in the 1970s by a team of researchers led by Dr. Wallace McDermott at the National Institutes of Health (NIH) in Bethesda, Maryland.\n\nThe LSI is based on a comprehensive review of the medical history and physical examination findings of patients with SLE. The index assigns a score to each organ system affected by the disease, ranging from 0 to 4, with higher scores indicating more severe disease. The LSI also takes into account the presence and severity of certain clinical manifestations, such as malar rash, discoid rash, photosensitivity, lupus nephritis, and serositis.\n\nThe LSI has been widely used in clinical practice and research to assess the severity of SLE and to monitor the response to treatment. It is also used to predict the likelihood of disease flares and the risk of organ damage over time.\n\nIn summary, the Lupus Severity Index (LSI) is a tool used to assess the severity of systemic lupus erythematosus (SLE), a chronic autoimmune disorder that can affect various organs and systems in the body. It is based on a comprehensive review of the medical history and physical examination findings of patients with SLE and assigns a score to each organ system affected by the disease, ranging from 0 to 4, with higher scores indicating more severe disease. The LSI has been widely used in clinical practice and research to assess the severity of SLE and to monitor the response to treatment, and it is also used to predict the likelihood of disease flares and the risk of organ damage over time.",
    "llama-7b_fact_raw": "1. The Lupus Severity Index (LSI) is a tool used to assess the severity of systemic lupus erythematosus (SLE).\n2. The LSI was developed in the 1970s by a team of researchers led by Dr. Wallace McDermott at the National Institutes of Health (NIH) in Bethesda, Maryland.\n3. The LSI assigns a score to each organ system affected by SLE, with scores ranging from 0 to 4.\n4. Higher scores on the LSI indicate more severe disease.\n5. The LSI is used in clinical practice and research to monitor the response to treatment and to predict the likelihood of disease flares and the risk of organ damage over time.",
    "llama-7b_fact": [
      "The Lupus Severity Index (LSI) is a tool used to assess the severity of systemic lupus erythematosus (SLE).",
      "The LSI was developed in the 1970s by a team of researchers led by Dr. Wallace McDermott at the National Institutes of Health (NIH) in Bethesda, Maryland.",
      "The LSI assigns a score to each organ system affected by SLE, with scores ranging from 0 to 4.",
      "Higher scores on the LSI indicate more severe disease.",
      "The LSI is used in clinical practice and research to monitor the response to treatment and to predict the likelihood of disease flares and the risk of organ damage over time."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: There is no widely recognized tool called the Lupus Severity Index (LSI) developed by Dr. Wallace McDermott or associated with the NIH. The SLE Disease Activity Index (SLEDAI) and the British Isles Lupus Assessment Group (BILAG) index are examples of tools used to assess SLE severity.\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe corrections and unknown responses are due to the fact that the Lupus Severity Index (LSI) is not a standard or widely recognized tool for assessing SLE, and there is no information available about a tool with that name being developed by Dr. Wallace McDermott or the specifics of how it scores organ system involvement. The SLEDAI and BILAG are established tools with their own scoring systems and uses in clinical practice and research.",
    "llama-7b_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3615,
    "user_query": "You MUST give a detailed answer to the following question: Which disorders are caused by de novo mutations in ZSWIM6?",
    "llama-7b_response": "De novo mutations are genetic changes that occur for the first time in an individual and are not inherited from the parents. ZSWIM6 is a gene that has been associated with several disorders that are caused by de novo mutations.\n\nOne of the disorders caused by de novo mutations in ZSWIM6 is Charcot-Marie-Tooth disease (CMT). CMT is a group of genetic disorders that affect the peripheral nervous system, which is responsible for transmitting signals between the brain and the rest of the body. CMT can cause a range of symptoms, including muscle weakness, muscle atrophy, and loss of sensation in the feet and hands.\n\nAnother disorder caused by de novo mutations in ZSWIM6 is autism spectrum disorder (ASD). ASD is a neurodevelopmental disorder that is characterized by social communication difficulties, repetitive behaviors, and restricted interests. While the exact causes of ASD are not fully understood, genetic factors are thought to play a role in the development of the disorder.\n\nOther disorders that have been associated with de novo mutations in ZSWIM6 include intellectual disability, epilepsy, and cardiac arrhythmias. However, more research is needed to fully understand the role of ZSWIM6 in these disorders and the specific mechanisms by which de novo mutations in the gene contribute to their development.",
    "llama-7b_fact_raw": "1. De novo mutations in ZSWIM6 can cause Charcot-Marie-Tooth disease (CMT).\n2. Charcot-Marie-Tooth disease affects the peripheral nervous system.\n3. Autism spectrum disorder (ASD) can be caused by de novo mutations in ZSWIM6.\n4. Genetic factors are considered to play a role in the development of autism spectrum disorder.\n5. De novo mutations in ZSWIM6 have been associated with intellectual disability, epilepsy, and cardiac arrhythmias.",
    "llama-7b_fact": [
      "De novo mutations in ZSWIM6 can cause Charcot-Marie-Tooth disease (CMT).",
      "Charcot-Marie-Tooth disease affects the peripheral nervous system.",
      "Autism spectrum disorder (ASD) can be caused by de novo mutations in ZSWIM6.",
      "Genetic factors are considered to play a role in the development of autism spectrum disorder.",
      "De novo mutations in ZSWIM6 have been associated with intellectual disability, epilepsy, and cardiac arrhythmias."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: De novo mutations in ZSWIM6 have been associated with developmental disorders, but there is no direct evidence linking them specifically to Charcot-Marie-Tooth disease (CMT).\n2. TRUE\n3. TRUE: De novo mutations in ZSWIM6 have been associated with conditions like autism spectrum disorder (ASD).\n4. TRUE\n5. TRUE: De novo mutations in ZSWIM6 have been linked to a range of conditions, including intellectual disability, epilepsy, and cardiac arrhythmias.",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3626,
    "user_query": "You MUST give a detailed answer to the following question: Which disease can be classified using the Koos Classification?",
    "llama-7b_response": "osteoarthriti",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3628,
    "user_query": "You MUST give a detailed answer to the following question: What are the in vivo effects of AZD8601?",
    "llama-7b_response": "AZD8601 is a potent and selective inhibitor of the c-Met receptor tyrosine kinase, which is overexpressed in various types of cancer, including non-small cell lung cancer (NSCLC). In vivo studies have shown that AZD8601 has antitumor activity in preclinical models of cancer, including NSCLC.\n\nOne study published in the Journal of Clinical Oncology in 2015 evaluated the safety and efficacy of AZD8601 in patients with advanced solid tumors. The study enrolled 110 patients with various types of solid tumors, including NSCLC, and treated them with AZD8601 at doses ranging from 100 mg to 600 mg per day. The results showed that AZD8601 was well-tolerated and had antitumor activity in patients with advanced solid tumors, including those with NSCLC.\n\nAnother study published in the Journal of Clinical Oncology in 2017 evaluated the safety and efficacy of AZD8601 in combination with erlotinib, an EGFR inhibitor, in patients with advanced NSCLC. The study enrolled 152 patients with advanced NSCLC and treated them with AZD8601 and erlotinib or erlotinib alone. The results showed that the combination of AZD8601 and erlotinib was well-tolerated and had improved antitumor activity compared to erlotinib alone in patients with advanced NSCLC harboring EGFR-activating mutations.\n\nOverall, the in vivo effects of AZD8601 have been shown to include antitumor activity in preclinical models of cancer, including NSCLC, and improved antitumor activity in combination with erlotinib in patients with advanced NSCLC harboring EGFR-activating mutations. However, further clinical trials are needed to fully evaluate the safety and efficacy of AZD8601 in patients with NSCLC.",
    "llama-7b_fact_raw": "1. AZD8601 is an inhibitor of the c-Met receptor tyrosine kinase.\n2. AZD8601 has shown antitumor activity in preclinical models of cancer, including non-small cell lung cancer (NSCLC).\n3. A study published in the Journal of Clinical Oncology in 2015 reported that AZD8601 was well-tolerated in patients with advanced solid tumors, including NSCLC.\n4. The same study indicated that patients were treated with doses of AZD8601 ranging from 100 mg to 600 mg per day.\n5. A 2017 study in the Journal of Clinical Oncology found that the combination of AZD8601 and erlotinib had improved antitumor activity compared to erlotinib alone in patients with advanced NSCLC harboring EGFR-activating mutations.",
    "llama-7b_fact": [
      "AZD8601 is an inhibitor of the c-Met receptor tyrosine kinase.",
      "AZD8601 has shown antitumor activity in preclinical models of cancer, including non-small cell lung cancer (NSCLC).",
      "A study published in the Journal of Clinical Oncology in 2015 reported that AZD8601 was well-tolerated in patients with advanced solid tumors, including NSCLC.",
      "The same study indicated that patients were treated with doses of AZD8601 ranging from 100 mg to 600 mg per day.",
      "A 2017 study in the Journal of Clinical Oncology found that the combination of AZD8601 and erlotinib had improved antitumor activity compared to erlotinib alone in patients with advanced NSCLC harboring EGFR-activating mutations."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: AZD8601 is not an inhibitor of the c-Met receptor tyrosine kinase. AZD8601 is actually a modified mRNA encoding for vascular endothelial growth factor A (VEGF-A), which is used for regenerative therapy.\n2. UNKNOWN: Without specific information on AZD8601's preclinical models, it is not possible to confirm its antitumor activity in non-small cell lung cancer (NSCLC) or any other cancer.\n3. UNKNOWN: Without access to the specific study from the Journal of Clinical Oncology in 2015, the tolerability of AZD8601 in patients cannot be confirmed.\n4. UNKNOWN: Without access to the specific study, it is not possible to confirm the dosage range of AZD8601 that was used in the treatment.\n5. UNKNOWN: Without access to the 2017 study in the Journal of Clinical Oncology, the efficacy of the combination of AZD8601 and erlotinib in patients with advanced NSCLC harboring EGFR-activating mutations cannot be confirmed.",
    "llama-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3640,
    "user_query": "You MUST give a detailed answer to the following question: How are SAHFS created?",
    "llama-7b_response": "SAHFs (Secure Attestation of Hardware Functionality) are created through a process called \"attestation.\" Attestation is the process of verifying the authenticity and integrity of a hardware device, such as a smart card or a secure element, to ensure that it is functioning as intended and has not been tampered with.\n\nThe attestation process typically involves the following steps:\n\n1. Device Enrollment: The device, such as a smart card or a secure element, is enrolled in the attestation system. This involves generating a unique identifier for the device and storing it in a secure database.\n2. Attestation Request: The attestation request is sent to the device by the attestation system. The request contains information about the services that the device is expected to provide, as well as any constraints or requirements that need to be met.\n3. Device Response: The device responds to the attestation request by providing information about its hardware and software components, as well as its current state and configuration. This information is used to verify the authenticity and integrity of the device.\n4. Attestation Report: The attestation system generates an attestation report that contains the results of the attestation process. This report includes information about the device's hardware and software components, as well as its current state and configuration.\n5. Certificate Generation: If the attestation process is successful, the attestation system generates a digital certificate that certifies the authenticity and integrity of the device. This certificate can be used to verify the identity of the device and ensure that it is functioning as intended.\n\nOverall, the process of creating a SAHF involves attesting the authenticity and integrity of a hardware device, such as a smart card or a secure element, to ensure that it is functioning as intended and has not been tampered with. The attestation process typically involves enrolling the device in the attestation system, sending an attestation request to the device, receiving a device response, generating an attestation report, and generating a digital certificate if the attestation process is successful.",
    "llama-7b_fact_raw": "1. SAHFs are created through a process called \"attestation,\" which verifies the authenticity and integrity of a hardware device.\n2. During device enrollment, a unique identifier for the device is generated and stored in a secure database.\n3. An attestation request is sent to the device, containing information about the services it should provide and any necessary constraints.\n4. The device responds to the attestation request with information about its hardware and software components, state, and configuration.\n5. If the attestation is successful, a digital certificate is generated to certify the device's authenticity and integrity.",
    "llama-7b_fact": [
      "SAHFs are created through a process called \"attestation,\" which verifies the authenticity and integrity of a hardware device.",
      "During device enrollment, a unique identifier for the device is generated and stored in a secure database.",
      "An attestation request is sent to the device, containing information about the services it should provide and any necessary constraints.",
      "The device responds to the attestation request with information about its hardware and software components, state, and configuration.",
      "If the attestation is successful, a digital certificate is generated to certify the device's authenticity and integrity."
    ],
    "llama-7b_judge_raw": "1. TRUE: SAHFs (Software Attestation to Hardware Flags) or more generally, attestation processes, are indeed used to verify the authenticity and integrity of a hardware device.\n2. TRUE: During device enrollment, a unique identifier is typically generated for the device and stored in a secure database to ensure that the device can be uniquely identified and managed.\n3. FALSE [correction]: An attestation request is typically sent to the device to verify its integrity and authenticity, not to provide information about the services it should provide or any necessary constraints. Those details are usually part of service provisioning, not the attestation process.\n4. TRUE: In response to an attestation request, the device usually provides information about its hardware and software components, state, and configuration to prove its integrity and authenticity.\n5. TRUE: If the attestation process is successful, a digital certificate or some form of attestation token is often generated to certify the device's authenticity and integrity.",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3672,
    "user_query": "You MUST give a detailed answer to the following question: What is the function of the PDZ domain in SATB1?",
    "llama-7b_response": "The PDZ domain is a protein interaction domain found in many proteins, including the transcription factor SATB1 (Special AT-rich sequence binding protein 1). The function of the PDZ domain in SATB1 is to mediate protein-protein interactions with other proteins.\n\nThe PDZ domain in SATB1 specifically interacts with other proteins that contain a PDZ-binding motif, which is a specific sequence of amino acids that is recognized by the PDZ domain. These proteins include other transcription factors, scaffold proteins, and signaling molecules.\n\nThe PDZ domain in SATB1 plays a crucial role in the regulation of gene expression by SATB1. By interacting with other proteins, SATB1 can recruit these proteins to specific regions of the genome, where they can regulate the expression of genes involved in a variety of biological processes.\n\nFor example, SATB1 has been shown to interact with other transcription factors, such as E2F1 and YY1, which are involved in the regulation of cell proliferation and differentiation. By interacting with these proteins through its PDZ domain, SATB1 can help to coordinate the expression of genes involved in these processes.\n\nIn addition to its role in transcriptional regulation, the PDZ domain in SATB1 also plays a role in the post-translational modification of SATB1. For example, the PDZ domain in SATB1 has been shown to interact with the ubiquitin ligase Nedd4-1, which can target SATB1 for degradation through the ubiquitin-proteasome pathway.\n\nOverall, the PDZ domain in SATB1 is an important protein interaction domain that plays a critical role in the regulation of gene expression and the post-translational modification of SATB1.",
    "llama-7b_fact_raw": "1. The PDZ domain in SATB1 mediates protein-protein interactions with other proteins that contain a PDZ-binding motif.\n2. SATB1 (Special AT-rich sequence binding protein 1) is a transcription factor.\n3. The PDZ domain in SATB1 is involved in the regulation of gene expression by recruiting proteins to specific regions of the genome.\n4. SATB1 interacts with other transcription factors such as E2F1 and YY1 through its PDZ domain.\n5. The PDZ domain in SATB1 has been shown to interact with the ubiquitin ligase Nedd4-1, which can target SATB1 for degradation through the ubiquitin-proteasome pathway.",
    "llama-7b_fact": [
      "The PDZ domain in SATB1 mediates protein-protein interactions with other proteins that contain a PDZ-binding motif.",
      "SATB1 (Special AT-rich sequence binding protein 1) is a transcription factor.",
      "The PDZ domain in SATB1 is involved in the regulation of gene expression by recruiting proteins to specific regions of the genome.",
      "SATB1 interacts with other transcription factors such as E2F1 and YY1 through its PDZ domain.",
      "The PDZ domain in SATB1 has been shown to interact with the ubiquitin ligase Nedd4-1, which can target SATB1 for degradation through the ubiquitin-proteasome pathway."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The PDZ domain is not a feature of SATB1; instead, SATB1 contains a PDZ-like domain that mediates protein-protein interactions, but it is not a classical PDZ domain.\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3678,
    "user_query": "You MUST give a detailed answer to the following question: What is the basis of the BLISS technique?",
    "llama-7b_response": "The BLISS technique is based on the idea that the brain can be trained to produce different states of consciousness.",
    "llama-7b_fact_raw": "1. The BLISS technique is based on the concept that the brain can be trained. \n2. The BLISS technique aims to produce different states of consciousness.",
    "llama-7b_fact": [
      "The BLISS technique is based on the concept that the brain can be trained.",
      "The BLISS technique aims to produce different states of consciousness."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n\nWithout additional context or information about the BLISS technique, it is not possible to determine the accuracy of these statements.",
    "llama-7b_judge": [
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3679,
    "user_query": "You MUST give a detailed answer to the following question: List 3 NK3R antagonists.",
    "llama-7b_response": "NK3 receptor antagonists are medications that block the action of the NK3 receptor, which is a subtype of the neurokinin-1 (NK1) receptor. The NK3 receptor is found primarily in the central nervous system and is involved in the regulation of pain, inflammation, and other physiological processes. Here are three examples of NK3R antagonists:\n\n1. Aprepitant: Aprepitant is a medication that is used to prevent nausea and vomiting caused by chemotherapy. It works by blocking the NK3 receptor and other receptors involved in the regulation of nausea and vomiting.\n2. Sitagliptin: Sitagliptin is a medication that is used to treat type 2 diabetes. It works by increasing the amount of insulin produced by the pancreas and by decreasing the amount of glucose produced by the liver. Sitagliptin also blocks the NK3 receptor, which may contribute to its effects on glucose metabolism.\n3. Pregabalin: Pregabalin is a medication that is used to treat neuropathic pain and anxiety disorders. It works by blocking the NK3 receptor and other receptors involved in the regulation of pain and anxiety. Pregabalin is also a member of a class of medications called gabapentinoids, which are structurally related to the neurotransmitter gamma-aminobutyric acid (GABA).",
    "llama-7b_fact_raw": "1. Aprepitant is a medication used to prevent nausea and vomiting caused by chemotherapy.\n2. Sitagliptin is a medication used to treat type 2 diabetes.\n3. Pregabalin is a medication used to treat neuropathic pain and anxiety disorders.",
    "llama-7b_fact": [
      "Aprepitant is a medication used to prevent nausea and vomiting caused by chemotherapy.",
      "Sitagliptin is a medication used to treat type 2 diabetes.",
      "Pregabalin is a medication used to treat neuropathic pain and anxiety disorders."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Pregabalin is a medication used to treat neuropathic pain and epilepsy. It is also used to treat generalized anxiety disorder, but not specifically anxiety disorders as a broad category.",
    "llama-7b_judge": [
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3691,
    "user_query": "You MUST give a detailed answer to the following question: Which drug is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects?",
    "llama-7b_response": "liraglutide",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3693,
    "user_query": "You MUST give a detailed answer to the following question: What is the protective efficacy of vaxchora against moderate to severe cholera?",
    "llama-7b_response": "Vaxchora is a vaccine that is approved for the prevention of cholera caused by the serogroup Ogawa in adults aged 18 years and older. The vaccine is administered as a single-dose subcutaneous injection.\n\nThe protective efficacy of Vaxchora against moderate to severe cholera was evaluated in a randomized, double-blind, placebo-controlled trial conducted in Bangladesh. The trial enrolled adults aged 18 years and older who were at risk of exposure to cholera. The participants were randomly assigned to receive either Vaxchora or placebo, and were followed for up to 12 months.\n\nThe results of the trial showed that Vaxchora was highly effective in protecting against cholera caused by the serogroup Ogawa. The vaccine was estimated to be 86% effective in preventing moderate to severe cholera cases, and 92% effective in preventing severe cholera cases. The vaccine was also found to be well-tolerated and had a good safety profile.\n\nIn summary, the protective efficacy of Vaxchora against moderate to severe cholera is high, with the vaccine estimated to be 86% effective in preventing moderate to severe cholera cases and 92% effective in preventing severe cholera cases. The vaccine is recommended for use in adults aged 18 years and older who are at risk of exposure to cholera.",
    "llama-7b_fact_raw": "1. Vaxchora is approved for the prevention of cholera caused by the serogroup Ogawa in adults aged 18 years and older.\n2. Vaxchora is administered as a single-dose subcutaneous injection.\n3. A randomized, double-blind, placebo-controlled trial conducted in Bangladesh evaluated the protective efficacy of Vaxchora.\n4. Vaxchora was estimated to be 86% effective in preventing moderate to severe cholera cases.\n5. Vaxchora was estimated to be 92% effective in preventing severe cholera cases.",
    "llama-7b_fact": [
      "Vaxchora is approved for the prevention of cholera caused by the serogroup Ogawa in adults aged 18 years and older.",
      "Vaxchora is administered as a single-dose subcutaneous injection.",
      "A randomized, double-blind, placebo-controlled trial conducted in Bangladesh evaluated the protective efficacy of Vaxchora.",
      "Vaxchora was estimated to be 86% effective in preventing moderate to severe cholera cases.",
      "Vaxchora was estimated to be 92% effective in preventing severe cholera cases."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Vaxchora is administered orally as a single-dose live attenuated vaccine.\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3716,
    "user_query": "You MUST give a detailed answer to the following question: Which was the first cholera vaccine approved in the US?",
    "llama-7b_response": "cholera vaccine",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3737,
    "user_query": "You MUST give a detailed answer to the following question: Which is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans?",
    "llama-7b_response": "adenosine deaminase deficiency",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3743,
    "user_query": "You MUST give a detailed answer to the following question: Which is the role of the IFIT1 gene in Systemic Lupus Erythematosus (SLE)?",
    "llama-7b_response": "The IFIT1 (Interferon, alpha-inducible) gene is a member of the type I interferon (IFN) gene family, which plays a crucial role in the immune response against viral infections. The IFIT1 gene encodes for a protein that is involved in the antiviral response by inducing the expression of other IFN-stimulated genes (ISGs).\n\nIn the context of Systemic Lupus Erythematosus (SLE), the role of the IFIT1 gene is not well understood. However, there is some evidence to suggest that the IFIT1 gene may be involved in the pathogenesis of SLE.\n\nFor example, a study published in the journal Arthritis & Rheumatology in 2018 found that individuals with SLE had lower levels of IFIT1 mRNA expression in their peripheral blood mononuclear cells compared to healthy controls. This suggests that the IFIT1 gene may be dysregulated in SLE.\n\nAdditionally, a study published in the journal PLoS One in 2016 found that the IFIT1 gene was downregulated in SLE patients compared to healthy controls. This suggests that the IFIT1 gene may play a role in the pathogenesis of SLE.\n\nHowever, further research is needed to fully understand the role of the IFIT1 gene in SLE.",
    "llama-7b_fact_raw": "1. The IFIT1 gene is a member of the type I interferon gene family.\n2. The IFIT1 gene encodes for a protein involved in the antiviral response by inducing the expression of other IFN-stimulated genes.\n3. A study published in Arthritis & Rheumatology in 2018 found that individuals with SLE had lower levels of IFIT1 mRNA expression in their peripheral blood mononuclear cells compared to healthy controls.\n4. A study published in PLoS One in 2016 found that the IFIT1 gene was downregulated in SLE patients compared to healthy controls.\n5. The role of the IFIT1 gene in the pathogenesis of Systemic Lupus Erythematosus is not fully understood and requires further research.",
    "llama-7b_fact": [
      "The IFIT1 gene is a member of the type I interferon gene family.",
      "The IFIT1 gene encodes for a protein involved in the antiviral response by inducing the expression of other IFN-stimulated genes.",
      "A study published in Arthritis & Rheumatology in 2018 found that individuals with SLE had lower levels of IFIT1 mRNA expression in their peripheral blood mononuclear cells compared to healthy controls.",
      "A study published in PLoS One in 2016 found that the IFIT1 gene was downregulated in SLE patients compared to healthy controls.",
      "The role of the IFIT1 gene in the pathogenesis of Systemic Lupus Erythematosus is not fully understood and requires further research."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The IFIT1 gene is not a member of the type I interferon gene family; it is a member of the interferon-induced proteins with tetratricopeptide repeats (IFIT) family.\n2. TRUE\n3. TRUE: Assuming the statement accurately reflects the findings of the study published in Arthritis & Rheumatology in 2018.\n4. TRUE: Assuming the statement accurately reflects the findings of the study published in PLoS One in 2016.\n5. TRUE: This statement is generally true for many genes involved in complex diseases like Systemic Lupus Erythematosus (SLE), as the pathogenesis is often not fully understood and requires ongoing research.",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3752,
    "user_query": "You MUST give a detailed answer to the following question: What is the use of the Liverpool Elbow Score?",
    "llama-7b_response": "​",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3763,
    "user_query": "You MUST give a detailed answer to the following question: Describe efforts on Sarcoma from the 100,000 Genomes Project",
    "llama-7b_response": "The 100,000 Genomes Project is a UK-based initiative that aims to sequence 100,000 whole genomes from NHS patients with cancer or rare diseases. As part of this project, efforts have been made to sequence genomes of patients with sarcoma, a type of cancer that affects the soft tissues and bones.\n\nOne of the key objectives of the 100,000 Genomes Project is to use genomic data to improve diagnosis, treatment, and care for patients with cancer and rare diseases. In the case of sarcoma, genomic data can be used to identify specific subtypes of the disease, which can then be targeted with more effective treatments.\n\nTo sequence the genomes of patients with sarcoma as part of the 100,000 Genomes Project, researchers used a combination of next-generation sequencing (NGS) technologies, including whole-exome sequencing and targeted sequencing. Whole-exome sequencing involves sequencing only the protein-coding regions of the genome, while targeted sequencing involves sequencing specific genes or regions of the genome that are known to be associated with a particular disease.\n\nIn addition to sequencing the genomes of patients with sarcoma, the 100,000 Genomes Project is also analyzing the data to identify genomic variants that may be associated with the disease. These variants can then be used to develop targeted therapies and personalized treatment plans for patients with sarcoma.\n\nOverall, the efforts on sarcoma from the 100,000 Genomes Project are aimed at improving diagnosis, treatment, and care for patients with this type of cancer. By sequencing the genomes of patients with sarcoma and analyzing the data, researchers hope to identify specific subtypes of the disease and develop targeted therapies that can improve patient outcomes.",
    "llama-7b_fact_raw": "1. The 100,000 Genomes Project is a UK-based initiative that aims to sequence 100,000 whole genomes from NHS patients with cancer or rare diseases.\n2. The project includes efforts to sequence genomes of patients with sarcoma, a type of cancer that affects the soft tissues and bones.\n3. One of the objectives of the 100,000 Genomes Project is to use genomic data to improve diagnosis, treatment, and care for patients with cancer and rare diseases, including sarcoma.\n4. Researchers involved in the project used next-generation sequencing technologies, such as whole-exome sequencing and targeted sequencing, to sequence the genomes of patients with sarcoma.\n5. The 100,000 Genomes Project is analyzing genomic data to identify variants associated with sarcoma, which may lead to the development of targeted therapies and personalized treatment plans.",
    "llama-7b_fact": [
      "The 100,000 Genomes Project is a UK-based initiative that aims to sequence 100,000 whole genomes from NHS patients with cancer or rare diseases.",
      "The project includes efforts to sequence genomes of patients with sarcoma, a type of cancer that affects the soft tissues and bones.",
      "One of the objectives of the 100,000 Genomes Project is to use genomic data to improve diagnosis, treatment, and care for patients with cancer and rare diseases, including sarcoma.",
      "Researchers involved in the project used next-generation sequencing technologies, such as whole-exome sequencing and targeted sequencing, to sequence the genomes of patients with sarcoma.",
      "The 100,000 Genomes Project is analyzing genomic data to identify variants associated with sarcoma, which may lead to the development of targeted therapies and personalized treatment plans."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Researchers involved in the 100,000 Genomes Project used whole-genome sequencing, not just whole-exome sequencing and targeted sequencing, to sequence the genomes of patients.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3777,
    "user_query": "You MUST give a detailed answer to the following question: Does protein ALEX1 contain armadillo repeats?",
    "llama-7b_response": "Yes, protein ALEX1 contains armadillo repeats.",
    "llama-7b_fact_raw": "1. Protein ALEX1 contains armadillo repeats.",
    "llama-7b_fact": [
      "Protein ALEX1 contains armadillo repeats."
    ],
    "llama-7b_judge_raw": "UNKNOWN\n\nWithout additional context or specific scientific references, it is not possible to confirm the accuracy of the statement regarding the protein ALEX1 containing armadillo repeats. Armadillo repeats are a protein structural motif involved in protein-protein interactions, and while they are found in various proteins, without specific information about ALEX1, the statement's truth cannot be determined.",
    "llama-7b_judge": [
      "unknown"
    ]
  },
  {
    "id": 3789,
    "user_query": "You MUST give a detailed answer to the following question: List enzymes that removes histone modifications.",
    "llama-7b_response": "There are several enzymes that can remove histone modifications, including:\n\n1. Histone deacetylases (HDACs): These enzymes remove acetyl groups from histones, leading to a decrease in histone acetylation and an increase in histone deacetylation.\n2. Histone methyltransferases (HMTs): These enzymes add methyl groups to histones, leading to a decrease in histone methylation and an increase in histone demethylation.\n3. Histone demethylases: These enzymes remove methyl groups from histones, leading to a decrease in histone methylation and an increase in histone demethylation.\n4. Lysine-specific demethylase 1 (LSD1): This enzyme removes methyl groups from lysine residues on histones, leading to a decrease in histone methylation and an increase in histone demethylation.\n5. Jumonji domain-containing protein 3 (JMJD3): This enzyme removes methyl groups from lysine residues on histones, leading to a decrease in histone methylation and an increase in histone demethylation.",
    "llama-7b_fact_raw": "1. Histone deacetylases (HDACs) remove acetyl groups from histones.\n2. Histone demethylases remove methyl groups from histones.\n3. Lysine-specific demethylase 1 (LSD1) removes methyl groups from lysine residues on histones.\n4. Jumonji domain-containing protein 3 (JMJD3) removes methyl groups from lysine residues on histones.",
    "llama-7b_fact": [
      "Histone deacetylases (HDACs) remove acetyl groups from histones.",
      "Histone demethylases remove methyl groups from histones.",
      "Lysine-specific demethylase 1 (LSD1) removes methyl groups from lysine residues on histones.",
      "Jumonji domain-containing protein 3 (JMJD3) removes methyl groups from lysine residues on histones."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3806,
    "user_query": "You MUST give a detailed answer to the following question: Does head ct increase brain tumor risk?",
    "llama-7b_response": "The relationship between head CT scans and the risk of brain tumors is a complex one, and the answer is not straightforward.\n\nA head CT scan, also known as a computed tomography scan, is a medical imaging test that uses X-rays to create detailed images of the head and brain. It is commonly used to diagnose a variety of conditions, including brain tumors.\n\nWhile head CT scans are generally considered safe, there is some evidence to suggest that they may increase the risk of developing a brain tumor. This is because CT scans use X-rays, which are a form of ionizing radiation. Exposure to ionizing radiation has been linked to an increased risk of developing certain types of cancer, including brain tumors.\n\nHowever, it is worth noting that the risk of developing a brain tumor from a single head CT scan is relatively low. The risk is generally considered to be low enough that the benefits of the scan outweigh the potential risks for the vast majority of patients.\n\nIn addition, the risk of developing a brain tumor from a head CT scan depends on a number of factors, including the type and frequency of the scan, the patient's age and health status, and their exposure to other sources of ionizing radiation.\n\nOverall, while there is some evidence to suggest that head CT scans may increase the risk of developing a brain tumor, the risk is generally considered to be low, and the benefits of the scan may outweigh the potential risks for the vast majority of patients. It is important for patients to discuss the risks and benefits of a head CT scan with their healthcare provider before undergoing the procedure.",
    "llama-7b_fact_raw": "1. Head CT scans use X-rays to create detailed images of the head and brain.\n2. CT scans use ionizing radiation, which has been linked to an increased risk of developing certain types of cancer, including brain tumors.\n3. The risk of developing a brain tumor from a single head CT scan is relatively low.\n4. The benefits of a head CT scan generally outweigh the potential risks for the vast majority of patients.\n5. The risk of developing a brain tumor from a head CT scan depends on factors such as the type and frequency of the scan, the patient's age and health status, and their exposure to other sources of ionizing radiation.",
    "llama-7b_fact": [
      "Head CT scans use X-rays to create detailed images of the head and brain.",
      "CT scans use ionizing radiation, which has been linked to an increased risk of developing certain types of cancer, including brain tumors.",
      "The risk of developing a brain tumor from a single head CT scan is relatively low.",
      "The benefits of a head CT scan generally outweigh the potential risks for the vast majority of patients.",
      "The risk of developing a brain tumor from a head CT scan depends on factors such as the type and frequency of the scan, the patient's age and health status, and their exposure to other sources of ionizing radiation."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3809,
    "user_query": "You MUST give a detailed answer to the following question: Which type of pluripotency is Otx2 associated with?",
    "llama-7b_response": "transcriptional",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3815,
    "user_query": "You MUST give a detailed answer to the following question: How many DNaseI hypersensitive sites (DHS) mark the murine beta globin locus region?",
    "llama-7b_response": "The number of DNaseI hypersensitive sites (DHS) that mark the murine beta globin locus region is not a fixed number, as the number of DHS can vary depending on the experimental conditions and the method used to detect them. However, the beta globin locus region is known to have a relatively high number of DHS compared to other regions of the genome.\n\nIn general, DHS are regions of the genome that are more accessible to DNaseI enzymes, indicating that the DNA in these regions is more easily digested by the enzyme. The beta globin locus region, which contains the genes that encode the beta globin subunits of hemoglobin, is known to have a high number of DHS due to the presence of repetitive sequences and other factors that make the DNA in this region more accessible to DNaseI enzymes.\n\nThe exact number of DHS in the murine beta globin locus region can vary depending on the experimental conditions and the method used to detect them. For example, some studies have reported that the beta globin locus region contains hundreds or even thousands of DHS, while other studies have reported lower numbers.\n\nIn summary, the number of DHS that mark the murine beta globin locus region is not a fixed number and can vary depending on the experimental conditions and the method used to detect them. However, the beta globin locus region is known to have a relatively high number of DHS compared to other regions of the genome.",
    "llama-7b_fact_raw": "1. The number of DNaseI hypersensitive sites (DHS) in the murine beta globin locus region is not fixed and can vary.\n2. The murine beta globin locus region is known to have a relatively high number of DHS compared to other regions of the genome.\n3. DNaseI hypersensitive sites are regions of the genome that are more accessible to DNaseI enzymes.\n4. The beta globin locus region contains genes that encode the beta globin subunits of hemoglobin.\n5. Studies have reported varying numbers of DHS in the murine beta globin locus region, ranging from hundreds to thousands.",
    "llama-7b_fact": [
      "The number of DNaseI hypersensitive sites (DHS) in the murine beta globin locus region is not fixed and can vary.",
      "The murine beta globin locus region is known to have a relatively high number of DHS compared to other regions of the genome.",
      "DNaseI hypersensitive sites are regions of the genome that are more accessible to DNaseI enzymes.",
      "The beta globin locus region contains genes that encode the beta globin subunits of hemoglobin.",
      "Studies have reported varying numbers of DHS in the murine beta globin locus region, ranging from hundreds to thousands."
    ],
    "llama-7b_judge_raw": "1. TRUE: The number of DNaseI hypersensitive sites (DHS) in any given genomic region, including the murine beta globin locus, can vary depending on the cell type and developmental stage, reflecting changes in chromatin structure and gene regulation.\n2. TRUE: The murine beta globin locus region is indeed known to have a relatively high number of DHS compared to other regions of the genome, which is indicative of active regulatory elements and open chromatin associated with gene expression.\n3. TRUE: DNaseI hypersensitive sites are indeed regions of the genome that are more accessible to DNaseI enzymes, which preferentially cut DNA at these locations, indicating a lack of nucleosomes and suggesting regulatory activity.\n4. TRUE: The beta globin locus region does contain genes that encode the beta globin subunits of hemoglobin, which are essential for oxygen transport in the blood.\n5. FALSE [correction]: While the exact number of DNaseI hypersensitive sites in the murine beta globin locus region can vary, it is unlikely that the number ranges from hundreds to thousands within this specific locus. The number of DHS is typically much smaller and more specific; such a large range would not be characteristic of a single, well-defined genomic locus like the beta globin region. The statement is too vague without specifying the conditions under which these numbers were reported, and the range given is implausibly broad for a single locus.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3822,
    "user_query": "You MUST give a detailed answer to the following question: List as many European influenza vaccines as possible.",
    "llama-7b_response": "1. Fluarix (GlaxoSmithKline)\n2. FluLaval (Sanofi Pasteur)\n3. Fluvirin (Novartis)\n4. FluMist (MedImmune)\n5. Fluad (Novartis)\n6. Fluarix Quadrivalent (GlaxoSmithKline)\n7. FluLaval Quadrivalent (Sanofi Pasteur)\n8. Fluvirin Quadrivalent (Novartis)\n9. FluMist Quadrivalent (MedImmune)\n10. Fluad Quadrivalent (Novartis)\n11. Fluarix Tetravalent (GlaxoSmithKline)\n12. FluLaval Tetravalent (Sanofi Pasteur)\n13. Fluvirin Tetravalent (Novartis)\n14. FluMist Tetravalent (MedImmune)\n15. Fluad Tetravalent (Novartis)\n16. Fluarix High-Dose (GlaxoSmithKline)\n17. FluLaval High-Dose (Sanofi Pasteur)\n18. Fluvirin High-Dose (Novartis)\n19. FluMist High-Dose (MedImmune)\n20. Fluad High-Dose (Novartis)\n21. Fluarix Quadrivalent Adjuvanted (GlaxoSmithKline)\n22. FluLaval Quadrivalent Adjuvanted (Sanofi Pasteur)\n23. Fluvirin Quadrivalent Adjuvanted (Novartis)\n24. FluMist Quadrivalent Adjuvanted (MedImmune)\n25. Fluad Quadrivalent Adjuvanted (Novartis)\n26. Fluarix Tetravalent Adjuvanted (GlaxoSmithKline)\n27. FluLaval Tetravalent Adjuvanted (Sanofi Pasteur)\n28. Fluvirin Tetravalent Adjuvanted (Nov",
    "llama-7b_fact_raw": "1. Fluarix is a European influenza vaccine produced by GlaxoSmithKline.\n2. FluLaval is a European influenza vaccine produced by Sanofi Pasteur.\n3. Fluvirin is a European influenza vaccine produced by Novartis.\n4. FluMist is a European influenza vaccine produced by MedImmune.\n5. Fluad is a European influenza vaccine produced by Novartis.",
    "llama-7b_fact": [
      "Fluarix is a European influenza vaccine produced by GlaxoSmithKline.",
      "FluLaval is a European influenza vaccine produced by Sanofi Pasteur.",
      "Fluvirin is a European influenza vaccine produced by Novartis.",
      "FluMist is a European influenza vaccine produced by MedImmune.",
      "Fluad is a European influenza vaccine produced by Novartis."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: FluLaval is an influenza vaccine produced by GlaxoSmithKline, not Sanofi Pasteur.\n3. FALSE [correction]: Fluvirin was originally produced by Novartis, but as of my knowledge cutoff in 2023, the influenza vaccine business of Novartis was acquired by CSL's Seqirus.\n4. FALSE [correction]: FluMist is an influenza vaccine produced by AstraZeneca's subsidiary MedImmune, primarily for the United States market.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 3832,
    "user_query": "You MUST give a detailed answer to the following question: Is the Paramyxovirus geneome segmented, negative-sense RNA?",
    "llama-7b_response": "Yes, the Paramyxovirus geneome is segmented and negative-sense RNA.\n\nParamyxoviruses are a family of viruses that cause a wide range of diseases in humans and animals, including the common cold, measles, mumps, and respiratory syncytial virus (RSV). The genome of paramyxoviruses is segmented, meaning that it is made up of multiple segments of negative-sense RNA.\n\nEach segment of the paramyxovirus genome encodes a specific protein that is necessary for the virus to replicate and cause infection. The negative-sense RNA means that the genetic information is read in the opposite direction to the usual sense RNA, from 3' to 5'.\n\nThe negative-sense RNA genome of paramyxoviruses is surrounded by a protein coat, which is made up of the proteins encoded by the other segments of the genome. This protein coat helps the virus to infect cells and to evade the immune system.\n\nOverall, the segmented, negative-sense RNA genome of paramyxoviruses is an important factor in their ability to cause disease and to evade the immune system.",
    "llama-7b_fact_raw": "1. Paramyxoviruses have a genome that is made up of multiple segments of negative-sense RNA.\n2. The genome of paramyxoviruses encodes specific proteins necessary for the virus to replicate and cause infection.\n3. The genetic information in the paramyxovirus genome is read in the opposite direction to the usual sense RNA, from 3' to 5'.\n4. The negative-sense RNA genome of paramyxoviruses is surrounded by a protein coat.\n5. Paramyxoviruses can cause a wide range of diseases in humans and animals, including the common cold, measles, mumps, and respiratory syncytial virus (RSV).",
    "llama-7b_fact": [
      "Paramyxoviruses have a genome that is made up of multiple segments of negative-sense RNA.",
      "The genome of paramyxoviruses encodes specific proteins necessary for the virus to replicate and cause infection.",
      "The genetic information in the paramyxovirus genome is read in the opposite direction to the usual sense RNA, from 3' to 5'.",
      "The negative-sense RNA genome of paramyxoviruses is surrounded by a protein coat.",
      "Paramyxoviruses can cause a wide range of diseases in humans and animals, including the common cold, measles, mumps, and respiratory syncytial virus (RSV)."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Paramyxoviruses have a non-segmented, single-stranded negative-sense RNA genome.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE (although it should be noted that the common cold is more commonly associated with rhinoviruses, paramyxoviruses can cause respiratory infections that may be similar to the common cold).",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3869,
    "user_query": "You MUST give a detailed answer to the following question: Roflumilast Cream is effective for which disease?",
    "llama-7b_response": "evere asthma",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3885,
    "user_query": "You MUST give a detailed answer to the following question: Which tools have been developed for identifying and visualising ncRNA promoters?",
    "llama-7b_response": "There are several tools that have been developed for identifying and visualizing ncRNA promoters. Some of the most commonly used tools include:\n\n1. UCSC Genome Browser: The UCSC Genome Browser is a web-based genome annotation resource that provides a variety of tools for identifying and visualizing ncRNA promoters. The browser allows users to search for and view genomic features, including promoters, using a variety of annotation tracks and tools.\n2. ENCODE Project: The ENCODE (Encyclopedia of DNA Elements) Project is a large-scale effort to identify and characterize all functional elements in the human genome. As part of this project, the ENCODE Consortium has developed a variety of tools and resources for identifying and visualizing ncRNA promoters, including the UCSC Genome Browser track \"Human ENCODE Promoter Roadmap\".\n3. DNase-seq Viewer: The DNase-seq Viewer is a web-based tool developed by the ENCODE Project that allows users to visualize DNase I hypersensitivity sites, which are often associated with ncRNA promoters. The tool allows users to search for and view DNase I hypersensitivity sites in a variety of genomic contexts, including across different cell types and tissues.\n4. RNA-seq Viewer: The RNA-seq Viewer is a web-based tool developed by the ENCODE Project that allows users to visualize RNA-seq data, including ncRNA transcripts and their corresponding expression levels. The tool allows users to search for and view RNA-seq data in a variety of genomic contexts, including across different cell types and tissues.\n5. CisGenome: CisGenome is a web-based tool developed by the ENCODE Project that allows users to search for and view genomic features, including ncRNA promoters, using a variety of annotation tracks and tools. The tool allows users to search for and view ncRNA promoters in a variety of genomic contexts, including across different cell types and tissues.\n\nOverall, these tools provide researchers with a variety of resources for identifying and visualizing ncRNA promoters, and can be used in conjunction with other bioinformatic",
    "llama-7b_fact_raw": "1. The UCSC Genome Browser is a tool used for identifying and visualizing ncRNA promoters.\n2. The ENCODE Project has developed tools and resources for identifying and visualizing ncRNA promoters.\n3. The DNase-seq Viewer is a web-based tool that visualizes DNase I hypersensitivity sites associated with ncRNA promoters.\n4. The RNA-seq Viewer is a web-based tool developed by the ENCODE Project for visualizing RNA-seq data, including ncRNA transcripts.\n5. CisGenome is a web-based tool that allows users to search for and view ncRNA promoters.",
    "llama-7b_fact": [
      "The UCSC Genome Browser is a tool used for identifying and visualizing ncRNA promoters.",
      "The ENCODE Project has developed tools and resources for identifying and visualizing ncRNA promoters.",
      "The DNase-seq Viewer is a web-based tool that visualizes DNase I hypersensitivity sites associated with ncRNA promoters.",
      "The RNA-seq Viewer is a web-based tool developed by the ENCODE Project for visualizing RNA-seq data, including ncRNA transcripts.",
      "CisGenome is a web-based tool that allows users to search for and view ncRNA promoters."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The UCSC Genome Browser is a tool used for a wide range of genomic data visualization, not exclusively for identifying and visualizing ncRNA promoters.\n2. TRUE: The ENCODE Project has developed various tools and resources that can be used for identifying and visualizing ncRNA promoters among other genomic features.\n3. UNKNOWN: Without specific information about a tool named \"DNase-seq Viewer,\" it is not possible to confirm the accuracy of this statement. DNase-seq data is indeed used to identify DNase I hypersensitivity sites, which can be associated with regulatory elements, but whether there is a specific web-based tool with this name for visualizing such sites is not clear.\n4. TRUE: The ENCODE Project provides various tools for visualizing RNA-seq data, which includes ncRNA transcripts.\n5. FALSE [correction]: CisGenome is a software tool that can be used for analyzing genome-wide chromatin immunoprecipitation (ChIP) data, among other functionalities. It is not specifically a web-based tool for searching and viewing ncRNA promoters.",
    "llama-7b_judge": [
      "false",
      "true",
      "unknown",
      "true",
      "false"
    ]
  },
  {
    "id": 3918,
    "user_query": "You MUST give a detailed answer to the following question: List example genes that SWIM tool has identified and which are down-regulated in glioblastoma",
    "llama-7b_response": "The SWIM tool is a web-based tool developed by the National Center for Biotechnology Information (NCBI) that uses gene expression data to identify genes that are down-regulated in specific types of cancer, including glioblastoma. Here are some examples of genes that the SWIM tool has identified as being down-regulated in glioblastoma:\n\n1. CDKN2A: This gene encodes a protein that inhibits the activity of cyclin-dependent kinases, which are enzymes that regulate cell division. Mutations in the CDKN2A gene have been implicated in the development of several types of cancer, including glioblastoma.\n2. TP53: This gene encodes a protein called p53, which is a key regulator of cell growth and division. Mutations in the TP53 gene are common in glioblastoma and other types of cancer.\n3. PTEN: This gene encodes a protein that negatively regulates the PI3K/AKT signaling pathway, which is involved in cell growth and survival. Mutations in the PTEN gene have been implicated in the development of several types of cancer, including glioblastoma.\n4. CDKN1A: This gene encodes a protein that inhibits the activity of cyclin-dependent kinases, which are enzymes that regulate cell division. Mutations in the CDKN1A gene have been implicated in the development of several types of cancer, including glioblastoma.\n5. RB1: This gene encodes a protein called retinoblastoma protein, which is a key regulator of cell growth and division. Mutations in the RB1 gene have been implicated in the development of several types of cancer, including glioblastoma.\n\nThese are just a few examples of the many genes that the SWIM tool has identified as being down-regulated in glioblastoma. The tool provides a comprehensive list of genes that are down-regulated in glioblastoma and other types of cancer, and can be used to identify potential therapeutic targets for the treatment of these diseases.",
    "llama-7b_fact_raw": "1. The SWIM tool has identified the CDKN2A gene as being down-regulated in glioblastoma.\n2. The TP53 gene is recognized by the SWIM tool as down-regulated in glioblastoma.\n3. According to the SWIM tool, the PTEN gene is down-regulated in glioblastoma.\n4. The CDKN1A gene has been identified by the SWIM tool as down-regulated in glioblastoma.\n5. The RB1 gene is listed by the SWIM tool as being down-regulated in glioblastoma.",
    "llama-7b_fact": [
      "The SWIM tool has identified the CDKN2A gene as being down-regulated in glioblastoma.",
      "The TP53 gene is recognized by the SWIM tool as down-regulated in glioblastoma.",
      "According to the SWIM tool, the PTEN gene is down-regulated in glioblastoma.",
      "The CDKN1A gene has been identified by the SWIM tool as down-regulated in glioblastoma.",
      "The RB1 gene is listed by the SWIM tool as being down-regulated in glioblastoma."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information on the results provided by the SWIM tool (Survival Weighted Integrative Method), it is not possible to verify the accuracy of these statements. The SWIM tool is a bioinformatics tool used to analyze gene expression data, but without access to the actual analysis or results, the status of the genes mentioned in relation to glioblastoma cannot be confirmed.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3926,
    "user_query": "You MUST give a detailed answer to the following question: Which R packages have been developed for studying TADs?",
    "llama-7b_response": "There are several R packages that have been developed for studying TADs (topologically associating domains). Some of the most commonly used R packages for studying TADs include:\n\n1. TADMatrix: TADMatrix is an R package for visualizing and analyzing TADs. It allows users to visualize TADs in 2D and 3D, and to perform various analyses on the TAD data.\n2. TADView: TADView is an R package for visualizing and analyzing TADs. It allows users to visualize TADs in 2D and 3D, and to perform various analyses on the TAD data.\n3. TADStack: TADStack is an R package for visualizing and analyzing TADs. It allows users to visualize TADs in 2D and 3D, and to perform various analyses on the TAD data.\n4. TADTree: TADTree is an R package for visualizing and analyzing TADs. It allows users to visualize TADs in 2D and 3D, and to perform various analyses on the TAD data.\n5. TADCover: TADCover is an R package for visualizing and analyzing TADs. It allows users to visualize TADs in 2D and 3D, and to perform various analyses on the TAD data.\n6. TADPlot: TADPlot is an R package for visualizing and analyzing TADs. It allows users to visualize TADs in 2D and 3D, and to perform various analyses on the TAD data.\n7. TADFusion: TADFusion is an R package for visualizing and analyzing TADs. It allows users to visualize TADs in 2D and 3D, and to perform various analyses on the TAD data.",
    "llama-7b_fact_raw": "1. TADMatrix is an R package designed for visualizing and analyzing topologically associating domains (TADs).\n2. TADView is an R package that provides tools for visualizing and analyzing TADs in both 2D and 3D.\n3. TADStack is an R package that includes functionality for visualizing TADs and performing analyses on TAD data.\n4. TADTree is an R package that offers visualization in 2D and 3D, as well as analysis capabilities for TADs.\n5. TADCover is an R package that allows for TAD visualization and analysis, including 2D and 3D representations.",
    "llama-7b_fact": [
      "TADMatrix is an R package designed for visualizing and analyzing topologically associating domains (TADs).",
      "TADView is an R package that provides tools for visualizing and analyzing TADs in both 2D and 3D.",
      "TADStack is an R package that includes functionality for visualizing TADs and performing analyses on TAD data.",
      "TADTree is an R package that offers visualization in 2D and 3D, as well as analysis capabilities for TADs.",
      "TADCover is an R package that allows for TAD visualization and analysis, including 2D and 3D representations."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe truth value of statements 2 through 5 cannot be determined without additional information about these specific R packages. While the names suggest they could be related to TAD analysis and visualization, without specific knowledge of these packages or confirmation from a reliable source, their existence and functionalities cannot be verified.",
    "llama-7b_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3927,
    "user_query": "You MUST give a detailed answer to the following question: Which bioconductor tool has been developed for accessing bacterial regulatory networks?",
    "llama-7b_response": "edgeR",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3933,
    "user_query": "You MUST give a detailed answer to the following question: What are the end products of the shikimate pathway?",
    "llama-7b_response": "aromatic amino acid",
    "llama-7b_fact_raw": "1. The end products of the shikimate pathway are aromatic amino acids.",
    "llama-7b_fact": [
      "The end products of the shikimate pathway are aromatic amino acids."
    ],
    "llama-7b_judge_raw": "1. TRUE",
    "llama-7b_judge": [
      "true"
    ]
  },
  {
    "id": 3936,
    "user_query": "You MUST give a detailed answer to the following question: Is cabergoline used for treatment of the Nelson's syndrome ?",
    "llama-7b_response": "Yes, it is.",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3939,
    "user_query": "You MUST give a detailed answer to the following question: What is the main manifestation of Liebenberg syndrome?",
    "llama-7b_response": "Liebenberg syndrome is a rare genetic disorder caused by mutations in the PIK3R1 gene, which encodes for the regulatory subunit of the phosphatidylinositol 3-kinase (PI3K) enzyme. The PI3K enzyme plays a crucial role in regulating various cellular processes, including cell growth, survival, and metabolism. Mutations in the PIK3R1 gene result in reduced expression or function of the PI3K enzyme, leading to the development of Liebenberg syndrome.\n\nThe main manifestation of Liebenberg syndrome is intellectual disability, which can range from mild to severe. Intellectual disability in Liebenberg syndrome is caused by abnormal brain development and function, which can result in impaired cognitive, social, and adaptive skills. Other common features of Liebenberg syndrome include delayed motor milestones, such as walking and talking, as well as speech and language delays. Some individuals with Liebenberg syndrome may also have feeding difficulties, gastrointestinal problems, and seizures.\n\nIn addition to intellectual disability and developmental delays, individuals with Liebenberg syndrome may also have characteristic physical features, such as a small head (microcephaly), wide-set eyes (hypertelorism), and a flat nasal bridge. Some individuals with Liebenberg syndrome may also have hearing loss, heart defects, and kidney abnormalities.\n\nLiebenberg syndrome is a genetic disorder that is inherited in an autosomal recessive manner. This means that an individual must inherit two copies of the mutated PIK3R1 gene, one from each parent, in order to develop the syndrome. If an individual only inherits one mutated copy of the gene, they will be a carrier of the condition but will not exhibit any symptoms themselves.\n\nDiagnosis of Liebenberg syndrome typically involves a combination of genetic testing and clinical evaluation. Treatment for Liebenberg syndrome is primarily supportive and focuses on managing the symptoms and complications associated with the condition. Speech and language therapy, occupational therapy, and physical therapy may be helpful in improving cognitive, motor, and adaptive skill",
    "llama-7b_fact_raw": "1. Liebenberg syndrome is caused by mutations in the PIK3R1 gene.\n2. The main manifestation of Liebenberg syndrome is intellectual disability.\n3. Liebenberg syndrome can include physical features such as microcephaly, hypertelorism, and a flat nasal bridge.\n4. Liebenberg syndrome is inherited in an autosomal recessive manner.\n5. Diagnosis of Liebenberg syndrome involves genetic testing and clinical evaluation.",
    "llama-7b_fact": [
      "Liebenberg syndrome is caused by mutations in the PIK3R1 gene.",
      "The main manifestation of Liebenberg syndrome is intellectual disability.",
      "Liebenberg syndrome can include physical features such as microcephaly, hypertelorism, and a flat nasal bridge.",
      "Liebenberg syndrome is inherited in an autosomal recessive manner.",
      "Diagnosis of Liebenberg syndrome involves genetic testing and clinical evaluation."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Liebenberg syndrome is caused by mutations in the LMNA gene, not the PIK3R1 gene.\n2. FALSE [correction]: The main manifestation of Liebenberg syndrome is limb malformations, particularly the upper limbs developing characteristics of the lower limbs.\n3. UNKNOWN: Liebenberg syndrome primarily involves limb malformations, but without specific context or a detailed description of the syndrome, it is unclear whether these features are associated with Liebenberg syndrome.\n4. FALSE [correction]: Liebenberg syndrome is inherited in an autosomal dominant manner.\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "false",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 3977,
    "user_query": "You MUST give a detailed answer to the following question: List orally bioavailable MPS1 kinase inhibitors",
    "llama-7b_response": "Sure, here are some orally bioavailable MPS1 kinase inhibitors:\n\n1. Sorafenib (Nexavar)\n2. Sunitinib (Sutent)\n3. Pazopanib (Votrient)\n4. Axitinib (Inlyta)\n5. Tofacitinib (Xeljanz)\n6. Cediranib (Cediranib Maleate)\n7. AZD8055 (ARQ 197)\n8. BAY 439001 (Sunitinib Malate)\n9. GSK2141795\n10. PF-04217903\n\nPlease note that this list is not exhaustive and there may be other orally bioavailable MPS1 kinase inhibitors that are not included here.",
    "llama-7b_fact_raw": "1. Sorafenib is an orally bioavailable MPS1 kinase inhibitor known by the brand name Nexavar.\n2. Sunitinib is an orally bioavailable MPS1 kinase inhibitor known by the brand name Sutent.\n3. Pazopanib is an orally bioavailable MPS1 kinase inhibitor known by the brand name Votrient.\n4. Axitinib is an orally bioavailable MPS1 kinase inhibitor known by the brand name Inlyta.\n5. Tofacitinib is an orally bioavailable MPS1 kinase inhibitor known by the brand name Xeljanz.",
    "llama-7b_fact": [
      "Sorafenib is an orally bioavailable MPS1 kinase inhibitor known by the brand name Nexavar.",
      "Sunitinib is an orally bioavailable MPS1 kinase inhibitor known by the brand name Sutent.",
      "Pazopanib is an orally bioavailable MPS1 kinase inhibitor known by the brand name Votrient.",
      "Axitinib is an orally bioavailable MPS1 kinase inhibitor known by the brand name Inlyta.",
      "Tofacitinib is an orally bioavailable MPS1 kinase inhibitor known by the brand name Xeljanz."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Sorafenib is an orally bioavailable kinase inhibitor known by the brand name Nexavar, but it primarily targets the RAF/MEK/ERK pathway, VEGFR, PDGFR, and others, not specifically MPS1.\n2. FALSE [correction]: Sunitinib is an orally bioavailable kinase inhibitor known by the brand name Sutent, but it is a multi-targeted receptor tyrosine kinase (RTK) inhibitor, not specifically an MPS1 kinase inhibitor.\n3. FALSE [correction]: Pazopanib is an orally bioavailable kinase inhibitor known by the brand name Votrient, but it is a multi-targeted receptor tyrosine kinase (RTK) inhibitor, not specifically an MPS1 kinase inhibitor.\n4. FALSE [correction]: Axitinib is an orally bioavailable kinase inhibitor known by the brand name Inlyta, but it primarily targets VEGFR, not specifically MPS1.\n5. FALSE [correction]: Tofacitinib is an orally bioavailable kinase inhibitor known by the brand name Xeljanz, but it is a Janus kinase (JAK) inhibitor, not an MPS1 kinase inhibitor.",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 4031,
    "user_query": "You MUST give a detailed answer to the following question: Was golimumab tested for diabetes?",
    "llama-7b_response": "Golimumab, also known as Simponi, is a monoclonal antibody drug that is used to treat several autoimmune disorders, including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. It works by targeting a specific protein called tumor necrosis factor-alpha (TNF-alpha), which is involved in the immune system's response to inflammation.\n\nTo my knowledge, there is no specific information available on whether golimumab has been tested for the treatment of diabetes. However, it is worth noting that some studies have suggested that TNF-alpha may play a role in the development of insulin resistance and type 2 diabetes. Therefore, it is possible that golimumab, or similar drugs that target TNF-alpha, could potentially be used to treat or prevent diabetes in the future. However, more research would be needed to determine the safety and effectiveness of golimumab for this purpose.",
    "llama-7b_fact_raw": "1. Golimumab is a monoclonal antibody drug used to treat autoimmune disorders.\n2. Golimumab is also known by the brand name Simponi.\n3. It is used to treat rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.\n4. Golimumab works by targeting the protein tumor necrosis factor-alpha (TNF-alpha).\n5. TNF-alpha is implicated in the immune system's response to inflammation.",
    "llama-7b_fact": [
      "Golimumab is a monoclonal antibody drug used to treat autoimmune disorders.",
      "Golimumab is also known by the brand name Simponi.",
      "It is used to treat rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.",
      "Golimumab works by targeting the protein tumor necrosis factor-alpha (TNF-alpha).",
      "TNF-alpha is implicated in the immune system's response to inflammation."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4055,
    "user_query": "You MUST give a detailed answer to the following question: Is progeria caused by an autosomal recessive gene?",
    "llama-7b_response": "Yes, progeria is caused by an autosomal recessive gene.\n\nProgeria, also known as Hutchinson-Gilford progeria syndrome (HGPS), is a rare genetic disorder that causes premature aging in children. It is caused by a mutation in the LMNA gene, which is located on chromosome 1q21. The LMNA gene provides instructions for making a protein called lamin A, which is a key component of the nucleus of cells.\n\nIn individuals with progeria, the mutation in the LMNA gene leads to the production of an abnormal form of lamin A, which accumulates in the cells and causes them to become rigid and dysfunctional. This leads to the characteristic features of progeria, such as premature graying, hardening of the skin, and heart disease.\n\nProgeria is a very rare disorder, affecting only about 200 children worldwide. It is typically diagnosed in children between the ages of 18 months and 2 years, and most children with progeria do not survive beyond their early 20s. Despite its rarity, progeria has been extensively studied, and researchers have made significant progress in understanding its genetic basis and potential treatments.",
    "llama-7b_fact_raw": "1. Progeria, also known as Hutchinson-Gilford progeria syndrome (HGPS), is a rare genetic disorder.\n2. The disorder is caused by a mutation in the LMNA gene, which is located on chromosome 1q21.\n3. The LMNA gene mutation leads to the production of an abnormal form of lamin A protein.\n4. Progeria affects about 200 children worldwide.\n5. Most children with progeria are typically diagnosed between the ages of 18 months and 2 years and do not survive beyond their early 20s.",
    "llama-7b_fact": [
      "Progeria, also known as Hutchinson-Gilford progeria syndrome (HGPS), is a rare genetic disorder.",
      "The disorder is caused by a mutation in the LMNA gene, which is located on chromosome 1q21.",
      "The LMNA gene mutation leads to the production of an abnormal form of lamin A protein.",
      "Progeria affects about 200 children worldwide.",
      "Most children with progeria are typically diagnosed between the ages of 18 months and 2 years and do not survive beyond their early 20s."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The exact number of children living with progeria worldwide can vary, and the prevalence is estimated to be about 1 in 4 million newborns. The number 200 is often cited as an estimate of known cases at any given time, but it is not a fixed number and can change as new cases are diagnosed and as affected children pass away.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 4082,
    "user_query": "You MUST give a detailed answer to the following question: What are common variants at 12q14 and 12q24 associated with?",
    "llama-7b_response": "The common variants at 12q14 and 12q24 are associated with schizophrenia.",
    "llama-7b_fact_raw": "1. Common variants at 12q14 and 12q24 are associated with schizophrenia.",
    "llama-7b_fact": [
      "Common variants at 12q14 and 12q24 are associated with schizophrenia."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n\nThe statement regarding the association of common variants at 12q14 and 12q24 with schizophrenia is very specific and would require access to current scientific literature or genetic studies to verify. Without the specific context or reference to a study that confirms or denies this association, it is not possible to determine the truthfulness of the statement.",
    "llama-7b_judge": [
      "unknown"
    ]
  },
  {
    "id": 4096,
    "user_query": "You MUST give a detailed answer to the following question: Which are the ligands of the Roundabout (Robo) receptors?",
    "llama-7b_response": "The Roundabout (Robo) receptors are a family of G protein-coupled receptors (GPCRs) that play a critical role in the development and maintenance of the nervous system. These receptors are primarily expressed in the nervous system and are involved in a variety of processes, including axon guidance, synaptic plasticity, and neurodegeneration.\n\nThe ligands of the Roundabout (Robo) receptors are a diverse group of molecules that include proteins, peptides, and small molecules. Some of the known ligands of the Roundabout (Robo) receptors include:\n\n1. Robo proteins: The Roundabout (Robo) proteins are the primary ligands of the Roundabout (Robo) receptors. There are several isoforms of the Robo proteins, including Robo1, Robo2, Robo3, Robo4, and Robo5. These proteins are expressed in various tissues and play important roles in the development and maintenance of the nervous system.\n2. Neurexins: Neurexins are another group of ligands of the Roundabout (Robo) receptors. There are several isoforms of neurexins, including Neurexin1, Neurexin2, Neurexin3, and Neurexin4. These proteins are expressed in various tissues and play important roles in the development and maintenance of the nervous system.\n3. Slit proteins: Slit proteins are another group of ligands of the Roundabout (Robo) receptors. There are several isoforms of slit proteins, including Slit1, Slit2, Slit3, and Slit4. These proteins are expressed in various tissues and play important roles in the development and maintenance of the nervous system.\n4. Growth factors: Growth factors, such as epidermal growth factor (EGF), fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF), have also been shown to act as ligands of the Roundabout (Robo) receptors.\n5. Small molecules: Small molecules, such as retinoic acid and thyroid hormones, have also been shown to act a",
    "llama-7b_fact_raw": "1. The Roundabout (Robo) receptors are a family of G protein-coupled receptors (GPCRs).\n2. Robo proteins, including Robo1, Robo2, Robo3, Robo4, and Robo5, are primary ligands of the Roundabout (Robo) receptors.\n3. Neurexins, with isoforms such as Neurexin1, Neurexin2, Neurexin3, and Neurexin4, are ligands of the Roundabout (Robo) receptors.\n4. Slit proteins, including Slit1, Slit2, Slit3, and Slit4, are ligands of the Roundabout (Robo) receptors.\n5. Growth factors like epidermal growth factor (EGF), fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF) act as ligands of the Roundabout (Robo) receptors.",
    "llama-7b_fact": [
      "The Roundabout (Robo) receptors are a family of G protein-coupled receptors (GPCRs).",
      "Robo proteins, including Robo1, Robo2, Robo3, Robo4, and Robo5, are primary ligands of the Roundabout (Robo) receptors.",
      "Neurexins, with isoforms such as Neurexin1, Neurexin2, Neurexin3, and Neurexin4, are ligands of the Roundabout (Robo) receptors.",
      "Slit proteins, including Slit1, Slit2, Slit3, and Slit4, are ligands of the Roundabout (Robo) receptors.",
      "Growth factors like epidermal growth factor (EGF), fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF) act as ligands of the Roundabout (Robo) receptors."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The Roundabout (Robo) receptors are not a family of G protein-coupled receptors (GPCRs); they are a family of single-pass transmembrane receptors.\n2. FALSE [correction]: Robo proteins, including Robo1, Robo2, Robo3, and Robo4, are not ligands but rather members of the Roundabout (Robo) receptor family itself.\n3. FALSE [correction]: Neurexins are not ligands of the Roundabout (Robo) receptors. They are a family of presynaptic cell adhesion molecules.\n4. TRUE: Slit proteins are indeed ligands for the Roundabout (Robo) receptors.\n5. FALSE [correction]: Growth factors like EGF, FGF, and PDGF are not ligands for the Roundabout (Robo) receptors. They typically bind to other types of receptors, such as receptor tyrosine kinases.",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 4112,
    "user_query": "You MUST give a detailed answer to the following question: Is there a role for TFII-I in megakaryopoiesis?",
    "llama-7b_response": "Yes, there is a role for TFII-I in megakaryopoiesis. TFII-I is a transcription factor that plays an important role in the regulation of gene expression during the process of megakaryopoiesis.\n\nMegakaryopoiesis is the process by which megakaryocytes, which are specialized bone marrow cells that produce platelets, are formed. This process involves the proliferation and differentiation of hematopoietic stem cells into megakaryocytes.\n\nTFII-I has been shown to play a crucial role in the regulation of genes involved in the differentiation of hematopoietic stem cells into megakaryocytes. For example, TFII-I has been shown to bind to the promoter region of the platelet-derived growth factor receptor alpha (PDGFRα) gene, which is a key regulator of megakaryopoiesis, and to activate its transcription.\n\nFurthermore, TFII-I has also been shown to play a role in the regulation of genes involved in the maturation of megakaryocytes. For example, TFII-I has been shown to bind to the promoter region of the glycoprotein Ibα (GPIbα) gene, which is a key regulator of platelet formation, and to activate its transcription.\n\nIn summary, TFII-I plays an important role in the regulation of gene expression during the process of megakaryopoiesis by binding to the promoter regions of genes involved in the differentiation and maturation of hematopoietic stem cells into megakaryocytes.",
    "llama-7b_fact_raw": "1. TFII-I is a transcription factor that plays a role in the regulation of gene expression during megakaryopoiesis.\n2. Megakaryopoiesis is the process by which megakaryocytes, the bone marrow cells that produce platelets, are formed.\n3. TFII-I is involved in the differentiation of hematopoietic stem cells into megakaryocytes.\n4. TFII-I binds to the promoter region of the platelet-derived growth factor receptor alpha (PDGFRα) gene to activate its transcription.\n5. TFII-I also binds to the promoter region of the glycoprotein Ibα (GPIbα) gene, which is involved in platelet formation, to activate its transcription.",
    "llama-7b_fact": [
      "TFII-I is a transcription factor that plays a role in the regulation of gene expression during megakaryopoiesis.",
      "Megakaryopoiesis is the process by which megakaryocytes, the bone marrow cells that produce platelets, are formed.",
      "TFII-I is involved in the differentiation of hematopoietic stem cells into megakaryocytes.",
      "TFII-I binds to the promoter region of the platelet-derived growth factor receptor alpha (PDGFRα) gene to activate its transcription.",
      "TFII-I also binds to the promoter region of the glycoprotein Ibα (GPIbα) gene, which is involved in platelet formation, to activate its transcription."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nThe first three statements are accurate in describing TFII-I's role in gene regulation during megakaryopoiesis and its involvement in the differentiation of hematopoietic stem cells into megakaryocytes. However, without specific information on the binding of TFII-I to the promoter regions of the PDGFRα and GPIbα genes, the truth of statements 4 and 5 cannot be determined from the given context.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4145,
    "user_query": "You MUST give a detailed answer to the following question: Is atenolol metabolized by CYP2D6?",
    "llama-7b_response": "Yes, atenolol is metabolized by the cytochrome P450 enzyme CYP2D6. Atenolol is a beta-adrenergic receptor blocker that is used to treat hypertension and angina pectoris. It works by blocking the beta-1 adrenergic receptors in the heart and blood vessels, which reduces the workload on the heart and lowers blood pressure.\n\nCYP2D6 is an enzyme that is involved in the metabolism of a wide range of drugs, including many cardiovascular medications. The metabolism of atenolol by CYP2D6 results in the formation of several metabolites, including tenoxicam and tenidap.\n\nThe metabolism of atenolol by CYP2D6 can be affected by genetic variations in the CYP2D6 gene. Some individuals may have reduced activity of the CYP2D6 enzyme, which can lead to reduced metabolism of atenolol and an increased risk of side effects. Conversely, some individuals may have increased activity of the CYP2D6 enzyme, which can lead to increased metabolism of atenolol and a reduced effectiveness of the medication.\n\nIn summary, atenolol is metabolized by the cytochrome P450 enzyme CYP2D6, which is involved in the metabolism of many cardiovascular medications. The metabolism of atenolol by CYP2D6 can be affected by genetic variations in the CYP2D6 gene, which can lead to changes in the effectiveness and side effects of the medication.",
    "llama-7b_fact_raw": "1. Atenolol is metabolized by the cytochrome P450 enzyme CYP2D6.\n2. Atenolol is used to treat hypertension and angina pectoris.\n3. Atenolol works by blocking the beta-1 adrenergic receptors in the heart and blood vessels.\n4. Genetic variations in the CYP2D6 gene can affect the metabolism of atenolol.\n5. The metabolism of atenolol by CYP2D6 results in the formation of metabolites such as tenoxicam and tenidap.",
    "llama-7b_fact": [
      "Atenolol is metabolized by the cytochrome P450 enzyme CYP2D6.",
      "Atenolol is used to treat hypertension and angina pectoris.",
      "Atenolol works by blocking the beta-1 adrenergic receptors in the heart and blood vessels.",
      "Genetic variations in the CYP2D6 gene can affect the metabolism of atenolol.",
      "The metabolism of atenolol by CYP2D6 results in the formation of metabolites such as tenoxicam and tenidap."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Atenolol is not significantly metabolized by the liver and is excreted primarily unchanged in the urine. It is not metabolized by the cytochrome P450 enzyme CYP2D6.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Since atenolol is not significantly metabolized by CYP2D6, genetic variations in the CYP2D6 gene would not be expected to affect the metabolism of atenolol.\n5. FALSE [correction]: Tenoxicam and tenidap are not metabolites of atenolol. Atenolol does not have active metabolites and is excreted largely unchanged.",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 4158,
    "user_query": "You MUST give a detailed answer to the following question: List versions of ExpansionHunter",
    "llama-7b_response": "I'm sorry, but I don't have any information about versions of ExpansionHunter. Can you provide more context or clarify your question?",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 4164,
    "user_query": "You MUST give a detailed answer to the following question: What is the role of Adamts18 in hormone receptor signaling?",
    "llama-7b_response": "Adamts18, also known as adamalysin-18, is a member of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) family of proteins. The role of Adamts18 in hormone receptor signaling is not well understood, but it has been suggested that it may play a role in the regulation of hormone receptor trafficking and signaling.\n\nHormone receptors, such as estrogen receptors (ERs) and progesterone receptors (PRs), are transmembrane proteins that bind to hormones and regulate the expression of target genes involved in various physiological processes. Upon hormone binding, the receptors undergo a series of post-translational modifications, including phosphorylation, ubiquitination, and sumoylation, which regulate their stability, localization, and activity.\n\nAdamts18 has been shown to interact with several hormone receptors, including ERs, PRs, and androgen receptors (ARs). In vitro studies have demonstrated that Adamts18 can modulate the activity of these receptors by regulating their trafficking and signaling. For example, Adamts18 has been shown to promote the endocytic internalization of ERs and PRs, which can inhibit their signaling activity. Conversely, Adamts18 has also been shown to promote the recycling of ERs and PRs back to the plasma membrane, which can enhance their signaling activity.\n\nIn addition to its effects on hormone receptor trafficking, Adamts18 has also been implicated in the regulation of hormone receptor signaling. For example, Adamts18 has been shown to modulate the phosphorylation of ERs and PRs, which can regulate their transcriptional activity. Adamts18 has also been shown to modulate the ubiquitination and sumoylation of hormone receptors, which can regulate their stability and activity.\n\nOverall, the role of Adamts18 in hormone receptor signaling is complex and multifaceted, and further research is needed to fully understand",
    "llama-7b_fact_raw": "1. Adamts18 is a member of the ADAMTS family of proteins.\n2. Adamts18 may play a role in the regulation of hormone receptor trafficking and signaling.\n3. Adamts18 has been shown to interact with estrogen receptors (ERs), progesterone receptors (PRs), and androgen receptors (ARs).\n4. In vitro studies suggest that Adamts18 can promote the endocytic internalization and recycling of ERs and PRs.\n5. Adamts18 has been implicated in modulating the phosphorylation, ubiquitination, and sumoylation of hormone receptors.",
    "llama-7b_fact": [
      "Adamts18 is a member of the ADAMTS family of proteins.",
      "Adamts18 may play a role in the regulation of hormone receptor trafficking and signaling.",
      "Adamts18 has been shown to interact with estrogen receptors (ERs), progesterone receptors (PRs), and androgen receptors (ARs).",
      "In vitro studies suggest that Adamts18 can promote the endocytic internalization and recycling of ERs and PRs.",
      "Adamts18 has been implicated in modulating the phosphorylation, ubiquitination, and sumoylation of hormone receptors."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe first statement is true as ADAMTS18 is indeed a member of the ADAMTS (A Disintegrin And Metalloproteinase with Thrombospondin Motifs) family, which is a group of proteases with various functions in the body. However, the specific roles of Adamts18 in hormone receptor trafficking and signaling, its interactions with estrogen, progesterone, and androgen receptors, and its effects on the endocytic internalization and recycling of ERs and PRs, as well as its implications in modulating the phosphorylation, ubiquitination, and sumoylation of hormone receptors, are not commonly established facts and would require specific scientific research to confirm. Therefore, without additional context or references, the truthfulness of statements 2 through 5 cannot be determined, and they are marked as UNKNOWN.",
    "llama-7b_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4208,
    "user_query": "You MUST give a detailed answer to the following question: What is the mode of action of Thiazovivin?",
    "llama-7b_response": "Thiazovivin is a chemotherapy drug that belongs to the class of alkylating agents. It works by interfering with the process of DNA replication, which is essential for the growth and survival of cancer cells.\n\nThe mechanism of action of thiazovivin involves the formation of a covalent adduct between the drug and the guanine base of DNA. This results in the inhibition of DNA replication and transcription, as well as the induction of apoptosis (programmed cell death) in cancer cells.\n\nThiazovivin also inhibits the enzyme topoisomerase II, which is involved in the relaxation of supercoiled DNA. This leads to the formation of DNA strand breaks and the accumulation of DNA damage, which further contributes to the cytotoxic effects of the drug.\n\nOverall, the mode of action of thiazovivin involves the interference with the processes of DNA replication, transcription, and repair, which are essential for the survival and proliferation of cancer cells.",
    "llama-7b_fact_raw": "1. Thiazovivin is a chemotherapy drug that belongs to the class of alkylating agents.\n2. Thiazovivin interferes with the process of DNA replication in cancer cells.\n3. The drug forms a covalent adduct with the guanine base of DNA, inhibiting DNA replication and transcription.\n4. Thiazovivin induces apoptosis in cancer cells.\n5. Thiazovivin inhibits the enzyme topoisomerase II, leading to DNA strand breaks and accumulation of DNA damage.",
    "llama-7b_fact": [
      "Thiazovivin is a chemotherapy drug that belongs to the class of alkylating agents.",
      "Thiazovivin interferes with the process of DNA replication in cancer cells.",
      "The drug forms a covalent adduct with the guanine base of DNA, inhibiting DNA replication and transcription.",
      "Thiazovivin induces apoptosis in cancer cells.",
      "Thiazovivin inhibits the enzyme topoisomerase II, leading to DNA strand breaks and accumulation of DNA damage."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Thiazovivin is not a chemotherapy drug; it is a small molecule inhibitor used to enhance the survival of human pluripotent stem cells during cell culture.\n2. FALSE [correction]: Since Thiazovivin is not a chemotherapy drug, it does not interfere with DNA replication in cancer cells as part of its primary known function.\n3. FALSE [correction]: Thiazovivin does not form a covalent adduct with the guanine base of DNA; this statement may describe the mechanism of action of some alkylating agents, but not Thiazovivin.\n4. UNKNOWN: Without specific context or evidence, it is unclear whether Thiazovivin induces apoptosis in cancer cells. Its primary known role is in enhancing stem cell survival.\n5. FALSE [correction]: Thiazovivin does not inhibit the enzyme topoisomerase II. This statement may describe the mechanism of action of some chemotherapy drugs, but not Thiazovivin.",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "unknown",
      "false"
    ]
  }
]